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INTRODUCTION 
 
The following paragraphs provide an introduction to and brief background of the topic of this 
thesis. The introduction elaborates on two drug classes that are the main drugs investigated in 
this thesis, namely non-steroidal anti-inflammatory drugs, also known as NSAIDs, and proton 
pump inhibitors, which are abbreviated as PPIs. 
 
Non-steroidal anti-inflammatory drugs 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are derivatives from acetylsalicyl acid, a drug 
that is also known as aspirin. The first NSAID that has been developed was ibuprofen. 
Ibuprofen was used for the first time in 1968 for its analgesic and anti-inflammatory 
properties.1 Since then many other NSAIDs have been developed and their use in the general 
population has gained a lot in popularity. In Europe, NSAIDs account for 7.7% of all drug 
prescriptions2 and the annual prevalence of NSAID use is estimated at around 20%.3 This 
translates to around 2.6 million subjects in the Netherlands that received NSAID prescriptions 
from their physician in 2013 (Figure 1). You may wonder why these drugs are one of the 
world’s most frequently prescribed drugs? This question is relatively easy to answer, since 
NSAIDs have analgesic, antipyretic and anti-inflammatory actions. Subsequently, NSAIDs can 
be given for a wide range of indications of diseases to treat, such as in the treatment of 
rheumatoid arthritis or other inflammatory conditions.5, 6 NSAIDs also have an important role 
in the management of pain. The first step in pain management includes the use of non-opioid 
drugs, such as paracetamol as this is very effective in many painful conditions. When 
paracetamol treatment is not sufficiently effective, NSAIDs may be considered as second 
treatment option. 
 
 
Figure 1. Number of users (solid line) and total costs in millions (dashed line) of non-steroidal anti-inflammatory 
drugs (NSAIDs) and proton pump inhibitors (PPIs) in the Netherlands between 2009 and 2013. 
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In the general population NSAIDs such as diclofenac or ibuprofen are considered effective 
drugs and relative safe or even harmless. Therefore they are widely used for mild symptoms 
such as: headache, migraine or musculoskeletal complaints. The mechanism by which NSAIDs 
diminish the pain and inflammation is via inhibition of specific enzymes, the so called cyclo-
oxygenase (COX) enzymes (Figure 2). One of the endproducts of these enzymes are 
prostaglandins, which play an important role in pain, thrombocyte aggregation and 
thrombosis. They are also responsible for the production of a protective mucus layer in the 
stomach.7-9 There are various isoforms of the COX-enzymes, but the most frequently studied 
are COX-1 and COX-2 enzyme. The COX-1 enzyme is among others responsible for production 
of thromboxane A2 for platelet function and production of prostacyclin for stomach 
endothelium protection. COX-1 is present in most body tissues. The other isoform, COX-2 
enzyme, is responsible for the perception and regulation of pain. Generally, COX-2 is present in 
some tissues, but during an inflammatory process the enzyme is present in other tissues as 
well. 
 
Figure 2. Mechanism of action of cyclo-oxygenase inhibitors. 
 
Now, given the underlying mechanisms of these enzymes, it becomes clear that the traditional 
nonselective (ns) NSAIDs such as ibuprofen, naproxen and diclofenac, inhibit both forms of 
cyclo-oxygenase enzymes. However, this results in gastrointestinal vulnerability and may lead 
to stomach bleeding. This was one of the key reasons for development of NSAIDs that 
specifically inhibited the COX-2 enzyme only, and thus should be safer for the stomach; the 
selective COX-2 inhibitors, such as celecoxib, etoricoxib, rofecoxib and valdecoxib.10, 11 
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Proton Pump Inhibitors 
 
Proton pump inhibitors (PPIs) are one of the most commonly used drugs worldwide. After 
introduction on the market of omeprazole in 1988, the use of PPIs rapidly rose. In later years, 
more PPIs became available (in particular lansoprazole, rabeprazole, pantoprazole and 
esomeprazole). Their share on the market for 2014 in the Netherlands was 7% of all drug 
dispensings. The superiority of PPIs in the treatment of non-erosive reflux disease and erosive 
esophagitis as compared to treatment with histamine-2 receptor antagonists (H2RA) has been 
proven in various randomized clinical trials and is generally accepted.13  
In the United States PPIs ranked ninth among the most frequently dispensed 
therapeutic classes in 2012. A similar rise in use of PPIs has been observed in European 
countries. In recent years, the total amount of units prescribed and number of persons using 
omeprazole is ranked within the top 5 of drugs in the Netherlands. This resulted in substantial 
expenditures, where PPIs accounted for $10.0 billion in 2012 in the United States and 110 
million Euros in the Netherlands in 2013 (Figure 1). Although some PPIs have become available 
over-the-counter (OTC) in some countries, most PPIs are used on prescription.  
The widespread use of PPIs is partly due to the application of PPIs for various medical 
conditions (Table 1). Despite the clear benefits of PPIs on upper GI safety, the minister of 
Health, Welfare and Sports in the Netherlands decided to exclude PPIs as part of the basic 
insurance and reimbursement of the costs. Nevertheless, it appeared that the number of 
upper GI bleedings decreased in the year following this decision.16 
 
Table 1. Common indications for Proton Pump Inhibitor use. 
 
Clinical indication of Proton Pump Inhibitor use 
Gastroesophageal Reflux Disease 
Peptic Ulcer Disease 
Non-ulcer dyspepsia 
Prophylaxis for NSAID or low-dose aspirin use 
Helicobacter pylori eradication 
Zollinger-Ellison syndrome 
Barrett’s esophagus 
 
NSAID, non-steroidal anti-inflammatory drug 
 
PPIs are considered relatively safe drugs because side effects are infrequent and mostly of 
modest severity; mainly including headache, diarrhea, constipation, nausea and rash. These 
occur in a small proportion of users (1% to 5%). The prolonged and potentially non-judicious 
use of PPIs, however, is associated with risks. Several of the adverse effects of PPIs that have 
been documented are pertinent to older people such as bone fractures,17-24 pneumonia,26-35 
vitamin B12,
36-47 and iron absorption problems,48-53 Clostridium difficile infection,55-57 
 
 
hypomagnesemia,58-63 and acute interstitial nephritis.65-68 However, due to their wide use any 
small adverse effect of PPIs may have a considerable impact on health and morbidity in the 
elderly population. 
 
NSAID-related Adverse Events 
 
For a long time it has been known that the use of NSAIDs is associated with various 
unintended side effects. The severity of these side effects range from experiencing mild 
symptoms; such as dyspepsia or heart burning, to severe gastroduodenal ulcerations and 
bleeding, leading to hospitalization and potentially even death. 
 
Gastrointestinal events 
 
Upper gastrointestinal (GI) bleeding is still one of the most common acute diseases in the field 
of gastroenterology.69 It occurs in around 50 to 60 persons out of 100,000 persons each year. 
When translating this to the Netherlands, around 8,000 to 9,000 patients suffer from acute 
upper GI bleeding each year. Although in recent years substantial improvement in the 
prevention and treatment of upper GI bleeding has been accomplished, the mortality rate of 
upper GI bleeding is still around 5%-10%.70, 71 The most common cause of upper GI bleeding is 
still the use of NSAIDs, which increases the risk of upper GI bleeding around 2 to 4 fold 72, 73 
and yields an annual absolute risk of upper GI bleeding of 1.36%, as based on the integration 
of event rates from meta-analyses and large randomized trials.74 However, within the group of 
NSAIDs, the selective COX-2 inhibitors have proven in clinical trials to result less often in 
symptomatic upper GI ulcers or ulcer complications compared to the traditional NSAIDS.10, 11, 75 
Yet, it is important to realize that still a considerable proportion of around 3.7% to 8.9% of 
selective COX-2 inhibitor users continues to experience upper GI events.76-79 
However, the effects of NSAIDs extend also beyond the duodenum. Currently, 
evidence is accumulating that NSAID use is also associated with injury to the small bowel and 
colon.80 It appeared that there are more small bowel and colonic mucosal breaks and erosions 
in patients when taking NSAIDs.81 However whether these physiological changes also translate 
to a clinically relevant outcome, such as hospitalization because of rectal bleeding or anemia 
remains unclear.82 Since the outcomes of the lower gastrointestinal system are difficult to 
establish, especially when considering electronic health care records for case identification, 
this outcome was not assessed in the current thesis. Yet the outcome of microscopic 
inflammation of the colon was included. NSAIDs, and to a lesser extent PPIs, are thought to 
interfere with the cell-to-cell attachment.83-88 When the bowel integrity and colonic 
permeability is affected, luminal antigens may enter easily the underlying layers of the 
intestines and elicit an immune and inflammatory reaction.83 
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Cardiovascular events 
 
After successful release of selective COX-2 inhibitors on the market10, 75 concerns were raised 
about their cardiovascular (CV) safety.11 In 2001 a pharmaceutical company commenced a 
randomized clinical trial (RCT) to evaluate the efficacy of rofecoxib on the prevention of 
colorectal polyps, as another selective COX-2 inhibitor namely celecoxib had already been 
approved for this indication.89 With the RCT the company aimed to further evaluate a prior 
cardiovascular safety issue of rofecoxib. The trial was terminated early when preliminary data 
showed an increased relative risk of adverse thrombotic cardiovascular events (including 
myocardial infarction and stroke) for rofecoxib. However, it took several years before 
regulatory decisions about the CV safety were made. In the meanwhile many patients were 
still taking rofecoxib, which led to many deaths. This rofecoxib scandal led to the voluntary 
withdrawal of the drug in 200411, 90 but as well to closer monitoring of newly marketed drugs. 
The United States Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) reviewed the safety of selective COX-2 inhibitors and concluded that selective COX-2 
inhibitors increased the risk of CV events, but the overall benefit-risk balance was still 
positive.93 They recommended to avoid selective COX-2 inhibitors in patients with ischemic 
heart disease, stroke or peripheral arterial disease.89, 94, 95 However, subsequently signals 
regarding the increased arterial thrombosis risk for use of the traditional nonselective NSAIDs 
arose, particularly when they were used at high doses and for long-term.96, 97 The Committee 
for Medicinal Products for Human use concluded in 2006 that there was insufficient evidence 
to conclude on a thrombotic risk. Therefore EMA requested a review of the safety of 
traditional NSAIDs as well. This led to the initiation of the Safety Of Non-Steroidal Anti-
Inflammatory Drugs (SOS)-project which aimed to assess the gastrointestinal and 
cardiovascular safety of NSAIDs. Parts are described in this thesis.  
 
GUIDELINE RECOMMENDATIONS 
 
Physicians prescribing NSAIDs to patients are faced with mainly two issues: 1) identification of 
patients at high-risk of developing adverse events; and 2) the selection of appropriate 
strategies to prevent upper GI bleeding and its complications. The clinical decision making is 
complex as the physician should not only balance the analgesic and anti-inflammatory potency 
of NSAIDs against the gastrointestinal risk profile, but also weigh the cardiovascular risk of 
NSAIDs for the individual patient. Several clinical guidelines have been published which aim to 
indicate preferred approaches for medical problems.98-100  
Risk factors for upper GI complications have been identified in a large variety of 
studies and with a considerable degree of consistency. Although most risk factors are common 
across each guideline, some guidelines include more risk factors than others. In general the 
following risk factors are considered as most important factors in all guidelines: 1) a history of 
an upper GI event; 2) older age, above 65 years of age; and concomitant use of 3) 
anticoagulants; 4) corticosteroids; or 5) antiplatelets (including low-dose aspirin). Based on 
 
 
these factors an arbitrarily stratification of patients being at ‘low’, ‘moderate’ or ‘high’ risk can 
be made.99 A patient is considered at ‘low’ risk if there are no risk factors present, at 
‘moderate’ risk if there are 1 or 2 risk factors present and at ‘high’ risk if there are more than 2 
risk factors present, or if the patient had experienced an upper GI complication before. Other 
factors that are occasionally mentioned in guidelines include concurrent use of selective 
serotonin reuptake inhibitors, using high dosages of NSAIDs and having comorbid diseases as 
rheumatoid arthritis, heart failure and diabetes mellitus.100 
Strikingly, despite the fact that there is very little evidence on the risk when several 
of these risk factors are combined it is stated in guidelines that the risk factors act 
cumulatively with an increasing (additive) risk when multiple risk factors are present.100 It is 
however unclear whether we can simply add the risks of the separate risk factors 
cumulatively; or whether we should be taking some multiplicative function of 
additional/excess risk into account. 
Possible preventive strategies for upper GI events include a concurrent prescription 
of a proton pump inhibitor or histamine-2 receptor antagonist to a nonselective NSAID, or to 
prescribe a selective COX-2 inhibitor instead of a nonselective NSAID. 
As can be understood from the cardiovascular risks of NSAIDs discussed above, the 
cardiovascular risk of patients should be considered in the recommendation of prevention of 
NSAID-related upper GI complications as well. In general, patients at risk of cardiovascular 
events, such as those with a history of a prior cardiovascular event, diabetes, hypertension, 
hyperlipidemia and obesity, often receive prophylactic low-dose aspirin.99 When considering 
patients receiving low-dose aspirin as ‘at risk of cardiovascular events’ we can summarize the 
recommendations for prevention of NSAID-related upper GI complications as is shown in Table 
2. The area of appropriate gastroprotection in patients at risk of upper GI events is still 
evolving and possibly we should prescribe a selective COX-2 inhibitor with a proton pump 
inhibitor to patients at risk.101, 102 
 
Table 2. Recommendations for prevention of NSAID-related upper GI complications according to gastrointestinal 
and cardiovascular risk.99 
 
  Gastrointestinal risk 
   Low Moderate High 
Ca
rd
io
va
sc
ul
ar
 
Ri
sk
 
No low-dose aspirin use 
Low CV risk 
NSAID alone NSAID + PPI 
Preferably no NSAID, 
otherwise COX-2 inhibitor + 
PPI 
Use of low-dose aspirin 
High CV risk 
Naproxen + PPI Naproxen + PPI 
Preferably no nsNSAID or 
COX-2 inhibitor 
 
CV, cardiovascular; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pum inhibitor 
  
1	 General	Introduction	|	15 
 
Cardiovascular events 
 
After successful release of selective COX-2 inhibitors on the market10, 75 concerns were raised 
about their cardiovascular (CV) safety.11 In 2001 a pharmaceutical company commenced a 
randomized clinical trial (RCT) to evaluate the efficacy of rofecoxib on the prevention of 
colorectal polyps, as another selective COX-2 inhibitor namely celecoxib had already been 
approved for this indication.89 With the RCT the company aimed to further evaluate a prior 
cardiovascular safety issue of rofecoxib. The trial was terminated early when preliminary data 
showed an increased relative risk of adverse thrombotic cardiovascular events (including 
myocardial infarction and stroke) for rofecoxib. However, it took several years before 
regulatory decisions about the CV safety were made. In the meanwhile many patients were 
still taking rofecoxib, which led to many deaths. This rofecoxib scandal led to the voluntary 
withdrawal of the drug in 200411, 90 but as well to closer monitoring of newly marketed drugs. 
The United States Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) reviewed the safety of selective COX-2 inhibitors and concluded that selective COX-2 
inhibitors increased the risk of CV events, but the overall benefit-risk balance was still 
positive.93 They recommended to avoid selective COX-2 inhibitors in patients with ischemic 
heart disease, stroke or peripheral arterial disease.89, 94, 95 However, subsequently signals 
regarding the increased arterial thrombosis risk for use of the traditional nonselective NSAIDs 
arose, particularly when they were used at high doses and for long-term.96, 97 The Committee 
for Medicinal Products for Human use concluded in 2006 that there was insufficient evidence 
to conclude on a thrombotic risk. Therefore EMA requested a review of the safety of 
traditional NSAIDs as well. This led to the initiation of the Safety Of Non-Steroidal Anti-
Inflammatory Drugs (SOS)-project which aimed to assess the gastrointestinal and 
cardiovascular safety of NSAIDs. Parts are described in this thesis.  
 
GUIDELINE RECOMMENDATIONS 
 
Physicians prescribing NSAIDs to patients are faced with mainly two issues: 1) identification of 
patients at high-risk of developing adverse events; and 2) the selection of appropriate 
strategies to prevent upper GI bleeding and its complications. The clinical decision making is 
complex as the physician should not only balance the analgesic and anti-inflammatory potency 
of NSAIDs against the gastrointestinal risk profile, but also weigh the cardiovascular risk of 
NSAIDs for the individual patient. Several clinical guidelines have been published which aim to 
indicate preferred approaches for medical problems.98-100  
Risk factors for upper GI complications have been identified in a large variety of 
studies and with a considerable degree of consistency. Although most risk factors are common 
across each guideline, some guidelines include more risk factors than others. In general the 
following risk factors are considered as most important factors in all guidelines: 1) a history of 
an upper GI event; 2) older age, above 65 years of age; and concomitant use of 3) 
anticoagulants; 4) corticosteroids; or 5) antiplatelets (including low-dose aspirin). Based on 
 
 
these factors an arbitrarily stratification of patients being at ‘low’, ‘moderate’ or ‘high’ risk can 
be made.99 A patient is considered at ‘low’ risk if there are no risk factors present, at 
‘moderate’ risk if there are 1 or 2 risk factors present and at ‘high’ risk if there are more than 2 
risk factors present, or if the patient had experienced an upper GI complication before. Other 
factors that are occasionally mentioned in guidelines include concurrent use of selective 
serotonin reuptake inhibitors, using high dosages of NSAIDs and having comorbid diseases as 
rheumatoid arthritis, heart failure and diabetes mellitus.100 
Strikingly, despite the fact that there is very little evidence on the risk when several 
of these risk factors are combined it is stated in guidelines that the risk factors act 
cumulatively with an increasing (additive) risk when multiple risk factors are present.100 It is 
however unclear whether we can simply add the risks of the separate risk factors 
cumulatively; or whether we should be taking some multiplicative function of 
additional/excess risk into account. 
Possible preventive strategies for upper GI events include a concurrent prescription 
of a proton pump inhibitor or histamine-2 receptor antagonist to a nonselective NSAID, or to 
prescribe a selective COX-2 inhibitor instead of a nonselective NSAID. 
As can be understood from the cardiovascular risks of NSAIDs discussed above, the 
cardiovascular risk of patients should be considered in the recommendation of prevention of 
NSAID-related upper GI complications as well. In general, patients at risk of cardiovascular 
events, such as those with a history of a prior cardiovascular event, diabetes, hypertension, 
hyperlipidemia and obesity, often receive prophylactic low-dose aspirin.99 When considering 
patients receiving low-dose aspirin as ‘at risk of cardiovascular events’ we can summarize the 
recommendations for prevention of NSAID-related upper GI complications as is shown in Table 
2. The area of appropriate gastroprotection in patients at risk of upper GI events is still 
evolving and possibly we should prescribe a selective COX-2 inhibitor with a proton pump 
inhibitor to patients at risk.101, 102 
 
Table 2. Recommendations for prevention of NSAID-related upper GI complications according to gastrointestinal 
and cardiovascular risk.99 
 
  Gastrointestinal risk 
   Low Moderate High 
Ca
rd
io
va
sc
ul
ar
 
Ri
sk
 
No low-dose aspirin use 
Low CV risk 
NSAID alone NSAID + PPI 
Preferably no NSAID, 
otherwise COX-2 inhibitor + 
PPI 
Use of low-dose aspirin 
High CV risk 
Naproxen + PPI Naproxen + PPI 
Preferably no nsNSAID or 
COX-2 inhibitor 
 
CV, cardiovascular; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pum inhibitor 
  
	 General	Introduction	|	17  16	|	Chapter	1.1
 
AIMS AND OUTLINE OF THIS THESIS 
 
This thesis aims to provide insight into several safety and beneficial aspects of non-steroidal 
anti-inflammatory drug (NSAID) use and proton pump inhibitor (PPI) use on different parts of 
the gastrointestinal system and the cardiovascular system. The thesis is divided in seven 
sections.  
The first section provides a general introduction to the thesis and summarizes the 
use of NSAIDs, PPIs and the potential complications of use. 
 
In Section 2 we focus on the use of PPIs. PPIs are frequently used drugs as it is recommended 
to co-prescribe PPIs with NSAIDs in order to mitigate the risk of NSAID-related upper 
gastrointestinal bleeding. The use of PPIs is however not without implications. The benefits 
and harms of PPI use in an elderly population are discussed in Chapter 2.1. 
 
In Section 3 we elaborate on two diseases of the esophagus and their relation with the use of 
NSAIDs and PPIs. Barrett’s esophagus (BE) is characterised by replacement of the squamous 
epithelium of the esophagus by metaplastic columnar epithelium and considered a 
consequence of prolonged gastro-esophageal reflux into the lower esophagus. BE is one of the 
most important risk factors for subsequent development of esophageal adenocarcinoma (EAC) 
via a stepwise pathway of low-grade and high-grade dysplasia. How often Barrett’s esophagus 
occurs in the general population in the Netherlands and the United Kingdom is described in 
Chapter 3.1. In this chapter we also elaborate on the frequency of development of esophageal 
adenocarcinoma within patients with Barrett’s esophagus. Recognizing that besides the 
decrease in death rates of most cancers in recent years in contrast to the increased mortality 
for esophageal cancer, and the 5-year survival rate of subjects with esophageal cancer is only 
between 13% to 17%, the need for effective prevention of esophageal cancer development is 
warranted. There was some promising information of cancer prevention via use of PPIs and 
NSAIDs in patients with BE, however, it remained unclear to which extent this could be 
applicable to a more general population of BE. In Chapter 3.2 we expand the knowledge by 
assessing whether NSAIDs and PPIs are effective in reducing the progression from Barrett’s 
esophagus to esophageal adenocarcinoma. 
 
The action of NSAIDs on the stomach is well-known. NSAIDs are ulcerogenic drugs and 
increase the risk of upper gastrointestinal bleeding, ulceration and complications. Section 4 is 
devoted to this topic. Upper GI bleeding has a major impact on patients’ quality of life and 
public health care costs. Although great improvements in prevention and treatment of upper 
GI bleeding have been achieved in recent decades, upper GI bleeding-related morbidity and 
mortality remain substantial. In clinical trials the benefit of selective COX-2 inhibitors over 
traditional nonselective NSAIDs with respect to upper GI events was shown. After selective 
COX-2 inhibitors came on the market, it became clear that physicians preferentially prescribed 
these ‘new’ and ‘safer’ drugs to patients at higher risk of upper GI bleeding than patients who 
 
 
received the traditional older nonselective NSAIDs. In observational studies using routinely 
prospectively collected data, it is difficult to take this channelling preference into account. In 
Chapter 4.1 we assess whether we are able to address this confounding issue. When 
comparing two comparable groups with regard to their upper gastrointestinal risk profile, the 
question of whether we should prefer prescribing a traditional nsNSAID together with a 
gastroprotective agent or a selective COX-2 inhibitor solely is addressed in Chapter 4.2. 
Not only NSAIDs are known to increase the risk of upper GI bleeding, use of low-dose 
aspirin, which is considered standard of care for cardiovascular prevention, increases the risk 
of upper GI bleeding up to 4-fold. Given the fact that around 30% of patients using low-dose 
aspirin will also use an NSAID, the risk of upper gastrointestinal bleeding may rise 
substantially. In clinical guidelines it is mentioned that combining certain drugs, for instance 
glucocorticoids and anticoagulants, with NSAIDs should be avoided. In Chapter 4.3 we 
estimate the risk of upper GI bleeding when multiple drugs are used concomitantly with 
nsNSAIDs, selective COX-2 inhibitors or low-dose aspirin. Additionally we assess whether drugs 
have synergy with each other resulting in an excess risk that would not have been expected on 
the basis of the individual risks of upper GI bleeding. 
 
The last organ of the gastrointestinal system that is studied in this thesis is the colon, also 
known as large bowel. One of the most important functions of the colon is the resorption of 
water from the wastes that pass through. Inflammation of the colon interferes with this 
process and results in decreased water resorption and ultimately diarrhea. Microscopic colitis 
(MC) is a condition characterized by chronic watery diarrhea, normal radiological and 
endoscopic appearance and microscopic inflammation of the colon. In recent years several 
studies reported on an increasing incidence of MC, however whether this holds for the 
Netherlands as well, is unknown. In Chapter 5.1 we investigate whether the substantial 
increase in colonoscopies in recent decades may be charged for that. The etiology of the 
disease is largely unknown, but NSAIDs and PPIs may be involved in the predisposition of MC 
development. In Chapter 5.2 we disentangle the effects of NSAIDs and PPIs on the colon and 
investigate whether the use of these drugs increases the risk of microscopic colitis, or whether 
they worsen symptoms of diarrhea. Continued chronic inflammation of the colon may result in 
conformational changes of cells in the colon. Patients with certain chronic inflammatory bowel 
diseases are more likely to develop colorectal neoplasia because of chronic inflammation. 
Whether this also holds for chronic inflammation in the context of microscopic colitis is 
investigated in Chapter 5.3. 
 
After the increased thrombotic risk with rofecoxib, it became clear that there is more than 
only the gut to look for harmful effects of NSAIDs. To assess whether the thrombotic risk is 
also seen for other frequently used individual NSAIDs or this was specifically an effect of 
selective COX-2 inhibitors, in Chapter 6.1 analysis of the risk of acute myocardial infarction for 
twenty-eight individual NSAID compounds is done. Summarizing the knowledge gathered from 
Chapters 4.1-4.3 and Chapter 6.1 you would like to assess for an individual patient given 
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his/her upper GI and cardiovascular risk profile which individual NSAID should be preferred 
over all others. Despite some guidance from the clinical guidelines, it remains difficult for a 
physician to tailor NSAID-therapy and to consider appropriate gastric protection for an 
individual patient. Chapter 6.2 incorporates evidence on the gastrointestinal and 
cardiovascular risk of NSAIDs and provides an overall decision tool to assess on individual 
patient-level which individual NSAID is relatively the safest choice.  
In the previous chapters we use and combine a variety of databases to address the 
research questions. In which way to consider combination of large-scale data and results is 
however, an area that does not have fully developed and validated methods. In the context of 
a common data model we compared two methods to combine results from several nested 
case-control studies in the SAFEGUARD project (Section 7, Chapter 7.1). 
In the last section (Section 8), the main findings of this thesis are summarized and 
discussed. 
 
Throughout this thesis a variety of data sources, study designs and exposures are being 
studied. In Table 3 an overview of these including the research question can be seen. 
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his/her upper GI and cardiovascular risk profile which individual NSAID should be preferred 
over all others. Despite some guidance from the clinical guidelines, it remains difficult for a 
physician to tailor NSAID-therapy and to consider appropriate gastric protection for an 
individual patient. Chapter 6.2 incorporates evidence on the gastrointestinal and 
cardiovascular risk of NSAIDs and provides an overall decision tool to assess on individual 
patient-level which individual NSAID is relatively the safest choice.  
In the previous chapters we use and combine a variety of databases to address the 
research questions. In which way to consider combination of large-scale data and results is 
however, an area that does not have fully developed and validated methods. In the context of 
a common data model we compared two methods to combine results from several nested 
case-control studies in the SAFEGUARD project (Section 7, Chapter 7.1). 
In the last section (Section 8), the main findings of this thesis are summarized and 
discussed. 
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ABSTRACT 
 
Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide and their 
intake increases with age. Despite a relatively safe profile, a range of studies reported 
associations between use of PPIs and various adverse events. The most important adverse 
events, such as pneumonia, bone fractures, bacterial enteric infections, and diminished 
vitamin absorption are critically discussed in this review in the view of body of evidence, 
including underlying biological mechanisms, evidence of causality and consistency. Most of the 
reported risks are relatively small and sometimes based on inconsistent evidence. For an 
individual patient and particularly the elderly, it is relevant to question the indication of use 
and balance the benefit and potential harm of PPI therapy. This approach can minimize 
morbidity and reduce health care costs. In this review the use and safety of proton pump 
inhibitors among the elderly is described. 
  
 
 
Use of Proton Pump Inhibitors 
 
Proton pump inhibitors (PPIs) are one of the most commonly used drugs worldwide. After 
introduction on the market of omeprazole in 1988, PPI use rapidly rose. In later years, more 
PPIs became available (in particular lansoprazole, rabeprazole, pantoprazole and 
esomeprazole). The superiority of PPIs in the treatment of non-erosive reflux disease and 
erosive esophagitis as compared to treatment with histamine-2 receptor antagonists (H2RA) 
has been proven in various randomized clinical trials and is generally accepted.13 
In the United States PPIs ranked ninth among the most frequently dispensed 
therapeutic classes in 2012.  A similar rise in use of PPIs has been observed in European 
countries. In recent years, the total amount of units prescribed and number of persons using 
omeprazole is ranked within the top 5 of drugs in the Netherlands. This resulted in substantial 
expenditures, where PPIs accounted for $10.0 billion in 2012 in the United States. Although 
some PPIs have become available over-the-counter (OTC) in some countries, most PPIs are 
used on prescription. 
Among the elderly, utilization patterns of PPIs are less well studied. The overall 
frequency of drug use is much higher among elderly as compared to the general population.104 
An Italian study showed that drugs used by elderly were in particular for acid-related 
disorders.104 Around 16% of elderly subjects recorded using drugs for acid-related disorders 
(H2RA, PPIs and antacids).104 
Depending on the indication, PPIs can be used both short and long-term. Short-term 
use of PPIs is not associated with severe, unexpected adverse effects. Obviously, safety of PPIs 
is more jeopardized during long-term treatment. Elderly in long-term need of PPIs form a 
population with frequent co-morbid disease and concomitant multi-drug use.105 Both factors 
affect the risk of adverse events. A third factor that is important when assessing associations in 
pharmaco-epidemiology is the presence of a dose-relationship. Though causality can never be 
fully established in observational studies, according to Bradford-Hill criteria, the presence of a 
dose-relationship strongly supports a causal association; i.e. meaning that higher dosages 
should be associated with a greater risk than lower dosages.106 
In this review the use and safety of PPIs in the elderly is discussed. PPIs are generally 
considered as safe drugs. However, a range of studies reported associations between use of 
PPIs and various adverse events. Some of the most relevant potential adverse events, such as 
pneumonia, bone fractures, bacterial enteric infections, and diminished vitamin absorption are 
critically discussed in this review in the view of body of evidence, including underlying 
biological mechanisms, evidence of causality and consistency. 
 
Indications of PPI use in the elderly 
 
The widespread use of PPIs is partly due to the application of PPIs for various medical 
conditions (Table 1). An observational study reported in 2006 that the most common 
indications for incident PPI use (defined as new users who did not take a PPI within the 
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previous 12 months) were gastroesophageal reflux disease (GERD) and non-reflux dyspepsia, 
accounting respectively for 27% and 25% of new prescriptions. Long-term PPI use (defined as 
receiving at least 3 PPI prescriptions) occurred in around 60% of patients with esophagitis Los 
Angeles classification grade A/B, in 75% of grade C/D esophagitis and in 70% of subjects 
diagnosed with Barrett’s esophagus.107 However, PPIs were prescribed only once in the 
majority of patients and particular for symptom relief of simple reflux.107 Only in 6% of PPI 
users the indication was defined as ‘other’.107 This contrasted to an Australian study, in which 
21% of PPI use was for acute gastrointestinal bleeding, and 40% for ‘other’ indications.108 Age 
of 65 years or older is an established risk factor for upper gastrointestinal (GI) bleeding in non-
steroidal anti-inflammatory drug (NSAID) users.99 Among the elderly PPIs are therefore often 
co-prescribed to NSAIDs as gastroprotective measure.109  
 
Table 1. Common indications for Proton Pump Inhibitor use in the elderly. 
 
Clinical indication of Proton Pump Inhibitor use 
Gastroesophageal Reflux Disease 
Peptic Ulcer Disease 
Non-ulcer dyspepsia 
Prophylaxis for NSAID or low-dose aspirin use 
Helicobacter pylori eradication 
Zollinger-Ellison syndrome 
Barrett’s esophagus 
 
NSAID, non-steroidal anti-inflammatory drug 
 
Additionally, the use of low-dose aspirin (LDA; up to 325mg/day for cardiovascular prevention) 
is considered an indication for PPI use. It has been shown that use of LDA increases the risk of 
upper GI bleeding 2 to 4 fold.73, 110-113 Clinical guidelines recommend use of PPIs in patients 
receiving LDA to minimize upper GI bleeding risk when one of the following risk factors is 
present: 1) history of peptic ulcer disease or upper GI bleeding; 2) aged 60 years or older; 3) 
concomitant use of corticosteroids; 4) presence of dyspepsia or GERD.114 Following this 
definition, elderly using LDA should be prescribed a PPI for appropriate gastroprotection. 
Adherence to these recommendations however still deserves improvement.98, 115, 116 
There is scarce evidence on the risk of upper GI bleeding during use of corticosteroids 
or anticoagulants, as the underlying co morbid disease or concomitant use of NSAIDs or LDA 
may partially explain the risk of upper GI bleeding.72, 73, 117-119 Nevertheless, PPIs can also be 
considered as appropriate gastroprotective treatment in vulnerable elderly using 
corticosteroids or anticoagulants. 
Eradication of Helicobacter pylori (H. pylori) is a common indication for short-term 
use of PPIs. It served as indication in 15% of PPI users.107 
 
 
 
Age related changes in the stomach of the elderly 
 
In the elderly, prostaglandin-levels decrease due to diminished conversion of arachidonic acid 
to prostaglandin via the cyclo-oxygenase (COX)-1 enzyme. This may result in a stomach being 
more prone to irritants and an increase in the risk of upper GI bleeding. This partially accounts 
for the recommendation that gastroprotective measures should be employed in the elderly 
when using NSAIDs.99 Supporting evidence comes from experimental studies, showing that 
older rats expressed lower levels of COX-enzyme mRNA than younger rats and had an 
impaired response of prostaglandin synthesis to irritants.120 In addition, in elderly there is a 
higher basal acid output in the stomach121 resulting in lower prostaglandin concentrations in 
the stomach and duodenum.122 Therefore, the stomach of the elderly is more vulnerable to 
exposure and toxic stimuli, such as drugs (i.e. NSAIDs, LDA). Protective measures including co-
prescription of a PPI are therefore recommended to the elderly.99 
Despite the fact that elderly patients may suffer from more pronounced esophageal 
mucosal injury and acid exposure than younger patients, the perception of symptom severity 
for heartburn is less.123 The time to symptom perception and sensory intensity is reduced in 
the elderly. An age-related reduction in chemosensitivity to acid is a possible underlying 
mechanism. However, it has been suggested that the altered perception of esophageal pain in 
elderly people is the result of an ageing process rather than an acquired phenomenon 
resulting from disease.124 
Thirdly, atrophic gastritis is more prevalent among the elderly, in particular among H. 
pylori-positive subjects.125 Gastric atrophy ultimately may occur in 40-50% of H. pylori infected 
individuals. The impact of acid suppression on H. pylori presence and its shift from gastric 
antrum to corpus has been extensively discussed previously. By decreasing gastric acidity in 
the gastric corpus, colonization of the corpus by H. pylori is enhanced.125, 126 Increased 
inflammation of the gastric corpus accelerates the progression to chronic atrophic gastritis.126 
Chronic atrophic gastritis increases the risk of gastric cancer. This explains the 
recommendation in international guidelines to consider a test-and-treat regimen for H. pylori 
infection in subjects who require long-term maintenance treatment with a PPI.127  
 
Harmful use of PPIs in the elderly 
 
Apart from the susceptibility of adverse outcomes due to long-term PPI treatment in elderly, 
several factors interact with each other that may lead to negative outcomes; including poor 
nutritional status, co morbid diseases and polypharmacy. Concerns were raised about the 
association between PPI use and increased mortality in institutionalized older people128 and in 
patients discharged from hospitals.129 The risk of death in the year following hospitalization 
increased by 51% (HR 1.51; 95%CI: 1.03-2.77) for PPI users compared to PPI non-users.130 In 
another study the risk increased by 36% (HR 1.36; 95%CI: 1.04-1.77) in elderly in long-term 
care hospitals and by 90% (HR 1.90; 95%CI: 1.23-2.94) among elderly in acute geriatric wards 
and nursing homes.129 These rates are in line with estimates from another study.128 The 
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Gastroesophageal Reflux Disease 
Peptic Ulcer Disease 
Non-ulcer dyspepsia 
Prophylaxis for NSAID or low-dose aspirin use 
Helicobacter pylori eradication 
Zollinger-Ellison syndrome 
Barrett’s esophagus 
 
NSAID, non-steroidal anti-inflammatory drug 
 
Additionally, the use of low-dose aspirin (LDA; up to 325mg/day for cardiovascular prevention) 
is considered an indication for PPI use. It has been shown that use of LDA increases the risk of 
upper GI bleeding 2 to 4 fold.73, 110-113 Clinical guidelines recommend use of PPIs in patients 
receiving LDA to minimize upper GI bleeding risk when one of the following risk factors is 
present: 1) history of peptic ulcer disease or upper GI bleeding; 2) aged 60 years or older; 3) 
concomitant use of corticosteroids; 4) presence of dyspepsia or GERD.114 Following this 
definition, elderly using LDA should be prescribed a PPI for appropriate gastroprotection. 
Adherence to these recommendations however still deserves improvement.98, 115, 116 
There is scarce evidence on the risk of upper GI bleeding during use of corticosteroids 
or anticoagulants, as the underlying co morbid disease or concomitant use of NSAIDs or LDA 
may partially explain the risk of upper GI bleeding.72, 73, 117-119 Nevertheless, PPIs can also be 
considered as appropriate gastroprotective treatment in vulnerable elderly using 
corticosteroids or anticoagulants. 
Eradication of Helicobacter pylori (H. pylori) is a common indication for short-term 
use of PPIs. It served as indication in 15% of PPI users.107 
 
 
 
Age related changes in the stomach of the elderly 
 
In the elderly, prostaglandin-levels decrease due to diminished conversion of arachidonic acid 
to prostaglandin via the cyclo-oxygenase (COX)-1 enzyme. This may result in a stomach being 
more prone to irritants and an increase in the risk of upper GI bleeding. This partially accounts 
for the recommendation that gastroprotective measures should be employed in the elderly 
when using NSAIDs.99 Supporting evidence comes from experimental studies, showing that 
older rats expressed lower levels of COX-enzyme mRNA than younger rats and had an 
impaired response of prostaglandin synthesis to irritants.120 In addition, in elderly there is a 
higher basal acid output in the stomach121 resulting in lower prostaglandin concentrations in 
the stomach and duodenum.122 Therefore, the stomach of the elderly is more vulnerable to 
exposure and toxic stimuli, such as drugs (i.e. NSAIDs, LDA). Protective measures including co-
prescription of a PPI are therefore recommended to the elderly.99 
Despite the fact that elderly patients may suffer from more pronounced esophageal 
mucosal injury and acid exposure than younger patients, the perception of symptom severity 
for heartburn is less.123 The time to symptom perception and sensory intensity is reduced in 
the elderly. An age-related reduction in chemosensitivity to acid is a possible underlying 
mechanism. However, it has been suggested that the altered perception of esophageal pain in 
elderly people is the result of an ageing process rather than an acquired phenomenon 
resulting from disease.124 
Thirdly, atrophic gastritis is more prevalent among the elderly, in particular among H. 
pylori-positive subjects.125 Gastric atrophy ultimately may occur in 40-50% of H. pylori infected 
individuals. The impact of acid suppression on H. pylori presence and its shift from gastric 
antrum to corpus has been extensively discussed previously. By decreasing gastric acidity in 
the gastric corpus, colonization of the corpus by H. pylori is enhanced.125, 126 Increased 
inflammation of the gastric corpus accelerates the progression to chronic atrophic gastritis.126 
Chronic atrophic gastritis increases the risk of gastric cancer. This explains the 
recommendation in international guidelines to consider a test-and-treat regimen for H. pylori 
infection in subjects who require long-term maintenance treatment with a PPI.127  
 
Harmful use of PPIs in the elderly 
 
Apart from the susceptibility of adverse outcomes due to long-term PPI treatment in elderly, 
several factors interact with each other that may lead to negative outcomes; including poor 
nutritional status, co morbid diseases and polypharmacy. Concerns were raised about the 
association between PPI use and increased mortality in institutionalized older people128 and in 
patients discharged from hospitals.129 The risk of death in the year following hospitalization 
increased by 51% (HR 1.51; 95%CI: 1.03-2.77) for PPI users compared to PPI non-users.130 In 
another study the risk increased by 36% (HR 1.36; 95%CI: 1.04-1.77) in elderly in long-term 
care hospitals and by 90% (HR 1.90; 95%CI: 1.23-2.94) among elderly in acute geriatric wards 
and nursing homes.129 These rates are in line with estimates from another study.128 The 
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association was even stronger for use of high-dose PPIs than for use of low-dose PPIs.130 The 
groups of PPI users were too small to allow for stratification of the analysis to individual PPIs, 
apart from esomeprazole and lansoprazole, which both demonstrated a significant increased 
risk of mortality.130 Thus elderly residents who reside in long-term care hospitals or in acute 
geriatric wards or nursing homes may be at increased risk of mortality when using PPIs 
compared to non-users of PPIs.129 Although underlying mechanism of increased mortality may 
be by some of the adverse events that are discussed in the current review, a potential 
explanation that also should be considered is that PPIs users reflect a group of older patients 
with complex medication regimens for multiple chronic conditions.130, 131 This hypothesis is 
supported by the fact that there was no increase in mortality risk among elderly in assisted-
living facilities, whereas an increase was seen for more care-dependent elderly.129 Adherence 
to PPIs in the year following hospitalization was not addressed, nor nutritional status nor the 
causes of death.130 In addition there is discrepancy between results from observational studies 
and clinical trials, which can be explained by residual confounding and confounding-by-
indication or channeling; as the more diseased subjects are the ones receiving PPIs. Although 
residual confounding cannot be fully accounted for in observational studies, these studies 
reflect daily clinical practice when using primary care data. In clinical trials often the frail 
elderly with greater burden of polypharmacy and multimorbidity are excluded.105, 132 As a 
consequence, observational studies are the only manner to study long-term safety of 
medication in the elderly in real-life practice. Observational studies utilizing electronic health 
care data from primary or secondary care are therefore particularly valuable when adverse 
events are unknown or considered rare.133 Though findings of increased mortality should be 
replicated by others, current available studies stress the need for better attention to 
indications for long-term use of PPIs in the hospital setting. 
 
Inappropriate use of PPIs in the elderly 
 
Inappropriate use of PPIs is common, particularly among the elderly. Some studies for instance 
reported inappropriate PPI use in 50% to 80% of patients admitted to and discharged from 
geriatric and internal medicine wards.134-136 Inappropriate use both consists of lack of a proper 
indication, inappropriate duration of treatment or inappropriate dosing.137 A study from the 
United Kingdom showed that PPIs at maximum therapeutic dosages for more than 8 weeks are 
among the most frequently inappropriate medications in elderly in residential care homes.138 
Inappropriate indications may be as high as 50% of elderly admitted to nursing homes139 and 
61% of elderly admitted to a hospital.140 Similar rates of inappropriateness were observed in 
other studies.141-143 Discontinuation of PPIs after H. pylori eradication remains an issue, as two 
studies report that 50% to 60% of subjects became chronic PPI users and subsequently 
contributed to 75% of PPI costs in the year after eradication.144, 145 Failure of discontinuation of 
PPI therapy is especially seen among the elderly (aged 65 years and over) after H. pylori 
eradication or in subjects who previously used anti-ulcer medication, or continue to use 
NSAIDs or aspirin.145 As a consequence, PPI use for symptom relief may result in a substantial 
 
 
proportion of subjects exposed for a long-term period. In an observational study using primary 
care data from the United Kingdom only 0.45% of subjects were classified as long-term users 
but they contributed to a large proportion of PPI-related expenditures.146 On the other hand, 
step-down management of PPIs for indications such as heartburn or acid regurgitation is 
particularly successful among the elderly.123, 147  
Educating and supporting physicians about the importance of reviewing the indications 
and duration of PPI use in elderly is relevant to reduce PPI prescription costs and maintain 
patients’ safety. Educational programs may successfully reduce inappropriate PPI prescriptions 
in elderly patients during their hospital stay.140 A randomized study among adults discharged 
from a hospital studied the impact of additional information in the discharge letter stressing 
review of PPI use after discharge compared to standard care (discharge letter without such 
information). This additional information did not result in higher rate of evaluation of PPI use 
by general practitioners (GPs).142 Educating patients in a patient-centered programme may be 
an alternative,148 although this likely will be less successful in the elderly who often use various 
drugs and may not be completely accurate about the need and use of all drugs they use. A 
study assessing the potential strategies to reduce PPI prescription in the UK and the associated 
costs identified a number of strategies that were used by GPs: 1) not starting PPIs; 2) dose 
reduction; 3) therapeutic substitution from PPIs to other anti-acid agents; 4) therapeutic 
switching to a cheaper brand of PPI; 5) self-regulation by encouraging patients to experiment 
with lowering dosages of PPI, or taking it as necessary, or any combination of these 
strategies.149 Although some patients may return to the initial PPI dose prescribed, almost 50% 
of patients reduced their PPI intake to a minimum and thus reduced health care costs and 
presumably improved patients’ safety.149 PPI dose reduction can be achieved in the elderly 
population, if the prescribing physician is encouraged to regularly, such as in every visit, review 
the medication list of the elderly. Adequate recommendations and clear documentation of the 
indication for PPI use in discharge letters may help clinicians in reducing inappropriate and 
prolonged PPI use and decrease polypharmacy among the elderly.143 Thus there is 
considerable evidence to encourage both patients, but also doctors to regulate PPI indication 
and duration of use. 
 
Adverse events with use of PPIs 
 
PPIs are considered relatively safe drugs because side effects are infrequent and mostly of 
modest severity; mainly including headache, diarrhea, constipation, nausea and rash. These 
occur in a small proportion of users (1% to 5%). The prolonged and potentially non-judicious 
use of PPIs however is associated with risks. Several of the adverse effects of PPIs that have 
been documented are pertinent to older people. Because PPIs are among the most commonly 
used drugs, any small adverse effect of PPIs may have a considerable impact on health and 
morbidity in the elderly population. Some of the most important PPI-related adverse events in 
the elderly will be discussed in this review and are summarized in Table 2. 
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association was even stronger for use of high-dose PPIs than for use of low-dose PPIs.130 The 
groups of PPI users were too small to allow for stratification of the analysis to individual PPIs, 
apart from esomeprazole and lansoprazole, which both demonstrated a significant increased 
risk of mortality.130 Thus elderly residents who reside in long-term care hospitals or in acute 
geriatric wards or nursing homes may be at increased risk of mortality when using PPIs 
compared to non-users of PPIs.129 Although underlying mechanism of increased mortality may 
be by some of the adverse events that are discussed in the current review, a potential 
explanation that also should be considered is that PPIs users reflect a group of older patients 
with complex medication regimens for multiple chronic conditions.130, 131 This hypothesis is 
supported by the fact that there was no increase in mortality risk among elderly in assisted-
living facilities, whereas an increase was seen for more care-dependent elderly.129 Adherence 
to PPIs in the year following hospitalization was not addressed, nor nutritional status nor the 
causes of death.130 In addition there is discrepancy between results from observational studies 
and clinical trials, which can be explained by residual confounding and confounding-by-
indication or channeling; as the more diseased subjects are the ones receiving PPIs. Although 
residual confounding cannot be fully accounted for in observational studies, these studies 
reflect daily clinical practice when using primary care data. In clinical trials often the frail 
elderly with greater burden of polypharmacy and multimorbidity are excluded.105, 132 As a 
consequence, observational studies are the only manner to study long-term safety of 
medication in the elderly in real-life practice. Observational studies utilizing electronic health 
care data from primary or secondary care are therefore particularly valuable when adverse 
events are unknown or considered rare.133 Though findings of increased mortality should be 
replicated by others, current available studies stress the need for better attention to 
indications for long-term use of PPIs in the hospital setting. 
 
Inappropriate use of PPIs in the elderly 
 
Inappropriate use of PPIs is common, particularly among the elderly. Some studies for instance 
reported inappropriate PPI use in 50% to 80% of patients admitted to and discharged from 
geriatric and internal medicine wards.134-136 Inappropriate use both consists of lack of a proper 
indication, inappropriate duration of treatment or inappropriate dosing.137 A study from the 
United Kingdom showed that PPIs at maximum therapeutic dosages for more than 8 weeks are 
among the most frequently inappropriate medications in elderly in residential care homes.138 
Inappropriate indications may be as high as 50% of elderly admitted to nursing homes139 and 
61% of elderly admitted to a hospital.140 Similar rates of inappropriateness were observed in 
other studies.141-143 Discontinuation of PPIs after H. pylori eradication remains an issue, as two 
studies report that 50% to 60% of subjects became chronic PPI users and subsequently 
contributed to 75% of PPI costs in the year after eradication.144, 145 Failure of discontinuation of 
PPI therapy is especially seen among the elderly (aged 65 years and over) after H. pylori 
eradication or in subjects who previously used anti-ulcer medication, or continue to use 
NSAIDs or aspirin.145 As a consequence, PPI use for symptom relief may result in a substantial 
 
 
proportion of subjects exposed for a long-term period. In an observational study using primary 
care data from the United Kingdom only 0.45% of subjects were classified as long-term users 
but they contributed to a large proportion of PPI-related expenditures.146 On the other hand, 
step-down management of PPIs for indications such as heartburn or acid regurgitation is 
particularly successful among the elderly.123, 147  
Educating and supporting physicians about the importance of reviewing the indications 
and duration of PPI use in elderly is relevant to reduce PPI prescription costs and maintain 
patients’ safety. Educational programs may successfully reduce inappropriate PPI prescriptions 
in elderly patients during their hospital stay.140 A randomized study among adults discharged 
from a hospital studied the impact of additional information in the discharge letter stressing 
review of PPI use after discharge compared to standard care (discharge letter without such 
information). This additional information did not result in higher rate of evaluation of PPI use 
by general practitioners (GPs).142 Educating patients in a patient-centered programme may be 
an alternative,148 although this likely will be less successful in the elderly who often use various 
drugs and may not be completely accurate about the need and use of all drugs they use. A 
study assessing the potential strategies to reduce PPI prescription in the UK and the associated 
costs identified a number of strategies that were used by GPs: 1) not starting PPIs; 2) dose 
reduction; 3) therapeutic substitution from PPIs to other anti-acid agents; 4) therapeutic 
switching to a cheaper brand of PPI; 5) self-regulation by encouraging patients to experiment 
with lowering dosages of PPI, or taking it as necessary, or any combination of these 
strategies.149 Although some patients may return to the initial PPI dose prescribed, almost 50% 
of patients reduced their PPI intake to a minimum and thus reduced health care costs and 
presumably improved patients’ safety.149 PPI dose reduction can be achieved in the elderly 
population, if the prescribing physician is encouraged to regularly, such as in every visit, review 
the medication list of the elderly. Adequate recommendations and clear documentation of the 
indication for PPI use in discharge letters may help clinicians in reducing inappropriate and 
prolonged PPI use and decrease polypharmacy among the elderly.143 Thus there is 
considerable evidence to encourage both patients, but also doctors to regulate PPI indication 
and duration of use. 
 
Adverse events with use of PPIs 
 
PPIs are considered relatively safe drugs because side effects are infrequent and mostly of 
modest severity; mainly including headache, diarrhea, constipation, nausea and rash. These 
occur in a small proportion of users (1% to 5%). The prolonged and potentially non-judicious 
use of PPIs however is associated with risks. Several of the adverse effects of PPIs that have 
been documented are pertinent to older people. Because PPIs are among the most commonly 
used drugs, any small adverse effect of PPIs may have a considerable impact on health and 
morbidity in the elderly population. Some of the most important PPI-related adverse events in 
the elderly will be discussed in this review and are summarized in Table 2. 
	 Use	of	PPIs	in	the	elderly	|	31  30	|	Chapter	2.1
 
Ta
bl
e 
2.
 P
ot
en
tia
l a
dv
er
se
 e
ve
nt
s d
ur
in
g 
Pr
ot
on
 P
um
p 
In
hi
bi
to
r u
se
, s
up
po
rt
in
g 
ev
id
en
ce
 a
nd
 p
re
ca
ut
io
ns
. 
 Ad
ve
rs
e 
ev
en
t 
Ba
ck
gr
ou
nd
 in
ci
de
nc
e 
Bi
ol
og
ic
al
 m
ec
ha
ni
sm
 
St
re
ng
th
 o
f 
as
so
ci
at
io
n 
Co
ns
is
te
nc
y 
of
 e
vi
de
nc
e 
Li
m
ita
tio
ns
 o
f 
st
ud
ie
s 
Co
nc
lu
si
on
s/
pr
ec
au
tio
ns
 
Dr
ug
 in
te
ra
ct
io
n 
w
ith
 c
lo
pi
do
gr
el
 
N
ot
 a
pp
lic
ab
le
 
Co
m
pe
tit
iv
e 
in
hi
bi
tio
n 
of
 C
YP
 2
C1
9 
by
 P
PI
s i
m
pa
iri
ng
 th
e 
co
nv
er
sio
n 
of
 
cl
op
id
og
re
l t
o 
its
 a
ct
iv
e 
su
bs
ta
nc
e 
an
d 
th
er
eb
y 
af
fe
ct
in
g 
th
e 
pl
at
el
et
 
in
hi
bi
tio
n 
fu
nc
tio
n 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
As
so
ci
at
io
n 
du
e 
to
 
co
nf
ou
nd
in
g 
by
 
in
di
ca
tio
n 
an
d 
re
sid
ua
l 
co
nf
ou
nd
in
g.
  
Fo
r a
ny
 s
m
al
l r
is
k 
re
m
ai
ni
ng
, b
yp
as
s 
co
m
pe
tit
iv
e 
in
hi
bi
tio
n 
vi
a 
di
ffe
re
nt
 
tim
in
gs
 o
f i
nt
ak
e.
 
Dr
ug
 in
te
ra
ct
io
n 
w
ith
 lo
w
-d
os
e 
as
pi
rin
 (L
DA
) 
N
ot
 a
pp
lic
ab
le
 
De
cr
ea
se
d 
ga
st
ric
 a
ci
di
ty
 li
m
its
 th
e 
lip
op
hy
lic
ity
 o
f L
DA
 a
nd
 th
er
eb
y 
re
du
ce
s t
he
 p
as
siv
e 
ab
so
rp
tio
n 
of
 
LD
A 
ac
ro
ss
 th
e 
ga
st
ric
 m
uc
os
al
 
m
em
br
an
e 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
Co
nf
lic
tin
g 
ev
id
en
ce
, 
as
so
ci
at
io
n 
m
ay
 b
e 
du
e 
to
 c
on
fo
un
di
ng
 
N
o 
pr
of
ou
nd
 e
vi
de
nc
e 
fo
r a
n 
in
te
ra
ct
io
n 
be
tw
ee
n 
LD
A 
an
d 
PP
Is
 th
at
 a
llo
w
s 
ch
an
gi
ng
 g
ui
de
lin
e 
re
co
m
m
en
da
tio
ns
 to
 
av
oi
d 
co
nc
om
ita
nt
 u
se
 o
f t
he
se
 a
ge
nt
s.
 
Dr
ug
 in
te
ra
ct
io
n 
w
ith
 le
vo
th
yr
ox
in
e 
N
ot
 a
pp
lic
ab
le
 
De
cr
ea
se
d 
ab
so
rp
tio
n 
of
 th
yr
ox
in
e 
in
 th
e 
je
ju
nu
m
 a
nd
 il
eu
m
 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
 
Sh
or
t t
er
m
 fo
llo
w
-u
p 
(6
 w
ee
ks
) 
/m
on
ito
rin
g 
of
 T
SH
 
le
ve
ls
 
Li
m
ite
d 
ev
id
en
ce
 fo
r a
n 
in
te
ra
ct
io
n,
 
ho
w
ev
er
 if
 p
re
se
nt
: p
re
fe
re
nt
ia
lly
 lo
ng
-
te
rm
 u
se
 o
f P
PI
s (
≥ 
6 
m
on
th
s)
 p
re
di
sp
os
es
. 
Se
pa
ra
te
 a
dm
in
ist
ra
tio
n 
(4
-6
ho
ur
s)
 is
 
re
co
m
m
en
de
d.
 
Bo
ne
 fr
ac
tu
re
s 
Cu
m
ul
at
iv
e 
1-
ye
ar
 
in
ci
de
nc
e 
of
 h
ip
 
fr
ac
tu
re
s:
  
W
om
en
  
-7
0-
74
 y
ea
rs
 : 
50
0 
pe
r 
10
0,
00
0 
pe
rs
on
s 
- 8
0-
84
 y
ea
rs
: 1
,0
00
 
pe
r 1
00
,0
00
 p
er
so
ns
 
M
en
: 
-7
0-
74
 y
ea
rs
: 3
00
 p
er
 
10
0,
00
0 
pe
rs
on
s 
-8
0-
84
 y
ea
rs
: 5
00
 p
er
 
10
0,
00
0 
pe
rs
on
s 
Se
ve
ra
l m
ec
ha
ni
sm
s:
 
1.
 D
ec
re
as
ed
 c
al
ci
um
 a
bs
or
pt
io
n 
2.
 B
lo
ck
in
g 
re
pa
ir 
m
ec
ha
ni
sm
 o
f 
m
ic
ro
 fr
ac
tu
re
s 
3.
 H
yp
er
ga
st
rin
em
ia
 le
ad
in
g 
to
 
pa
ra
th
yr
oi
d 
hy
pe
rp
la
sia
 a
nd
 
in
cr
ea
se
d 
pa
ra
th
yr
oi
d 
ho
rm
on
e 
le
ve
ls
 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
- N
o 
do
se
- o
r 
du
ra
tio
n-
re
sp
on
se
s 
ob
se
rv
ed
. 
- A
ss
oc
ia
tio
n 
lik
el
y 
in
flu
en
ce
d 
by
 
pr
ev
al
en
ce
 o
f 
po
ly
ph
ar
m
ac
y 
an
d 
co
 
m
or
bi
d 
di
se
as
es
 
am
on
g 
th
e 
el
de
rly
 
Fr
ac
tu
re
s o
cc
ur
 li
ke
ly
 in
 e
ld
er
ly
 su
bj
ec
ts
 
th
at
 a
re
 a
lre
ad
y 
m
or
e 
pr
on
e 
to
 fr
ac
tu
re
s 
du
e 
to
 c
o 
m
or
bi
d 
di
se
as
es
. 
Co
ns
id
er
 lo
w
er
in
g 
th
e 
do
se
 a
nd
 s
ho
rt
er
 
th
e 
du
ra
tio
n 
of
 u
se
 a
nd
 e
va
lu
at
in
g 
ris
k 
fa
ct
or
s f
or
 o
st
eo
po
ro
sis
. 
   
 
 
 
Ta
bl
e 
2.
 P
ot
en
tia
l a
dv
er
se
 e
ve
nt
s d
ur
in
g 
Pr
ot
on
 P
um
p 
In
hi
bi
to
r u
se
, s
up
po
rt
in
g 
ev
id
en
ce
 a
nd
 p
re
ca
ut
io
ns
 (c
on
tin
ue
d)
. 
 Ad
ve
rs
e 
ev
en
t 
Ba
ck
gr
ou
nd
 in
ci
de
nc
e 
Bi
ol
og
ic
al
 m
ec
ha
ni
sm
 
St
re
ng
th
 o
f 
as
so
ci
at
io
n 
Co
ns
is
te
nc
y 
of
 e
vi
de
nc
e 
Li
m
ita
tio
ns
 o
f 
st
ud
ie
s 
Co
nc
lu
si
on
s/
pr
ec
au
tio
ns
 
Pn
eu
m
on
ia
 
An
nu
al
 in
ci
de
nc
e:
 
- 2
5-
44
 p
er
 1
,0
00
 
pe
rs
on
s f
or
 n
on
-
in
st
itu
tio
na
liz
ed
 
el
de
rly
 
-3
3-
11
4 
pe
r 1
,0
00
 
pe
rs
on
s f
or
 e
ld
er
ly
 in
 
re
sid
en
tia
l c
ar
e 
By
 su
pp
re
ss
io
n 
of
 th
e 
ga
st
ric
 a
ci
d 
en
vi
ro
nm
en
t b
ac
te
ria
l a
nd
 v
ira
l 
co
lo
ni
za
tio
n 
m
ay
 o
cc
ur
 
Lo
w
 to
 
m
od
er
at
e 
st
re
ng
th
 (r
isk
 
es
tim
at
es
 <
 2
 
- 4
) 
In
co
ns
ist
en
t 
N
o 
du
ra
tio
n 
re
sp
on
se
 o
bs
er
ve
d.
 
Co
nf
ou
nd
in
g 
by
 
in
di
ca
tio
n 
an
d 
pr
ot
op
at
hi
c 
bi
as
 
lik
el
y 
pr
es
en
t 
 
A 
ve
ry
 s
m
al
l e
ffe
ct
 o
f P
PI
s o
n 
pn
eu
m
on
ia
 
m
ay
 re
m
ai
n 
pr
es
en
t b
ut
 w
ill
 h
av
e 
ve
ry
 
lit
tle
 im
pa
ct
 o
n 
cl
in
ic
al
 p
ra
ct
ic
e.
 
Vi
ta
m
in
 B
12
 
ab
so
rp
tio
n 
W
id
el
y 
va
ry
in
g 
pr
ev
al
en
ce
s o
f v
ita
m
in
 
B1
2 
de
fic
ie
nc
y 
re
po
rt
ed
 (3
-4
0%
). 
 
At
 le
as
t 5
-1
5%
 o
f 
el
de
rly
 (o
ve
r 6
5 
ye
ar
s 
of
 a
ge
) a
ffe
ct
ed
. 
Se
ve
ra
l m
ec
ha
ni
sm
s:
 
1.
 H
yp
oc
hl
or
hy
dr
ia
 re
su
lti
ng
 in
 
di
m
in
is
he
d 
re
le
as
e 
of
 p
ro
te
in
-
bo
un
d 
vi
ta
m
in
 B
12
 
2.
 D
ec
re
as
ed
 se
cr
et
io
n 
of
 in
tr
in
sic
 
fa
ct
or
 
3.
 G
as
tr
ic
 b
ac
te
ria
l o
ve
rg
ro
w
th
 d
ue
 
to
 a
ch
lo
rh
yd
ria
 
4.
 D
ec
re
as
ed
 b
io
av
ai
la
bi
lit
y 
of
 
vi
ta
m
in
 B
12
 v
ia
 sm
al
l b
ow
el
 
ba
ct
er
ia
l o
ve
rg
ro
w
th
 in
 b
lin
d 
lo
op
s 
of
 d
uo
de
nu
m
 a
nd
 je
ju
nu
m
 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
N
o 
da
ta
 o
n 
ef
fe
ct
 o
f 
PP
Is
 o
n 
ot
he
r 
se
ns
iti
ve
 m
ea
su
re
s o
f 
vi
ta
m
in
 B
12
 
de
fic
ie
nc
y 
(M
M
A 
or
 
ho
m
oc
ys
te
in
e)
 
H.
 p
yl
or
i i
nf
ec
tio
n 
ag
gr
av
at
es
 im
pa
ire
d 
vi
ta
m
in
 B
12
 a
bs
or
pt
io
n.
 
M
on
ito
rin
g 
of
 v
ita
m
in
 B
12
 le
ve
ls 
ev
er
y 
1 
or
 2
 y
ea
rs
 d
ur
in
g 
lo
ng
-t
er
m
 P
PI
 th
er
ap
y 
is 
no
t r
ec
om
m
en
de
d,
 b
ut
 m
ay
 b
e 
co
ns
id
er
ed
 in
 s
ub
je
ct
s a
t r
isk
. 
Iro
n 
ab
so
rp
tio
n 
Pr
ev
al
en
ce
 a
ne
m
ia
  
-w
om
en
 ≥
65
 y
ea
rs
: 
10
.2
%
 
- m
en
 ≥
65
 y
ea
rs
 1
1%
  
Pr
ev
al
en
ce
 ir
on
 
de
fic
ie
nc
y 
an
em
ia
: 
-4
%
 o
f e
ld
er
ly
 p
at
ie
nt
s 
Di
m
in
ish
ed
 n
on
-h
em
e 
iro
n 
ab
so
rp
tio
n 
U
nk
no
w
n 
In
co
ns
ist
en
t 
La
ck
 o
f c
lin
ic
al
 a
nd
 
ob
se
rv
at
io
na
l s
tu
di
es
 
pr
ov
id
in
g 
ev
id
en
ce
 
on
 a
ss
oc
ia
tio
n 
of
 P
PI
-
iro
n 
ab
so
rp
tio
n 
am
on
g 
th
e 
el
de
rly
 
In
 th
e 
el
de
rly
 w
ith
 ir
on
 d
ef
ic
ie
nc
y 
de
m
an
di
ng
 in
cr
ea
se
d 
iro
n 
ab
so
rp
tio
n 
or
 
iro
n 
su
pp
le
m
en
ta
tio
n,
 P
PI
 th
er
ap
y 
m
ay
 
re
ta
rd
 re
pl
en
is
hm
en
t o
f t
he
 ir
on
 s
to
ra
ge
. 
N
o 
da
ta
 is
 a
va
ila
bl
e 
on
 ro
ut
in
el
y 
m
on
ito
rin
g 
of
 ir
on
 le
ve
ls,
 b
ut
 th
is 
m
ay
 b
e 
co
ns
id
er
ed
 e
ve
ry
 1
-2
 y
ea
rs
 in
 su
bj
ec
ts
 a
t 
ris
k.
 
  
 
	 Use	of	PPIs	in	the	elderly	|	31 
2
 
Ta
bl
e 
2.
 P
ot
en
tia
l a
dv
er
se
 e
ve
nt
s d
ur
in
g 
Pr
ot
on
 P
um
p 
In
hi
bi
to
r u
se
, s
up
po
rt
in
g 
ev
id
en
ce
 a
nd
 p
re
ca
ut
io
ns
. 
 Ad
ve
rs
e 
ev
en
t 
Ba
ck
gr
ou
nd
 in
ci
de
nc
e 
Bi
ol
og
ic
al
 m
ec
ha
ni
sm
 
St
re
ng
th
 o
f 
as
so
ci
at
io
n 
Co
ns
is
te
nc
y 
of
 e
vi
de
nc
e 
Li
m
ita
tio
ns
 o
f 
st
ud
ie
s 
Co
nc
lu
si
on
s/
pr
ec
au
tio
ns
 
Dr
ug
 in
te
ra
ct
io
n 
w
ith
 c
lo
pi
do
gr
el
 
N
ot
 a
pp
lic
ab
le
 
Co
m
pe
tit
iv
e 
in
hi
bi
tio
n 
of
 C
YP
 2
C1
9 
by
 P
PI
s i
m
pa
iri
ng
 th
e 
co
nv
er
sio
n 
of
 
cl
op
id
og
re
l t
o 
its
 a
ct
iv
e 
su
bs
ta
nc
e 
an
d 
th
er
eb
y 
af
fe
ct
in
g 
th
e 
pl
at
el
et
 
in
hi
bi
tio
n 
fu
nc
tio
n 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
As
so
ci
at
io
n 
du
e 
to
 
co
nf
ou
nd
in
g 
by
 
in
di
ca
tio
n 
an
d 
re
sid
ua
l 
co
nf
ou
nd
in
g.
  
Fo
r a
ny
 s
m
al
l r
is
k 
re
m
ai
ni
ng
, b
yp
as
s 
co
m
pe
tit
iv
e 
in
hi
bi
tio
n 
vi
a 
di
ffe
re
nt
 
tim
in
gs
 o
f i
nt
ak
e.
 
Dr
ug
 in
te
ra
ct
io
n 
w
ith
 lo
w
-d
os
e 
as
pi
rin
 (L
DA
) 
N
ot
 a
pp
lic
ab
le
 
De
cr
ea
se
d 
ga
st
ric
 a
ci
di
ty
 li
m
its
 th
e 
lip
op
hy
lic
ity
 o
f L
DA
 a
nd
 th
er
eb
y 
re
du
ce
s t
he
 p
as
siv
e 
ab
so
rp
tio
n 
of
 
LD
A 
ac
ro
ss
 th
e 
ga
st
ric
 m
uc
os
al
 
m
em
br
an
e 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
Co
nf
lic
tin
g 
ev
id
en
ce
, 
as
so
ci
at
io
n 
m
ay
 b
e 
du
e 
to
 c
on
fo
un
di
ng
 
N
o 
pr
of
ou
nd
 e
vi
de
nc
e 
fo
r a
n 
in
te
ra
ct
io
n 
be
tw
ee
n 
LD
A 
an
d 
PP
Is
 th
at
 a
llo
w
s 
ch
an
gi
ng
 g
ui
de
lin
e 
re
co
m
m
en
da
tio
ns
 to
 
av
oi
d 
co
nc
om
ita
nt
 u
se
 o
f t
he
se
 a
ge
nt
s.
 
Dr
ug
 in
te
ra
ct
io
n 
w
ith
 le
vo
th
yr
ox
in
e 
N
ot
 a
pp
lic
ab
le
 
De
cr
ea
se
d 
ab
so
rp
tio
n 
of
 th
yr
ox
in
e 
in
 th
e 
je
ju
nu
m
 a
nd
 il
eu
m
 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
 
Sh
or
t t
er
m
 fo
llo
w
-u
p 
(6
 w
ee
ks
) 
/m
on
ito
rin
g 
of
 T
SH
 
le
ve
ls
 
Li
m
ite
d 
ev
id
en
ce
 fo
r a
n 
in
te
ra
ct
io
n,
 
ho
w
ev
er
 if
 p
re
se
nt
: p
re
fe
re
nt
ia
lly
 lo
ng
-
te
rm
 u
se
 o
f P
PI
s (
≥ 
6 
m
on
th
s)
 p
re
di
sp
os
es
. 
Se
pa
ra
te
 a
dm
in
ist
ra
tio
n 
(4
-6
ho
ur
s)
 is
 
re
co
m
m
en
de
d.
 
Bo
ne
 fr
ac
tu
re
s 
Cu
m
ul
at
iv
e 
1-
ye
ar
 
in
ci
de
nc
e 
of
 h
ip
 
fr
ac
tu
re
s:
  
W
om
en
  
-7
0-
74
 y
ea
rs
 : 
50
0 
pe
r 
10
0,
00
0 
pe
rs
on
s 
- 8
0-
84
 y
ea
rs
: 1
,0
00
 
pe
r 1
00
,0
00
 p
er
so
ns
 
M
en
: 
-7
0-
74
 y
ea
rs
: 3
00
 p
er
 
10
0,
00
0 
pe
rs
on
s 
-8
0-
84
 y
ea
rs
: 5
00
 p
er
 
10
0,
00
0 
pe
rs
on
s 
Se
ve
ra
l m
ec
ha
ni
sm
s:
 
1.
 D
ec
re
as
ed
 c
al
ci
um
 a
bs
or
pt
io
n 
2.
 B
lo
ck
in
g 
re
pa
ir 
m
ec
ha
ni
sm
 o
f 
m
ic
ro
 fr
ac
tu
re
s 
3.
 H
yp
er
ga
st
rin
em
ia
 le
ad
in
g 
to
 
pa
ra
th
yr
oi
d 
hy
pe
rp
la
sia
 a
nd
 
in
cr
ea
se
d 
pa
ra
th
yr
oi
d 
ho
rm
on
e 
le
ve
ls
 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
- N
o 
do
se
- o
r 
du
ra
tio
n-
re
sp
on
se
s 
ob
se
rv
ed
. 
- A
ss
oc
ia
tio
n 
lik
el
y 
in
flu
en
ce
d 
by
 
pr
ev
al
en
ce
 o
f 
po
ly
ph
ar
m
ac
y 
an
d 
co
 
m
or
bi
d 
di
se
as
es
 
am
on
g 
th
e 
el
de
rly
 
Fr
ac
tu
re
s o
cc
ur
 li
ke
ly
 in
 e
ld
er
ly
 su
bj
ec
ts
 
th
at
 a
re
 a
lre
ad
y 
m
or
e 
pr
on
e 
to
 fr
ac
tu
re
s 
du
e 
to
 c
o 
m
or
bi
d 
di
se
as
es
. 
Co
ns
id
er
 lo
w
er
in
g 
th
e 
do
se
 a
nd
 s
ho
rt
er
 
th
e 
du
ra
tio
n 
of
 u
se
 a
nd
 e
va
lu
at
in
g 
ris
k 
fa
ct
or
s f
or
 o
st
eo
po
ro
sis
. 
   
 
 
 
Ta
bl
e 
2.
 P
ot
en
tia
l a
dv
er
se
 e
ve
nt
s d
ur
in
g 
Pr
ot
on
 P
um
p 
In
hi
bi
to
r u
se
, s
up
po
rt
in
g 
ev
id
en
ce
 a
nd
 p
re
ca
ut
io
ns
 (c
on
tin
ue
d)
. 
 Ad
ve
rs
e 
ev
en
t 
Ba
ck
gr
ou
nd
 in
ci
de
nc
e 
Bi
ol
og
ic
al
 m
ec
ha
ni
sm
 
St
re
ng
th
 o
f 
as
so
ci
at
io
n 
Co
ns
is
te
nc
y 
of
 e
vi
de
nc
e 
Li
m
ita
tio
ns
 o
f 
st
ud
ie
s 
Co
nc
lu
si
on
s/
pr
ec
au
tio
ns
 
Pn
eu
m
on
ia
 
An
nu
al
 in
ci
de
nc
e:
 
- 2
5-
44
 p
er
 1
,0
00
 
pe
rs
on
s f
or
 n
on
-
in
st
itu
tio
na
liz
ed
 
el
de
rly
 
-3
3-
11
4 
pe
r 1
,0
00
 
pe
rs
on
s f
or
 e
ld
er
ly
 in
 
re
sid
en
tia
l c
ar
e 
By
 su
pp
re
ss
io
n 
of
 th
e 
ga
st
ric
 a
ci
d 
en
vi
ro
nm
en
t b
ac
te
ria
l a
nd
 v
ira
l 
co
lo
ni
za
tio
n 
m
ay
 o
cc
ur
 
Lo
w
 to
 
m
od
er
at
e 
st
re
ng
th
 (r
isk
 
es
tim
at
es
 <
 2
 
- 4
) 
In
co
ns
ist
en
t 
N
o 
du
ra
tio
n 
re
sp
on
se
 o
bs
er
ve
d.
 
Co
nf
ou
nd
in
g 
by
 
in
di
ca
tio
n 
an
d 
pr
ot
op
at
hi
c 
bi
as
 
lik
el
y 
pr
es
en
t 
 
A 
ve
ry
 s
m
al
l e
ffe
ct
 o
f P
PI
s o
n 
pn
eu
m
on
ia
 
m
ay
 re
m
ai
n 
pr
es
en
t b
ut
 w
ill
 h
av
e 
ve
ry
 
lit
tle
 im
pa
ct
 o
n 
cl
in
ic
al
 p
ra
ct
ic
e.
 
Vi
ta
m
in
 B
12
 
ab
so
rp
tio
n 
W
id
el
y 
va
ry
in
g 
pr
ev
al
en
ce
s o
f v
ita
m
in
 
B1
2 
de
fic
ie
nc
y 
re
po
rt
ed
 (3
-4
0%
). 
 
At
 le
as
t 5
-1
5%
 o
f 
el
de
rly
 (o
ve
r 6
5 
ye
ar
s 
of
 a
ge
) a
ffe
ct
ed
. 
Se
ve
ra
l m
ec
ha
ni
sm
s:
 
1.
 H
yp
oc
hl
or
hy
dr
ia
 re
su
lti
ng
 in
 
di
m
in
is
he
d 
re
le
as
e 
of
 p
ro
te
in
-
bo
un
d 
vi
ta
m
in
 B
12
 
2.
 D
ec
re
as
ed
 se
cr
et
io
n 
of
 in
tr
in
sic
 
fa
ct
or
 
3.
 G
as
tr
ic
 b
ac
te
ria
l o
ve
rg
ro
w
th
 d
ue
 
to
 a
ch
lo
rh
yd
ria
 
4.
 D
ec
re
as
ed
 b
io
av
ai
la
bi
lit
y 
of
 
vi
ta
m
in
 B
12
 v
ia
 sm
al
l b
ow
el
 
ba
ct
er
ia
l o
ve
rg
ro
w
th
 in
 b
lin
d 
lo
op
s 
of
 d
uo
de
nu
m
 a
nd
 je
ju
nu
m
 
Lo
w
 s
tr
en
gt
h 
(r
isk
 
es
tim
at
es
 <
 2
) 
In
co
ns
ist
en
t 
N
o 
da
ta
 o
n 
ef
fe
ct
 o
f 
PP
Is
 o
n 
ot
he
r 
se
ns
iti
ve
 m
ea
su
re
s o
f 
vi
ta
m
in
 B
12
 
de
fic
ie
nc
y 
(M
M
A 
or
 
ho
m
oc
ys
te
in
e)
 
H.
 p
yl
or
i i
nf
ec
tio
n 
ag
gr
av
at
es
 im
pa
ire
d 
vi
ta
m
in
 B
12
 a
bs
or
pt
io
n.
 
M
on
ito
rin
g 
of
 v
ita
m
in
 B
12
 le
ve
ls 
ev
er
y 
1 
or
 2
 y
ea
rs
 d
ur
in
g 
lo
ng
-t
er
m
 P
PI
 th
er
ap
y 
is 
no
t r
ec
om
m
en
de
d,
 b
ut
 m
ay
 b
e 
co
ns
id
er
ed
 in
 s
ub
je
ct
s a
t r
isk
. 
Iro
n 
ab
so
rp
tio
n 
Pr
ev
al
en
ce
 a
ne
m
ia
  
-w
om
en
 ≥
65
 y
ea
rs
: 
10
.2
%
 
- m
en
 ≥
65
 y
ea
rs
 1
1%
  
Pr
ev
al
en
ce
 ir
on
 
de
fic
ie
nc
y 
an
em
ia
: 
-4
%
 o
f e
ld
er
ly
 p
at
ie
nt
s 
Di
m
in
ish
ed
 n
on
-h
em
e 
iro
n 
ab
so
rp
tio
n 
U
nk
no
w
n 
In
co
ns
ist
en
t 
La
ck
 o
f c
lin
ic
al
 a
nd
 
ob
se
rv
at
io
na
l s
tu
di
es
 
pr
ov
id
in
g 
ev
id
en
ce
 
on
 a
ss
oc
ia
tio
n 
of
 P
PI
-
iro
n 
ab
so
rp
tio
n 
am
on
g 
th
e 
el
de
rly
 
In
 th
e 
el
de
rly
 w
ith
 ir
on
 d
ef
ic
ie
nc
y 
de
m
an
di
ng
 in
cr
ea
se
d 
iro
n 
ab
so
rp
tio
n 
or
 
iro
n 
su
pp
le
m
en
ta
tio
n,
 P
PI
 th
er
ap
y 
m
ay
 
re
ta
rd
 re
pl
en
is
hm
en
t o
f t
he
 ir
on
 s
to
ra
ge
. 
N
o 
da
ta
 is
 a
va
ila
bl
e 
on
 ro
ut
in
el
y 
m
on
ito
rin
g 
of
 ir
on
 le
ve
ls,
 b
ut
 th
is 
m
ay
 b
e 
co
ns
id
er
ed
 e
ve
ry
 1
-2
 y
ea
rs
 in
 su
bj
ec
ts
 a
t 
ris
k.
 
  
 
	 Use	of	PPIs	in	the	elderly	|	33  32	|	Chapter	2.1
 
Ta
bl
e 
2.
 P
ot
en
tia
l a
dv
er
se
 e
ve
nt
s d
ur
in
g 
Pr
ot
on
 P
um
p 
In
hi
bi
to
r u
se
, s
up
po
rt
in
g 
ev
id
en
ce
 a
nd
 p
re
ca
ut
io
ns
 (c
on
tin
ue
d)
. 
 Ad
ve
rs
e 
ev
en
t 
Ba
ck
gr
ou
nd
 in
ci
de
nc
e 
Bi
ol
og
ic
al
 m
ec
ha
ni
sm
 
St
re
ng
th
 o
f 
as
so
ci
at
io
n 
Co
ns
is
te
nc
y 
of
 e
vi
de
nc
e 
Li
m
ita
tio
ns
 o
f 
st
ud
ie
s 
Co
nc
lu
si
on
s/
pr
ec
au
tio
ns
 
Cl
os
tr
id
iu
m
 d
iff
ici
le
 
in
fe
ct
io
n 
In
ci
de
nc
e:
 
22
 c
as
es
 p
er
 1
00
,0
00
 
pe
rs
on
s i
n 
th
e 
ge
ne
ra
l 
po
pu
la
tio
n.
 
Ag
e≥
65
 y
ea
rs
 
in
cr
ea
se
s t
he
 ri
sk
 u
p 
to
 1
6-
fo
ld
. 
Se
ve
ra
l m
ec
ha
ni
sm
s:
 
1.
 C
on
ve
rs
io
n 
of
 sp
or
e-
fo
rm
in
g 
C.
di
ffi
ci
le
 to
 a
 v
eg
et
at
iv
e 
fo
rm
 a
bl
e 
to
 su
rv
iv
e 
in
 th
e 
en
te
ric
 lu
m
en
 
2.
 P
ro
m
ot
in
g 
of
 sm
al
l i
nt
es
tin
al
 
ba
ct
er
ia
l o
ve
rg
ro
w
th
 a
ffe
ct
in
g 
th
e 
co
m
m
en
sa
l i
nt
es
tin
al
 m
ic
ro
bi
ot
a 
M
od
er
at
e 
st
re
ng
th
 (r
isk
 
es
tim
at
es
 ≈
2-
3)
 
In
co
ns
ist
en
t 
- U
nc
on
tr
ol
le
d 
co
nf
ou
nd
in
g 
fo
r 
se
ve
rit
y 
of
 il
ln
es
s o
r 
ot
he
r c
o 
m
or
bi
d 
di
se
as
es
 
- P
PI
s m
ay
 a
ct
 a
s a
n 
in
te
rm
ed
ia
te
 fa
ct
or
 
fo
r a
nt
ib
io
tic
 th
er
ap
y 
- L
im
ite
d 
da
ta
 o
n 
do
se
- a
nd
 d
ur
at
io
n 
ef
fe
ct
s 
Co
ns
id
er
in
g 
ad
va
nc
in
g 
ag
e 
as
 
in
de
pe
nd
en
t r
isk
 fa
ct
or
, w
ith
 P
PI
s a
s 
po
te
nt
ia
l r
isk
 fa
ct
or
, c
lin
ic
ia
ns
 s
ho
ul
d 
be
 
aw
ar
e 
of
 C
DI
 ri
sk
 w
he
n 
pr
es
cr
ib
in
g 
PP
Is
 to
 
th
e 
el
de
rly
. T
he
y 
sh
ou
ld
 te
st
 fo
r C
.d
iff
ic
ile
 
pr
es
en
ce
 in
 th
e 
el
de
rly
 w
he
n 
th
ey
 p
re
se
nt
 
w
ith
 d
ia
rr
he
a 
us
in
g 
a 
lo
w
 te
st
 th
re
sh
ol
d 
O
th
er
 e
nt
er
ic
 
in
fe
ct
io
ns
 
(S
al
m
on
el
la
 sp
p.
, 
Ca
m
py
lo
ba
ct
er
 
sp
p.
) 
In
ci
de
nc
e 
in
 th
e 
el
de
rly
: 
-C
am
py
lo
ba
ct
er
 
in
fe
ct
io
n:
 1
5.
3 
ca
se
s 
pe
r 1
00
,0
00
 p
er
so
ns
 
- S
al
m
on
el
la
 in
fe
ct
io
n:
 
17
.2
 c
as
es
 p
er
 1
00
,0
00
 
pe
rs
on
s 
Di
m
in
is
he
d 
ga
st
ric
 a
ci
d 
ba
rr
ie
r 
de
fe
ns
e 
al
lo
w
in
g 
su
rv
iv
al
 o
f 
ba
ct
er
ia
l o
rg
an
ism
s 
M
od
er
at
e 
st
re
ng
th
 (r
isk
 
es
tim
at
es
 ≈
2-
4)
 
In
co
ns
ist
en
t 
Li
m
ite
d 
ev
id
en
ce
 o
n 
cl
ea
rly
 d
ef
in
ed
 P
PI
 
ex
po
su
re
 a
nd
 
du
ra
tio
n 
- N
o 
de
fin
ite
 c
on
cl
us
io
ns
 fr
om
 th
e 
cu
rr
en
t 
av
ai
la
bl
e 
da
ta
  
- R
ec
on
sid
er
 th
e 
in
di
ca
tio
n 
of
 P
PI
 u
se
, 
pa
rt
ic
ul
ar
ly
 a
m
on
g 
th
e 
el
de
rly
 p
re
se
nt
in
g 
w
ith
 d
ia
rr
he
a 
Hy
po
m
ag
ne
se
m
ia
 
Pr
ev
al
en
ce
: 
-3
6%
 o
f e
ld
er
ly
 in
 
lo
ng
-t
er
m
 c
ar
e 
fa
ci
lit
ie
s a
ffe
ct
ed
 
Po
or
ly
 u
nd
er
st
oo
d 
U
nk
no
w
n 
In
co
ns
ist
en
t 
Li
m
ite
d 
da
ta
 
Sc
ar
ce
 d
at
a 
on
 th
e 
as
so
ci
at
io
n 
of
 P
PI
s a
nd
 
hy
po
m
ag
ne
se
m
ia
 b
ut
 th
is 
m
ay
 b
e 
du
e 
to
 
ab
se
nc
e 
of
 e
vi
de
nc
e 
Ac
ut
e 
in
te
rs
tit
ia
l 
ne
ph
rit
is 
(A
IN
) 
N
o 
ba
ck
gr
ou
nd
 
in
ci
de
nc
e 
nu
m
be
rs
 
kn
ow
n.
 
Es
tim
at
ed
 th
at
 A
IN
 
ac
co
un
ts
 fo
r 6
-8
%
 o
f 
re
na
l f
ai
lu
re
 c
as
es
. 
- I
di
os
yn
cr
at
ic
 re
ac
tio
n 
- D
ue
 to
 re
du
ce
d 
pe
rit
ub
ul
ar
 b
lo
od
 
flo
w
, l
on
ge
r e
xp
os
ur
e 
tim
e 
of
 re
na
l 
in
te
rs
tit
iu
m
 to
 P
PI
s 
U
nk
no
w
n 
In
co
ns
ist
en
t 
Li
m
ite
d 
da
ta
 
N
ot
 s
uf
fic
ie
nt
 e
vi
de
nc
e 
fo
r c
au
sa
l r
el
at
io
n,
 
bu
t a
 s
m
al
l a
ss
oc
ia
tio
n 
m
ay
 re
m
ai
n 
pr
es
en
t. 
Gi
ve
n 
th
e 
de
va
st
at
in
g 
ef
fe
ct
s a
nd
 
po
or
 p
ro
gn
os
is 
of
 la
te
 d
ia
gn
os
is
, c
lin
ic
al
 
aw
ar
en
es
s i
s r
eq
ui
re
d 
 Ab
br
ev
ia
tio
ns
: L
DA
, l
ow
-d
os
e 
as
pi
rin
; C
DI
, C
lo
st
rid
iu
m
 d
iff
ici
le
 in
fe
ct
io
n;
 A
IN
, a
cu
te
 in
te
rs
tit
ia
l n
ep
hr
iti
s.
 
 
 
Search Strategy 
 
An extensive literature search in PubMed was performed using defined keywords and 
synonyms (i.e., proton pump inhibitors, drug effects, drug prescriptions, polypharmacy, drug 
toxicity, adverse events, pneumonia, Clostridium difficile, gastrointestinal bacterial infections, 
fractures, vitamin B12 deficiency, iron deficiency) for each of the adverse events of interest. 
Original and review articles were considered eligible for this current review. Review articles 
were first and subsequently related original articles extracted to cover the current available 
literature for each outcome separately. No systematic approach was considered as for each 
adverse event separately systematic reviews have been published and the current review 
provides an expert opinion review. 
 
Drug metabolism 
 
There are differences across the various PPIs with respect to bioavailability, peak plasma 
levels, acid dissociation constant (pKa), excretion and route of metabolization. The latter may 
subsequently affect the clinical efficacy and interaction with other drugs in certain patient 
groups. Hepatic cytochrome P-450 (CYP) enzymes are responsible for metabolization of PPIs, 
with CYP2C19 being the most important enzyme. Omeprazole, rabeprazole, pantoprazole and 
esomeprazole are primarily metabolized by CYP2C19, whereas lansoprazole is mainly 
metabolized by CYP3A4. Gene polymorphisms affect the activity of CYP2C19. Genotypes with 
lower enzymatic activity of CYP2C19 are most prevalent in Asian populations. In contrast, this 
slow metabolizer phenotype is present in less than 5% of the Caucasian population.150-153 The 
vast majority of Caucasians are rapid metabolizers. Plasma levels of PPIs depend on the CYP 
metabolism, and as such, differences in metabolization result in different clinical efficacy with 
an inverse relation between metabolizer status and acid suppressive effect.153-156 It has been 
demonstrated in several studies that the efficacy of for instance omeprazole and rabeprazole 
differed across individuals according to CYP2C19 genotypes. Treatment for H. pylori infection 
was more successful in patients with a slow metabolizer phenotype.151, 152, 154 Similar different 
success rates across individual PPIs were seen for treatment of GERD.152, 157 The CYP2C19 
dependent action of PPIs indicates that the majority of Caucausians may benefit from higher 
dosages of PPIs, which should lead to more successful treatments.158 Nevertheless, if subjects 
are slow-metabolizers and take concomitant drugs which interfere with CYP2C19 metabolism, 
increasing dosages of PPIs increase the risk of adverse events and drug interaction. 
 
Drug-drug interaction 
 
All PPIs increase the gastric pH. This impairs the absorption of several drugs. These drugs 
include antimycotics for systemic use (i.e. ketoconazole, itraconazole, posoconazole),159 
digoxin, nifedipin, tyrosin kinase inhibitors (i.e erlotinib),160 antiretroviral drugs,161 
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Search Strategy 
 
An extensive literature search in PubMed was performed using defined keywords and 
synonyms (i.e., proton pump inhibitors, drug effects, drug prescriptions, polypharmacy, drug 
toxicity, adverse events, pneumonia, Clostridium difficile, gastrointestinal bacterial infections, 
fractures, vitamin B12 deficiency, iron deficiency) for each of the adverse events of interest. 
Original and review articles were considered eligible for this current review. Review articles 
were first and subsequently related original articles extracted to cover the current available 
literature for each outcome separately. No systematic approach was considered as for each 
adverse event separately systematic reviews have been published and the current review 
provides an expert opinion review. 
 
Drug metabolism 
 
There are differences across the various PPIs with respect to bioavailability, peak plasma 
levels, acid dissociation constant (pKa), excretion and route of metabolization. The latter may 
subsequently affect the clinical efficacy and interaction with other drugs in certain patient 
groups. Hepatic cytochrome P-450 (CYP) enzymes are responsible for metabolization of PPIs, 
with CYP2C19 being the most important enzyme. Omeprazole, rabeprazole, pantoprazole and 
esomeprazole are primarily metabolized by CYP2C19, whereas lansoprazole is mainly 
metabolized by CYP3A4. Gene polymorphisms affect the activity of CYP2C19. Genotypes with 
lower enzymatic activity of CYP2C19 are most prevalent in Asian populations. In contrast, this 
slow metabolizer phenotype is present in less than 5% of the Caucasian population.150-153 The 
vast majority of Caucasians are rapid metabolizers. Plasma levels of PPIs depend on the CYP 
metabolism, and as such, differences in metabolization result in different clinical efficacy with 
an inverse relation between metabolizer status and acid suppressive effect.153-156 It has been 
demonstrated in several studies that the efficacy of for instance omeprazole and rabeprazole 
differed across individuals according to CYP2C19 genotypes. Treatment for H. pylori infection 
was more successful in patients with a slow metabolizer phenotype.151, 152, 154 Similar different 
success rates across individual PPIs were seen for treatment of GERD.152, 157 The CYP2C19 
dependent action of PPIs indicates that the majority of Caucausians may benefit from higher 
dosages of PPIs, which should lead to more successful treatments.158 Nevertheless, if subjects 
are slow-metabolizers and take concomitant drugs which interfere with CYP2C19 metabolism, 
increasing dosages of PPIs increase the risk of adverse events and drug interaction. 
 
Drug-drug interaction 
 
All PPIs increase the gastric pH. This impairs the absorption of several drugs. These drugs 
include antimycotics for systemic use (i.e. ketoconazole, itraconazole, posoconazole),159 
digoxin, nifedipin, tyrosin kinase inhibitors (i.e erlotinib),160 antiretroviral drugs,161 
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phenytoin,159 diazepam,159 didanosine, methadone and aspirin. After the absorption of PPIs 
into the systemic circulation, some inhibit various components of the CYP enzyme in the liver 
and intestine, in particular CYP2C19 and CYP3A4. As discussed above, CYP2C19 genetic 
polymorphisms affect PPI metabolism. The effect of these polymorphisms thus may also affect 
metabolization of other drugs by CYP2C19. Therefore, interaction between PPIs and other 
drugs differs across individuals. Given the fact that rabeprazole depends less on CYP2C19 
metabolization, CYP2C19 genotypes have less effect on rabeprazole plasma levels and 
clearance. However, it remains controversial whether the risk of drug-drug interaction among 
PPIs is highest for omeprazole and lowest for rabeprazole and pantoprazole.153, 155, 156 Although 
drug-drug interactions may have deleterious effects, most of the interactions are uncommon 
and clinically irrelevant. Some of the drug-drug interactions with PPIs are discussed below. 
 
Clopidogrel 
 
Some years ago a possible interaction of clopidogrel with PPIs associated with an increased 
risk of cardiovascular (CV) events gained a lot of public attention and concern. In 2009 both 
the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
recommended to restrict concurrent use of PPIs and clopidogrel.164 A detrimental interaction 
between these drugs was suggested by several clinical and observational studies.165 
Clopidogrel is an inactive prodrug that requires metabolization and activation to its active thiol 
metabolite. The latter targets and irreversibly inhibits the ADP P2Y12 receptor to achieve 
effective platelet inhibition.166 In the liver, metabolization is achieved by several CYP 
isoenzymes, of which CYP2C19 is the main contributor. PPIs may influence this process. As PPIs 
can competitively bind to the catalytic site of this enzyme, they can impair the conversion of 
clopidogrel to its active substance and thereby affect the platelet inhibition function. A recent 
meta-analysis showed that there is no differential risk of CV events across individual PPIs, 
arguing against a suggested differential effect of omeprazole or pantoprazole on CYP2C19 
inhibitions platelet function and pharmacokinetic data.167 
Nevertheless, the studies that showed an association between concurrent PPI and 
clopidogrel therapy and an increased risk of recurrent acute myocardial infarction (MI) were 
subject to considerable confounding by indication168 (i.e. those subjects at increased risk of 
recurrent MI were more likely to receive clopidogrel instead of another platelet aggregation 
inhibitor compared to those subjects with a lower risk of recurrent acute MI). When the issue 
of confounding by indication was addressed (by comparing current use of clopidogrel plus 
current use of PPI not only to current clopidogrel without PPI use but also with current 
clopidogrel plus past use of PPIs) - current PPI use was compared with past PPI use - the 
association between PPI use and increase risk of recurrent MI during clopidogrel disappeared. 
This suggests that the observed association between current PPI use and recurrent acute MI, is 
likely the result of residual confounding169 or bias.165 If however, any small effect remains to be 
truly present, a solution would be to use both drugs on varying timings as the half-life of PPIs 
range from within 1 hour up to 2 hours and clopidogrel 6 hours. Even though the half-life of 
 
 
drugs in elderly might be prolonged, competitive inhibition can be by-passed by different 
timings of drug intake. 
 
Low-dose aspirin 
 
It has been suggested that the bioavailability of low-dose aspirin (LDA) may be reduced by 
PPIs, resulting in reduced inhibition of platelet aggregation. There is debate whether the 
possible interaction has a significant clinical effect, i.e. leads to more CV events. An 
observational study among patients experiencing a first-time MI when using PPI concomitantly 
with LDA found an increase in risk of recurrent MI, stroke or death from cardiovascular causes 
in concomitant PPI users.170 However, several other studies did not find evidence for such an 
effect,171, 172 nor demonstrated an increase in risk of non-fatal MI or coronary death events.173 
The conflicting results from observational studies may be explained by differences in study 
design such as differences in start of LDA (within 30 days after first-time MI vs. any time after 
CV event), exposure definition (daily assessment of concomitant use of PPIs and LDA vs. 
claimed PPI prescription). Nevertheless, the current available data thus do not provide 
evidence that guideline recommendations on concomitant PPI and LDA use in patients at high 
risk of CV and GI events should be changed. 
 
Levothyroxine 
 
Orally ingested thyroxine is absorbed for 60% to 80%, which occurs in the jejunum and ileum. 
The absorption is optimal when the stomach is empty. Patients with jejuno-ileal bypass 
surgery or bowel resection are in need of higher doses of levothyroxine after surgery.174 It was 
shown that thyroid-stimulating hormone (TSH) suppression decreased in patients with 
atrophic gastritis and H. pylori infection.175 Both of these observations emphasize the 
importance of gastric acid in the absorption of thyroxine.176 Previously it was demonstrated 
that calcium- and aluminium-containing antacids increase TSH and/or decrease thyroxine (T4) 
levels in patients previously stabilized on levothyroxine substitution.177 It has therefore been 
recommended to administer levothyroxine and anti-acid agents at least 4 hours separately 
from each other. Whether this also holds for PPIs has been under debate in recent studies. In 
two studies initiation of PPI therapy (omeprazole and lansoprazole) resulted in an increase in 
TSH levels after 2 months, which required increasing doses of levothryoxine up to 37% in order 
to suppress TSH.175, 178 Others did not demonstrate such interaction between PPIs 
(esomeprazole and pantoprazole) and levothyroxine, likely due to the short period of follow-
up (6 weeks),179, 180 in which changes of hormone levels may not be expected.181 Although 
gastric acidity is important for the absorption of levothyroxine, findings on the interference 
with proton pump inhibitors are inconsistent. The evidence is limited and indicates that long-
term use of PPIs (≥ 6 months) may predispose to drug-interaction. Patients with 
hypothyroidism receiving levothyroxine may need additional thyroid function tests after start 
of PPI therapy, particularly if symptoms of hypothyroidism emerge. The precise underlying 
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phenytoin,159 diazepam,159 didanosine, methadone and aspirin. After the absorption of PPIs 
into the systemic circulation, some inhibit various components of the CYP enzyme in the liver 
and intestine, in particular CYP2C19 and CYP3A4. As discussed above, CYP2C19 genetic 
polymorphisms affect PPI metabolism. The effect of these polymorphisms thus may also affect 
metabolization of other drugs by CYP2C19. Therefore, interaction between PPIs and other 
drugs differs across individuals. Given the fact that rabeprazole depends less on CYP2C19 
metabolization, CYP2C19 genotypes have less effect on rabeprazole plasma levels and 
clearance. However, it remains controversial whether the risk of drug-drug interaction among 
PPIs is highest for omeprazole and lowest for rabeprazole and pantoprazole.153, 155, 156 Although 
drug-drug interactions may have deleterious effects, most of the interactions are uncommon 
and clinically irrelevant. Some of the drug-drug interactions with PPIs are discussed below. 
 
Clopidogrel 
 
Some years ago a possible interaction of clopidogrel with PPIs associated with an increased 
risk of cardiovascular (CV) events gained a lot of public attention and concern. In 2009 both 
the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
recommended to restrict concurrent use of PPIs and clopidogrel.164 A detrimental interaction 
between these drugs was suggested by several clinical and observational studies.165 
Clopidogrel is an inactive prodrug that requires metabolization and activation to its active thiol 
metabolite. The latter targets and irreversibly inhibits the ADP P2Y12 receptor to achieve 
effective platelet inhibition.166 In the liver, metabolization is achieved by several CYP 
isoenzymes, of which CYP2C19 is the main contributor. PPIs may influence this process. As PPIs 
can competitively bind to the catalytic site of this enzyme, they can impair the conversion of 
clopidogrel to its active substance and thereby affect the platelet inhibition function. A recent 
meta-analysis showed that there is no differential risk of CV events across individual PPIs, 
arguing against a suggested differential effect of omeprazole or pantoprazole on CYP2C19 
inhibitions platelet function and pharmacokinetic data.167 
Nevertheless, the studies that showed an association between concurrent PPI and 
clopidogrel therapy and an increased risk of recurrent acute myocardial infarction (MI) were 
subject to considerable confounding by indication168 (i.e. those subjects at increased risk of 
recurrent MI were more likely to receive clopidogrel instead of another platelet aggregation 
inhibitor compared to those subjects with a lower risk of recurrent acute MI). When the issue 
of confounding by indication was addressed (by comparing current use of clopidogrel plus 
current use of PPI not only to current clopidogrel without PPI use but also with current 
clopidogrel plus past use of PPIs) - current PPI use was compared with past PPI use - the 
association between PPI use and increase risk of recurrent MI during clopidogrel disappeared. 
This suggests that the observed association between current PPI use and recurrent acute MI, is 
likely the result of residual confounding169 or bias.165 If however, any small effect remains to be 
truly present, a solution would be to use both drugs on varying timings as the half-life of PPIs 
range from within 1 hour up to 2 hours and clopidogrel 6 hours. Even though the half-life of 
 
 
drugs in elderly might be prolonged, competitive inhibition can be by-passed by different 
timings of drug intake. 
 
Low-dose aspirin 
 
It has been suggested that the bioavailability of low-dose aspirin (LDA) may be reduced by 
PPIs, resulting in reduced inhibition of platelet aggregation. There is debate whether the 
possible interaction has a significant clinical effect, i.e. leads to more CV events. An 
observational study among patients experiencing a first-time MI when using PPI concomitantly 
with LDA found an increase in risk of recurrent MI, stroke or death from cardiovascular causes 
in concomitant PPI users.170 However, several other studies did not find evidence for such an 
effect,171, 172 nor demonstrated an increase in risk of non-fatal MI or coronary death events.173 
The conflicting results from observational studies may be explained by differences in study 
design such as differences in start of LDA (within 30 days after first-time MI vs. any time after 
CV event), exposure definition (daily assessment of concomitant use of PPIs and LDA vs. 
claimed PPI prescription). Nevertheless, the current available data thus do not provide 
evidence that guideline recommendations on concomitant PPI and LDA use in patients at high 
risk of CV and GI events should be changed. 
 
Levothyroxine 
 
Orally ingested thyroxine is absorbed for 60% to 80%, which occurs in the jejunum and ileum. 
The absorption is optimal when the stomach is empty. Patients with jejuno-ileal bypass 
surgery or bowel resection are in need of higher doses of levothyroxine after surgery.174 It was 
shown that thyroid-stimulating hormone (TSH) suppression decreased in patients with 
atrophic gastritis and H. pylori infection.175 Both of these observations emphasize the 
importance of gastric acid in the absorption of thyroxine.176 Previously it was demonstrated 
that calcium- and aluminium-containing antacids increase TSH and/or decrease thyroxine (T4) 
levels in patients previously stabilized on levothyroxine substitution.177 It has therefore been 
recommended to administer levothyroxine and anti-acid agents at least 4 hours separately 
from each other. Whether this also holds for PPIs has been under debate in recent studies. In 
two studies initiation of PPI therapy (omeprazole and lansoprazole) resulted in an increase in 
TSH levels after 2 months, which required increasing doses of levothryoxine up to 37% in order 
to suppress TSH.175, 178 Others did not demonstrate such interaction between PPIs 
(esomeprazole and pantoprazole) and levothyroxine, likely due to the short period of follow-
up (6 weeks),179, 180 in which changes of hormone levels may not be expected.181 Although 
gastric acidity is important for the absorption of levothyroxine, findings on the interference 
with proton pump inhibitors are inconsistent. The evidence is limited and indicates that long-
term use of PPIs (≥ 6 months) may predispose to drug-interaction. Patients with 
hypothyroidism receiving levothyroxine may need additional thyroid function tests after start 
of PPI therapy, particularly if symptoms of hypothyroidism emerge. The precise underlying 
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pharmacokinetic mechanism remains unknown, however separate administration of 
levothyroxine and PPIs by 4 to 6 hours is currently recommended. 
 
Effects on Bone Metabolism and Fractures 
 
Fractures, in particular hip fractures, are common in the elderly and are a major cause of 
morbidity and mortality in the elderly worldwide.182, 183 The annual incidence of fractures 
among subjects aged 50 years and over is estimated at 0.38% for women, and 0.25% for 
men.184 The incidence of hip fracture may be as high as 6.2% and 4.9% among female and male 
elderly nursing home residents, respectively. At the age of 80 years every one out of five 
women and at the age of 90 every one of two women has developed a hip fracture.185 Age 
related modifications in bone density and bone strength affect the likelihood of a fracture in 
the elderly. There were concerns that PPI use may exacerbate the age related bone 
modifications and subsequently increase the risk of fractures. 
A proposed mechanism of PPIs resulting in increased risk of fractures is the inhibition 
of bone resorption and calcium malabsorption. This was demonstrated both in vitro186, 187 and 
in vivo188 and consequently resulted in decreased bone turnover. Calcium absorption 
decreases with advancing age (fractional calcium absorption decreases with 5.6% from women 
aged 69-74 years to women aged 85 years and over) and is dependent on several interacting 
factors, such as intake of calcium supplements and food.189 PPIs have been suggested to 
significantly decrease calcium absorption, although this study was performed in elderly 
women taking omeprazole and under fasting conditions.190 
In addition, profound acid suppression by PPI therapy may indirectly cause hypergastrinemia 
(via suppression of somatostatin release).191 This in turn may stimulate the parathyroid glands 
leading to hyperplasia and hypertrophy of the parathyroid glands and increased parathyroid 
hormone (PTH) levels up to 28%.188 Again, this will result in inappropriate rates of bone 
resorption and weakening of the bone. 
If the calcium absorption is indeed impaired during long-term PPI use, it could 
contribute to the development of osteoporosis by bone mineral loss. However, this theory is 
disputed by a study from Targownik et al. which did not show an association between chronic 
PPI use and bone mineral density (BMD) loss.192 Four other studies also could not find any 
association between PPI therapy and BMD, as PPI users had very similar BMD to non-users of 
PPIs.193-196 One study among adult patients (18 to 56 years) with GERD demonstrated that PPI 
treatment was associated with a lower BMD.197 A second study, among a small group of 
community dwelling older subjects (65 years or older) showed that PPI use was inversely 
associated with trabecular BMD, which is an early marker of osteoporosis.198 A possible 
association between PPI use and fracture could therefore be related to factors of 
osteoporosis, at least in subjects that already are predisposed to osteoporosis. 
An alternative mechanism of PPIs causing fractures would be an effect of PPIs on the 
central nervous system (such as dizziness, visual disturbances) which may result in falls and 
 
 
possibly an increase in fracture incidence. However, this hypothesis was disputed by a nested 
case-control study on 20,000 subjects who had a fall recorded in their primary care record.199 
Studies on the risk of PPI-related fractures show conflicting results. Some 
demonstrated an association between chronic use of PPIs and risk of hip fracture17, 24 or 
fractures in general (including hip, wrist, vertebral).22, 23 Reported risks (relative risks or odds 
ratios) ranged from 1.18 (95% confidence interval (CI): 1.12-1.43) to 4.55 (95% CI: 1.68-
12.29).17, 22-24 Yet, these studies included a mixture of fracture types. Other studies could not 
confirm these positive associations, and moreover, only some were able to demonstrate a 
dose-response effect24 or a duration-effect.17, 21, 22 When exploring cause-effect associations, 
the presence of a dose- and duration-effect supports a causal-relation.19 In addition, if the 
mechanism of fractures is through the antisecretory effect, one might also expect to see an 
increased risk of fractures for other acid suppressant medications, such as H2RAs. However 
while some studies indeed showed that H2RAs increased the risk of fractures,22, 24 a case-
control study in contrast reported that H2RAs protected against fractures.23 An overall OR of 
1.08 (95%CI: 1.00-1.18) for fractures overall was observed during H2RA use.18 When 
comparing PPIs with H2RA directly, the risk of fractures was increased during PPI use (hazard 
ratio 1.34; 95%CI: 1.14-1.38).18, 193 
Several methodological issues may have biased these studies. Firstly, many of the 
studies were not able to address confounding factors such as the use of calcium supplements, 
vitamin D or tobacco and alcohol intake. Secondly, the low magnitude of the observed 
associations, the lack of a dose- and duration-response and the inability to address and control 
for important confounding factors may have influenced any reported association between PPIs 
and bone fractures. Despite the conflicting results and methodological issues from studies, the 
FDA announced on May 25, 2010 to change the labeling information of PPIs and indicate a 
possible increased risk of fracture when using PPIs. After systematically reviewing the 
literature, the Canadian Association of Gastroenterology did not support the FDA statement 
and stated that in the light of uncertainty about the magnitude of risk, clinicians should 
consider whether a lower dose or shorter duration of PPI therapy would adequately treat the 
patient's condition.20 
Nevertheless, when summarizing the available data, a possible increased risk of fractures 
of hip, wrist and spine in patients using PPIs cannot be ruled out. The risk depends on duration 
and dose of use, though at which threshold of dose and duration is unknown and may differ 
across individuals. There remains uncertainty about the magnitude of risk, therefore, clinicians 
should consider in patients receiving PPI therapy to lower the dose and shorten the duration, 
while evaluating risk factors for osteoporosis before routinely prescribing PPIs. 
 
Pneumonia 
 
The gastric acid barrier is an important defense mechanism against pathogen invasion through 
the gastrointestinal tract. Suppression of gastric acid, may increase the susceptibility to 
microbial colonization. From studies in mechanically ventilated subjects,31 we know that use of 
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pharmacokinetic mechanism remains unknown, however separate administration of 
levothyroxine and PPIs by 4 to 6 hours is currently recommended. 
 
Effects on Bone Metabolism and Fractures 
 
Fractures, in particular hip fractures, are common in the elderly and are a major cause of 
morbidity and mortality in the elderly worldwide.182, 183 The annual incidence of fractures 
among subjects aged 50 years and over is estimated at 0.38% for women, and 0.25% for 
men.184 The incidence of hip fracture may be as high as 6.2% and 4.9% among female and male 
elderly nursing home residents, respectively. At the age of 80 years every one out of five 
women and at the age of 90 every one of two women has developed a hip fracture.185 Age 
related modifications in bone density and bone strength affect the likelihood of a fracture in 
the elderly. There were concerns that PPI use may exacerbate the age related bone 
modifications and subsequently increase the risk of fractures. 
A proposed mechanism of PPIs resulting in increased risk of fractures is the inhibition 
of bone resorption and calcium malabsorption. This was demonstrated both in vitro186, 187 and 
in vivo188 and consequently resulted in decreased bone turnover. Calcium absorption 
decreases with advancing age (fractional calcium absorption decreases with 5.6% from women 
aged 69-74 years to women aged 85 years and over) and is dependent on several interacting 
factors, such as intake of calcium supplements and food.189 PPIs have been suggested to 
significantly decrease calcium absorption, although this study was performed in elderly 
women taking omeprazole and under fasting conditions.190 
In addition, profound acid suppression by PPI therapy may indirectly cause hypergastrinemia 
(via suppression of somatostatin release).191 This in turn may stimulate the parathyroid glands 
leading to hyperplasia and hypertrophy of the parathyroid glands and increased parathyroid 
hormone (PTH) levels up to 28%.188 Again, this will result in inappropriate rates of bone 
resorption and weakening of the bone. 
If the calcium absorption is indeed impaired during long-term PPI use, it could 
contribute to the development of osteoporosis by bone mineral loss. However, this theory is 
disputed by a study from Targownik et al. which did not show an association between chronic 
PPI use and bone mineral density (BMD) loss.192 Four other studies also could not find any 
association between PPI therapy and BMD, as PPI users had very similar BMD to non-users of 
PPIs.193-196 One study among adult patients (18 to 56 years) with GERD demonstrated that PPI 
treatment was associated with a lower BMD.197 A second study, among a small group of 
community dwelling older subjects (65 years or older) showed that PPI use was inversely 
associated with trabecular BMD, which is an early marker of osteoporosis.198 A possible 
association between PPI use and fracture could therefore be related to factors of 
osteoporosis, at least in subjects that already are predisposed to osteoporosis. 
An alternative mechanism of PPIs causing fractures would be an effect of PPIs on the 
central nervous system (such as dizziness, visual disturbances) which may result in falls and 
 
 
possibly an increase in fracture incidence. However, this hypothesis was disputed by a nested 
case-control study on 20,000 subjects who had a fall recorded in their primary care record.199 
Studies on the risk of PPI-related fractures show conflicting results. Some 
demonstrated an association between chronic use of PPIs and risk of hip fracture17, 24 or 
fractures in general (including hip, wrist, vertebral).22, 23 Reported risks (relative risks or odds 
ratios) ranged from 1.18 (95% confidence interval (CI): 1.12-1.43) to 4.55 (95% CI: 1.68-
12.29).17, 22-24 Yet, these studies included a mixture of fracture types. Other studies could not 
confirm these positive associations, and moreover, only some were able to demonstrate a 
dose-response effect24 or a duration-effect.17, 21, 22 When exploring cause-effect associations, 
the presence of a dose- and duration-effect supports a causal-relation.19 In addition, if the 
mechanism of fractures is through the antisecretory effect, one might also expect to see an 
increased risk of fractures for other acid suppressant medications, such as H2RAs. However 
while some studies indeed showed that H2RAs increased the risk of fractures,22, 24 a case-
control study in contrast reported that H2RAs protected against fractures.23 An overall OR of 
1.08 (95%CI: 1.00-1.18) for fractures overall was observed during H2RA use.18 When 
comparing PPIs with H2RA directly, the risk of fractures was increased during PPI use (hazard 
ratio 1.34; 95%CI: 1.14-1.38).18, 193 
Several methodological issues may have biased these studies. Firstly, many of the 
studies were not able to address confounding factors such as the use of calcium supplements, 
vitamin D or tobacco and alcohol intake. Secondly, the low magnitude of the observed 
associations, the lack of a dose- and duration-response and the inability to address and control 
for important confounding factors may have influenced any reported association between PPIs 
and bone fractures. Despite the conflicting results and methodological issues from studies, the 
FDA announced on May 25, 2010 to change the labeling information of PPIs and indicate a 
possible increased risk of fracture when using PPIs. After systematically reviewing the 
literature, the Canadian Association of Gastroenterology did not support the FDA statement 
and stated that in the light of uncertainty about the magnitude of risk, clinicians should 
consider whether a lower dose or shorter duration of PPI therapy would adequately treat the 
patient's condition.20 
Nevertheless, when summarizing the available data, a possible increased risk of fractures 
of hip, wrist and spine in patients using PPIs cannot be ruled out. The risk depends on duration 
and dose of use, though at which threshold of dose and duration is unknown and may differ 
across individuals. There remains uncertainty about the magnitude of risk, therefore, clinicians 
should consider in patients receiving PPI therapy to lower the dose and shorten the duration, 
while evaluating risk factors for osteoporosis before routinely prescribing PPIs. 
 
Pneumonia 
 
The gastric acid barrier is an important defense mechanism against pathogen invasion through 
the gastrointestinal tract. Suppression of gastric acid, may increase the susceptibility to 
microbial colonization. From studies in mechanically ventilated subjects,31 we know that use of 
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acid-suppressive drugs facilitates intestinal pathogen colonization from the stomach to the 
lower respiratory tract.34 Aspiration of gastric contents, which occurs rather frequently among 
the elderly, may then promote respiratory tract infection.32 
Although several studies provided evidence to support an association between PPI 
use and the risk of community-acquired pneumonia,27 the overall results were inconsistent. 
The observed odds ratios in observational studies for PPI use ranged from 0.63 to 1.80; and for 
H2RA use from 1.10 to 2.00.27 In absolute terms these risks are considered modest given the 
fact that relative effects were estimated. When pooling the relative risk estimates from 
randomized clinical trials for PPI or H2RA use combined, the risks ranged from 0.12 up to 
5.00.27 However, the latter should be interpreted with caution, as risks of drug-related adverse 
events cannot be well studied using data from clinical trials because of selective patient 
inclusion in trials.133 Careful monitoring of drug safety relies on monitoring of events in ‘real 
life practice’. Observational studies utilizing electronic health care data from primary or 
secondary care are therefore particularly valuable when side effects are unknown or 
considered rare.133 
Furthermore, the studies performed suffer from important limitations. As the largest 
increase in risk was seen shortly after start of use of PPIs (within 2 weeks) without any 
duration-response relation - which supports the causality of the effect - , confounding and 
protopathic bias likely affected the results. Confounding by indication occurred as GERD 
symptoms were a predominant indication for PPI use, while GERD also acts as independent 
risk factor for pneumonia.26 Protopathic bias occurred by misclassification of early signs of 
pneumonia (including non-specific chest symptoms and discomfort) as GERD. A way to 
mitigate against bias from unmeasured confounding is to restrict the study population to PPI 
users without GERD as indication for PPI use. This particular design has been used by Filion et 
al., including four databases from Canada with people aged 66 years and over.28 Indeed they 
showed that the proposed hypothesis of an association between PPIs and hospitalization for 
community acquired pneumonia disappeared when applying a restricted study population.28 In 
addition, there was no increase in the risk when comparing younger individuals with older 
individuals – in fact the opposite was observed.30 Neither was the risk of PPI-related 
pneumonia different for subjects aged younger than 60 years of age compared to subjects 
aged 60 years and over.33  
In mechanically ventilated patients the risk of aspiration pneumonia is increased due 
to gastroesophageal reflux by the presence of nasogastric tubes. PPIs do not have any 
preventive effect on aspiration pneumonia, apart from the effect of PPIs on the gastric 
volume.35 
Although there is no evidence to support the risk of community-acquired pneumonia in 
the elderly, caution should be taken in elderly at increased risk for infection and for whom 
pneumonia may be an important cause of morbidity and mortality, or in those with asthma or 
chronic obstructive lung disease.29 Due to decreased immune responses elderly patients often 
suffer from more severe infection. Despite the fact that a very modest effect of PPIs on 
 
 
pneumonia may remain present, even considering the drawbacks of the studies, the impact in 
clinical practice is very limited. 
 
Vitamin B12 absorption 
 
Vitamin B12, a water-soluble vitamin, is ingested via food in a protein-bound state. Gastric 
acid is essential to release the vitamin from the proteins in the food. Vitamin B12 then binds to 
intrinsic factor and eventually is absorbed in the ileal part of the small intestine. Inhibition of 
gastric acid secretion by PPIs may therefore reduce the bioavailability of dietary vitamin B12. 
Deficiency of vitamin B12 may have devastating effects, ranging from anemia to neurological 
(peripheral neuropathy) or psychiatric diseases (dementia, sensory ataxia).201 
Four mechanisms may explain PPI-associated vitamin B12 malabsorption. Firstly, in 
hypochlorhydria state (when there is a deficit in acid- and pepsin-availability) the protein-
bound vitamin B12 may not be adequately released. Secondly, long-term PPI use may result in 
a decrease of intrinsic factor secretion. Thirdly, achlorhydria may cause gastric bacterial 
overgrowth. This may accelerate vitamin B12 deficiency development by production of vitamin 
B12 analogs that compete with absorption and use of vitamin B12. Nevertheless, gastric 
bacterial overgrowth has not been associated with nutritional consequences. Fourthly, 
profound acid suppression may decrease the bioavailability of vitamin B12 via small bowel 
bacterial overgrowth in blind loops of the duodenum and jejunum.202 
The decrease in absorption of protein bound vitamin B12 was first observed for H2RA 
treatment in a small group of patients.45 This effect was also seen for PPI use. In particular, a 
clinical study showed that the vitamin B12 absorption-rate decreased from 3.2% to 0.9% in 
healthy male volunteers when using daily 20 mg omeprazole for 2 weeks.39 This observation 
was confirmed by others.42, 43 When using a higher dose of omeprazole (40mg) vitamin B12 
absorption decreased further.39 Causality of the association was supported as a duration-effect 
was observed in another study.46 It was shown that PPI use (with a mean duration of 4.5 years 
among the 111 omeprazole users) was inversely associated with vitamin B12 levels. Thus with 
longer PPI use serum levels of vitamin B12 were lower. 46 
A case-control study among patients aged 65 years and over identified from a 
geriatric primary care setting, showed that the odds of vitamin B12 deficiency was 4.45 (95% 
CI: 1.47-13.34) times higher for current long-term PPI users (using at least 12 months 
PPIs/H2RAs) compared to non-users.47 A study on older subjects (aged 60 to 102 years) from 
an ambulatory geriatric clinic − including a total of 141 PPI users − showed that individuals 
having used PPIs for a longer period had a lower serum B12 level. This trend was particularly 
true for those subjects that did not use vitamin B12 supplementation (n=107).37 The results of 
this study should be interpreted with care as no effect over time can be concluded from a 
cross-sectional study. 
It is important to realize that elderly patients compared to younger patients already 
have a higher background vitamin B12 deficiency-risk. Elderly frequently have a borderline 
vitamin B12 status. One would therefore expect the effect of PPIs on vitamin B12 level to be 
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acid-suppressive drugs facilitates intestinal pathogen colonization from the stomach to the 
lower respiratory tract.34 Aspiration of gastric contents, which occurs rather frequently among 
the elderly, may then promote respiratory tract infection.32 
Although several studies provided evidence to support an association between PPI 
use and the risk of community-acquired pneumonia,27 the overall results were inconsistent. 
The observed odds ratios in observational studies for PPI use ranged from 0.63 to 1.80; and for 
H2RA use from 1.10 to 2.00.27 In absolute terms these risks are considered modest given the 
fact that relative effects were estimated. When pooling the relative risk estimates from 
randomized clinical trials for PPI or H2RA use combined, the risks ranged from 0.12 up to 
5.00.27 However, the latter should be interpreted with caution, as risks of drug-related adverse 
events cannot be well studied using data from clinical trials because of selective patient 
inclusion in trials.133 Careful monitoring of drug safety relies on monitoring of events in ‘real 
life practice’. Observational studies utilizing electronic health care data from primary or 
secondary care are therefore particularly valuable when side effects are unknown or 
considered rare.133 
Furthermore, the studies performed suffer from important limitations. As the largest 
increase in risk was seen shortly after start of use of PPIs (within 2 weeks) without any 
duration-response relation - which supports the causality of the effect - , confounding and 
protopathic bias likely affected the results. Confounding by indication occurred as GERD 
symptoms were a predominant indication for PPI use, while GERD also acts as independent 
risk factor for pneumonia.26 Protopathic bias occurred by misclassification of early signs of 
pneumonia (including non-specific chest symptoms and discomfort) as GERD. A way to 
mitigate against bias from unmeasured confounding is to restrict the study population to PPI 
users without GERD as indication for PPI use. This particular design has been used by Filion et 
al., including four databases from Canada with people aged 66 years and over.28 Indeed they 
showed that the proposed hypothesis of an association between PPIs and hospitalization for 
community acquired pneumonia disappeared when applying a restricted study population.28 In 
addition, there was no increase in the risk when comparing younger individuals with older 
individuals – in fact the opposite was observed.30 Neither was the risk of PPI-related 
pneumonia different for subjects aged younger than 60 years of age compared to subjects 
aged 60 years and over.33  
In mechanically ventilated patients the risk of aspiration pneumonia is increased due 
to gastroesophageal reflux by the presence of nasogastric tubes. PPIs do not have any 
preventive effect on aspiration pneumonia, apart from the effect of PPIs on the gastric 
volume.35 
Although there is no evidence to support the risk of community-acquired pneumonia in 
the elderly, caution should be taken in elderly at increased risk for infection and for whom 
pneumonia may be an important cause of morbidity and mortality, or in those with asthma or 
chronic obstructive lung disease.29 Due to decreased immune responses elderly patients often 
suffer from more severe infection. Despite the fact that a very modest effect of PPIs on 
 
 
pneumonia may remain present, even considering the drawbacks of the studies, the impact in 
clinical practice is very limited. 
 
Vitamin B12 absorption 
 
Vitamin B12, a water-soluble vitamin, is ingested via food in a protein-bound state. Gastric 
acid is essential to release the vitamin from the proteins in the food. Vitamin B12 then binds to 
intrinsic factor and eventually is absorbed in the ileal part of the small intestine. Inhibition of 
gastric acid secretion by PPIs may therefore reduce the bioavailability of dietary vitamin B12. 
Deficiency of vitamin B12 may have devastating effects, ranging from anemia to neurological 
(peripheral neuropathy) or psychiatric diseases (dementia, sensory ataxia).201 
Four mechanisms may explain PPI-associated vitamin B12 malabsorption. Firstly, in 
hypochlorhydria state (when there is a deficit in acid- and pepsin-availability) the protein-
bound vitamin B12 may not be adequately released. Secondly, long-term PPI use may result in 
a decrease of intrinsic factor secretion. Thirdly, achlorhydria may cause gastric bacterial 
overgrowth. This may accelerate vitamin B12 deficiency development by production of vitamin 
B12 analogs that compete with absorption and use of vitamin B12. Nevertheless, gastric 
bacterial overgrowth has not been associated with nutritional consequences. Fourthly, 
profound acid suppression may decrease the bioavailability of vitamin B12 via small bowel 
bacterial overgrowth in blind loops of the duodenum and jejunum.202 
The decrease in absorption of protein bound vitamin B12 was first observed for H2RA 
treatment in a small group of patients.45 This effect was also seen for PPI use. In particular, a 
clinical study showed that the vitamin B12 absorption-rate decreased from 3.2% to 0.9% in 
healthy male volunteers when using daily 20 mg omeprazole for 2 weeks.39 This observation 
was confirmed by others.42, 43 When using a higher dose of omeprazole (40mg) vitamin B12 
absorption decreased further.39 Causality of the association was supported as a duration-effect 
was observed in another study.46 It was shown that PPI use (with a mean duration of 4.5 years 
among the 111 omeprazole users) was inversely associated with vitamin B12 levels. Thus with 
longer PPI use serum levels of vitamin B12 were lower. 46 
A case-control study among patients aged 65 years and over identified from a 
geriatric primary care setting, showed that the odds of vitamin B12 deficiency was 4.45 (95% 
CI: 1.47-13.34) times higher for current long-term PPI users (using at least 12 months 
PPIs/H2RAs) compared to non-users.47 A study on older subjects (aged 60 to 102 years) from 
an ambulatory geriatric clinic − including a total of 141 PPI users − showed that individuals 
having used PPIs for a longer period had a lower serum B12 level. This trend was particularly 
true for those subjects that did not use vitamin B12 supplementation (n=107).37 The results of 
this study should be interpreted with care as no effect over time can be concluded from a 
cross-sectional study. 
It is important to realize that elderly patients compared to younger patients already 
have a higher background vitamin B12 deficiency-risk. Elderly frequently have a borderline 
vitamin B12 status. One would therefore expect the effect of PPIs on vitamin B12 level to be 
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more pronounced in the elderly, particularly given the fact that around 5% to 15% of the 
elderly suffer from decreased vitamin B12 levels.38, 40 While a normal diet usually contains 
substantially more vitamin B12 than is needed, in the elderly the functional reserve is 
diminished because vitamin B12 absorption is decreased. It is postulated that malabsorption is 
the most important factor in development of vitamin B12 deficiency in the elderly, rather than 
diminished secretion of intrinsic factor. This is probably related with the development of 
atrophic gastritis and hypochlorhydria with advancing age, again reducing the levels of acid 
and pepsin and subsequent release of protein-bound vitamin B12 to its unbound state. Other 
factors may interfere in this process, such as H. pylori infection.36 In a Dutch study H. pylori 
positive GERD patients had a significant drop in vitamin B12 level during omeprazole 
treatment, whereas in H. pylori negative GERD patients no influence on vitamin B12 level was 
seen.44  
In a subgroup of patients use of PPIs may worsen the potential decrease in vitamin 
B12 level. This concerns patients with higher plasma levels of PPIs, as occurs in patients with a 
slow CYP2C19 metabolizer status. It was shown that CYP2C19 polymorphisms affected vitamin 
B12 levels during long-term (>1 year) treatment with omeprazole 20 mg daily, with lower 
vitamin B12 levels for subjects heterozygous for mutated CYP2C19 alleles as compared to 
homozygous for wild type alleles.41 In clinical practice, genotyping of CYP2C19 is not standard 
of care. 
There are however quite some gaps in the current knowledge. Vitamin B12 itself 
serves as a coenzyme in the conversion of methyl malonyl coenzyme A (MMA) to succinyl 
coenzyme A and of homocysteine to methionine. More sensitive measures to assess a vitamin 
B12 deficit therefore are elevated levels of either MMA or homocysteine.203 No studies so far 
have examined the effect of PPIs or H2RAs on these indicators. This may be relevant because 
alarming neuropsychiatric disorders may occur, even despite normal levels of serum vitamin 
B12. Such severe outcomes are however very rare. Yet, given the frequent occurrence of lower 
vitamin B12 levels and the reversible aspect of symptoms by early detection of vitamin B12 
deficiency, regular testing and monitoring of vitamin B12 levels in elderly every 1 or 2 years – if 
PPI therapy is continued – may be considered, but is not considered routine practice.204 
Particularly H. pylori positive patients or those with long-term higher PPI dose treatment may 
be assessed as the decrease in vitamin B12 levels may be more explicit.36, 41, 44 Once vitamin 
B12 deficiency is diagnosed in a patient, levels can be orally or parenterally supplemented. 
Furthermore, when the deficiency might be a complication from long-term use of PPIs, 
attention should be paid to the indication, dose and potential discontinuation of the PPI. 
 
Iron absorption 
 
Iron is present in food as heme or non-heme iron. Gastric acid is involved in the process of 
non-heme iron absorption as is known from studies where the addition of gastric acid 
improved the absorption in patients with achlorhydria.205, 206 First, it facilitates the dissociation 
of iron salts from food but also reduces ferric iron to ferrous iron, which is more soluble. 
 
 
Secondly, it facilitates complex forming with sugars and amines for enhanced absorption in the 
duodenum. 
Subsequently one may expect that reducing gastric acid by PPI use, particularly over 
a prolonged period, may result in reduced iron absorption. However, there is only little 
evidence on the occurrence of iron-deficiency anemia during PPI use. It has been shown that 
in Zollinger-Ellison patients, who are provided continuous long-term PPI treatment, 
omeprazole did not decrease body iron stores and did not result in iron deficiency.53 However, 
the ‘negative results’ of this study may not be generalizable to or true for the general 
population or the elderly. In addition, in a small group of hereditary hemochromatosis patients 
(n=7) (which results in excessive accumulation of iron in parenchymal cells of e.g. the liver and 
pancreas), PPI use reduced non-heme iron absorption by 50%.52 Still, whether these effects are 
also present under non-hemochromatosis circumstances and to which extent they might 
accelerate iron deficiency among the elderly remains unknown. It is clear that the iron-binding 
capacity decreases with aging and is affected by factors such as malnutrition and chronic 
disease, which are more prevalent in the elderly.50  
Yet, in the elderly with iron deficiency demanding increased iron absorption or iron 
supplementation, PPI therapy may retard replenishment of the iron storage. Since iron 
deficiency is the second most common cause of anemia in the elderly, any effect of PPIs may 
have clinically significant impact by worsening angina and congestive heart failure, prolonged 
hospitalization, leading to falls and fractures.48, 49 There are no data available on the timing of 
testing and monitoring of iron levels in elderly using PPI therapy long-term, if monitoring is 
considered. Testing of iron levels every 1-2 years, during long-term PPI therapy may be 
considered in subjects at risk of iron-deficiency. It is however more important that the clinician 
is aware of the slight increased risk of iron deficiency during long-term PPI therapy. 
 
Bacterial enteric infections 
 
Many studies have examined the association between PPIs and bacterial enteric infections. 
The most commonly investigated organism is Clostridium difficile (C. difficile). 
 
Clostridium difficile 
 
C. difficile is a Gram-positive anaerobic spore-forming bacterium. Colonization of the intestinal 
tract occurs via the fecal-oral route and is facilitated by disruption of the commensal intestinal 
microbiota for instance due to antimicrobial therapy. The organism is capable of producing 
exotoxins responsible for symptomatic C. difficile infection (CDI): toxin A, a powerful 
enterotoxin; and toxin B, a potent cytotoxin (Figure 1). Both toxins bind to receptors on 
intestinal epithelial cells and can cause disruption of the actin cytoskeleton and impairment of 
tight junctions. Furthermore, they are cytotoxic and lead to the production of pro-
inflammatory cytokines.51, 207 It is well known that the elderly represent a particular risk group 
prone for CDI. This is partly due to the high prevalence of risk factors for C. difficile among the 
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more pronounced in the elderly, particularly given the fact that around 5% to 15% of the 
elderly suffer from decreased vitamin B12 levels.38, 40 While a normal diet usually contains 
substantially more vitamin B12 than is needed, in the elderly the functional reserve is 
diminished because vitamin B12 absorption is decreased. It is postulated that malabsorption is 
the most important factor in development of vitamin B12 deficiency in the elderly, rather than 
diminished secretion of intrinsic factor. This is probably related with the development of 
atrophic gastritis and hypochlorhydria with advancing age, again reducing the levels of acid 
and pepsin and subsequent release of protein-bound vitamin B12 to its unbound state. Other 
factors may interfere in this process, such as H. pylori infection.36 In a Dutch study H. pylori 
positive GERD patients had a significant drop in vitamin B12 level during omeprazole 
treatment, whereas in H. pylori negative GERD patients no influence on vitamin B12 level was 
seen.44  
In a subgroup of patients use of PPIs may worsen the potential decrease in vitamin 
B12 level. This concerns patients with higher plasma levels of PPIs, as occurs in patients with a 
slow CYP2C19 metabolizer status. It was shown that CYP2C19 polymorphisms affected vitamin 
B12 levels during long-term (>1 year) treatment with omeprazole 20 mg daily, with lower 
vitamin B12 levels for subjects heterozygous for mutated CYP2C19 alleles as compared to 
homozygous for wild type alleles.41 In clinical practice, genotyping of CYP2C19 is not standard 
of care. 
There are however quite some gaps in the current knowledge. Vitamin B12 itself 
serves as a coenzyme in the conversion of methyl malonyl coenzyme A (MMA) to succinyl 
coenzyme A and of homocysteine to methionine. More sensitive measures to assess a vitamin 
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Secondly, it facilitates complex forming with sugars and amines for enhanced absorption in the 
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Clostridium difficile 
 
C. difficile is a Gram-positive anaerobic spore-forming bacterium. Colonization of the intestinal 
tract occurs via the fecal-oral route and is facilitated by disruption of the commensal intestinal 
microbiota for instance due to antimicrobial therapy. The organism is capable of producing 
exotoxins responsible for symptomatic C. difficile infection (CDI): toxin A, a powerful 
enterotoxin; and toxin B, a potent cytotoxin (Figure 1). Both toxins bind to receptors on 
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inflammatory cytokines.51, 207 It is well known that the elderly represent a particular risk group 
prone for CDI. This is partly due to the high prevalence of risk factors for C. difficile among the 
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elderly; such as chronic comorbid diseases, residence in hospitals or nursing homes and the 
dominant risk factor: antibiotic therapy (particularly fluorquinolones, clindamycin, broad 
spectrum penicillins and cephalosporins).208, 209 A potential additional risk factor that should be 
added to the list is PPI use (Figure 2). 
 
 
 
 
 
 
 
Figure 1. Endoscopic image of the colonic wall with irregular yellow pseudomembranes consistent with 
pseudomembranous colitis caused by Clostridium difficile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pathophysiology of Proton Pump Inhibitor - related Clostridium difficile infection. 
 
 
PPIs may facilitate conversion of spore-formulation C. difficile to its more virulent vegetative 
form which survives in the enteric lumen. These C. difficile spores are easily spread between 
patients and in particular in hospitals or nursing homes. The vegetative C. difficile may be 
harmless but may also return to a toxin-producing strain causing C. difficile associated 
diarrhea. A normal enteric flora is the most important protective factor against CDI; it is 
therefore not surprising that antibiotic therapy, disrupting the commensal intestinal 
microbiota, increases the risk of CDI. PPIs may also interfere in this process, as it was 
suggested that PPIs promote small intestinal bacterial overgrowth, at least in subgroups of 
patients (such as H. pylori infected subjects or irritable bowel syndrome patients), including 
the elderly.210 In fact, in 2012 the FDA issued a warning that PPIs may predispose to CDI.54  
Several reviews and meta-analyses on currently available studies have been 
conducted. One systematic review of the risk of enteric infection in patients taking acid 
suppression included 19 observational studies (case-control and cohort studies) and showed 
that the odds ratio of CDI when using acid suppression in general was estimated at 1.95 (95% 
CI: 1.48-2.58).57 When looking at PPI use separately (n=126,999 patients) the odds ratio was 
2.05 (1.47-2.85) and for H2RA use only 1.48 (95% CI: 1.06-2.06). Two recent meta-analyses 
confirmed this association.55, 56 In the review by Janarthanan et al. a summary risk estimate of 
1.69 was observed (when considering case-control studies only (n=17) a risk estimate of 2.31 
was observed, and for cohort studies only (n=6) a risk estimate of 1.48).55 Kwok et al. included 
42 studies (using broader inclusion criteria) and provided a pooled estimate of PPI use (OR 
1.74; 95% CI 1.47-2.85) compared to non-use of PPI.56 Interestingly, Kwok et al. also pooled the 
risk estimates of studies that evaluated PPI use in patients with recurrent CDI, resulting in a 
pooled OR of 2.51 (95%CI 1.16-5.44).56 All three reviews however, are affected by substantial 
differences between the results of the included studies as the measure of heterogeneity (I2) 
was 92%,55 78%57 and 85%56 (0% representing no heterogeneity between studies, and a 
greater value representing substantial heterogeneity).  
As mentioned before, antibiotic use is the dominant risk factor for CDI. Concomitant 
use of PPIs and antibiotics may confer an even greater risk than what may be expected based 
on the risks of each drug alone. This has been shown in a meta-analysis, where the excess risk 
of CDI during concomitant use of PPIs and antibiotics was estimated at 19%.56 In other words, 
the risk of CDI was 19% higher than expected, and increases with 1.96 respectively 1.75 times 
for concomitant use of PPIs and antibiotics compared to use of PPIs or antibiotics alone. It is 
important to realize that statistically significant interaction does not directly imply biological 
drug synergism.212 
That acid suppression decreases the gastric defense barrier is supported by the fact 
that a higher odds ratio of C. difficile infection is observed with more pronounced acid 
suppression during PPI use than during H2RA therapy.57 More importantly, there may be 
uncontrolled confounding in the studies, as they could not adjust for severity of illness or 
other co morbid diseases. This is particularly important as the co-morbid disease itself may 
increase the susceptibility of CDI and given the fact that PPIs may be preferentially prescribed 
to patients with more severe co-morbid disease.168 Secondly, PPIs may be an intermediate 
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factor or a proxy for antibiotic therapy. Although the association of PPIs with pneumonia is 
definitely not certain, it can also not be ruled out. Therefore, if PPIs would act in such a way, 
the subsequent use of antibiotics for PPI-induced pneumonia may be the underlying 
explanation for the association of PPIs with CDI. Thirdly, there is limited data on a dose- and 
duration-relation of PPIs with CDI. 
Adequately performed systematic reviews and meta-analyses generally are able to 
provide the strongest possible evidence when individual studies may have produced 
conflicting evidence. Though given the risk of bias within studies that are included in reviews 
and meta-analyses, the latter may produce spurious summary result estimates if many studies 
with a high risk of bias are included. This could be the case of the reviews discussed above. 
Nevertheless, considering that PPIs and advancing age both are independent risk factors for 
CDI, results from the studies should alert clinicians when prescribing PPIs to the elderly and 
lower the threshold for testing for C. difficile when elderly on PPI treatment suffer from 
diarrhea. 
 
Other bacterial enteric infections 
 
Decreased gastric acidity may also increase the risk of other bacterial enteric infections, such 
as Salmonella spp. and Campylobacter spp infection. Both bacteria are acid sensitive 
organisms that cannot survive at a low pH.213 There are however limited data on these 
infections during PPI use, let alone among the elderly. Current available studies show that the 
odds ratios for Salmonella infections range widely from 2.6 to 11.2 for gastric acid-suppressive 
agents (PPIs and H2RAs combined), while for PPIs only the odds ratios were, depending on the 
strain of Salmonella species, between 4.2 and 8.3.214 The same authors conclude in another 
study that the odds ratio of PPIs for Campylobacter infection was 4.5 (95% CI: 3.3-6.1) and for 
Salmonella infection 4.3 (95% CI: 2.9-6.5) when adjusting for age, sex, degree of urbanization 
and educational level.215 The study is however biased as a definition on PPI exposure (such as 
determination of PPI use either by interview or prescription; or the division into current versus 
past use) was lacking. A case-control study using primary care data from the United Kingdom 
provided evidence to support the association of PPIs on bacterial infections. The outcome was 
gastroenteritis caused by several specific bacteria (Salmonella, Campylobacter, Shigella, 
Clostridium or other bacteria) that was proven by fecal culture. Current PPI exposure (defined 
as exposure to PPIs within one week before the date of bacterial gastroenteritis) regardless of 
PPI treatment duration, showed a risk estimate of 2.9 (95% CI: 2.5-3.5), which was higher than 
that of H2RA use (relative risk 1.1; 95% CI: 0.9-1.4). They also demonstrated a dose and 
duration effect.216  
In view of the limited evidence on the risk of bacterial infections during PPI use, and 
specifically among the elderly, no definite conclusion can be drawn. However, this should 
prompt clinicians in reconsidering the indication of PPI use among the elderly and particularly 
when the elderly present with diarrhea. Enteropathogenic bacterial stool testing is easy and 
can prevent substantial morbidity of bacterial gastroenteritis among the elderly. Thus when an 
 
 
elderly person on long-term PPI treatment presents with diarrhea, the possibility of enteric 
bacterial infection, caused by C. difficile, Salmonella spp. or Campylobacter spp. should be 
considered. 
 
Other adverse events 
 
There are some more rare PPI-related adverse events mentioned in the literature. Two of 
these will be discussed in this section, namely hypomagnesemia and interstitial nefritis. 
After publication of two cases of hypomagnesemic hypoparathyroidism associated 
with PPI use,59 several case series have been reported on the association between PPI use and 
hypomagnesemia.58, 60-63 This concerned the FDA to publish a warning in 2011.64 The 
underlying mechanism remains poorly understood and might act via hereditary predisposition 
such as mutations in ion channels for active magnesium transport. Theoretically, PPI-induced 
hypochlorhydria may reduce mineral absorption and cause mineral deficiency. However, there 
is no evidence that PPIs inhibit magnesium absorption.217 Despite detrimental consequences of 
severe hypomagnesemia on neuromuscular and cardiovascular functions, no studies or reports 
have documented the clinical consequences of PPI related hypomagnesemia. Whether the 
effects of PPIs on magnesium levels are mainly applicable to the elderly is unclear, but 
hypomagnesemia during PPI use seems to be more common in co-users of diuretics, a 
combination of drugs which is more common in elderly.218 
The second rare adverse event is acute interstitial nephritis (AIN). AIN is characterized by 
renal injury due to inflammation and edema of the renal interstitium. This can eventually lead 
to acute renal failure. Drug use is the most common cause of AIN, accounting for around 60% 
of cases.66 Most frequently reported drugs causing AIN are antibiotics, NSAIDs and diuretics. If 
drug-induced AIN is diagnosed in an early stage and the drug is withdrawn promptly, a poor 
prognosis (as severe as requiring renal transplantation) can be prevented. Many case reports 
in the context of PPI use have been published in the last decade.67 However, the evidence to 
support an association between PPIs and AIN is very concise. PPI-induced AIN is an 
idiosyncratic drug reaction to the drug or its metabolite and has so far not been related to 
time of exposure or dose of the drug.67 Besides, PPI-induced AIN is a rare disease, with a 
precautionary estimated incidence of 1 per 12,500 person-years.68 Case reports and case 
series do not allow measuring or controlling for confounding or for drawing conclusions on 
causality of the association. This is particularly important, since other concomitantly used 
drugs may have been the cause of AIN. Nevertheless, given the reduced peritubular blood flow 
among the elderly, the renal interstitium is exposed for a longer time to PPIs. This may result 
in the elderly being more prone for PPI-related renal damage. Although 45% of the elderly 
have a poor metabolizer phenotype for omeprazole, neither CYP2C19 poor metabolizer 
phenotype or genotype is a risk factor for AIN.65 So far, there is insufficient evidence to 
establish a causal relationship, but any small association may be present. Therefore, clinical 
suspicion and awareness of renal adverse effects among the elderly with a poor renal function 
and using PPIs is required.  
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Conclusions 
 
Proton pump inhibitors are nowadays among the most widely drugs. The efficacy of PPIs for 
various medical conditions has led to its wide-scale use. In turn, due to its relative safety 
profile, the overuse of PPIs both in terms of prolonged use and use for inappropriate 
indications is substantial and particularly among the elderly residing in hospitals or nursing 
homes. There have been several risks associated with PPIs, such as fractures, bacterial enteric 
infections and vitamin deficiencies which may be especially relevant for the elderly. There is 
no profound evidence to support an interaction between PPIs and clopidogrel or low-dose 
aspirin. Long term use of PPIs may predispose to drug-interaction with levothyroxine and may 
be avoided by separate administration. Uncertainty remains about the magnitude of risk of 
fractures during PPI therapy, therefore, clinicians should consider in patients receiving PPI 
therapy to lower the dose and shorten the duration, while evaluating risk factors for 
osteoporosis before routinely prescribing PPIs. There is no conclusive evidence that PPIs 
increase the risk of community acquired pneumonia. Routine testing for Helicobacter pylori in 
subjects starting on long-term PPI therapy is not recommended, but should be considered in 
long-term users (>12 months). Severe outcomes due to vitamin B12 deficiency occur rarely. In 
H. pylori positive patients or those with long-term higher PPI dose treatment the decrease in 
vitamin B12 levels may be more explicit. PPIs may retard replenishment in the elderly resulting 
in iron deficiency in the elderly. Monitoring of vitamin B12 and iron levels is not 
recommended, but may be considered every 1-2 years in subjects at risk of vitamin B12- or 
iron-deficiency. Bacterial enteric infection by C. difficile, Salmonella spp., Campylobacter spp., 
should be considered when elderly subjects on long-term PPI therapy present with diarrhea. 
The risks reported in studies are modest and there are many limitations when interpreting the 
results. Considering the rarity of the outcomes even in absence of PPIs and the fact that the 
studies risks are relative to the underlying baseline risk, doubling a small risk remains a modest 
effect in absolute sense. The relevant question to ask nowadays is probably not so much how 
large the potential risk for an adverse event during or due to PPI use might be, but whether 
the elderly patient has the proper indication for continued use of the PPI. Properly balancing 
the indication, benefits and harms of PPI therapy on an individual level can substantially 
minimize avoidable risk, morbidity and reduce health care costs. 
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ABSTRACT 
 
BACKGROUND 
Barrett’s esophagus (BE) is a risk factor for esophageal adenocarcinoma (EAC). Several studies 
report increasing incidences of BE with substantial variation.  
 
AIM 
Aim of this study was to determine age- and sex-stratified incidence rates (IR) of BE and EAC. 
 
METHODS 
Cohort study using two primary care databases in the United Kingdom (UK) and the 
Netherlands (NL) (2000- 2012). BE and EAC cases were identified using disease-specific READ 
codes (UK) and free-text search with manual validation (NL). Age-and sex-specific incidence 
rates (IRs) were calculated for both BE and EAC. 
 
RESULTS 
From the study population of 6,885,420 subjects in UK we identified 12,312 incident BE and 40 
(0.3%) subsequent incident EAC cases. There were 1,383 incident BE, and subsequent 5 (0.4%) 
incident EAC cases among the 1,487,191 subjects in NL. The IR of BE increased linearly with 
age: 15.6/100,000 PYs (UK) and 23.7/100,000 PYs (NL) for patients aged 40-44 years, 
increasing to 85.6/100,000 PYs (UK) and 87.0/100,000 PYs (NL) for 70-74 years. In both UK and 
NL, IR of BE was 2 to 4 times higher in males than females across all age groups. With respect 
to calendar time, the IR of BE increased by 35% (UK) and 41% (NL) from 2000 to 2003, after 
which IRs remained stable until 2012. 
 
CONCLUSION 
Incidence rates of BE in the UK and NL increased until 2003, but levelled off thereafter. Around 
0.3% of patients with BE developed EAC at least one year after BE diagnosis. These findings 
may help tailor endoscopic surveillance strategies among patients with BE. 
 
 
INTRODUCTION 
 
Barrett’s esophagus (BE) is characterised by replacement of the squamous epithelium of the 
esophagus by metaplastic columnar epithelium and considered a consequence of prolonged 
gastro-esophageal reflux into the lower esophagus.219, 220 BE is an important risk factor for the 
development of EAC via a stepwise pathway of low-grade and high-grade dysplasia.219, 220 It is 
estimated that the risk of EAC is increased by approximately 30 to 125 fold in persons with 
BE.221 Endoscopic surveillance for EAC among patients with BE is therefore recommended.222 
 Several studies reported increasing incidence rates (IRs) of BE,223-226 although these 
vary widely, from 23 to 62 cases per 100,000 person-years (PYs).223, 226 A single-center Dutch 
study observed an increase in the prevalence of BE from 2.6% to 4.7% between the 1990s and 
2004.225 A study in Northern Ireland showed an 159% increase from 24 to 62 cases per 100,000 
PYs between the periods of 1993-1997 and 2002-2005.223 The rise in incidence may partially be 
explained by a ‘true’ increase of BE and partially by better clinical awareness of physicians 
resulting in more gastroscopies.227, 228  
 The increase in incidence of BE goes hand in hand with a similar marked increase in 
EAC incidence in the USA and Western Europe, at a more rapid rate than any other type of 
malignancy.229 Several studies report estimates of EAC IR among BE patients ranging between 
1.2-6.5 EAC cases per 1,000 PYs 230-232 to 6.6 per 100 patient-years.233 In general, the increased 
incidence of EAC is observed mostly in males below 60 years of age.226 There is, however, 
significant heterogeneity across performed studies since study populations differed 
substantially.231 Most studies are based on selected patients in hospitals or specialty clinics 
rather than being population-based.234, 235 The currently available population-based studies 
report data only until 2009.223, 226, 231, 232, 236  
The aim of our study was to determine the incidence of BE in the general population 
in the Netherlands and in the United Kingdom and to determine the risk of EAC among 
patients diagnosed with BE. 
 
METHODS 
 
Data sources 
 
Two European population-based primary care registries served as data source: 1) The Health 
Improvement Network (THIN) database from the United Kingdom (UK)237 and 2) the Integrated 
Primary Care Information database (IPCI) from the Netherlands (NL).238 Both databases contain 
prospectively collected data as part of routine care representing real-life practice. In both 
countries, all citizens are registered with a primary care practitioner, who acts as a gatekeeper 
to secondary and tertiary medical care. THIN collects anonymised information on >3 million 
active patients from >400 participating practices, IPCI contains >1.5 million active patients 
from 340 practices. For each individual patient all relevant medical information from primary 
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and secondary care are documented in the electronic record. This information includes 
demographics, diagnoses and drug prescriptions. 
THIN employs the READ clinical terminology system for coding medical diagnosis and 
symptoms,239 whereas IPCI employs the International Classification for Primary Care.240 
Information on drug use is captured in THIN using the MULTILEX product dictionary and British 
National Formulary (BNF) codes, whereas in IPCI drugs are coded according to the World 
Health Organization’s Anatomical Therapeutic Chemical (ATC) classification.242 
 
Study Design and Population 
 
A dynamic population-based retrospective cohort study was conducted, in which we included 
patients aged ≥18 years. At least one year of available healthcare data prior to study entry was 
required in order to assess patient’s medical history and to discriminate between prevalent 
and incident BE cases. Follow up started on 1 January 2000; date of reaching 18 years of age; 
or the date that one year of valid data was accrued within the database, whichever came later.  
Follow up ended on date of occurrence of study outcome (BE or EAC); date of 
transfer out of the general practitioner’s (GP) practice; death; or 31st of December 2011 (THIN) 
or 2012 (IPCI), whichever was earliest. 
Patients with esophageal or stomach cancer at any time before study entry were 
excluded. Patients with a diagnosis of stomach cancer within 6 months after BE diagnosis date 
were also excluded.  
 
Outcome Definition 
 
Barrett’s esophagus 
In THIN, incident BE cases were identified using corresponding READ codes (Supplementary 
Table 1).239 To explore outcome misclassification, we performed sensitivity analyses including 
additional evidence supporting the BE diagnosis. In the first sensitivity analysis we defined a 
case of BE as a subject with a BE record confirmed on at least two occasions, or when the 
clinical record contained additional evidence based on a prescription of a gastroprotective 
agent (GPA) (proton pump inhibitors, histamine 2 receptor antagonists or misoprostol). The 
prescription had to be recorded within 3 months prior to or after the date of BE diagnosis 
(‘case definition 2’). In the second sensitivity analysis we included also procedure codes for 
diagnostic gastroscopy within 1 year prior, or up to 1 year after BE diagnosis (‘case definition 
3’).  
As the ICPC coding system does not contain a specific code for Barrett’s esophagus 
(BE), case identification in IPCI was based on free-text search of clinical narratives (including 
synonyms for BE such as ‘Barrett’, ‘intestinal metaplasia’, ‘columnar epithelium’) in 
combination with relevant (but less specific) codes. An iterative search was performed using 
relevant key words in appropriate sections of the clinical narratives to distinguish between 
affirmative and negative mentions of items included in the criteria for BE. Automatic case 
 
 
identification as such would yield a positive predictive value of only 44%; therefore, we 
validated all cases by manual review of the medical records to ensure that the cases analysed 
were all confirmed cases of BE and to confirm the date of diagnosis. Cases were included 
when: 1) a record of a BE diagnosis; and 2) additional evidence consisting of either a 
gastroscopy or histology report confirming BE diagnosis were present. We performed 
sensitivity analysis including only histologically confirmed BE cases.  
BE cases were classified as incident if the date of BE diagnosis occurred after 
inclusion in the study cohort and classified as prevalent if the date of BE diagnosis occurred 
prior to study entry.  
 
Esophageal Adenocarcinoma 
In THIN, EAC cases were identified by two algorithms, one specific and one less specific 
algorithm (for detailed information see Supplementary Table 1). In IPCI, all patients with a 
record of ICPC codes D77.1 (malignant neoplasia of the esophagus) and D77.0 (malignant 
neoplasia of the digestive tract—not specified), or with a record by free text search including 
word combinations of ‘esophagus’, ‘cancer’, ‘carcinoma’, ‘malignancy’ or ‘neoplasia’ manually 
validated for confirmation of EAC diagnosis, date of diagnosis and the type of carcinoma 
(squamous cell-, adeno-, or other types of carcinoma). EAC cases were considered incident if 
the date of diagnosis occurred after inclusion into the BE cohort and was at least 12 months 
after BE diagnosis. Cases occurring within one year from BE diagnosis were considered to be 
already existent at BE diagnosis date and in relation to the BE diagnostic work-up. 
 
Gastroscopies 
Since endoscopic confirmation is necessary for the diagnosis of BE, changes in the rate of 
gastroscopies may change the incidence rate of BE as well. We therefore determined the IR of 
BE with the number of gastroscopies as denominator. We identified in THIN all gastroscopies 
using pertinent READ codes, whereas in IPCI an extended automated search using free text 
search in medical records was performed. Key words including ‘gastroscopy’, ‘duodenoscopy’ 
and synonyms were used and negations or referrals for gastroscopies were automatically 
excluded. Gastroscopies performed after the date of BE or EAC diagnosis were not considered, 
thereby excluding surveillance gastroscopies for either BE or EAC. In order to prevent 
overestimation of the number of gastroscopies during which BE could be detected (such as 
several gastroscopies performed during hospitalization for upper GI bleeding) gastroscopies 
performed within three months of the previous one were excluded. We compared the number 
of gastroscopies to the rate of gastroscopies per capita from a national register recording all 
procedures from all hospitals in NL.244  
 
Statistical analysis  
 
IR of BE and of EAC with 95% confidence intervals (95% CI) were estimated by dividing the 
number of incident cases by the number of person-years (PYs) at-risk within the study 
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population. The IR of BE in relation to number of gastroscopies performed was calculated by 
dividing the number of BE cases by the number of gastroscopies performed in the study 
population. This analysis was done stratified on calendar year, sex and age group. Time trends 
of incidence of BE were evaluated from 2000 to 2012 by regression analysis (R2) using the 
method of least squares, where a value 1 indicates a perfect fit, and by joint point analysis. 
Using multivariate Poisson regression we calculated relative risks of developing BE while 
adjusting for age and sex. Survival analysis was performed to estimate the 1-year risk of EAC 
since incident BE diagnosis. 
 
RESULTS 
 
Study population 
 
The source population comprised 8,372,611 persons (UK: 6,885,420; NL: 1,487,191) 
contributing to 48,918,172 person years (PYs) (UK: 44,505,240; NL: 4,412,932) of follow-up 
during the study period.  
Figure 1 illustrates the composition of the study cohorts. We identified 12,312 (THIN) 
and 1,383 (IPCI) incident BE cases. In IPCI, after manual validation of the 4,978 potential BE 
patients (Figure 1) 2,171 (44%) were classified as definite cases (both prevalent and incident) 
of whom histological confirmation was seen in 1,338 (62%) cases. From the BE cases 1,383 
were incident and histological confirmation was available for 701 cases. 
Cases were more frequently male (UK: 63% and NL: 62%). Mean age at BE diagnosis was 
significantly lower in men than in women, both in UK: 63.3 years (SD 13.6) vs. 67.5 years (SD 
13.7), and NL: 59.7 years (SD 13.3) vs. 63.8 years (SD 13.2).  
 
 
Figure 1. Flowchart of study cohort in the United Kingdom and the Netherlands. 
 
* Case definition 2: incident BE subjects included who had at least two times BE diagnosis mentioned or additional support from a 
prescription of a gastroprotective agent (GPA) (proton pump inhibitors, histamine 2 receptor antagonists or misoprostol) that 
had to be recorded within 3 months prior up to 3 months after the date of BE diagnosis. 
# Case definition 3: Additional to case definition 2 we also included procedure codes for diagnostic gastroscopy within 1 year 
prior or up to 1 year after BE diagnosis.  
 
 
Incidence rate of Barrett’s esophagus 
 
The IR of BE in the UK was 27.7/100,000 PYs and in the Netherlands 31.4/100,000 PYs (Table 
1). In the UK the IR of BE increased linearly with age: from 15.6/100,000 PYs for patients 40-44 
years of age up to 85.6/100,000 PYs for patients aged 70-74 years (Figure 2, R2=0.993). The IR 
remained stable hereafter; the IR of BE in NL showed the same linear increase from 
23.7/100,000 PYs for patients aged 40-44 years to 87.0/100,000 PYs for those aged 70-74 
years (R2=0.939). IR remained stable thereafter for those aged 75 years or older. Across all age 
groups the IR of BE was higher for males than for females: 2 to 4 times in UK, and 2 to 3 times 
in NL. 
 
Table 1. Incidence rates of BE in the United Kingdom and the Netherlands per 100,000 person-years and 
gastroscopies. 
 
  THIN (United Kingdom) 
  
No of BE 
cases 
No of Person-
Years (PYs)* 
No of 
gastroscopies 
BE/100,000 PYs 
(95% CI) 
BE/1,000 
gastroscopies (95% CI) 
Overall 12,312 44,505,240 386,185 27.7 (27.2 - 28.2) 31.9 (31.3 - 32.4) 
        
Age (years)       
   < 40  546 21,347,680 62,826 2.6 (2.3 - 2.8) 8.7 (8.0 - 9.4) 
   40-60  3,751 12,873,488 130,862 29.1 (28.2 -30.1) 28.7 (27.8 - 29.6) 
   > 60  8,015 10,284,072 192,497 78.0 (76.2 - 79.7) 41.6 (40.8 - 42.5) 
      
Calendar year  
2000 723 3,409,933 24,873 21.2 (19.7 - 22.8) 29.1 (27.0 - 31.2) 
2001 834 3,446,739 28,059 24.2 (22.6 - 25.9) 29.7 (27.7 - 31.7) 
2002 954 3,496,061 30,836 27.3 (25.6 - 29.1) 30.9 (29.0 - 32.9) 
2003 1,019 3,555,199 31,788 28.7 (26.9 - 30.5) 32.1 (30.1 – 34.0) 
2004 986 3,629,212 32,634 27.2 (25.5 - 28.9) 30.2 (28.4 - 32.1) 
2005 958 3,679,156 31,549 26.0 (24.4 - 27.7) 30.4 (28.5 - 32.3) 
2006 1,009 3,736,764 32,769 27.0 (25.4 - 28.7) 30.8 (28.9 - 32.7) 
2007 992 3,784,897 33,010 26.2 (24.6 - 27.9) 30.1 (28.2 - 31.9) 
2008 1,150 3,858,063 35,128 29.8 (28.1 - 31.6) 32.7 (30.9 - 34.6) 
2009 1,190 3,919,243 35,881 30.4 (28.7 - 32.1) 33.2 (31.3 – 35.0) 
2010 1,170 3,974,886 35,148 29.4 (27.8 - 31.2) 33.3 (31.4 - 35.2) 
2011 1,327 4,015,087 34,510 33.1 (31.3 - 34.9) 38.5 (36.4 - 40.5) 
2012 
        
Sex       
   Male 7,811 22,142,206 173,735 35.3 (34.5 - 36.1) 40.6 (44.0 - 45.9) 
   Female 4,501 22,363,032 212,450 20.1 (19.5 - 20.7) 21.2 (20.6 - 21.8) 
 
* Number of person-years by year may not add up to overall number due to truncation of decimals. 
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2005 958 3,679,156 31,549 26.0 (24.4 - 27.7) 30.4 (28.5 - 32.3) 
2006 1,009 3,736,764 32,769 27.0 (25.4 - 28.7) 30.8 (28.9 - 32.7) 
2007 992 3,784,897 33,010 26.2 (24.6 - 27.9) 30.1 (28.2 - 31.9) 
2008 1,150 3,858,063 35,128 29.8 (28.1 - 31.6) 32.7 (30.9 - 34.6) 
2009 1,190 3,919,243 35,881 30.4 (28.7 - 32.1) 33.2 (31.3 – 35.0) 
2010 1,170 3,974,886 35,148 29.4 (27.8 - 31.2) 33.3 (31.4 - 35.2) 
2011 1,327 4,015,087 34,510 33.1 (31.3 - 34.9) 38.5 (36.4 - 40.5) 
2012 
        
Sex       
   Male 7,811 22,142,206 173,735 35.3 (34.5 - 36.1) 40.6 (44.0 - 45.9) 
   Female 4,501 22,363,032 212,450 20.1 (19.5 - 20.7) 21.2 (20.6 - 21.8) 
 
* Number of person-years by year may not add up to overall number due to truncation of decimals. 
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Table 1. Incidence rates of BE in the United Kingdom and the Netherlands per 100,000 person-years and 
gastroscopies (continued). 
 
  IPCI (The Netherlands) 
  
No of BE 
cases 
No of Person-
Years (PYs)* 
No of 
gastroscopies 
BE/100,000 PYs 
(95% CI) 
BE/1,000 
gastroscopies (95% CI) 
Overall 1,383 4,409,995 87,635 31.4 (29.7 - 33.0) 15.8 (14.9 - 16.6) 
            
Age (years)           
   < 40  83 2,164,425 16,061 3.8 (3.1 - 4.7) 5.2 (4.2 - 6.4) 
   40-60  544 129,871 32,111 41.9 (38.5- 45.5) 16.9 (15.6 - 18.4) 
   > 60  756 946,799 39,463 79.8 (74.3 - 85.7) 19.2 (17.9 - 20.6) 
      
Calendar year 
2000 23 87,187 960 26.4 (17.2 - 38.9) 24.0 (16.0 - 35.7) 
2001 29 84,393 1,018 34.4 (23.5 - 48.7) 29.5 (20.7 - 41.8) 
2002 28 82,542 956 33.9 (23.0 - 48.3) 30.3 (21.2 - 43.2) 
2003 32 86,193 1,264 37.1 (25.9 - 51.7) 25.3 (18.0 - 35.5) 
2004 24 88,701 1,464 27.1 (17.8 - 39.6) 16.4 (11.0 - 24.3) 
2005 28 92,030 1,570 30.4 (20.7 - 43.3) 17.8 (12.4 - 25.7) 
2006 14 67,970 1,222 20.6 (11.8 - 33.6) 12.3 (7.5 - 20.2) 
2007 38 147,402 2,423 25.8 (18.5 – 35.0) 16.1 (11.8 - 21.9) 
2008 113 361,775 6825 31.2 (25.9 - 37.4) 16.6 (13.8 - 19.9) 
2009 176 592,740 11,941 29.7 (25.5 - 34.3) 14.9 (12.9 - 17.2) 
2010 268 758,719 15,832 35.3 (31.3 - 39.7) 16.0 (14.2 - 18.1) 
2011 289 925,060 18,908 31.2 (27.8 – 35.0) 13.6 (12.1 - 15.4) 
2012 307 994,892 23,252 30.9 (27.5 - 34.5) 11.4 (10.1 - 12.8) 
  
Sex 
   Male 856 2,159,543 40,104 39.6 (37.0 - 42.4) 21.3 (20.0 - 22.8) 
   Female 527 2,250,452 47,531 23.4 (21.5 - 25.5) 11.1 (10.2 - 12.1) 
 
* Number of person-years by year may not add up to overall number due to truncation of decimals. 
 
With respect to calendar time, in the UK IR of BE increased by 35% from 21.2/100,000 (95%CI: 
19.7-22.8) PYs in 2000 to 28.7/100,000 (95%CI: 26.9-30.5) PYs in 2003. In the NL the IR 
increased by 41% from 26.4/100,000 (95%CI: 17.2-38.9) PYs in 2000 to 37.1/100,000 (95%CI: 
25.9-51.7) PYs in 2003. In both UK and NL, the IR remained fairly stable after 2003 up to 2011 
(Table 1). Joint point analysis showed that the average percentage change after 2002 in the UK 
was 1.08, which was significantly different from the period before 2003. 
We then calculated the IR of BE per 1,000 gastroscopies. In the UK, IR of BE per 1,000 
gastroscopies increased by 32% from 29.1 in 2000 up to 38.5 in 2011 (Figure 3 and Table 1). In 
NL IR of BE increased from 24.0/1,000 gastroscopies in 2000 to 30.3/1,000 in 2002 and 
decreased thereafter to 11.4 in 2012. The decrease in IR of BE per gastroscopies was slightly 
 
 
more pronounced for subjects aged 60 years and over in NL but not in the UK. However, 
similar trends in the IR of BE across age groups in the UK and NL were observed (Figure 3). 
Multivariable Poisson regression showed that a male subject had a 2.8-fold increased risk of 
BE, compared to a female subject of the same age. The risk of BE diverged significantly 
between males and females from the age of 35-39 years (data not shown). 
 
Figure 2. Incidence Rates of BE in the United Kingdom and the Netherlands by age group. 
Figure 3. Incidence Rate of BE in the United Kingdom and the Netherlands per 1,000 gastroscopies over all ages 
and by age groups. 
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Esophageal adenocarcinoma 
 
From the BE cases, we identified 40 (0.3%) incident EAC cases in the UK and 5 (0.4%) incident 
EAC cases in the NL. Forty-five patients in the UK (0.4%) and 2 patients in NL (0.1%) were 
diagnosed with EAC within one year of BE diagnosis and were considered prevalent EAC and 
therefore excluded in the analysis. Mean age of BE diagnosis in the incident EAC cases was 
67.0 years (SD 10.3) and mean time from BE diagnosis until EAC diagnosis was 4.2 years (SD 
2.5). 
In NL, incident EAC cases were diagnosed with BE at a mean age of 63.5 years (SD 
11.3) and mean time to EAC diagnosis was 3.5 years (SD 0.8). The overall IR of EAC was 
22.6/100,000 PYs in UK and 80.1/100,000 PYs in NL. In 2000 the IR of EAC was 8.9/100,000 PYs 
and increased 4-fold up to 38.1/100,000 PYs in 2010. Time from BE until EAC diagnosis is 
shown in Figure 4. The one-year risk of EAC after BE diagnosis, excluding EAC cases within one 
year after BE diagnosis, was 0.086% (95% CI: 0.04 – 0.17) overall, 0.11% (95% CI: 0.05-0.23) for 
males and 0.06% (95% CI: 0.02-0.24) for females. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Survival curve from BE diagnosis until EAC diagnosis excluding the one year after BE diagnosis. 
 
Sensitivity analyses 
 
We employed different BE definitions in THIN as sensitivity analyses. No differences in the IRs 
was observed when the three case definitions were compared (Figure 1 & Figure 5). IR of BE 
was 26.0/100,000 PYs by applying case definition 3 (cases with a BE record confirmed on at 
least two occasions; evidence derived from a GPA-prescription or gastroscopy letter). IR was 
25.9/100,000 PYs by applying case definition 2 (only GPA prescription as evidence). 
 
 
As we might have overestimated the number of BE cases in NL, we performed a sensitivity 
analysis including only histologically confirmed cases. Among these, IR showed similar, 
although slightly lower, estimates with an overall incidence of 15.2/100,000 PYs. IR increased 
from 3.3/100,000 PYs among subjects aged 30-34 years to 48.3/100,000 PYs for those aged 70-
74 years. Over time IR remained fairly stable from 13.8/100,000 PYs in 2000 and 12.6/100,000 
PYs in 2012.  
 
Figure 5. Incidence Rates of BE in United Kingdom with different case definitions. 
 
Main analysis: all incident BE subjects included. Case definition 2: incident BE subjects included who had at least two times BE 
diagnosis mentioned or additional support from a prescription of a gastroprotective agent (GPA) (proton pump inhibitors, 
histamine 2 receptor antagonists or misoprostol) that had to be recorded within 3 months prior up to 3 months after the date of 
BE diagnosis. Case definition 3: Additional to case definition 2 we also included procedure codes for diagnostic gastroscopy within 
1 year prior or up to 1 year after BE diagnosis. 
 
DISCUSSION 
 
This study showed that the incidence of Barrett’s esophagus increased in the beginning of the 
millennium both in the United Kingdom and the Netherlands, but levelled off after 2003. In 
contrast, the IR of EAC continued to increase until now, although among BE patients, incident 
EAC occurred in only 0.3% of BE patients, demonstrating a one-year risk of 0.09%. This 
persistent increase may reflect the long lag time between BE and progression to high-grade 
dysplasia and EAC. In other words, the current increase in EAC incidence may reflect the 
increase in BE incidence that happened a decade ago. 
Our data are consistent with a previous Dutch study that showed an increase in BE 
incidence between 1996 up to 2003, most pronounced in young males below 60 years of 
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age.226 This increase was not explained by a rise in gastroscopies performed.226 These findings 
were confirmed by another Dutch study using a nationwide registry of pathology records.224 A 
population-based study from Northern Ireland also observed that the increase in BE was not 
explained by a rise in gastroscopies and truly increased over the period of 1993 up to 2005.223 
However, from 2003 onwards, we could not confirm such a linear rise in incidence of BE 
anymore. A levelling off of the BE incidence trend was already observed by Coleman et al. 223 
They found a decline in the increase between four time periods; from 1993-1997 to 1998-2001 
the increase was 94%, but from 1998-2001 to 2002-2005 the increase was only 34%. 223 
In the late 1990s, dyspepsia guidelines alerted clinicians to suspect BE more readily in 
symptomatic subjects. Indeed, referrals for gastroscopy increased, although the proportion of 
symptomatic subjects remained more or less stable until mid-2000s.224 Additionally in 1996 
the Dutch GP guidelines restricted referral indications for gastroscopy to subjects with alarm 
symptoms or recurrent dyspepsia.246 This restriction was included in the UK guidelines (NICE) 
eight years later, in 200426 after which a gradual decline in referrals has been noted.248 This 
explains the difference in BE incidence per gastroscopy over calendar time between the NL, 
which decreased from 2000 onwards, and the UK, which showed an increase. 
One explanation why there is a levelling of the incidence of BE could be a birth cohort 
effect. Another is that better and earlier diagnosis and treatment of GERD and dyspepsia may 
have resulted in fewer patients developing BE. Increased awareness of clinicians may have 
resulted in an initial increase in incidence of BE, this effect was more pronounced in the late 
1990s and early 2000s since guidelines at that time recommended gastroscopy for indications 
as dyspepsia and GERD. As was shown before, the incidence of BE increased tremendously and 
was already expected to level off at a certain point.223 As a large proportion of EAC occurs via 
the stepwise pathway of BE via dysplasia towards EAC, an effect of the incidence of BE is also 
expected to impact the incidence of EAC. As we observed that the levelling off occurred after 
2003, we expect that the incidence of EAC will also level off, but due to the decade long lag 
time between BE and development of EAC, any effect of this is likely to appear in the next 10 
to 15 years. 
To study the risk of incident EAC after BE diagnosis, a relatively long follow-up time 
from the first Barrett’s cell to the final carcinoma progression is needed. Although BE is a well 
acknowledged risk factor for development of EAC, the absolute risk remains fairly low. The 
most recent meta-analysis showed an annual risk of 0.6% of EAC among all BE subjects,231 
whereas another meta-analysis estimated an 0.33% annual risk for non-dysplastic BE 
subjects,249 very similar to an annual risk of 0.39% when including only high-quality studies.230 
Though an Irish population-based study estimated the annual EAC risk at 0.13%,236 the ten-
year risk of EAC is 5%.250 We found a one-year risk of 0.09%, lower than the ones reported in 
meta-analyses, because of differences in characteristics of the data sources; primary care 
databases may be limited by underreporting of carcinoma cases. Additionally we could not 
retrieve segment-length or dysplasia status at time of BE diagnosis. This may have resulted in 
classifying subjects as BE whereas histology may not support BE diagnosis. 
 
 
It is difficult to identify the ‘true’ IR of a disease that is present in symptomatic and 
asymptomatic subjects and diagnosed by gastroscopy and may be complicated by diagnostic 
work-up in symptomatic subjects only. Depending on the type of data used, each study faces 
challenges. Clinical endoscopic studies may suffer from biased retrieval of cases using 
symptom-based questionnaires leading to remarkably high IR of BE.235, 251 Population-based 
studies are challenged by the lack of detail from histology reports, which is particularly true for 
routinely collected GP data without free text in medical records,223 whereas studies using 
nation-wide registries lack clinical characteristics.224 Nevertheless, we believe the sensitivity 
analysis including only histologically confirmed BE cases is representative of the true incidence 
of BE. In only 12% of cases BE diagnosis was negated and when theoretically considering the 
subjects in which we had no information on histology (26%) also were negated, the sensitivity 
analysis would likely reflect the true incidence of BE. On the other hand, when considering this 
26% as being histologically confirmed, the true IR of BE would be 12% lower than our main 
analysis. 
Strengths of the current study include the scale and setting as we combined primary 
healthcare data from two European countries. Whereas previous studies may have suffered 
from selection of Barrett’s patients in referral centers, we were able to estimate the IR of BE in 
the general population. 
We acknowledge the following limitations. First of all, although both data sources 
provide a representative sample of the country specific population, under-recording of BE and 
EAC cases cannot be ruled out. However, GPs participating in both data sources are instructed 
to code all medical diagnoses and symptoms electronically. In IPCI we encountered different 
results depending on software systems, as some are richer in free text information than 
others. This is relevant considering that the ICPC coding system does not contain a specific 
code for Barrett’s esophagus. Nevertheless, as for BE endoscopic surveillance is needed, it is 
very unlikely that a GP has not recorded a BE diagnosis in the patient’s medical record. 
Misclassification of BE might have occurred, due to miscoding by GPs. We mitigated this by 
performing sensitivity analyses, including additional evidence (including histology) to support 
the diagnosis. We might have underestimated the number of gastroscopies. Therefore we 
used the national information system recording all procedures in all hospitals from the 
Netherlands to validate the number of gastroscopies per capita in the Netherlands.244 From 
2007 till 2011 the national numbers confirmed the slight underreporting of gastroscopies in 
IPCI, though without large differences. 
In conclusion, the incidence rate of Barrett’s esophagus in the United Kingdom and 
the Netherlands has increased substantially in both males and females at the beginning of the 
millennium but has remained stable since then. The rise in incidence was not explained by an 
increase in gastroscopies. Around 0.3% of BE patients are diagnosed with esophageal 
adenocarcinoma at least one year after diagnosis of BE, demonstrating a one-year risk of 
0.09%. The observed current increase in the EAC incidence among BE patients probably 
reflects the increase in the incidence of BE a decade ago. 
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code for Barrett’s esophagus. Nevertheless, as for BE endoscopic surveillance is needed, it is 
very unlikely that a GP has not recorded a BE diagnosis in the patient’s medical record. 
Misclassification of BE might have occurred, due to miscoding by GPs. We mitigated this by 
performing sensitivity analyses, including additional evidence (including histology) to support 
the diagnosis. We might have underestimated the number of gastroscopies. Therefore we 
used the national information system recording all procedures in all hospitals from the 
Netherlands to validate the number of gastroscopies per capita in the Netherlands.244 From 
2007 till 2011 the national numbers confirmed the slight underreporting of gastroscopies in 
IPCI, though without large differences. 
In conclusion, the incidence rate of Barrett’s esophagus in the United Kingdom and 
the Netherlands has increased substantially in both males and females at the beginning of the 
millennium but has remained stable since then. The rise in incidence was not explained by an 
increase in gastroscopies. Around 0.3% of BE patients are diagnosed with esophageal 
adenocarcinoma at least one year after diagnosis of BE, demonstrating a one-year risk of 
0.09%. The observed current increase in the EAC incidence among BE patients probably 
reflects the increase in the incidence of BE a decade ago. 
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ABSTRACT 
 
BACKGROUND 
Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose 
aspirin and statins may decrease the risk of esophageal adenocarcinoma (EAC) among patients 
with Barrett’s esophagus (BE). However, previous studies did not adequately address bias and 
confounding.  
 
AIM 
Our objective was to estimate the risk of EAC among patients with BE exposed to NSAIDs, PPIs, 
low-dose aspirin and statins. 
 
METHODS 
We conducted a case–control study nested within a BE cohort. From two primary care 
databases (the United Kingdom (UK) and the Netherlands (NL)) we identified cases being 
adults ≥18 years of age with EAC or high-grade dysplasia (HGD) diagnosis ≥1 year after BE 
diagnosis. Controls were matched on age, sex, year of BE diagnosis and database. Drug use 
was assessed from BE diagnosis until matching date. Adjusted ORs with 95% CI were calculated 
by conditional logistic regression. 
 
RESULTS 
Within the BE cohort (n=15,134), 45 EAC (UK: 40, NL: 5) and 12 HGD cases (NL: 12) were 
identified. ORa for EAC during NSAID use was 1.2 (95% CI 0.6 to 2.5) and during statin use for 
>3 years 0.5 (95% CI 0.1 to 1.7). When including HGD cases (n=57), ORa for NSAID use was 0.9 
(95% CI 0.5 to 1.8) and for statin use >3 years 0.5 (95% CI 0.1 to 1.7). Higher doses of statins 
showed lower estimates for EAC and HGD, though not statistically significant. Low-dose aspirin 
and PPIs did not significantly decrease the risk of EAC and HGD. 
 
CONCLUSION 
In this population-based nested case-control study, use of NSAIDs, PPIs, low-dose aspirin or 
statins did not reduce the risk of HGD and EAC among patients with BE. These findings indicate 
that for an unselected group of patients with BE chemoprevention by use of drugs to reduce 
progression to HGD and EAC should not be directly considered as routine care. 
 
 
INTRODUCTION 
 
Barrett’s esophagus (BE) is a premalignant condition in which the squamous epithelium of the 
esophagus is replaced by metaplastic columnar epithelium.252 BE is considered a consequence 
of prolonged gastro-esophageal reflux222 and is the most important risk factor for 
development of esophageal adenocarcinoma (EAC) via a stepwise pathway of low-grade and 
high-grade dysplasia. It is estimated that the risk of EAC is increased by approximately 30 to 
125-fold in persons with BE,221 and occurs in a small proportion of patients with BE yearly.253 
Endoscopic surveillance for BE is therefore recommended.222 
 In recent decades, the incidence of BE increased, accompanied by a marked increase 
in EAC incidence in the USA and Western Europe.249, 254 However, estimates of EAC incidence 
among patients with BE vary substantially.230, 231, 233, 255 Generally, gastrointestinal cancers 
account for 25% of all cancers and approximately 4.9% of all deaths worldwide.35 Death rates 
of most cancers decreased in recent years in contrast to the 3% increase in death rates of all 
esophageal cancers (squamous cell carcinoma as well as adenocarcinoma) among males.35 The 
age-standardised mortality rate for esophageal cancer overall is 5.1 per 100,000 persons.254 
The need for effective prevention of esophageal cancer, in general, is therefore warranted, 
particularly given the low 5-year survival rate of 13% to 17%.36 
Several studies reported that use of non-steroidal anti-inflammatory drugs (NSAIDs), 
low-dose aspirin, statins and proton pump inhibitors (PPIs) may decrease the risk of EAC 
among patients with BE.14, 163, 245, 258-263 However, these studies were based on small, selected 
samples of EAC cases. PPIs are considered standard care for symptom relief in patients with 
BE, thus it was suggested that PPIs may decrease the risk of progression to high-grade 
dysplasia (HGD) or EAC.245 In contrast, other studies showed an increase in risk of EAC with PPI 
use, probably because the underlying treatment indication may be a risk factor for EAC rather 
than that PPIs being harmful for EAC among patients with BE.259, 264 Nevertheless, one cannot 
directly assume that PPIs, which are efficacious for treatment of erosive esophagitis, will also 
be beneficial in the pathway from BE to EAC development. Two meta-analyses both including 
nine observational studies showed that the risk of esophageal cancer258 and HGD/EAC265 
among those who frequently use NSAIDs or aspirin was significantly lower compared with 
never users.258 However, studies included in the earlier meta-analysis did not specifically 
include patients with BE. A pooled analysis on individual patient data confirmed the significant 
reduction in risk of EAC in BE patients with NSAID prescriptions.266 Two case-control studies 
observed an association between use of NSAIDs259 and statins,259, 267 and the risk of EAC among 
patients with BE. Generalisation and extrapolation of results from the latter studies to the 
general population is, however, difficult as both studies were performed in US veterans.259, 267 
Additionally, there was no adjustment for important risk factors of EAC progression such as 
alcohol use and smoking.259 Nevertheless, a recent systematic review and meta-analysis 
showed a risk reduction in development of esophageal cancer in general and EAC among 
patients with BE who took statins.268 
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Causality of an apparent association is generally supported by a dose-duration relationship.162 
However, studies to date neither reported a clear exposure definition free of recall bias 14, 260, 
266 nor conducted dose-duration analyses. Finally, concerns have been raised about publication 
bias of these studies on chemoprevention of EAC in BE patients.262  
Thus, to what extent NSAIDs, low-dose aspirin, statins and PPIs may reduce the risk 
of EAC among patients with BE in clinical practice remains unknown. Therefore, we conducted 
a matched case-control study to evaluate the risk of EAC among patients with BE associated 
with use of NSAIDs, low-dose aspirin, statins and PPIs. 
 
METHODS 
 
Data sources 
 
Two European population-based general practice registries served as data sources: 1) The 
Health Improvement Network (THIN) from the UK (1996-2011)237 and the 2) Integrated 
Primary Care Information database (IPCI) from the Netherlands (NL, 1996–2012).238 Both 
databases contain prospectively collected data that represent real-life practice. In the UK and 
in NL, all citizens are registered with a general practitioner (GP), who acts as a gatekeeper to 
secondary and tertiary medical care. THIN collects anonymised data on more than 3 million 
active patients from over 400 participating general practices, IPCI contains over 1.5 million 
active patients from 340 practices. For each individual patient all relevant medical information, 
from primary and secondary care, as well as additional information, including demographics 
and drug prescriptions, is documented in the medical record. Both data sources comply with 
European Union guidelines on the use of medical data for research.  
THIN employs the READ clinical terminology system for coding medical diagnosis and 
symptoms,239 whereas IPCI uses the International Classification for Primary Care (ICPC).240 
Information on drug prescriptions is captured in THIN with the Multilex product dictionary and 
British National Formulary (BNF) codes, whereas in IPCI, information on drug prescriptions is 
coded according to the WHO’s Anatomical Therapeutic Chemical (ATC) classification.242 The 
Scientific and Ethical Advisory Boards of both databases approved the study. Identification of 
the source and study population has been described previously.255 
 
Source population 
 
The source population consisted of all patients aged ≥18 years who contributed data to the 
database between 1 January 1996 and 31 December 2011 (THIN) or March 2013 (IPCI). At least 
1 year of available data prior to study entry were required to assess patient’s medical history 
for exclusion criteria and risk factors. Follow-up started on 1 January 1996, or the date of 
reaching 18 years of age, or the date that 1 year of valid data were accrued within the 
database, whichever came later. Follow-up ended on the date of occurrence of study outcome 
 
 
(EAC), date of transfer out of the GP’s practice, death, or last data drawn, whichever was 
earliest. 
 
Definition of Barrett’s esophagus  
 
Patients with BE were identified using diagnosis codes; in THIN using corresponding READ 
codes (see Supplementary Table 1 in Chapter 3.1).239 In IPCI, each potential BE case was 
manually validated to confirm the histological diagnosis of BE and the date of first diagnosis or 
mentioning of BE in the clinical record. Patients were excluded if they had a history of 
esophageal cancer any time before BE diagnosis and if they had a history of gastric cancer 
within 6 months after BE diagnosis. In IPCI, we could utilise free text from the medical record 
to assess the Barrett segment length and grade of dysplasia. 
 
Definition of esophageal adenocarcinoma 
 
In THIN, EAC cases were identified by READ codes (see Supplementary Table 1 in Chapter 3.1). 
In IPCI, all patients with a record of ICPC codes D77.1 (malignant neoplasia of the esophagus) 
and D77.0 (malignant neoplasia of the digestive tract—not specified), or with a record from 
free text search including word combinations of ‘esophagus’, ‘cancer’, ‘carcinoma’, 
‘malignancy’ or ‘neoplasia’ were identified. Similar to BE, all potential cases were manually 
validated for confirmation of the EAC diagnosis, date of first diagnosis and the type of 
carcinoma (squamous cell-, adeno-, or other types of carcinoma). Early cancer (HGD) was 
identified in IPCI also, but could not be assessed in THIN. 
We only considered incident HGD or EAC cases: that is, if the date of diagnosis 
occurred after inclusion into the BE cohort and was at least 12 months after BE diagnosis. 
Cases occurring within 1 year from BE diagnosis were considered to be already existent at BE 
diagnosis date and in relation to the BE diagnostic work-up. 
 
Cases and controls selection 
 
Two nested case–control studies were conducted assessing the risk of EAC for use of four 
drugs (NSAIDs, PPIs, statins and low-dose aspirin); one including only EAC cases and a second 
case–control study including HGD cases from IPCI as well.  
Cases were adults diagnosed with EAC ≥12 months after BE diagnosis, because cases 
occurring within 1 year of BE diagnosis were considered to be existent and related to BE 
diagnostic work-up (eg, missed EAC at BE diagnosis). Index date was defined as date of first 
reporting of EAC diagnosis during follow-up. Controls were members of the incident BE cohort 
who did not develop EAC up to matching date. Controls were matched by incidence density 
sampling on age (±5 years), sex, year of BE diagnosis (±1 year) and database. We matched on 
year of BE diagnosis in order to account for any influence of guideline changes in endoscopic 
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Drug exposure 
 
Drug exposures of interest included four drug groups: NSAIDs, PPIs, statins and low-dose 
aspirin. They were assessed in terms of outpatient prescriptions for NSAIDs (including high-
dose aspirin, ie, >325 mg/day), PPIs, statins and low-dose aspirin (up to 325 mg/day) from BE 
diagnosis until EAC diagnosis. In order to compare the OR of NSAIDs, PPIs and statins to other 
drugs, we considered another group of medications, which served as control. Antidepressants 
(selective serotonin re-uptake inhibitors (SSRIs)) are currently not known to be either 
positively or negatively associated with EAC. 
Duration of prescriptions was calculated based on the prescribed quantity and dosing 
regimen. As the most likely preventive effect of drugs on cancer progression is through a 
cumulative mechanism, we calculated all duration and defined daily dose (DDD) values from 
date of BE diagnosis until index date. Duration was classified according to never use (reference 
category), cumulative use of less than 1 month, between 1 and 12 months, >12 months (or if 
applicable 1–2 years; 2–3 years and >3 years). Considering that PPIs are indicated as treatment 
for patients with BE, duration was classified as 0–6 months (reference category), 6–12 months, 
1–2 years and >2 years. Dose of exposure was classified using the ratio of prescribed daily dose 
compared with DDD using quartiles into categories (<0.8, 0.8–1.2, ≥1.2 DDD per day). As there 
is no DDD for low-dose aspirin, dose analysis was not performed for use of low-dose aspirin. 
 
Potential confounders 
 
We considered as potential confounders: concurrent diagnosis of esophagitis or gastritis 
within 1 year before BE diagnosis; hiatal hernia; smoking habits (non-smoker, ex-smoker, 
current smoker) and alcohol abuse (never, current, past). 
 
Statistical analyses 
 
Baseline characteristics of cases and controls were described per database and compared 
using univariate conditional logistic regression. To estimate the risk of HGD and EAC among 
patients with BE, matched and adjusted odds ratios (ORa) with 95% confidence intervals (CIs) 
were calculated using conditional logistic regression for both databases separately and as a 
pooled analysis on patient-level pooled data. 
Potential confounders were included in the adjusted analysis (ORa) if they resulted in 
a change of more than 10% of the initial estimate. Time since BE diagnosis was forced into the 
adjusted model.  
Subsequent analyses included dose-duration analyses. The risk of EAC and HGD-EAC 
was also assessed for concomitant use of NSAIDs, low-dose aspirin, statins and/or PPIs. Use of 
PPIs only was considered as reference category considering that PPIs are standard therapy for 
BE. All analyses were performed using SAS V.9.2 (Cary, North Carolina, USA). 
 
 
 
Power Calculation 
 
Given an exposure prevalence of NSAIDs of 30%, statins of 22% or 36%, PPIs of 87% or 52% 
and low-dose aspirin of 25% among controls and a correlation of 0.5 between exposed and 
unexposed patients we have 80% power (with a type 1 error of 5%) to detect a true OR of EAC 
of 0.34 for NSAIDs, around 0.38–0.40 for statins, around 0.32–0.45 for PPIs and 0.29 for low-
dose aspirin, which would be in concordance with previous studies.  
 
RESULTS 
 
Study population 
 
From the source population of 7,570,765 subjects in the UK and 1,496,276 subjects in NL we 
identified 13,696 and 1,438 incident BE cases, respectively. Men accounted for 63% (UK) and 
62% (NL) of patients with BE. Mean age at BE diagnosis was 64.8 (SD 13.8) years in the UK and 
61.2 (SD 13.4) years in NL. 
In the UK, we identified 40 incident EAC cases within the BE cohort (0.3%) to whom 
we could match 656 controls. Median number of controls per case was 17 (interquartile range 
(IQR): 9-23). In NL we identified five incident EAC cases among the BE cohort (0.3%). These 
were matched to 76 control subjects, with a median of 5 controls per case (IQR: 4-6). In 
addition, we identified 12 HGD cases, resulting in a second case-control set of 17 cases (5 
EAC+12 HGD) matched to 753 controls (median 44 controls; IQR: 6-61). Figure 1 shows a 
flowchart of the study population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart of Barrett’s esophagus and Esophageal Adenocarcinoma cases in the United Kingdom and 
the Netherlands. 
BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; THIN, The Health Improvement Network; 
IPCI, Integrated Primary Care Information; PYs, person years.  
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Drug exposure 
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aspirin. They were assessed in terms of outpatient prescriptions for NSAIDs (including high-
dose aspirin, ie, >325 mg/day), PPIs, statins and low-dose aspirin (up to 325 mg/day) from BE 
diagnosis until EAC diagnosis. In order to compare the OR of NSAIDs, PPIs and statins to other 
drugs, we considered another group of medications, which served as control. Antidepressants 
(selective serotonin re-uptake inhibitors (SSRIs)) are currently not known to be either 
positively or negatively associated with EAC. 
Duration of prescriptions was calculated based on the prescribed quantity and dosing 
regimen. As the most likely preventive effect of drugs on cancer progression is through a 
cumulative mechanism, we calculated all duration and defined daily dose (DDD) values from 
date of BE diagnosis until index date. Duration was classified according to never use (reference 
category), cumulative use of less than 1 month, between 1 and 12 months, >12 months (or if 
applicable 1–2 years; 2–3 years and >3 years). Considering that PPIs are indicated as treatment 
for patients with BE, duration was classified as 0–6 months (reference category), 6–12 months, 
1–2 years and >2 years. Dose of exposure was classified using the ratio of prescribed daily dose 
compared with DDD using quartiles into categories (<0.8, 0.8–1.2, ≥1.2 DDD per day). As there 
is no DDD for low-dose aspirin, dose analysis was not performed for use of low-dose aspirin. 
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current smoker) and alcohol abuse (never, current, past). 
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Baseline characteristics of cases and controls were described per database and compared 
using univariate conditional logistic regression. To estimate the risk of HGD and EAC among 
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were calculated using conditional logistic regression for both databases separately and as a 
pooled analysis on patient-level pooled data. 
Potential confounders were included in the adjusted analysis (ORa) if they resulted in 
a change of more than 10% of the initial estimate. Time since BE diagnosis was forced into the 
adjusted model.  
Subsequent analyses included dose-duration analyses. The risk of EAC and HGD-EAC 
was also assessed for concomitant use of NSAIDs, low-dose aspirin, statins and/or PPIs. Use of 
PPIs only was considered as reference category considering that PPIs are standard therapy for 
BE. All analyses were performed using SAS V.9.2 (Cary, North Carolina, USA). 
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Figure 1. Flowchart of Barrett’s esophagus and Esophageal Adenocarcinoma cases in the United Kingdom and 
the Netherlands. 
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Table 1 provides baseline characteristics of cases and controls. In the UK a larger proportion of 
cases had a body mass index (BMI) over 25 kg/m²; 68% of cases and 59% of controls. In NL, the 
BMI of only one case within 1 year of EAC diagnosis was available (21.3 kg/ m²). Controls had a 
mean BMI of 28.7 kg/m² (SD 4.7) in NL. Presence of esophagitis or gastritis at time of BE 
diagnosis was more often seen in controls than in cases. In the UK, a hiatal hernia was more 
often present among cases, whereas the opposite was found in NL. In the UK, EAC cases were 
more likely to be current smokers than controls (OR 3.3; 95%CI: 1.4-8.0), as seen in NL though 
not significantly. Mean time from BE diagnosis until EAC diagnosis was 4.2 (SD 2.5) years in the 
UK and 3.5 (SD 0.8) years in NL. 
 
Drug exposure 
 
Table 2 provides characteristics of drug use from BE diagnosis until index date for cases and 
controls per database. Statins were used by 30% and 0% of EAC cases; and by 36% and 22% of 
controls in the UK and NL, respectively. PPIs were used by EAC cases for a mean of 4.1 years 
(UK) and 2.3 years (NL), and by controls for 2.9 years (UK) and 1.9 years (NL). SSRIs were used 
by 12.5% of EAC cases in UK for a mean duration of 1 year, and by 7.6% of controls for a mean 
duration of 1.7 years. Low-dose aspirin was used by 26% of BE subjects in the UK and 6% of 
patients with BE in NL. 
 
Risk of Esophageal Adenocarcinoma 
 
To estimate the risk of EAC with use of NSAIDs, PPIs, statins and low-dose aspirin, a nested 
case–control study was conducted. From the adjusted model, on patient-level pooled data, 
exposure to NSAIDs and PPIs did not provide a significant decrease in the risk of EAC (Table 3); 
for statins a non-significant effect was seen (ORa 0.7; 95% CI 0.4 to 1.5). This was seen in both 
databases separately as well (data not shown). 
For NSAID use, ORs ranged between 1.1 and 1.4 for all duration categories; regarding 
dose-analysis, no difference in risk was found between higher and lower dosages (Table 4). 
Although not significant, a dose-duration-response was seen for statins, with lower OR for 
longer duration of use compared with non-use of statins. Statin use ≥1.2 times higher 
compared to the recommended DDD resulted in an OR of 0.7 (95%CI: 0.2-2.3). For PPIs an 
increase in OR was seen with prolonged duration, in the matched and in the adjusted analyses. 
PPIs used at highest dose showed an OR for HGD-EAC of 0.9 (95% CI: 0.3-2.3). The ORs varied 
for duration categories of SSRIs. No dose-response was seen for SSRI use. Use of low-dose 
aspirin provided ORs below 1 for EAC for matched and adjusted analysis, when considering the 
exposure at any time between BE diagnosis and EAC diagnosis; however the 95% confidence 
limits still included the 1. When considering duration analysis, the adjusted model provided for 
the prolonged duration of use (> 1 year) an OR of 0.9 (95%CI 0.4-2.1).  
Concomitant use of drugs of interest did not decrease the risk of EAC (Table 5) 
compared to use of PPIs only, probably due to the smaller number of cases. 
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Table 1 provides baseline characteristics of cases and controls. In the UK a larger proportion of 
cases had a body mass index (BMI) over 25 kg/m²; 68% of cases and 59% of controls. In NL, the 
BMI of only one case within 1 year of EAC diagnosis was available (21.3 kg/ m²). Controls had a 
mean BMI of 28.7 kg/m² (SD 4.7) in NL. Presence of esophagitis or gastritis at time of BE 
diagnosis was more often seen in controls than in cases. In the UK, a hiatal hernia was more 
often present among cases, whereas the opposite was found in NL. In the UK, EAC cases were 
more likely to be current smokers than controls (OR 3.3; 95%CI: 1.4-8.0), as seen in NL though 
not significantly. Mean time from BE diagnosis until EAC diagnosis was 4.2 (SD 2.5) years in the 
UK and 3.5 (SD 0.8) years in NL. 
 
Drug exposure 
 
Table 2 provides characteristics of drug use from BE diagnosis until index date for cases and 
controls per database. Statins were used by 30% and 0% of EAC cases; and by 36% and 22% of 
controls in the UK and NL, respectively. PPIs were used by EAC cases for a mean of 4.1 years 
(UK) and 2.3 years (NL), and by controls for 2.9 years (UK) and 1.9 years (NL). SSRIs were used 
by 12.5% of EAC cases in UK for a mean duration of 1 year, and by 7.6% of controls for a mean 
duration of 1.7 years. Low-dose aspirin was used by 26% of BE subjects in the UK and 6% of 
patients with BE in NL. 
 
Risk of Esophageal Adenocarcinoma 
 
To estimate the risk of EAC with use of NSAIDs, PPIs, statins and low-dose aspirin, a nested 
case–control study was conducted. From the adjusted model, on patient-level pooled data, 
exposure to NSAIDs and PPIs did not provide a significant decrease in the risk of EAC (Table 3); 
for statins a non-significant effect was seen (ORa 0.7; 95% CI 0.4 to 1.5). This was seen in both 
databases separately as well (data not shown). 
For NSAID use, ORs ranged between 1.1 and 1.4 for all duration categories; regarding 
dose-analysis, no difference in risk was found between higher and lower dosages (Table 4). 
Although not significant, a dose-duration-response was seen for statins, with lower OR for 
longer duration of use compared with non-use of statins. Statin use ≥1.2 times higher 
compared to the recommended DDD resulted in an OR of 0.7 (95%CI: 0.2-2.3). For PPIs an 
increase in OR was seen with prolonged duration, in the matched and in the adjusted analyses. 
PPIs used at highest dose showed an OR for HGD-EAC of 0.9 (95% CI: 0.3-2.3). The ORs varied 
for duration categories of SSRIs. No dose-response was seen for SSRI use. Use of low-dose 
aspirin provided ORs below 1 for EAC for matched and adjusted analysis, when considering the 
exposure at any time between BE diagnosis and EAC diagnosis; however the 95% confidence 
limits still included the 1. When considering duration analysis, the adjusted model provided for 
the prolonged duration of use (> 1 year) an OR of 0.9 (95%CI 0.4-2.1).  
Concomitant use of drugs of interest did not decrease the risk of EAC (Table 5) 
compared to use of PPIs only, probably due to the smaller number of cases. 
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Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma 
 
In NL, we were able to retrieve HGD cases as well. When including these in the case definition, 
the effects were attenuated but in the same direction as the case-control study including EAC 
cases only. There was no significant decrease in the risk of HGD-EAC for exposure to NSAIDs, 
statins, PPIs and low-dose aspirin in the adjusted analysis (Table 3). For NSAIDs, the OR 
increased with use of higher dosages (Table 4). Again, for statins a duration-response 
relationship with the longest duration yielding the lowest ORa (0.5; 95% CI: 0.1-1.7) and an 
inverse association with increasing dose was observed, though none significant. For low-dose 
aspirin, PPI and SSRI use, no dose-response effects were shown.  
The risk of HGD-EAC was 13% lower for concomitant use of NSAIDs+PPIs (ORa 0.9; 
95%CI:0.3-2.2) (Table 5). None of the associations were statistically significant. 
 
DISCUSSION 
 
In this population-based case–control study nested within a cohort of patients with BE, statin 
use may decrease the risk of EAC and HGD by up to 50%. PPIs did not reduce the risk of HGD 
and EAC, however, only when used at highest dose (eg, at least 1.2 times the recommended 
daily dose) a non-significant reduction may be present. In this unselected group of patients 
with BE, use of low-dose aspirin or NSAIDs was not associated with a decrease in risk of EAC. 
This is the first population-based study that looked at the preventive effect of these four 
different drugs used individually and also concomitantly. 
The mechanism of EAC prevention is possibly related to inhibition of cyclo-oxygenase 
(COX)-2 production. Elevated levels of COX-2 in esophageal epithelial cells have been observed 
in BE, and noted to increase with disease progression from BE to EAC.200 In experimental 
studies, COX-2 inhibitors inhibited the growth of BE cells, potentially through suppression of 
basic fibroblast growth factor.269 Another study confirmed that the end product of COX-2 
conversion (prostaglandin E2) is reduced in patients with BE without HGD when using 
esomeprazole combined with higher doses (up to 325 mg/day) of cardiovascular aspirin.270 
 Statins exert antineoplastic properties in several ways. By inhibition of the 3-hydroxy-
3-methylglutanyl coenzyme A (HMG-CoA) reductase enzyme, subsequent modulation of 
growth signal transduction, cellular proliferation and cell death is achieved, which affects 
different organs.4 In EAC cells particularly, statins inhibit cell proliferation and induce 
apoptosis271 and limit the metastatic potential by reducing intracellular adhesion molecules.272  
However, statins also inhibit COX-2 expression in BE cells.273 
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Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma 
 
In NL, we were able to retrieve HGD cases as well. When including these in the case definition, 
the effects were attenuated but in the same direction as the case-control study including EAC 
cases only. There was no significant decrease in the risk of HGD-EAC for exposure to NSAIDs, 
statins, PPIs and low-dose aspirin in the adjusted analysis (Table 3). For NSAIDs, the OR 
increased with use of higher dosages (Table 4). Again, for statins a duration-response 
relationship with the longest duration yielding the lowest ORa (0.5; 95% CI: 0.1-1.7) and an 
inverse association with increasing dose was observed, though none significant. For low-dose 
aspirin, PPI and SSRI use, no dose-response effects were shown.  
The risk of HGD-EAC was 13% lower for concomitant use of NSAIDs+PPIs (ORa 0.9; 
95%CI:0.3-2.2) (Table 5). None of the associations were statistically significant. 
 
DISCUSSION 
 
In this population-based case–control study nested within a cohort of patients with BE, statin 
use may decrease the risk of EAC and HGD by up to 50%. PPIs did not reduce the risk of HGD 
and EAC, however, only when used at highest dose (eg, at least 1.2 times the recommended 
daily dose) a non-significant reduction may be present. In this unselected group of patients 
with BE, use of low-dose aspirin or NSAIDs was not associated with a decrease in risk of EAC. 
This is the first population-based study that looked at the preventive effect of these four 
different drugs used individually and also concomitantly. 
The mechanism of EAC prevention is possibly related to inhibition of cyclo-oxygenase 
(COX)-2 production. Elevated levels of COX-2 in esophageal epithelial cells have been observed 
in BE, and noted to increase with disease progression from BE to EAC.200 In experimental 
studies, COX-2 inhibitors inhibited the growth of BE cells, potentially through suppression of 
basic fibroblast growth factor.269 Another study confirmed that the end product of COX-2 
conversion (prostaglandin E2) is reduced in patients with BE without HGD when using 
esomeprazole combined with higher doses (up to 325 mg/day) of cardiovascular aspirin.270 
 Statins exert antineoplastic properties in several ways. By inhibition of the 3-hydroxy-
3-methylglutanyl coenzyme A (HMG-CoA) reductase enzyme, subsequent modulation of 
growth signal transduction, cellular proliferation and cell death is achieved, which affects 
different organs.4 In EAC cells particularly, statins inhibit cell proliferation and induce 
apoptosis271 and limit the metastatic potential by reducing intracellular adhesion molecules.272  
However, statins also inhibit COX-2 expression in BE cells.273 
	 NSAIDs	and	PPIs	and	risk	of	EAC	|	81  80	|	Chapter	3.2
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Table 5. Risk of Esophageal Adenocarcinoma and High-grade Dysplasia-Esophageal Adenocarcinoma for 
concomitant drug exposure of NSAIDs, low-dose aspirin, statins and PPIs. 
 
  EAC only 
Drug exposure# 
Case 
N (%) 
Control 
N (%) 
ORmatched  
(95% CI) 
P-value ORadj model*  
(95% CI) 
P-value 
Total 45 (100) 732 (100)         
PPI only 19 (42) 284 (39) Ref - Ref - 
No NSAID or LDA or 
statin or PPI 3 (7) 65 (9) 0.9 (0.2-3.2) 0.837 0.9 (0.3-3.4) 0.919 
NSAID + PPI 6 (13) 72 (10) 1.2 (0.5-3.2) 0.700 1.1 (0.4-3.0) 0.773 
Statin + PPI 5 (11) 85 (12) 1.0 (0.4-2.9) 0.963 1.0 (0.3-2.8) 0.988 
LDA + PPI 3 (7) 30 (4) 1.4 (0.4-5.5) 0.597 1.3 (0.4-5.2) 0.655 
LDA + PPI + Statin 
NSAID + LDA + Statin + 
PPI 4 (9) 41 (6) 1.2 (0.4-3.8) 0.744 1.2 (0.4-3.8) 0.760 
 
  HGD-EAC 
Drug exposure# 
Case 
N (%) 
Control 
N (%) 
ORmatched 
(95% CI) 
P-value ORadj model* 
(95% CI) 
P-value 
Total 57 (100) 1,409 (100)         
PPI only 22 (39) 441 (31) Ref - Ref - 
No NSAID or LDA or 
statin or PPI 9 (16) 407 (29) 1.0 (0.4-2.4) 0.947 1.1 (0.4-2.8) 0.839 
NSAID + PPI 6 (11) 124 (9) 0.9 (0.4-2.4) 0.898 0.9 (0.3-2.2) 0.774 
Statin + PPI 7 (12) 143 (10) 1.2 (0.5-3.1) 0.630 1.2 (0.5-3.0) 0.674 
LDA + PPI 3 (5) 42 (3) 1.3 (0.4-4.9) 0.691 1.2 (0.3-4.7) 0.742 
LDA + PPI + Statin 2 (4) 104 (7) 0.4 (0.1-1.7) 0.202 0.4 (0.1-1.7) 0.198 
NSAID + LDA + Statin 
+ PPI 4 (7) 43 (3) 1.2 (0.4-3.9) 0.727 1.2 (0.4-3.8) 0.745 
 
# Numbers do not add up due to drug exposure categories with only one exposed case, not shown in the Table.  
* Adjusted for duration of follow-up since BE diagnosis. 
BE, Barrett’s esophagus; HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma; NSAID, non-steroidal anti-inflammatory 
drugs; LDA, low-dose aspirin; PPI, proton pump inhibitor. 
 
Contrasting to other studies, we did not observe a significant preventive effect of NSAIDs, low-
dose aspirin and statins with respect to the risk of HGD-EAC. 14, 258, 266, 274 Based on the 
biological mechanisms, combined use of statins and NSAIDs or statins with low-dose aspirin 
may be expected to result in a greater risk reduction compared to either drug alone. We did 
not observe NSAIDs or low-dose aspirin with statins combined resulting in a significant risk 
reduction of EAC. This may be due to several reasons. First, despite our large BE cohort, the 
number of identified cases was smaller. Although we may have not have identified all 
potential EAC cases from the database, in a case– control study this is not necessary to obtain 
unbiased estimates. However, it limited the power of the study and resulted in statistically 
non-significant results. For assessment of concomitant drug exposure, in particular, we did not 
reach statistical significance due to the lack of power, though this was not the primary aim of 
the study. 
	 NSAIDs	and	PPIs	and	risk	of	EAC	|	81 
3
 
Ta
bl
e 
4.
 R
isk
 o
f E
so
ph
ag
ea
l A
de
no
ca
rc
in
om
a 
an
d 
Hi
gh
-g
ra
de
 D
ys
pl
as
ia
-E
so
ph
ag
ea
l A
de
no
ca
rc
in
om
a 
by
 d
ru
g 
cl
as
s b
y 
da
ily
 d
os
e 
on
 d
at
a 
po
ol
ed
 o
n 
pa
tie
nt
-le
ve
l. 
 
 
 
EA
C 
on
ly
 
HG
D-
EA
C 
Dr
ug
 e
xp
os
ur
e 
Do
se
 c
at
eg
or
y 
Ca
se
  
N
(%
) 
Co
nt
ro
l  
N
(%
) 
O
Rm
at
ch
ed
  
(9
5%
 C
I) 
P-
va
lu
e 
Ca
se
  
N
(%
) 
Co
nt
ro
l  
N
(%
) 
O
Rm
at
ch
ed
  
(9
5%
 C
I) 
P-
va
lu
e 
To
ta
l  
  
45
 (1
00
) 
73
2 
(1
00
) 
  
  
57
 (1
00
) 
1,
40
9 
(1
00
) 
  
  
N
SA
ID
 
N
on
e 
32
 (7
1)
 
56
6 
(7
7)
 
Re
f 
- 
44
 (7
7)
 
1,
15
9 
(8
2)
 
Re
f 
- 
  
<0
.8
 D
DD
/d
ay
 
3 
(7
) 
39
 (5
) 
1.
1 
(0
.3
-3
.7
) 
0.
90
9 
3 
(5
) 
10
7 
(8
) 
0.
6 
(0
.2
-2
.2
) 
0.
47
5 
  
≥0
.8
 - 
< 
1.
2 
DD
D/
da
y 
4 
(9
) 
74
 (1
0)
 
0.
9 
(0
.3
-2
.5
) 
0.
78
3 
4 
(7
) 
84
 (6
) 
0.
8 
(0
.3
-2
.3
) 
0.
63
3 
  
≥1
.2
 D
DD
/d
ay
 
6 
(1
3)
 
53
 (7
) 
2.
2 
(0
.8
-5
.6
) 
0.
11
1 
6 
(1
1)
 
59
 (4
) 
1.
9 
(0
.8
-5
.0
) 
0.
16
0 
St
at
in
 
N
on
e 
33
 (7
3)
 
47
9 
(6
5)
 
Re
f 
- 
42
 (7
4)
 
1,
05
0 
(7
5)
 
Re
f 
- 
  
<0
.8
 D
DD
/d
ay
 
8 
(1
8)
 
12
6 
(1
7)
 
0.
9 
(0
.4
-2
.2
) 
0.
88
0 
9 
(1
6)
 
17
4 
(1
2)
 
1.
0 
(0
.5
-2
.1
) 
0.
95
9 
  
≥0
.8
 - 
< 
1.
2 
DD
D/
da
y 
1 
(2
) 
49
 (7
) 
0.
3 
(0
.0
5-
2.
6)
 
0.
30
5 
2 
(4
) 
62
 (4
) 
0.
7 
(0
.2
-3
.1
) 
0.
63
7 
  
≥1
.2
 D
DD
/d
ay
 
3 
(7
) 
78
 (1
1)
 
0.
7 
(0
.2
-2
.3
) 
0.
51
9 
4 
(7
) 
12
3 
(9
) 
0.
8 
(0
.3
-2
.4
) 
0.
73
1 
PP
I 
N
on
e 
5 
(1
1)
 
10
3 
(1
4)
 
Re
f 
- 
11
 (1
9)
 
45
0 
(3
2)
 
Re
f 
- 
  
<0
.8
 D
DD
/d
ay
 
9 
(2
0)
 
16
8 
(2
3)
 
0.
9 
(0
.3
-3
.0
) 
0.
91
4 
11
 (1
9)
 
19
6 
(1
4)
 
1.
1 
(0
.4
-2
.8
) 
0.
91
0 
  
≥0
.8
 - 
< 
1.
2 
DD
D/
da
y 
23
 (5
1)
 
31
5 
(4
3)
 
1.
2 
(0
.4
-3
.4
) 
0.
72
3 
27
 (4
7)
 
45
4 
(3
2)
 
1.
1 
(0
.5
-2
.6
) 
0.
76
8 
  
≥1
.2
 D
DD
/d
ay
 
8 
(1
8)
 
14
6 
(2
0)
 
1.
1 
(0
.4
-3
.6
) 
0.
82
2 
8 
(1
4)
 
30
9 
(2
2)
 
0.
9 
(0
.3
-2
.3
) 
0.
81
3 
SS
RI
 
N
on
e 
40
 (8
9)
 
67
9 
(9
3)
 
Re
f 
- 
52
 (9
1)
 
1,
34
4 
(9
5)
 
Re
f 
- 
  
<0
.8
 D
DD
/d
ay
 
1 
(2
) 
8 
(1
) 
3.
0 
(0
.4
-2
5.
4)
 
0.
31
7 
1 
(2
) 
8 
(1
) 
3.
0 
(0
.3
-2
5.
1)
 
0.
32
1 
  
≥0
.8
 - 
< 
1.
2 
DD
D/
da
y 
4 
(9
) 
32
 (4
) 
2.
3 
(0
.7
-7
.1
) 
0.
14
9 
4 
(7
) 
44
 (3
) 
2.
0 
(0
.7
-6
.0
) 
0.
21
8 
  
≥1
.2
 D
DD
/d
ay
 
0 
(0
) 
13
 (2
) 
- 
0.
98
7 
0 
(0
) 
13
 (1
) 
- 
0.
98
7 
 DD
D,
 d
ef
in
ed
 d
ai
ly
 d
os
e;
 H
GD
, h
ig
h-
gr
ad
e 
dy
sp
la
sia
; E
AC
, e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a;
 N
SA
ID
, n
on
-s
te
ro
id
al
 a
nt
i-i
nf
la
m
m
at
or
y 
dr
ug
s;
 P
PI
s, 
pr
ot
on
 p
um
p 
in
hi
bi
to
rs
; S
SR
Is
, s
el
ec
tiv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
bi
to
rs
. 
  
 
 
Table 5. Risk of Esophageal Adenocarcinoma and High-grade Dysplasia-Esophageal Adenocarcinoma for 
concomitant drug exposure of NSAIDs, low-dose aspirin, statins and PPIs. 
 
  EAC only 
Drug exposure# 
Case 
N (%) 
Control 
N (%) 
ORmatched  
(95% CI) 
P-value ORadj model*  
(95% CI) 
P-value 
Total 45 (100) 732 (100)         
PPI only 19 (42) 284 (39) Ref - Ref - 
No NSAID or LDA or 
statin or PPI 3 (7) 65 (9) 0.9 (0.2-3.2) 0.837 0.9 (0.3-3.4) 0.919 
NSAID + PPI 6 (13) 72 (10) 1.2 (0.5-3.2) 0.700 1.1 (0.4-3.0) 0.773 
Statin + PPI 5 (11) 85 (12) 1.0 (0.4-2.9) 0.963 1.0 (0.3-2.8) 0.988 
LDA + PPI 3 (7) 30 (4) 1.4 (0.4-5.5) 0.597 1.3 (0.4-5.2) 0.655 
LDA + PPI + Statin 
NSAID + LDA + Statin + 
PPI 4 (9) 41 (6) 1.2 (0.4-3.8) 0.744 1.2 (0.4-3.8) 0.760 
 
  HGD-EAC 
Drug exposure# 
Case 
N (%) 
Control 
N (%) 
ORmatched 
(95% CI) 
P-value ORadj model* 
(95% CI) 
P-value 
Total 57 (100) 1,409 (100)         
PPI only 22 (39) 441 (31) Ref - Ref - 
No NSAID or LDA or 
statin or PPI 9 (16) 407 (29) 1.0 (0.4-2.4) 0.947 1.1 (0.4-2.8) 0.839 
NSAID + PPI 6 (11) 124 (9) 0.9 (0.4-2.4) 0.898 0.9 (0.3-2.2) 0.774 
Statin + PPI 7 (12) 143 (10) 1.2 (0.5-3.1) 0.630 1.2 (0.5-3.0) 0.674 
LDA + PPI 3 (5) 42 (3) 1.3 (0.4-4.9) 0.691 1.2 (0.3-4.7) 0.742 
LDA + PPI + Statin 2 (4) 104 (7) 0.4 (0.1-1.7) 0.202 0.4 (0.1-1.7) 0.198 
NSAID + LDA + Statin 
+ PPI 4 (7) 43 (3) 1.2 (0.4-3.9) 0.727 1.2 (0.4-3.8) 0.745 
 
# Numbers do not add up due to drug exposure categories with only one exposed case, not shown in the Table.  
* Adjusted for duration of follow-up since BE diagnosis. 
BE, Barrett’s esophagus; HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma; NSAID, non-steroidal anti-inflammatory 
drugs; LDA, low-dose aspirin; PPI, proton pump inhibitor. 
 
Contrasting to other studies, we did not observe a significant preventive effect of NSAIDs, low-
dose aspirin and statins with respect to the risk of HGD-EAC. 14, 258, 266, 274 Based on the 
biological mechanisms, combined use of statins and NSAIDs or statins with low-dose aspirin 
may be expected to result in a greater risk reduction compared to either drug alone. We did 
not observe NSAIDs or low-dose aspirin with statins combined resulting in a significant risk 
reduction of EAC. This may be due to several reasons. First, despite our large BE cohort, the 
number of identified cases was smaller. Although we may have not have identified all 
potential EAC cases from the database, in a case– control study this is not necessary to obtain 
unbiased estimates. However, it limited the power of the study and resulted in statistically 
non-significant results. For assessment of concomitant drug exposure, in particular, we did not 
reach statistical significance due to the lack of power, though this was not the primary aim of 
the study. 
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Our nesting cohort included all incident BE patients from the general population, and by 
matching on duration since BE diagnosis and excluding patients with prevalent BE, we 
removed any effect of selective survival bias, disease severity275 or time window bias,276 as 
those patients with BE with a longer follow-up are more likely to develop HGD or EAC. By 
doing so, observing any spurious association was avoided. Second, we mitigated against 
immortal time bias277 by defining the exposure period from BE diagnosis up to matching date, 
thus avoiding an overestimation of the preventive effect. The estimates from our study are 
likely more generalisable to the daily clinical practice in the general population, also including 
patients with less severe BE, that is, those with a shorter BE segment. A potential preventive 
effect of NSAIDs might therefore be only observed within selected high-risk subgroups. 
Thirdly, the inability to show a significant decrease in HGD and EAC risk for drug use may be 
explained by the distinct exposure definition that we applied. Contrasting with others 14, 274, we 
classified exposure cumulatively and performed dose-duration-analyses rather than assessing 
drug exposure at a single moment. This, however, also limited the analyses by creating 
multiple exposure categories. Drug exposure changes over time, especially in the long time 
taken to develop cancer. Assessment of exposure on a fixed moment will result in bias that 
exaggerates the effect downwards; showing a protective effect while actually it has no 
effect.276 A pooled analysis of observational studies demonstrated an inverse association 
between the risk of HGD-EAC and use of NSAIDs.266 A prospective cohort study also showed a 
decreased hazard ratio of HGD-EAC for use of NSAIDs and statins, however, the study results 
were influenced by immortal time bias.15, 261 In that study, the majority of cases included HGD 
cases. In line with the other Dutch study,261 when we included HGD cases the risk of HGD-EAC 
was lower than including EAC cases only. The preventive effect is possibly achieved in 
premalignant stage of dysplasia-development rather than of adenocarcinoma. It is, however, 
difficult to disentangle drug exposure effects in three different risk periods: induction 
(dysplasia), latent (between dysplasia and cancer) and disease period (cancer). Ideally, this 
requires knowledge on exact timing of the first aberrant Barrett’s cell and subsequent stages 
towards HGD and EAC develop. The fourth explanation for not observing a preventive effect 
may be the exposure prevalence. Regarding NSAID exposure prevalence, we could not capture 
over-the-counter use of NSAIDs. During the study period NSAIDs and PPIs were reimbursable 
in the Netherlands and United Kingdom, and thus we assume that over-the-counter use of 
NSAIDs and PPIs did not confound the results to a great extent. Prevalence of PPI (81%) and 
statin (26%) exposure in our study is, however, comparable to other studies and is therefore 
unlikely to have limited our power.261, 278 
 A large prospective US cohort study showed a tremendous protective effect of 
NSAIDs on EAC risk.274 However, NSAID exposure was assessed in a personal interview and 
classified very broadly by NSAIDs used at least once a week for 6 months.274 If the preventive 
effect of NSAIDs would be as high as reported (up to 80%), a duration and dose response 
effect is to be expected. This study failed to demonstrate an inverse association between 
duration of NSAID use and the risk of EAC. In fact, the opposite was observed; the most 
protective effect was seen for the shortest duration,274 contradicting a causal association.162, 279 
 
 
A pooled analysis also could not demonstrate that prolonged duration of NSAID use was 
associated with a lower risk of EAC.266 Additionally, heterogeneity between studies was 
observed,266 which emphasizes the controversy around clinically effective chemoprevention 
with NSAIDs. 
 The preventive effect of statins is shown in several studies,14, 261 yielding a risk 
reduction of EAC up to 48% for statin use >1 year.259 However, in a meta-analysis, the risk 
reduction of EAC among patients with BE was only seen when studies were included that 
assessed drug exposure by patient interview, which may be prone to recall bias, whereas the 
risk reduction was not significant, including studies that assessed drug exposure by use of 
prescription/dispensing data in electronic medical records.268 Also, for statins, the most 
pronounced effect was seen when HGD was included.260 Results from the latter study should 
be interpreted with caution as drug exposure was classified by self-report as ‘ever’ instead of a 
duration classification. A recent case-control study, using a GP database from the UK, showed 
that statins may also decrease the risk of EAC and esophagogastric junctional adenocarcinoma 
in the general population.280 The chemopreventive action of statins was more pronounced 
when combined with low-dose aspirin in a previous study.14 It could be that the preventive 
effect of statins is explained by other risk factors common to statin users and patients with 
EAC, such as cardiovascular risk factors or lifestyle changes: smoking, exercise and weight.280 
Also it may be that patients with BE died from vascular diseases rather than of cancer-related 
causes or before HGD or EAC developed.281 In our study, statin users were less likely to be 
current smokers, were of older age and were more often men. However, whether lifestyle 
changes due to comorbid cardiovascular diseases and initiating statin therapy may have 
resulted in healthier behavior, and subsequent EAC risk reduction, is open to debate. 
Strengths of the current study include the scale and setting by combining healthcare 
data from two European countries with comparable GP databases and applying a common 
study protocol and drug exposure definition. The nested case–control design in a well-defined 
population representing the general population minimised selection bias. While previous 
studies may have suffered from recall bias or the lack of detailed drug prescription data, we 
were able to estimate the risk of HGD and EAC within patients with BE during drug use in the 
general population. Although our analysis may be limited by the small number of cases in the 
dose–duration analyses, partly due to the fact that we only included incident cases (diagnosed 
≥1 year after BE diagnosis), our study is unlikely to suffer from biases (immortal time bias, time 
window bias) and confounding (disease severity) by matching on important risk factors. 
Matched and adjusted analyses were in line with each other suggesting that there was little 
confounding. 
 A limitation of the study is the lack of detailed pathology information on the Barrett 
segment length and grade of dysplasia, as is current practice for risk stratification of patients 
with BE. This may have resulted in misclassification of BE and EAC. However, the 1-year risk of 
EAC after BE diagnosis, excluding EAC cases within 1 year after BE diagnosis, was 0.086% (95% 
CI: 0.04–0.17) in the current study,255 which is similar to other population-based studies.232, 236, 
253 Because we could not verify the diagnosis of BE against a clinical prespecified standard and 
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multiple exposure categories. Drug exposure changes over time, especially in the long time 
taken to develop cancer. Assessment of exposure on a fixed moment will result in bias that 
exaggerates the effect downwards; showing a protective effect while actually it has no 
effect.276 A pooled analysis of observational studies demonstrated an inverse association 
between the risk of HGD-EAC and use of NSAIDs.266 A prospective cohort study also showed a 
decreased hazard ratio of HGD-EAC for use of NSAIDs and statins, however, the study results 
were influenced by immortal time bias.15, 261 In that study, the majority of cases included HGD 
cases. In line with the other Dutch study,261 when we included HGD cases the risk of HGD-EAC 
was lower than including EAC cases only. The preventive effect is possibly achieved in 
premalignant stage of dysplasia-development rather than of adenocarcinoma. It is, however, 
difficult to disentangle drug exposure effects in three different risk periods: induction 
(dysplasia), latent (between dysplasia and cancer) and disease period (cancer). Ideally, this 
requires knowledge on exact timing of the first aberrant Barrett’s cell and subsequent stages 
towards HGD and EAC develop. The fourth explanation for not observing a preventive effect 
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statin (26%) exposure in our study is, however, comparable to other studies and is therefore 
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 A large prospective US cohort study showed a tremendous protective effect of 
NSAIDs on EAC risk.274 However, NSAID exposure was assessed in a personal interview and 
classified very broadly by NSAIDs used at least once a week for 6 months.274 If the preventive 
effect of NSAIDs would be as high as reported (up to 80%), a duration and dose response 
effect is to be expected. This study failed to demonstrate an inverse association between 
duration of NSAID use and the risk of EAC. In fact, the opposite was observed; the most 
protective effect was seen for the shortest duration,274 contradicting a causal association.162, 279 
 
 
A pooled analysis also could not demonstrate that prolonged duration of NSAID use was 
associated with a lower risk of EAC.266 Additionally, heterogeneity between studies was 
observed,266 which emphasizes the controversy around clinically effective chemoprevention 
with NSAIDs. 
 The preventive effect of statins is shown in several studies,14, 261 yielding a risk 
reduction of EAC up to 48% for statin use >1 year.259 However, in a meta-analysis, the risk 
reduction of EAC among patients with BE was only seen when studies were included that 
assessed drug exposure by patient interview, which may be prone to recall bias, whereas the 
risk reduction was not significant, including studies that assessed drug exposure by use of 
prescription/dispensing data in electronic medical records.268 Also, for statins, the most 
pronounced effect was seen when HGD was included.260 Results from the latter study should 
be interpreted with caution as drug exposure was classified by self-report as ‘ever’ instead of a 
duration classification. A recent case-control study, using a GP database from the UK, showed 
that statins may also decrease the risk of EAC and esophagogastric junctional adenocarcinoma 
in the general population.280 The chemopreventive action of statins was more pronounced 
when combined with low-dose aspirin in a previous study.14 It could be that the preventive 
effect of statins is explained by other risk factors common to statin users and patients with 
EAC, such as cardiovascular risk factors or lifestyle changes: smoking, exercise and weight.280 
Also it may be that patients with BE died from vascular diseases rather than of cancer-related 
causes or before HGD or EAC developed.281 In our study, statin users were less likely to be 
current smokers, were of older age and were more often men. However, whether lifestyle 
changes due to comorbid cardiovascular diseases and initiating statin therapy may have 
resulted in healthier behavior, and subsequent EAC risk reduction, is open to debate. 
Strengths of the current study include the scale and setting by combining healthcare 
data from two European countries with comparable GP databases and applying a common 
study protocol and drug exposure definition. The nested case–control design in a well-defined 
population representing the general population minimised selection bias. While previous 
studies may have suffered from recall bias or the lack of detailed drug prescription data, we 
were able to estimate the risk of HGD and EAC within patients with BE during drug use in the 
general population. Although our analysis may be limited by the small number of cases in the 
dose–duration analyses, partly due to the fact that we only included incident cases (diagnosed 
≥1 year after BE diagnosis), our study is unlikely to suffer from biases (immortal time bias, time 
window bias) and confounding (disease severity) by matching on important risk factors. 
Matched and adjusted analyses were in line with each other suggesting that there was little 
confounding. 
 A limitation of the study is the lack of detailed pathology information on the Barrett 
segment length and grade of dysplasia, as is current practice for risk stratification of patients 
with BE. This may have resulted in misclassification of BE and EAC. However, the 1-year risk of 
EAC after BE diagnosis, excluding EAC cases within 1 year after BE diagnosis, was 0.086% (95% 
CI: 0.04–0.17) in the current study,255 which is similar to other population-based studies.232, 236, 
253 Because we could not verify the diagnosis of BE against a clinical prespecified standard and 
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did not review biopsy specimens, it is also possible that we inadvertently included patients at 
very low risk of developing EAC. In the Dutch database, we could search through the medical 
records and noted that 8% had a segment length <2 cm, 13.7% between 2 and 3 cm, 11.8% 
longer than 3 cm, whereas for 60% of BE controls the length was not mentioned. Regarding 
the grade of dysplasia at time of BE diagnosis, 45% of controls had no dysplasia; there was 
low-grade dysplasia in 6% of BE subjects, indefinite for dysplasia in 1.8%, whereas no 
information on dysplasia grade was available in 46% of controls. Of the cases that developed 
HGD or EAC, 24% had a prior histology report of low-grade dysplasia. In the Dutch database we 
could utilise all free text entered in the medical record, enabling us to look for more detailed 
information in clinical letters, resulting in higher proportion of risk factors, such as presence of 
esophagitis and a hiatal hernia at time of BE diagnosis as compared with the UK database, in 
which we relied on diagnosis codes. We tried to address confounding-by-indication and time-
window bias by matching on age, sex and year of BE diagnosis.276 This is seen by the fact that 
individual risk factors did not increase the risk of EAC and adjustment for these confounders 
did not change the estimate by ≥10%. The observation that PPIs appear to increase the risk of 
EAC is explained by the treatment indication being a risk factor for EAC, reverse causation and 
the phenomenon of ‘channeling’, where high-risk patients are being prescribed PPIs whereas 
low-risk patients with lower doses or not at all,168, 259, 264, 280, 282 a phenomenon often seen with 
PPIs and upper gastrointestinal bleeding.283 It could also be that the effect of PPIs is apparent 
after minimally 2 years of use,245, 259 an observation that was not significant in our study.  
In conclusion, in this population-based nested case-control study, use of NSAIDs, 
PPIs, low-dose aspirin or statins did not reduce the risk of HGD and EAC among patients with 
Barrett’s esophagus. These findings indicate that for an unselected group of patients with BE, 
chemoprevention by use of drugs to reduce progression should not be considered directly as 
routine care. 
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ABSTRACT 
 
BACKGROUND 
Propensity score (PS) methods are commonly used to control for confounding in comparative 
effectiveness studies. Electronic health records (EHRs) contain much unstructured data that 
could be used as proxies for potential confounding factors.  
 
AIM 
To assess whether the unstructured information can also be used to construct PS models that 
would allow to properly deal with confounding. 
 
METHODS 
In a cohort study of new users of non-steroidal anti-inflammatory drugs (NSAIDs) from the 
Dutch Integrated Primary Care Information (IPCI) database, we identified all patients who 
experienced an upper gastrointestinal (GI) bleeding. We used a large-scale regularized 
regression to fit two PS models using all structured and unstructured information in the EHR. 
We calculated hazard ratios (HRs) to estimate the risk of upper GI bleeding among selective 
cyclo-oxygenase-2 (COX-2) inhibitor users compared to nonselective NSAID (nsNSAID) users. 
 
RESULTS 
The crude hazard ratio of upper GI bleeding for COX-2 inhibitors compared to nsNSAIDs was 
0.50 (95% confidence interval 0.18-1.36). Matching only on age resulted in an HR of 0.36 (0.11-
1.16), and of 0.35 (0.11-1.11) when further adjusted for sex. Matching on PS only, the first 
model yielded an HR of 0.42 (0.13-1.38), which reduced to 0.35 (0.96-1.25) when adjusted for 
age and sex. The second model resulted in an HR of 0.42 (0.13-1.39), which dropped to 0.31 
(0.09-1.08) after adjustment for age and sex. 
 
CONCLUSION 
PS models can be created using unstructured information in EHRs. An incremental benefit was 
observed by matching on PS over traditional matching and adjustment for covariates. 
 
 
 
INTRODUCTION 
 
Electronic health records (EHRs) are primarily used for routine medical care, but secondary use 
of EHR data for observational research is becoming increasingly popular especially in studying 
of drug effects postmarketing.284 In this era data is used to generate information on drug 
safety and effectiveness in a cost-efficient way and by exploiting actual care patterns, which 
differ largely from experimental settings.285-288 In an experimental setting such as in 
randomized clinical trials, the choice for a treatment is randomized, which would take care of 
potential confounding by indication.289 In actual care the treatment decision is usually 
influenced by measurable patient characteristics such as medical history, concomitant drug 
intake but also by personal prescriber preferences, which cannot be measured easily. This 
phenomenon of preferential prescribing is also known as channeling and may lead to 
confounding by indication.290, 291 A well-known example of channeling is the preference of 
doctors to prescribe selective cyclo-oxygenase-2 inhibitors (COX-2 inhibitors) over 
nonselective (ns) non-steroidal anti-inflammatory drugs (NSAIDs) to patients at risk of 
developing upper gastrointestinal (GI) bleeding, as the COX-2 inhibitors were developed on 
purpose to mitigate the GI effects of NSAIDs.243, 292 Although clinical trials showed that 
selective COX-2 inhibitors are ‘safer’ than nsNSAIDs in relation to upper GI bleeding,293 
observational studies showed no large differences between the rate of upper GI bleeding 
between COX-2 inhibitor and nsNSAIDs, possibly due to residual confounding by indications 
arising from channeling.294 In order to obtain unbiased estimates in observational studies this 
confounding must be dealt with. However, it is challenging to capture all relevant confounders 
in the EHR databases because information is not primarily recorded for research purposes. 
Moreover, often relevant information is recorded in EHRs in an unstructured way.295, 296 
 Attempts to construct methods that deal with confounding have resulted in the 
propensity score method. The propensity score is an estimated conditional probability of 
receiving one particular treatment over another given a set of measured covariates.297 It can 
be regarded as a comprehensive way to look at channeling. Propensity score methods can be 
used to control for the unbalance between the treatment groups in order to estimate the 
comparative effectiveness of treatments.297 Four different methods of using the propensity to 
reduce confounding have been described298: (1) matching on propensity score; (2) 
stratification on the propensity score; (3) inverse probability of treatment weighting using the 
propensity score; (4) and covariate adjustment using the propensity score. Typically, all 
variables related to either the outcome and/or exposure are included in the propensity score 
model,299, 300 sometimes these variables are not the exact confounding factors but proxies 
thereof. 301 Yet, identifying appropriate proxies in large EHRs is challenging. Schneeweiss et 
al.302 proposed a high-dimensional propensity score (hd-PS) algorithm to empirically identify a 
large number of relevant covariates, with high prevalence, to control for confounding. In a 
case study on selective COX-2 inhibitors and nsNSAIDs using claims data in the USA, 
application of the hd-PS algorithm to control for confounding was found to produce an effect 
estimate for the risk of upper GI complications between selective COX-2 inhibitors and 
	 Generating	a	propensity	score	model	|	91 
4
 
ABSTRACT 
 
BACKGROUND 
Propensity score (PS) methods are commonly used to control for confounding in comparative 
effectiveness studies. Electronic health records (EHRs) contain much unstructured data that 
could be used as proxies for potential confounding factors.  
 
AIM 
To assess whether the unstructured information can also be used to construct PS models that 
would allow to properly deal with confounding. 
 
METHODS 
In a cohort study of new users of non-steroidal anti-inflammatory drugs (NSAIDs) from the 
Dutch Integrated Primary Care Information (IPCI) database, we identified all patients who 
experienced an upper gastrointestinal (GI) bleeding. We used a large-scale regularized 
regression to fit two PS models using all structured and unstructured information in the EHR. 
We calculated hazard ratios (HRs) to estimate the risk of upper GI bleeding among selective 
cyclo-oxygenase-2 (COX-2) inhibitor users compared to nonselective NSAID (nsNSAID) users. 
 
RESULTS 
The crude hazard ratio of upper GI bleeding for COX-2 inhibitors compared to nsNSAIDs was 
0.50 (95% confidence interval 0.18-1.36). Matching only on age resulted in an HR of 0.36 (0.11-
1.16), and of 0.35 (0.11-1.11) when further adjusted for sex. Matching on PS only, the first 
model yielded an HR of 0.42 (0.13-1.38), which reduced to 0.35 (0.96-1.25) when adjusted for 
age and sex. The second model resulted in an HR of 0.42 (0.13-1.39), which dropped to 0.31 
(0.09-1.08) after adjustment for age and sex. 
 
CONCLUSION 
PS models can be created using unstructured information in EHRs. An incremental benefit was 
observed by matching on PS over traditional matching and adjustment for covariates. 
 
 
 
INTRODUCTION 
 
Electronic health records (EHRs) are primarily used for routine medical care, but secondary use 
of EHR data for observational research is becoming increasingly popular especially in studying 
of drug effects postmarketing.284 In this era data is used to generate information on drug 
safety and effectiveness in a cost-efficient way and by exploiting actual care patterns, which 
differ largely from experimental settings.285-288 In an experimental setting such as in 
randomized clinical trials, the choice for a treatment is randomized, which would take care of 
potential confounding by indication.289 In actual care the treatment decision is usually 
influenced by measurable patient characteristics such as medical history, concomitant drug 
intake but also by personal prescriber preferences, which cannot be measured easily. This 
phenomenon of preferential prescribing is also known as channeling and may lead to 
confounding by indication.290, 291 A well-known example of channeling is the preference of 
doctors to prescribe selective cyclo-oxygenase-2 inhibitors (COX-2 inhibitors) over 
nonselective (ns) non-steroidal anti-inflammatory drugs (NSAIDs) to patients at risk of 
developing upper gastrointestinal (GI) bleeding, as the COX-2 inhibitors were developed on 
purpose to mitigate the GI effects of NSAIDs.243, 292 Although clinical trials showed that 
selective COX-2 inhibitors are ‘safer’ than nsNSAIDs in relation to upper GI bleeding,293 
observational studies showed no large differences between the rate of upper GI bleeding 
between COX-2 inhibitor and nsNSAIDs, possibly due to residual confounding by indications 
arising from channeling.294 In order to obtain unbiased estimates in observational studies this 
confounding must be dealt with. However, it is challenging to capture all relevant confounders 
in the EHR databases because information is not primarily recorded for research purposes. 
Moreover, often relevant information is recorded in EHRs in an unstructured way.295, 296 
 Attempts to construct methods that deal with confounding have resulted in the 
propensity score method. The propensity score is an estimated conditional probability of 
receiving one particular treatment over another given a set of measured covariates.297 It can 
be regarded as a comprehensive way to look at channeling. Propensity score methods can be 
used to control for the unbalance between the treatment groups in order to estimate the 
comparative effectiveness of treatments.297 Four different methods of using the propensity to 
reduce confounding have been described298: (1) matching on propensity score; (2) 
stratification on the propensity score; (3) inverse probability of treatment weighting using the 
propensity score; (4) and covariate adjustment using the propensity score. Typically, all 
variables related to either the outcome and/or exposure are included in the propensity score 
model,299, 300 sometimes these variables are not the exact confounding factors but proxies 
thereof. 301 Yet, identifying appropriate proxies in large EHRs is challenging. Schneeweiss et 
al.302 proposed a high-dimensional propensity score (hd-PS) algorithm to empirically identify a 
large number of relevant covariates, with high prevalence, to control for confounding. In a 
case study on selective COX-2 inhibitors and nsNSAIDs using claims data in the USA, 
application of the hd-PS algorithm to control for confounding was found to produce an effect 
estimate for the risk of upper GI complications between selective COX-2 inhibitors and 
	 Generating	a	propensity	score	model	|	93  92	|	Chapter	4.1
 
nsNSAIDs that was comparable to the one found in randomized trials.296 The hd-PS model is 
constructed by using many covariates of which some could serve as proxies for unobserved 
factors that otherwise may not be considered. Typically, only structured information such as 
diagnostic or procedure codes that is available in the claims databases, are included in the 
model. Electronic health records comprise much unstructured data and we propose that this 
information could also be used as proxies for potential confounding factors. 
The aim of this study was therefore to assess whether unstructured text in EHRs can 
be used to construct a propensity score model that would allow to properly deal with 
confounding. We assessed the performance of propensity score models in addressing 
confounding by indication using as an example the association between selective COX-2 
inhibitors and nonselective NSAIDs in relation to upper gastrointestinal bleeding. 
 
METHODS 
 
Data source 
 
We used the Dutch Integrated Primary Care Information database (IPCI),238 a population-based 
general practice (GP) EHR database. This database contains prospectively collected routine 
care data representing real-life practice. In the Netherlands, all citizens are registered with a 
GP, who acts as a gatekeeper to secondary and tertiary medical care. IPCI contains over 1.8 
million patients from 340 GP practices. For each individual person, all relevant medical 
information from primary and secondary care is documented in the medical record. Apart 
from patient demographics, the recorded information in the EHRs contains medical notes 
(including symptoms, physical examination, assessments and diagnoses), drug prescriptions, 
laboratory results, referrals for hospitalization or specialist care, and hospital discharge 
summaries. In the IPCI database, drug prescriptions are coded using the Z-index, but are 
recoded according to the Anatomical Therapeutic Chemical (ATC) classification for research 
purposes.242 Diagnoses are coded according to the International Classification for Primary Care 
(ICPC).240 Almost 60% of the medical record are clinical narratives, which do not contain coded 
information, but contain important information such as patient-reported symptoms and notes 
from the GP. 
 
Selection of NSAID cohort 
 
We created a cohort of all new adult (≥18 years) users of NSAIDs between 1996 and 2013. 
Patients had to be enrolled for at least one year in the database in order to be eligible for 
cohort entry. ATC codes used for NSAID exposure are presented in Supplementary Table 1. 
Within the NSAID cohort we selected all episodes of NSAID use. A new NSAID episode was 
created if the following criteria were met: (a) at least six months of data available before 
NSAID exposure, (b) no prescription of any nonselective NSAID or selective COX-2 inhibitor in 
the previous six months, and (c) no mentioning of drug names, in the free-text, corresponding 
 
 
with NSAID-related ATC codes in the previous six months. An NSAID episode continued when 
consecutive NSAID prescriptions started before or within 30 days of the end of the duration of 
the previous prescription. The duration of a prescription was calculated by dividing the 
prescribed quantity by daily dose regimen. The end of the episode was defined as the end of 
the last NSAID prescription. The episode selection is illustrated in Figure 1. Episodes were 
classified as an nsNSAID or selective COX-2 inhibitor episode based on the first prescription in 
that episode being an nsNSAID or a selective COX-2 inhibitor, respectively. If a patient 
switched between exposure (from selective COX-2 inhibitor to nsNSAID or vice versa) the 
duration of the NSAID episode was ended at the switch of the exposure. A patient could have 
multiple NSAID episodes, but only if the above mentioned criteria were met. 
 
Figure 1. Episode selection. 
 
Selection of Upper Gastrointestinal bleeding patients 
 
Within the cohort of new NSAID users we identified all potential subjects who experienced an 
upper gastrointestinal (GI) bleeding via an automated search.303 Upper GI bleeding was 
defined as all forms of ulcer complications such as bleeding, perforation, or obstruction. The 
entire medical record of all potential upper GI bleeding patients was extensively reviewed to 
ensure the diagnosis and the date of onset. Any other cause of upper GI bleeding (such as 
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variceal bleeding or Mallory Weiss bleeding) was excluded. The date of upper GI bleeding was 
determined as the date of first mentioning of symptoms leading to the upper GI bleeding 
diagnosis or if this date was unknown, the date of diagnosis. 
 
Propensity score model 
 
A propensity model was fitted using all information (structured and unstructured) in the EHR. 
To reduce the number of potential variables we first converted all text to lowercase after 
which we removed special characters, words not starting with a letter or a digit, stop words 
(such as de, het – the article the in English), and punctuation. All unique words (also known as 
unigrams) in the 6 months prior to cohort entry were extracted and used as textual features 
(potential covariates). We tested two methods to limit the number of covariates that would be 
included in the regression. The first method generated models using covariates of which the 
frequency in the cohort was above a certain threshold, e.g., 1,000 without any further 
selection. In the second method, we generated a model using covariates that were associated 
with the outcome. The chi-square test was used to select covariates that were statistically 
significantly associated with the outcome (p-value less than 0.05).  
The selected features were subsequently used in a large-scale regularized regression 
using a LaPlace prior304 with the hyperparameter of 0.01 to construct a propensity model for 
each method. The advantage of using a regularized regression is that it can handle high-
dimensional data.305 A flowchart depicting the process of propensity score model generation 
(for methods 1 and 2) is presented in Figure 2. 
 
 
Figure 2. Flowchart showing the process of generating a propensity score model from unstructured free text. 
 
We used three-fold cross-validation306 to evaluate the predictive accuracy of the two models. 
The data set was randomly divided in three equally-sized subsets or folds. In three cross-
validation runs, each time, the model was successively trained on two folds and tested on the 
third fold. For each cross-validation run, an area under the receiver operating characteristic 
curve (AUC) was calculated. The averaged AUC was used as the overall performance measure. 
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One-to-many propensity score matching 
 
The propensity score was used to account for the preferential prescribing of selective COX-2 
inhibitors to patients at high-risk of developing an upper GI bleeding294. In this study, we used 
the greedy one-to-many matching as described by Rassen et al.307: 
1. For each selective COX-2 inhibitor user the difference in PS with all nsNSAID users 
was computed 
2. Starting with the lowest difference, each selective COX-2 inhibitor user was matched 
with one nsNSAID user. Once an nsNSAID user was matched, he or she was precluded 
from further matching. A caliper of 0.01 was used, meaning no matches were made if 
the difference in PS was greater than 0.01. 
3. After all selective COX-2 inhibitor users were matched with one nsNSAID user, the 
process was repeated until all new nsNSAID users were matched to new selective 
COX-2 inhibitor users or there was no match possible.  
The algorithm ensured that all selective COX-2 inhibitor users were matched with at least one 
nsNSAID user if such a match was available within the caliper. 
 
Statistical Analysis 
 
To estimate the risk of upper GI bleeding among selective COX-2 inhibitor users compared to 
nsNSAID users we calculated hazard ratios with their corresponding 95% confidence intervals 
(CIs) using Cox proportional hazard regression. We conducted the analysis for four datasets: 1) 
a crude comparison (unmatched); 2) matched on age (± 2 years) and adjusted for sex and 
exposure to low-dose aspirin; 3) matched on PS with covariate frequency above 1,000 and 
then adjusted for age, sex, and exposure to low-dose aspirin; and 4) matched on PS with 
covariates having an association with the outcome and then adjustment for age, sex, and 
exposure to low-dose aspirin. 
 
RESULTS 
 
NSAID cohort 
 
From the source population of more than 1.8 million patients we identified 518,768 new users 
of NSAIDs based on ATC codes. We then processed the unstructured free-text in the entries of 
the new users to identify mentioning of drug names corresponding with NSAID-related ATC 
codes. In total, 36,188 new users were removed because either an nsNSAID or selective COX-2 
inhibitor drug was mentioned in the free-text in the six months preceding first NSAID 
exposure. This resulted in 482,580 new NSAID users in the study cohort. Out of these, 459,701 
(95%) were nsNSAID users and 22,879 (5%) were selective COX-2 inhibitor users. Within the 
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RESULTS 
 
NSAID cohort 
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of NSAIDs based on ATC codes. We then processed the unstructured free-text in the entries of 
the new users to identify mentioning of drug names corresponding with NSAID-related ATC 
codes. In total, 36,188 new users were removed because either an nsNSAID or selective COX-2 
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NSAID cohort we retrieved 11,994 potential upper GI bleeding patients. After reviewing the 
medical records we retained 1,048 upper GI bleedings. 
The average duration of episodes for initiators of selective COX-2 inhibitors was 94 
days and 66 days for initiators of nsNSAIDs. Baseline characteristics of initiators of selective 
COX-2 inhibitors and nsNSAIDs are shown in Table 1. Most of the episodes of selective COX-2 
inhibitors and nsNSAIDs were started after the year 2004. 
 
Propensity model 
 
In total, we extracted 2,762,326 covariates (i.e., unique words) from approximately 2.4 million 
entries in the 6 months prior to NSAID episodes from the medical records of 482,580 new 
NSAID users. Table 2 shows the performance of the propensity models built using different 
covariates selection methods. The first model used all covariates with a frequency of 100 or 
more in the cohort, which resulted in 95,078 unique covariates entered into the model. 
Increasing the frequency to 1,000 resulted in a reduction of the number of covariates to 
27,619. The number of covariates further reduced when frequency was increased to 5,000. 
The performance of the models in terms of their predictive accuracy was comparable. The 
predictive performance of the propensity model that was built using 3,650 covariates that had 
an association with the outcome according to the chi-square test. This resulted in an AUC of 
70.59. The performance of the propensity model that included only the established 
confounders resulted in an AUC of 66.27. The number of covariates in the models however 
were only 111. 
 
Risk of upper gastrointestinal bleeding  
 
The crude hazard ratio of upper GI bleeding for selective COX-2 inhibitors compared to 
nsNSAIDs was 0.50 (95% 0.18-1.36) (Table 3). When matched on age, the hazard ratio of 
selective COX-2 inhibitor use compared to nsNSAID use was 0.36 (95% CI: 0.11-1.16). Further 
adjusting for sex and exposure to low-dose aspirin resulted in HR of 0.35 and 0.36 respectively. 
Matching on PS only, using one-to-many matching with a covariate frequency above 1,000, 
yielded a hazard ratio of 0.42 (95% CI: 0.13 – 1.38). Subsequent adjustment for age resulted in 
a hazard ratio of 0.36 (95% CI: 0.10 – 1.22). Matching on PS with covariates associated with 
outcome gave a hazard ratio of 0.42 (95% CI: 0.13 – 1.39). Adjusting for age reduced the ratio 
to 0.32 (95%: 0.09 – 1.09). The top 25 covariates, in terms of their weights (beta values), from 
both propensity score models are presented in Supplementary Table 2-3.  
  
 
 
Table 1. Baseline characteristics of initiators of selective COX-2 inhibitors and nonselective NSAIDs. 
 
Characteristics % 
 Selective COX-2 initiators 
(n=22,879) 
nsNSAID initiators 
(n=459,701) 
Age (mean) 57.7 47.9 
Male 36.5 43.2 
Female 63.5 56.8 
Exposure to low-dose aspirin 2.8 1.1 
Age (years)   
    ≤ 30 6.5 17.3 
    31 – 40 8.4 16.1 
    41 – 50 17.7 22.4 
    51 – 60 22.4 19.7 
    61 – 70 20.8 13.8 
    71 - 80 15.9 7.7 
    > 80 8.3 3.0 
Calendar year of treatment initiation   
    before 2003 0.1 10.8 
    2003 1.4 2.0 
    2004 3.1 1.9 
    2005 1.6 1.9 
    2006 1.5 1.3 
    2007 2.6 2.3 
    2008 7.3 6.7 
    2009 11.5 12.3 
    2010 15.6 16.4 
    2011 22.7 20.6 
    2012 30.7 22.7 
    2013 1.9 1.1 
Upper GI risk factors   
     Use of antiplatelets 6.3 3.2 
     Use of anticoagulants 3.2 1.3 
     Use of gastroprotective agents 23.4 11.8 
Other comorbidities   
     Dyspepsia 0.2 0.2 
     Smoking 0.5 0.5 
     Heart failure 0.4 0.2 
     Diabetes mellitus 0.5 0.3 
Concomitant use of other medications   
     Selective serotonin reuptake inhibitors 4.4 3.3 
     Spironolactone 0.7 0.3 
     Calcium channel blockers 7.2 3.7 
 
Table 2. Predictive performance of different hd-PS models built using covariates with different frequencies in 
the data set.  
 
 PS Model Number of 
covariates 
AUC* 
 Covariate frequency ≥ 100 95,078 72.27 
Method 1 Covariate frequency ≥ 1,000 27,619 72.32 
 Covariate frequency ≥ 5,000 11,699 72.17 
Method 2 Covariates selected using Chi-square test (independent of frequency) 3,650 70.59 
 
* AUC, area under the Receiver Operating Characteristic curve. 
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Table 3. Hazard ratios with 95% confidence intervals (CI) comparing selective COX-2 inhibitors with nsNSAIDs. 
 
Matching Adjustment Hazard ratio 95% CI 
Unmatched None 0.50 0.18 – 1.36 
Age None 0.36 0.11 – 1.16 
 Sex 0.35 0.11 – 1.18 
 Sex, Aspirin 0.36 0.11 – 1.18 
Propensity Score  
covariate frequencies > 1,000 
None 0.42 0.13 – 1.38 
Age 0.36 0.10 – 1.22 
Sex 0.39 0.12 – 1.30 
Age, Sex 0.35 0.96 – 1.25 
Sex, Aspirin 0.39 0.12 – 1.32 
Propensity Score  
covariates based on association test 
None 0.42 0.13—1.39 
Age 0.32 0.09—1.09 
Sex 0.43 0.13—1.42 
Age, Sex 0.31 0.09 – 1.08 
Sex, Aspirin 0.43 0.13—1.42 
 Age, Sex, Aspirin 0.31 0.09 – 1.10 
 
For (a) Unmatched -crude, (b) Matched on age only and then adjusting for sex and similar exposure to low-dose aspirin (c) 
Matched on PS only and then adjusting on age, sex, and similar exposure to low-dose aspirin (d) Matched on PS built using 
covariates selected with chi-square test and then adjusting on age, sex, and similar exposure to low-dose aspirin. 
 
DISCUSSION 
 
In this study, we generated a propensity model using unstructured information from electronic 
healthcare records (EHR). We tested different methods to construct this and demonstrated 
the feasibility to do so as well as its performance. Since electronic health records are now 
widely available for secondary use, we need to develop methods and test performance of 
these methods for use in epidemiological evaluations such as drug effects. 
Our method to generate a propensity score model is substantially different from the 
high-dimensional propensity score (hd-PS) approach proposed by Schneeweiss et al.302 The hd-
PS algorithm that was developed for claims data uses structured information such as 
diagnostic codes, in-patient procedure codes, and drugs dispensed. In each identified data 
dimension, the highest ranked codes are selected to enter in the hd-PS model. Our method is 
different since we used as the basis unstructured text to generate propensity models, using a 
large-scale regularized regression, without pre-identified data dimensions. Several methods 
other than logistic regression such as data-adaptive and classification trees have been 
proposed for fitting a propensity model.305 To reduce the number of ‘meaningless’ features, 
we needed various textual data cleaning steps. We subsequently extracted all unigrams from 
the cleaned free-text, which served as potential covariates. Here we applied different 
approaches, to look at the impact of our choices. In the first method, the most-frequent 
covariates in the cohort were selected to enter the propensity score model. Since the 
covariates were selected merely on the basis of their frequency in the cohort, this method is 
 
 
prone to include covariates that may actually be instrumental variables. Instrumental variables 
have an association with the exposure but not with the outcome except through their effect 
on exposure. If covariates are included that are not true confounders, the variance increases 
and sometimes  a small amount of bias may be introduced.103, 308-310 In order to mitigate the 
potential to include covariates that are instrumental variables we included covariates with a 
significant association with the outcome to the propensity score model in the second method 
we applied.310  
We used three-fold cross-validation to evaluate the predictive performance of each 
generated model. The propensity models generated using covariates with only high frequency 
in the cohort performed better. This may be due to the presence of some instrumental 
variables which can result in a decrease in performance (mean squared error) but increase in 
predictive performance.311 Increasing the frequency threshold for covariate selection reduced 
the number of covariates that entered into the propensity score model but the performance 
of the models was still comparable. This suggests that the performance of the models was 
mostly based on a few covariates with high occurrence in the text. Reducing the number of 
covariates reduced the computation time needed to fit the model. By selecting covariates with 
an association with the outcome we significantly reduced the total number of covariates 
without greatly affecting the performance. The propensity models generated using covariates 
with only high frequency in the cohort performed better than the one where association with 
the outcome was verified. This may be due to the presence of some instrumental variables 
which can result in an increase in predictive performance.305 We used another propensity 
model for the comparison purposes where only the established confounders age, sex, and 
exposure to low-dose aspirin were included. The predictive performance of this model was 
lower than the other two models which were generated from the free-text covariates. The 
second method, where covariate association with the outcome was verified, showed large 
decrease in the hazard ratios after further adjustments. 
Whereas previous studies have constructed the hd-PS with structured information, 
such as ICD and READ codes across different data dimensions in different sources,296, 301, 302, 312 
large proportions of information may be unstructured. We showed that this unstructured free-
text can be used to construct propensity models. A high number of removals (7%) from the 
cohort based on a drug mentioned in the free-text indicates the importance of processing 
unstructured free-text instead of only relying on the structured information such as 
prescription tables containing ATC codes.  
Our study also has several limitations. First, by including covariates based on their 
frequencies we might have selected covariates that are not necessarily related to the outcome 
or the exposure, which could introduce bias.299, 313 Second, since we only used unigrams, 
covariates like ‘congestive heart failure’ cannot be recognized as such. Instead it will be 
recognized as individual words ‘congestive’ ‘heart’ and ‘failure’ which might lead to over- and 
underestimation of some covariates. Like previous studies using hd-PS methods, we also used 
the known association between NSAIDs and upper GI bleeding as an example. It is unclear 
whether our findings regarding the PS generated from unstructured free-text apply to other 
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treatment-outcome pairs. Since the PS algorithm in general relies on the information present 
in the cohort, a similar approach using a different data set might have different results even 
when using the known example of NSAID-upper GI bleeding. 
The majority of selective COX-2 inhibitor episodes started after the year 2004, the 
period after the withdrawal of rofecoxib from the market because of cardiovascular risks.11 
This may explain the strong protective effect of selective COX-2 inhibitors in the crude analysis 
which we would expect, but is different from previous observational studies that were done 
more closely to the introduction of selective COX-2 inhibitors.296, 301, 302, 312 Since most of our 
patients started after the contra-indications were introduced, channeling towards high risk 
patients was less of an issue.314 
In conclusion, our study showed that PS models can be created using unstructured 
information in electronic healthcare records. This is useful for database studies using a large 
amount of unstructured free-text as in EHRs. We observed a small incremental benefit by 
matching on PS over traditional matching and adjustment for covariates. Better methods for 
extracting meaningful covariates from the free-text may be required for effective proxy 
adjustment via propensity scores. 
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Supplementary Table 1. List of ATC codes used for NSAID exposure assessment. 
 
ATC code Name Type of NSAID 
M01AA* butylpyrazolidines nonselective NSAID 
M01AB* Acetic acid derivatives nonselective NSAID 
M01AC* Oxicams nonselective NSAID 
M01AE* Propionic acid derivatives nonselective NSAID 
M01AG* Fenamates nonselective NSAID 
M01AH01 Celecoxib Selective COX-2 inhibitor 
M01AH03 Valdecoxib Selective COX-2 inhibitor 
M01AH04 Parecoxib Selective COX-2 inhibitor 
M01AH05 Etoricoxib Selective COX-2 inhibitor 
M01AH06 Lumiracoxib Selective COX-2 inhibitor 
 
*all drugs from this group are included. 
  
 
 
Supplementary Table 2. Top 25 covariates by their weights selected by the regression model (covariates 
frequency > 1000). 
 
Rank Unigram Translation Beta value 
1 dh* Diakonesse huis (type of hospital) 0.565 
2 rrzit 
Blood pressure measurement in sitting 
position 0.548 
3 nabehandeling Follow-up treatment 0.532 
4 school School  0.430 
5 orthopaedisch Orthopedic 0.376 
6 specialistische Specialist/Specialistic 0.360 
7 bacteri Bacteria 0.334 
8 tonsillen Tonsils 0.326 
9 acne Acne 0.319 
10 rfe* Reason for Encounter 0.312 
11 tonsillitis Tonsillitis 0.303 
12 bloedafname Blood sampling 0.287 
13 nvgb* Patient did not appear at appoint, no message 0.285 
14 origineel Original 0.282 
15 menstruatie Menstruation 0.279 
16 arthroscopie Arthroscopy 0.241 
17 housenumber “House number”  0.238 
18 bloedbeeld Complete blood test 0.236 
19 waarneming Observation 0.225 
20 ref* Reference/referral 0.225 
21 abnormaal Abnormal 0.223 
22 n89 ICPC Code N89 (Migraine) 0.217 
23 glu* Glucose  0.203 
24 assistent Assistant 0.202 
25 spastische Spastic 0.201 
 
* Abbreviations, might have other meanings as well depending on the context. 
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* Abbreviations, might have other meanings as well depending on the context. 
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Supplementary Table 3. Top 25 covariates by their weights selected by the regression model (chi-square test). 
 
Rank Unigram Translation Beta value 
1 rrzit Blood pressure measurement in sitting position 0.675 
2 dh* Diakonesse huis (type of hospital) 0.656 
3 school School 0.545 
4 izh* Hospital 0.413 
5 rfe* Reason for Encounter 0.376 
6 tonsillen Tonsils 0.369 
7 acne Acne 0.357 
8 cvx* Cervix 0.347 
9 declareren Declare 0.345 
10 menstruatie Menstruation 0.343 
11 tonsillitis Tonsillitis 0.309 
12 ref* Reference/referral 0.306 
13 diak* Diakonesse huis (type of hospital) 0.295 
14 erythro Erythrocyte  0.264 
15 kindergeneeskunde Pediatrics 0.263 
16 bultje Bump 0.254 
17 exfoliatieve exfoliation 0.248 
18 intensieve Intensive 0.247 
19 arthroscopie Arthroscopy 0.240 
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24 regulair Regular 0.224 
25 zelfcontrole Self-control 0.214 
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Supplementary Table 3. Top 25 covariates by their weights selected by the regression model (chi-square test). 
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ABSTRACT 
 
BACKGROUND 
Two strategies for prevention of upper gastrointestinal (GI) events for nonselective (ns)NSAID 
users are replacement of the nsNSAID by a cyclo-oxygenase-2 (COX-2)-selective inhibitor or co-
prescription of a gastroprotective agent (GPA).  
 
AIM 
Aim was to identify whether and in whom either of these strategies should be preferred in 
daily practice. 
 
METHODS 
A nested case-control study was conducted using three European primary care databases. We 
selected a cohort including all naive nsNSAID+GPA (≥ 80% GPA adherence) and COX-2 inhibitor 
users (without GPA use) aged ≥50 years. Cases with an upper GI event (i.e. symptomatic upper 
GI ulcer or bleeding (upper GI bleeding)) were matched to cohort members without an upper 
GI event on age, sex and number of individual upper GI risk factors (i.e. upper GI event history, 
age≥65 years, concomitant use of anticoagulants, antiplatelets, or glucocorticoids) and 
calendar time. Conditional logistic regression analysis was used to calculate odds ratios (ORs) 
with 95% confidence intervals (CI), while adjusting for potential confounders. 
 
RESULTS 
Within the NSAID cohort (n=617,220), 398 upper GI event cases were identified. The risk of 
upper GI events was equivalent for COX-2 inhibitor and nsNSAID+GPA (≥80% adherence) users 
(OR: 1.02; 95%CI:0.77-1.37). In concurrent glucocorticoid users, the risk of upper GI events was 
significantly elevated for nsNSAID+GPA (≥80% adherence) compared to COX-2 inhibitor users 
(OR: 9.01; 95%CI:1.61-50.50). 
 
CONCLUSION 
The risk of upper GI events was similar in nsNSAID+GPA (≥80% adherence) and COX-2 
inhibitors users. In patients concurrently using glucocorticoids a significant increase in the risk 
of upper GI events for nsNSAID+GPA users was observed and COX-2 inhibitors should be 
preferred.  
 
 
INTRODUCTION 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed by both general 
practitioners and medical specialists, and serve as key pharmacological agents in the 
management of arthralgic and inflammatory conditions. Multiple epidemiologic studies and 
prospective clinical outcome trials have characterized the risk of NSAID-related 
gastrointestinal (GI) complications, which include upper gastrointestinal (GI) ulcers and 
bleeding. To mitigate the increased risk among long term NSAID users, guidelines have been 
developed and strategies are recommended 99, 100, 315, 316 including prescription of cyclo-
oxygenase (COX)-2-selective inhibitors or concurrent use of gastroprotective agents (GPAs), 
such as proton pump inhibitors (PPIs). Although both preventive strategies aim to reduce the 
incidence of upper GI events, the risk of such complications is not eliminated; a considerable 
proportion of NSAID plus GPA users (6.3% to 8.5%) and COX-2 inhibitor users (3.7% to 8.9%) 
continues to experience upper GI events. 76-79  
Defining which of the two preventive strategies is preferred in terms of upper GI 
safety has been the scope of recent studies. Most of the randomized clinical trials showed no 
superiority for one of the preventive strategies over the other. 76-78, 317 Only one large 
randomized clinical trial showed a beneficial effect in favor of celecoxib.82 In this 6 month trial 
patients randomized to celecoxib, as compared to the combination of diclofenac and 
omeprazole, had a reduced rate of clinically significant overall gastrointestinal events when a 
composite endpoint was considered (events from both the upper and lower GI tract). Looking 
at the upper gastrointestinal tract specifically, this head to head comparison demonstrated 
similar rates for upper gastrointestinal bleeding. 82 Extrapolation of the previously described 
body of literature to guide clinicians in the care of the general population has several 
limitations. Many of the prospective randomized clinical studies have included patients using 
supra-therapeutic doses of COX-2 inhibitors or included a selected group of high-risk patients 
(i.e. those with a recent upper GI event).76-78, 82 Alternatively in some of the prospective trials, 
the presence of co-morbid diseases such as ischemic heart disease, peripheral arterial 
disease82, or congestive heart failure 78 were considered as exclusion criterion, thereby 
preferentially selecting patients at lower risk of upper GI events. Additionally, the exclusion of 
patients with frequently used co-medication (e.g. low-dose aspirin 78, anticoagulant agents 77, 78 
and corticosteroids 77) in some of the studies might be an important issue, considering that the 
use of low-dose aspirin clearly influences the efficacy of upper GI protection in COX-2 
inhibitors. 73, 318 Finally, as a consequence of protocol driven inclusion of patients with recent 
or past upper GI bleeding and in some studies, the recruitment of patients from hospital-
setting 78, 82 or endoscopy centers 76, 77, a substantial number of enrolled subjects may have had 
NSAID-associated complications and as such a higher risk.  
Apart from the clinical studies, one population-based cohort study concluded that 
COX-2 inhibitors alone were not superior to nonselective (ns)NSAID combined with PPI in the 
prevention of hospitalization for a perforated or bleeding ulcer.319 This observation was 
confirmed in an observational case-control study, using a population-based claims-database in 
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Canada, in which both gastroprotective strategies were similarly effective in the prevention of 
NSAID-related upper GI events, but it did not address the lack of adherence to PPIs.101 
However, we and others have demonstrated that in real life, GPA adherence during nsNSAID 
use is an important factor to consider when evaluating and comparing the effectiveness of 
different gastroprotective strategies. If the NSAID and PPI are given as separate medications 
non- or low adherence to GPAs is often seen320 and associated with significantly increased risk 
of nsNSAID-related upper GI events. 294, 321, 322  
Thus, whether COX-2 inhibitors and nsNSAIDs plus GPA are similarly effective in 
preventing incident NSAID-related upper GI events in daily clinical practice including patients 
both at high- and low-risk is still unknown. Therefore, we conducted a case-control study to 
compare the risk of upper GI events between COX-2 inhibitor users and nsNSAID users, who 
were highly GPA adherent (at least 80% adherence to GPAs), making use of population-based 
primary health care data from three European countries. As COX-2 inhibitors might be 
preferentially prescribed to specific patient groups, we restricted to nsNSAID users who were 
highly GPA adherent (at least 80% adherence to GPAs). 
 
METHODS 
 
Description of data sources 
 
Three similar European population-based primary care registries served as data sources: 1) the 
General Practice Research Database (GPRD) from the United Kingdom (UK, 1998–2008), 2) the 
Integrated Primary Care Information database (IPCI) from the Netherlands (1996–2007), and 
3) the Health Search/CSD Longitudinal Patient Database (HSD) from Italy (2000–2007). In these 
three countries, all citizens are registered with a primary care practice, which acts as a 
gatekeeper to secondary and tertiary medical care. For each individual patient all relevant 
medical information from primary and secondary care, as well as additional information, 
including demographics and drug prescriptions, is recorded in the health care medical record. 
All three registries comply with European Union guidelines on the use of medical data for 
research. The protocol of the present study was approved by the Medical Ethics Committee of 
each database. We have previously shown the validity to combine and to compare data from 
these databases.102, 294 For GPRD, the READ dictionary was used to identify medical diagnosis 
and symptoms, whereas the International Classification for Primary Care240 and the 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM)323 were 
used for that purpose in IPCI and HSD, respectively. In IPCI and HSD information on drug 
prescription was coded according to the Anatomical Therapeutic Chemical (ATC) 
classification.242  In GPRD information on drugs is captured with MULTILEX product dictionary 
and British National Formulary (BNF) codes.  
 
 
 
 
Determination of NSAID cohort 
 
The identification of the source population and NSAID cohort has been described elsewhere.294 
In brief, a source population was identified within each database by inclusion of patients from 
start of the study period, 50 years of age or the date that one year of valid data within the 
database was available, whichever was the most recent. The one-year period prior to inclusion 
in the source population was required for valid assessment of baseline characteristics and 
inclusion and exclusion criteria at the time of NSAID prescription. We identified a cohort of all 
new users (i.e. no NSAID prescriptions within 6 months prior to inclusion) of either COX-2 
inhibitors or nsNSAIDs (excluding the fixed combination of diclofenac with misoprostol) was 
identified. Exclusion criteria were history of gastrointestinal tract cancer, alcohol abuse, 
chronic liver disease, inflammatory bowel disease, or coagulopathy. Within the cohort of new 
users, all episodes of NSAID use were determined and defined as consecutive NSAID 
prescriptions with intervening gaps not exceeding the duration of the previous NSAID 
prescription (Figure 1). The duration of an NSAID episode was calculated by dividing the 
prescribed quantity by daily dose regimen (GPRD/IPCI) or the indication-specific defined daily 
dose (HSD). The end of an NSAID episode was defined as the end of the duration of the last 
NSAID prescription within that episode or the end of follow-up, whichever was earliest. All 
episodes from a patient were eligible for inclusion if the previous NSAID-prescription ended at 
least 6 months before the start of the next episode. The density of NSAID use was calculated 
by the number of NSAID prescription days divided by episode length. Eligible gastroprotective 
agents (GPAs) were proton pump inhibitors (PPIs), double-dosed histamine2 receptor 
antagonists (H2RAs), and misoprostol.  
For the present study, nonselective NSAID users were excluded if they did not use a 
GPA concomitantly, or if they were non-adherent to the concomitantly used GPA (i.e. coverage 
of less than 80% of the nsNSAID days). In total, 68.1% of NSAID plus GPA users were highly 
adherent.294 The exposure assessment and GPA adherence calculation are schematically 
depicted in Figure 1. The GPA adherence calculation has been described previously.322 NSAID 
episodes during which patients switched between classes of NSAIDs (from nsNSAID to COX-2 
inhibitor or vice versa) were excluded. Episodes during which COX-2 inhibitors were used 
concurrently with a GPA were also excluded. Overall, in 83.4% of COX-2 inhibitor episodes no 
GPA was used concomitantly.102 This resulted in a cohort including only nsNSAID plus GPA (≥80 
% adherence) and COX-2 inhibitor (alone) users.  
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Figure 1. Schematic illustration of NSAID exposure and GPA adherence calculation. 
 
GPA, gastroprotective agents; GI, gastrointestinal; nsNSAID, nonselective non-steroidal anti-inflammatory drugs, N adh, non 
adherent; NA, not applicable, time period not included in adherence calculation. 
 
Cases and controls selection 
 
Outcomes of interest were a composite of upper GI events (including symptomatic ulceration, 
upper GI bleeding, perforation or obstruction) and upper GI bleeding alone. Identification of 
the outcomes has been described in more detail elsewhere. 294 The date of outcome (i.e. index 
date) was determined as date of start of symptoms leading to the diagnosis of the upper GI 
event, or if this date was unknown, date of diagnosis. Events occurring within 60 days after the 
end of an NSAID episode were attributed to the previous NSAID use.325 
A nested case-control study was conducted. To each case experiencing an upper GI 
event during or within 60 days after the end of an NSAID episode, we matched all control 
persons from the cohort of the corresponding database. Controls had not experienced any 
upper GI event at the index date of the corresponding case and were at the index date alive, 
using an NSAID within 60 days prior, had equal number of upper GI risk factors (see below) as 
the case and had similar age (±3 years) and same gender.  
 
Covariates 
 
We considered as risk factors for upper GI events those that are commonly reported in 
literature: (i) age ≥ 65 years; (ii) a history of upper GI events (bleeding/ulceration); (iii) 
concurrent use of anticoagulants; (iv) concomitant use of antiplatelets (including aspirin ≤ 325 
mg/day); and (v) concomitant use of glucocorticoids (equipotent dose of ≥5 mg prednisone). 
 
 
Presence of risk factors was determined by electronic searches in all available data prior to or 
noted at the index date. Additional potential confounding factors were assessed: dyspepsia in 
the year before the NSAID episode, (history of) smoking, presence of heart failure or diabetes 
mellitus, and concomitant use of drugs associated with increased risk of bleeding (selective 
serotonin reuptake inhibitors (SSRI), spironolactone or calcium antagonists) at the index date.  
 
Statistical analyses 
 
Baseline characteristics of cases and controls were described by database and compared using 
univariate conditional logistic regression analyses. 
To estimate the risk for upper GI events and upper GI bleeding among nsNSAID + GPA 
users(≥80% adherence) in comparison to COX-2 inhibitor users, matched and adjusted odds 
ratios (OR) with 95% confidence intervals (CIs) were calculated using conditional logistic 
regression analyses for each database separately and as pooled analysis. The odds ratio can be 
interpreted as an estimate of the relative risk, as person-time is inherently accounted for in 
the analysis and the underlying source population is representative of the general 
population.326 The pooling of data across databases was performed by two methods: 1) on 
patient-level (respecting matched cases and controls from the original database); and 2) on 
study-level by estimating the risk of upper GI events for nsNSAID + GPA(≥80% adherence) use 
versus COX-2 inhibitor use per database and pooling the three obtained risk estimates using a 
meta-analytic approach, resulting in an overall risk estimate (inverse variance model) using a 
random-effects model. The latter method is only appropriate when there is no heterogeneity.  
Identification of confounders was performed by entering each potential confounder 
into the model one by one and were kept in the final model if the risk estimate for the drug 
exposure changed by more than 10%. As the duration COX-2 inhibitor use might differ from 
use of nsNSAIDs+GPA (≥80% adherence), we adjusted also for duration of the episodes and 
density of NSAID use. 
Subsequent analyses evaluated the risk of upper GI events and upper GI bleeding 
stratified by the presence of individual risk factors: age ≥65 years, history of upper GI event, 
and use of concomitant medications (antiplatelets, anticoagulants and glucocorticoids). For 
glucocorticoids, we considered an equipotent dose of prednisone 5 to 10 mg/day as low-
dosage; > 10 to 20 mg/day as moderate dosage and >20 mg/day as high-dosage. Multiplicative 
interaction was tested to identify effect modification by all of the individual upper GI risk 
factors. 
All analyses were performed using SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill). 
Statistical significance was defined as a two-sided p-value<0.05.  
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interpreted as an estimate of the relative risk, as person-time is inherently accounted for in 
the analysis and the underlying source population is representative of the general 
population.326 The pooling of data across databases was performed by two methods: 1) on 
patient-level (respecting matched cases and controls from the original database); and 2) on 
study-level by estimating the risk of upper GI events for nsNSAID + GPA(≥80% adherence) use 
versus COX-2 inhibitor use per database and pooling the three obtained risk estimates using a 
meta-analytic approach, resulting in an overall risk estimate (inverse variance model) using a 
random-effects model. The latter method is only appropriate when there is no heterogeneity.  
Identification of confounders was performed by entering each potential confounder 
into the model one by one and were kept in the final model if the risk estimate for the drug 
exposure changed by more than 10%. As the duration COX-2 inhibitor use might differ from 
use of nsNSAIDs+GPA (≥80% adherence), we adjusted also for duration of the episodes and 
density of NSAID use. 
Subsequent analyses evaluated the risk of upper GI events and upper GI bleeding 
stratified by the presence of individual risk factors: age ≥65 years, history of upper GI event, 
and use of concomitant medications (antiplatelets, anticoagulants and glucocorticoids). For 
glucocorticoids, we considered an equipotent dose of prednisone 5 to 10 mg/day as low-
dosage; > 10 to 20 mg/day as moderate dosage and >20 mg/day as high-dosage. Multiplicative 
interaction was tested to identify effect modification by all of the individual upper GI risk 
factors. 
All analyses were performed using SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill). 
Statistical significance was defined as a two-sided p-value<0.05.  
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RESULTS 
 
Patient characteristics 
 
We identified 384,469 new NSAID users in the United Kingdom (UK), 307 of who experienced 
an upper GI event (194 with upper GI bleeding). In the Netherlands 17 cases with an upper GI 
event (14 with upper GI bleeding) were identified from 55,004 new users of NSAIDs and in Italy 
74 cases with an upper GI event (17 with upper GI bleeding) were identified from 177,747 new 
NSAID users. Overall, 57,568 event-free controls were matched to these 398 upper GI event 
cases. Median number of controls was 120 per case (interquartile range: 43-201). 
Baseline characteristics of the cases and matched controls are shown in Table 1. In 
the UK, the most commonly prescribed nsNSAID was ibuprofen (56%), while celecoxib and 
rofecoxib were the most commonly prescribed COX-2 inhibitors (48% and 40%, respectively). 
In NL, the most commonly prescribed COX-2 inhibitor and nsNSAID were rofecoxib (58%) and 
diclofenac (52%), respectively. Diclofenac and nimesulide accounted for the greater part of 
nsNSAIDs in Italy (22% and 25%, respectively), whereas celecoxib (51%) and rofecoxib (41%) 
were the most frequently prescribed COX-2 inhibitors. Proton pump inhibitors comprised the 
majority of co-prescribed GPAs in nsNSAID users across countries (UK: 99.6%, NL: 97.0%, IT: 
95.8%). 
In the UK, upper GI event cases reported more often a history of upper GI event (OR: 
1.50; 95% CI: 1.04-2.16) and used concomitant anticoagulant therapy (OR: 1.85; 95% CI: 1.06-
3.25) and SSRIs more frequently (OR: 1.92; 95% CI: 1.33-2.77). In the Netherlands and Italy, 
upper GI event cases were significantly more likely to receive concomitant antiplatelet therapy 
in comparison to controls (ORNL: 6.91; 95% CI: 1.07-44.57, and ORIT: 3.12; 95% CI: 1.36-7.17). 
Upper GI bleeding cases in UK were more likely to receive concomitant anticoagulants (OR: 
2.56; 95% CI: 1.38-4.75), whereas no significant differences in anticoagulant use were 
observed between upper GI bleeding cases and controls in the Netherlands and Italy. From all 
upper GI event cases in the UK, the Netherlands and Italy, respectively 11.7%, 11.8% and 
32.4% had no documented upper GI risk factor. The majority of cases were identified as having 
one or two documented upper GI risk factors. 
Across all three countries, most NSAID episodes were of short duration (i.e. less than 
1 month), ranging from 53% in the UK to 85% in IT. The proportion of patients treated for 1-6 
months ranged from 14% in IT to 29% in UK, while 0.9% to 19% of patients in the three 
countries were treated for more than 6 months. The median duration of COX-2 inhibitor 
episodes was 30 days (interquartile range: 20-91 days) and median duration of nsNSAID +GPA 
(≥80% adherence) episodes was 28 days (interquartile range: 14-79 days). 
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RESULTS 
 
Patient characteristics 
 
We identified 384,469 new NSAID users in the United Kingdom (UK), 307 of who experienced 
an upper GI event (194 with upper GI bleeding). In the Netherlands 17 cases with an upper GI 
event (14 with upper GI bleeding) were identified from 55,004 new users of NSAIDs and in Italy 
74 cases with an upper GI event (17 with upper GI bleeding) were identified from 177,747 new 
NSAID users. Overall, 57,568 event-free controls were matched to these 398 upper GI event 
cases. Median number of controls was 120 per case (interquartile range: 43-201). 
Baseline characteristics of the cases and matched controls are shown in Table 1. In 
the UK, the most commonly prescribed nsNSAID was ibuprofen (56%), while celecoxib and 
rofecoxib were the most commonly prescribed COX-2 inhibitors (48% and 40%, respectively). 
In NL, the most commonly prescribed COX-2 inhibitor and nsNSAID were rofecoxib (58%) and 
diclofenac (52%), respectively. Diclofenac and nimesulide accounted for the greater part of 
nsNSAIDs in Italy (22% and 25%, respectively), whereas celecoxib (51%) and rofecoxib (41%) 
were the most frequently prescribed COX-2 inhibitors. Proton pump inhibitors comprised the 
majority of co-prescribed GPAs in nsNSAID users across countries (UK: 99.6%, NL: 97.0%, IT: 
95.8%). 
In the UK, upper GI event cases reported more often a history of upper GI event (OR: 
1.50; 95% CI: 1.04-2.16) and used concomitant anticoagulant therapy (OR: 1.85; 95% CI: 1.06-
3.25) and SSRIs more frequently (OR: 1.92; 95% CI: 1.33-2.77). In the Netherlands and Italy, 
upper GI event cases were significantly more likely to receive concomitant antiplatelet therapy 
in comparison to controls (ORNL: 6.91; 95% CI: 1.07-44.57, and ORIT: 3.12; 95% CI: 1.36-7.17). 
Upper GI bleeding cases in UK were more likely to receive concomitant anticoagulants (OR: 
2.56; 95% CI: 1.38-4.75), whereas no significant differences in anticoagulant use were 
observed between upper GI bleeding cases and controls in the Netherlands and Italy. From all 
upper GI event cases in the UK, the Netherlands and Italy, respectively 11.7%, 11.8% and 
32.4% had no documented upper GI risk factor. The majority of cases were identified as having 
one or two documented upper GI risk factors. 
Across all three countries, most NSAID episodes were of short duration (i.e. less than 
1 month), ranging from 53% in the UK to 85% in IT. The proportion of patients treated for 1-6 
months ranged from 14% in IT to 29% in UK, while 0.9% to 19% of patients in the three 
countries were treated for more than 6 months. The median duration of COX-2 inhibitor 
episodes was 30 days (interquartile range: 20-91 days) and median duration of nsNSAID +GPA 
(≥80% adherence) episodes was 28 days (interquartile range: 14-79 days). 
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Risk of upper GI events and upper GI bleeding  
 
To compare the risk of upper GI events between use of COX-2 inhibitors alone versus highly 
adherent nsNSAID+GPA use, a nested case-control study was conducted. From the adjusted 
model, no statistically significant decreased or increased risk was observed for nsNSAID + GPA 
users (≥80% adherence) as compared to COX-2 inhibitor users (Table 2). This holds true for the 
three countries separately and as pooled estimates on patient level (Table 2). Regarding upper 
GI bleeding specifically, similar results were observed. For both outcomes, a trend towards a 
more protective effect for nsNSAID+GPA (≥80% adherence) as compared to COX-2 inhibitors 
was observed in the Netherlands and Italy, but the adjusted model did not show a significant 
benefit (Table 2). 
Meta-analysis of studies conducted at individual database-level using a random 
effects model (no significant heterogeneity between databases was shown, I-squared values of 
0%) did not report different results from pooling on patient-level (Supplementary Figure 1). 
Using this meta-analytic approach, adjusted ORs for upper GI events and upper GI bleeding 
following nsNSAID+GPA (≥80% adherence) compared to COX-2 inhibitor use were 1.00 (95% 
CI: 0.73-1.33) and 1.11 (95% CI: 0.76-1.63), respectively. 
 
Subgroup analyses 
 
Stratification according to the predefined individual upper GI risk factors was performed to 
identify a possible preference for either strategy in specific risk groups (Table 3). Since most 
cases of upper GI events occurred in subjects aged 75 years and older, we performed 
additional analyses taking a different cut-off age of 75 years, which did not demonstrate 
different estimates from the cut-off of 65 years (data not shown). In non-antiplatelet users a 
non-significant increased risk both for upper GI events and upper GI bleeding was observed for 
nsNSAID+GPA (≥80% adherence), whereas the opposite was found for antiplatelet users. This 
interaction term was significant. 
When we compared COX-2 inhibitor use with highly adherent nsNSAID+GPA use in 
glucocorticoid users, the use of nsNSAID+GPA increased the risk for upper GI events 
considerably (OR: 7.03; 95% CI 1.35-36.45)(P=0.020). When adjusting for the dosage of 
glucocorticoids, the estimated risk increased even more (OR: 9.01; 95% CI: 1.61-
50.50)(P=0.012). Higher dosage of glucocorticoids affected the risk of upper GI events more as 
a dose-response relationship was observed (data not shown). Regarding multiplicative 
interaction, the interaction term for use of glucocorticoids was not significant.  
The withdrawal of rofecoxib from the market in 2004 influenced in general the 
prescription pattern of NSAIDs. After 2004 only celecoxib, etoricoxib, valdecoxib and parecoxib 
were available in Europe. Therefore, stratification according to time period was performed. A 
decrease in percentage of cases and controls using a COX-2 inhibitor was noticed after 
rofecoxib was not available on the market anymore. However, this did not impact on the risk  
of an upper GI event for nsNSAIDs+GPA versus COX-2 inhibitors (Table 3). 
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Risk of upper GI events and upper GI bleeding  
 
To compare the risk of upper GI events between use of COX-2 inhibitors alone versus highly 
adherent nsNSAID+GPA use, a nested case-control study was conducted. From the adjusted 
model, no statistically significant decreased or increased risk was observed for nsNSAID + GPA 
users (≥80% adherence) as compared to COX-2 inhibitor users (Table 2). This holds true for the 
three countries separately and as pooled estimates on patient level (Table 2). Regarding upper 
GI bleeding specifically, similar results were observed. For both outcomes, a trend towards a 
more protective effect for nsNSAID+GPA (≥80% adherence) as compared to COX-2 inhibitors 
was observed in the Netherlands and Italy, but the adjusted model did not show a significant 
benefit (Table 2). 
Meta-analysis of studies conducted at individual database-level using a random 
effects model (no significant heterogeneity between databases was shown, I-squared values of 
0%) did not report different results from pooling on patient-level (Supplementary Figure 1). 
Using this meta-analytic approach, adjusted ORs for upper GI events and upper GI bleeding 
following nsNSAID+GPA (≥80% adherence) compared to COX-2 inhibitor use were 1.00 (95% 
CI: 0.73-1.33) and 1.11 (95% CI: 0.76-1.63), respectively. 
 
Subgroup analyses 
 
Stratification according to the predefined individual upper GI risk factors was performed to 
identify a possible preference for either strategy in specific risk groups (Table 3). Since most 
cases of upper GI events occurred in subjects aged 75 years and older, we performed 
additional analyses taking a different cut-off age of 75 years, which did not demonstrate 
different estimates from the cut-off of 65 years (data not shown). In non-antiplatelet users a 
non-significant increased risk both for upper GI events and upper GI bleeding was observed for 
nsNSAID+GPA (≥80% adherence), whereas the opposite was found for antiplatelet users. This 
interaction term was significant. 
When we compared COX-2 inhibitor use with highly adherent nsNSAID+GPA use in 
glucocorticoid users, the use of nsNSAID+GPA increased the risk for upper GI events 
considerably (OR: 7.03; 95% CI 1.35-36.45)(P=0.020). When adjusting for the dosage of 
glucocorticoids, the estimated risk increased even more (OR: 9.01; 95% CI: 1.61-
50.50)(P=0.012). Higher dosage of glucocorticoids affected the risk of upper GI events more as 
a dose-response relationship was observed (data not shown). Regarding multiplicative 
interaction, the interaction term for use of glucocorticoids was not significant.  
The withdrawal of rofecoxib from the market in 2004 influenced in general the 
prescription pattern of NSAIDs. After 2004 only celecoxib, etoricoxib, valdecoxib and parecoxib 
were available in Europe. Therefore, stratification according to time period was performed. A 
decrease in percentage of cases and controls using a COX-2 inhibitor was noticed after 
rofecoxib was not available on the market anymore. However, this did not impact on the risk  
of an upper GI event for nsNSAIDs+GPA versus COX-2 inhibitors (Table 3). 
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DISCUSSION 
 
In this case-control study we demonstrate that the risk of an upper GI event or upper GI 
bleeding is not different between users of nonselective (ns)NSAIDs in combination with 
adherent use of a gastroprotective agent (GPA) and COX-2 inhibitor users. 
Lowering the risk of NSAID-related upper GI events can be achieved by concomitant 
use of GPAs. In particular increasing adherence to GPAs is important in reducing the risk 
nsNSAID-related upper GI events.294, 321, 322 As another preventive strategy, COX-2- selective 
inhibitors were developed to improve the gastrointestinal safety of NSAID therapy, especially 
in high-risk patients such as elderly (aged ≥65 years) patients, those with a history of upper GI 
events or concomitantly using anticoagulants, antiplatelets or corticosteroids. After the 
introduction of COX-2 inhibitors, it was shown that they indeed were associated with less 
gastrointestinal toxicity as compared to the traditional nonselective NSAIDs alone. 10, 11, 318, 327 
Several studies on this topic have been published in recent years.328 Though the 
implementation of preventive strategies has increased in recent years, there is still room for 
considerable improvement with regard to use of preventive strategies during NSAID 
therapy.321, 329 In order to investigate which preventive strategy is superior with regard to 
upper GI safety, head-to-head comparisons between COX-2 inhibitors and NSAIDs combined 
with GPAs have been performed in randomized studies. These studies showed no preference 
of one strategy over the other.76-78, 82, 317  
However, most clinical studies do not allow generalization of their results to daily 
clinical practice in Western countries, as many studies included selected categories of patients 
(i.e. high-risk patients with endoscopically documented upper GI bleed/ulcer- or with specific 
disease, in particular rheumatoid arthritis), and were performed in non-Caucasian persons, 
and in persons at very high risk of an upper GI event.  
Our results are in keeping with another observational study by Targownik et al. 
showing no superiority of nsNSAID combined with PPI use to COX-2 inhibitors in the 
prevention of NSAID-related upper GI events.101 Although the efficacy of both preventive 
strategies overall seems equivalent for the upper gastrointestinal tract in the CONDOR study, 
the COX-2 inhibitor-treated patients appeared to have a reduced risk of lower GI events as 
compared to nsNSAID plus PPI use. 82, 330 However, results from other studies evaluating lower 
GI tract events as an outcome were conflicting. 84, 86, 331, 332 A post hoc analysis of a prospective 
study showed a lower rate of serious lower GI events for rofecoxib compared to naproxen,30 
whereas this was not confirmed in a cross-sectional capsule enteroscopy study showing 
comparable small-bowel damage between long-term NSAID and COX-2 inhibitor users.34 
Mechanistically, whether the impact of NSAIDs on lower GI events reflect a reduction in risk by 
COX-2 inhibitor-use or an increase in risk by PPI-use due to altered intestinal bacteria and 
increased susceptibility to small intestinal bacterial overgrowth is still under debate.333 
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DISCUSSION 
 
In this case-control study we demonstrate that the risk of an upper GI event or upper GI 
bleeding is not different between users of nonselective (ns)NSAIDs in combination with 
adherent use of a gastroprotective agent (GPA) and COX-2 inhibitor users. 
Lowering the risk of NSAID-related upper GI events can be achieved by concomitant 
use of GPAs. In particular increasing adherence to GPAs is important in reducing the risk 
nsNSAID-related upper GI events.294, 321, 322 As another preventive strategy, COX-2- selective 
inhibitors were developed to improve the gastrointestinal safety of NSAID therapy, especially 
in high-risk patients such as elderly (aged ≥65 years) patients, those with a history of upper GI 
events or concomitantly using anticoagulants, antiplatelets or corticosteroids. After the 
introduction of COX-2 inhibitors, it was shown that they indeed were associated with less 
gastrointestinal toxicity as compared to the traditional nonselective NSAIDs alone. 10, 11, 318, 327 
Several studies on this topic have been published in recent years.328 Though the 
implementation of preventive strategies has increased in recent years, there is still room for 
considerable improvement with regard to use of preventive strategies during NSAID 
therapy.321, 329 In order to investigate which preventive strategy is superior with regard to 
upper GI safety, head-to-head comparisons between COX-2 inhibitors and NSAIDs combined 
with GPAs have been performed in randomized studies. These studies showed no preference 
of one strategy over the other.76-78, 82, 317  
However, most clinical studies do not allow generalization of their results to daily 
clinical practice in Western countries, as many studies included selected categories of patients 
(i.e. high-risk patients with endoscopically documented upper GI bleed/ulcer- or with specific 
disease, in particular rheumatoid arthritis), and were performed in non-Caucasian persons, 
and in persons at very high risk of an upper GI event.  
Our results are in keeping with another observational study by Targownik et al. 
showing no superiority of nsNSAID combined with PPI use to COX-2 inhibitors in the 
prevention of NSAID-related upper GI events.101 Although the efficacy of both preventive 
strategies overall seems equivalent for the upper gastrointestinal tract in the CONDOR study, 
the COX-2 inhibitor-treated patients appeared to have a reduced risk of lower GI events as 
compared to nsNSAID plus PPI use. 82, 330 However, results from other studies evaluating lower 
GI tract events as an outcome were conflicting. 84, 86, 331, 332 A post hoc analysis of a prospective 
study showed a lower rate of serious lower GI events for rofecoxib compared to naproxen,30 
whereas this was not confirmed in a cross-sectional capsule enteroscopy study showing 
comparable small-bowel damage between long-term NSAID and COX-2 inhibitor users.34 
Mechanistically, whether the impact of NSAIDs on lower GI events reflect a reduction in risk by 
COX-2 inhibitor-use or an increase in risk by PPI-use due to altered intestinal bacteria and 
increased susceptibility to small intestinal bacterial overgrowth is still under debate.333 
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Another area of potential benefit of COX-2 inhibitors over nsNSAID plus GPA use might be in 
selected high-risk groups. In this study, we found that in glucocorticoid users, adherent use of 
an nsNSAID plus GPA was associated with a nine times higher upper GI event risk compared to 
COX-2 inhibitors. This finding is supported by the dose-response relationship we observed 
where a higher dosage of glucocorticoids affected the risk of upper GI events more than a 
lower dosage. The interaction term was not significant, but this is due to limited power since 
the estimates differed largely. To our knowledge, no previous study studied the comparison of 
COX-2 inhibitor and nsNSAID plus GPA use in glucocorticoid users separately. Although data on 
glucocorticoids as an independent risk factor for upper GI events are scarce, prior studies have 
shown a two-fold increased risk of upper GI bleeding during glucocorticoid use alone. 118, 211, 311, 
334 When glucocorticoids are used in combination with NSAIDs, the risk of upper GI bleeding is 
estimated higher as compared to NSAID use alone or glucocorticoid use alone.118, 211, 311, 334 Up 
to now, the reason for the interaction between both drugs has not been elucidated. One might 
speculate that glucocorticoids and NSAIDs act synergistically; experimental studies have shown 
that glucocorticoids inhibit the healing of gastric mucosal damage 335, 336 as well as NSAIDs do, 
although the mechanism of inhibition differs. Alternatively, gastric bacterial overgrowth due to 
acid-suppression such as what occurs by PPI use 337, 338 might aggravate gastric mucosal 
damage by increased exposure time of gastric flora to the mucosal surface or by delayed 
gastric emptying caused by PPIs. 339 The combination of nsNSAIDs and PPIs therefore may have 
led to the observed increased risk in concurrent glucocorticoid users. As use of steroids is a risk 
factor that according to guidelines often will initiate GPA in NSAID-treated patients, this aspect 
is important to investigate in future studies. 
Although not significant, we found a tendency towards an increased upper GI event 
risk in patients with a history of an upper GI event among nsNSAID plus adherent GPA users as 
compared to COX-2 inhibitor users. In this particular high-risk patient group, one might 
consider the addition of a GPA to a COX-2 inhibitor. This combination has been shown to 
reduce the risk of NSAID-related upper GI events to a higher degree than COX-2 inhibitors 
alone or nsNSAIDs plus PPIs. 101 
In line with previous studies, concomitant use of low-dose aspirin seems to eliminate 
the upper GI risk benefit of COX-2 inhibitors. 10, 73, 327, 340 Though not significant, we observed an 
increased upper GI risk among nsNSAID plus adherent GPA compared to COX-2 inhibitor users 
who did not concomitantly use aspirin, whereas the opposite was true for concomitant aspirin 
users. The interaction term was significant, pointing to an increase in risk of upper GI events 
for COX-2 inhibitors when aspirin is used concurrently. In patients concomitantly using 
antiplatelets (including low-dose aspirin), GPAs should be recommended not only to nsNSAIDs 
users, but perhaps also to COX-2 inhibitor users.99, 101, 102  
The strength of the current study is the scale and setting: primary health care data 
from three European countries were combined reflecting real-life prescription patterns. Due 
to the setting it was possible to study both low-risk as well as high-risk patients. Previous 
evidence from clinical trials focused generally on high risk patients only. 76-78  
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Another area of potential benefit of COX-2 inhibitors over nsNSAID plus GPA use might be in 
selected high-risk groups. In this study, we found that in glucocorticoid users, adherent use of 
an nsNSAID plus GPA was associated with a nine times higher upper GI event risk compared to 
COX-2 inhibitors. This finding is supported by the dose-response relationship we observed 
where a higher dosage of glucocorticoids affected the risk of upper GI events more than a 
lower dosage. The interaction term was not significant, but this is due to limited power since 
the estimates differed largely. To our knowledge, no previous study studied the comparison of 
COX-2 inhibitor and nsNSAID plus GPA use in glucocorticoid users separately. Although data on 
glucocorticoids as an independent risk factor for upper GI events are scarce, prior studies have 
shown a two-fold increased risk of upper GI bleeding during glucocorticoid use alone. 118, 211, 311, 
334 When glucocorticoids are used in combination with NSAIDs, the risk of upper GI bleeding is 
estimated higher as compared to NSAID use alone or glucocorticoid use alone.118, 211, 311, 334 Up 
to now, the reason for the interaction between both drugs has not been elucidated. One might 
speculate that glucocorticoids and NSAIDs act synergistically; experimental studies have shown 
that glucocorticoids inhibit the healing of gastric mucosal damage 335, 336 as well as NSAIDs do, 
although the mechanism of inhibition differs. Alternatively, gastric bacterial overgrowth due to 
acid-suppression such as what occurs by PPI use 337, 338 might aggravate gastric mucosal 
damage by increased exposure time of gastric flora to the mucosal surface or by delayed 
gastric emptying caused by PPIs. 339 The combination of nsNSAIDs and PPIs therefore may have 
led to the observed increased risk in concurrent glucocorticoid users. As use of steroids is a risk 
factor that according to guidelines often will initiate GPA in NSAID-treated patients, this aspect 
is important to investigate in future studies. 
Although not significant, we found a tendency towards an increased upper GI event 
risk in patients with a history of an upper GI event among nsNSAID plus adherent GPA users as 
compared to COX-2 inhibitor users. In this particular high-risk patient group, one might 
consider the addition of a GPA to a COX-2 inhibitor. This combination has been shown to 
reduce the risk of NSAID-related upper GI events to a higher degree than COX-2 inhibitors 
alone or nsNSAIDs plus PPIs. 101 
In line with previous studies, concomitant use of low-dose aspirin seems to eliminate 
the upper GI risk benefit of COX-2 inhibitors. 10, 73, 327, 340 Though not significant, we observed an 
increased upper GI risk among nsNSAID plus adherent GPA compared to COX-2 inhibitor users 
who did not concomitantly use aspirin, whereas the opposite was true for concomitant aspirin 
users. The interaction term was significant, pointing to an increase in risk of upper GI events 
for COX-2 inhibitors when aspirin is used concurrently. In patients concomitantly using 
antiplatelets (including low-dose aspirin), GPAs should be recommended not only to nsNSAIDs 
users, but perhaps also to COX-2 inhibitor users.99, 101, 102  
The strength of the current study is the scale and setting: primary health care data 
from three European countries were combined reflecting real-life prescription patterns. Due 
to the setting it was possible to study both low-risk as well as high-risk patients. Previous 
evidence from clinical trials focused generally on high risk patients only. 76-78  
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The following limitations should be acknowledged. By performing observational studies, 
certain biases can be introduced of which confounding by indication is the most important one 
to discuss. The general practitioner’s awareness of the upper GI risk profile of the patient 
might have influenced the prescription of preventive strategy and thereby possibly introducing 
confounding by indication. After the introduction of COX-2 inhibitors, high-risk patients were 
more likely to receive a COX-2 inhibitor instead of co-prescription of a GPA to NSAIDs. 341 
Nevertheless, the preference for preventive strategies changed after warnings for an 
increased cardiovascular risk related to COX-2 inhibitors were released by regulatory 
agencies.342 Although the risk of upper GI complications with rofecoxib used to be higher than 
with celecoxib,343 in a stratified analysis the estimate of nsNSAIDs plus GPAs compared to COX-
2 inhibitors without rofecoxib after 2004 (i.e. celecoxib, etoricoxib, valdecoxib and lumiracoxib 
only) did not differ from the estimate including rofecoxib (before withdrawal). It is therefore 
unlikely that data on the use of rofecoxib prior to its withdrawal would have skewed the GI 
safety data in favor of the nsNSAID. We feel that it is therefore unlikely that the channeling 
away from COX-2 inhibitors for patients with cardiovascular disease would have led to 
important confounding. 
We tried to address confounding-by-indication by matching on the number of upper 
GI risk factors and by restricting the comparator group to nsNSAID users who were highly 
adherent to GPA (defined as at least 80% of nsNSAID days covered by a GPA prescription). 
Although crude incidence rates appeared to be equal between different levels of GPA 
adherence,294 from previous studies, we know that patients adherent to the prescribed GPA 
are at the highest risk of nsNSAID-related upper GI events.294, 322 Residual confounding due to 
exclusion of users with a lower GPA adherence level is therefore unlikely. In addition, we 
selected patient groups with a similar upper GI risk profile, by matching on number of upper GI 
risk factors, as well as gender and age. Comparison between COX-2 inhibitor and nsNSAID plus 
highly adherent GPA users showed no differences in number of upper GI risk factors. 
Confounding was also dealt with by adjusting for several co-morbid conditions. The indication 
of glucocorticoid use could only be identified in the Netherlands, of which 64% was for 
rheumatoid disorders. Nevertheless, residual confounding cannot be ruled out in 
observational studies.  
In addition, over-the-counter use of nsNSAIDs and GPA is not recorded in the 
databases and could have led to a potential underestimation of its use. We used drug 
prescription data rather than precise information on the actual use. Furthermore, the method 
of GPA adherence calculation used in the present study determined adherence based on days 
of GPA and of nsNSAID use, rather than daily coverage. However, we selected a group of 
highly adherent nsNSAID plus GPA users based on a cut off of 80% of GPA adherence. 
In conclusion, there is no difference in the risk of upper GI events between the use of 
COX-2 inhibitors and use of nsNSAIDs plus adherent GPA in daily clinical practice. Neither 
strategy was superior in the prevention of a first or a recurrent upper GI event or upper GI 
bleeding. A significant increase in the risk of upper GI events for COX-2 inhibitors was observed 
when aspirin is used concurrently, whereas during concomitant glucocorticoid use nsNSAID 
 
 
plus GPA users are at increased risk of an upper GI event compared to COX-2 inhibitor users. 
Future studies on this topic are needed, as use of steroids is a risk factor that, according to 
guidelines, often will initiate GPA therapy in NSAID-treated patients. 
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Supplementary Figure 1. Forest plots of the adjusted analysis for Upper GI events and Upper GI bleeding. 
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ABSTRACT 
 
BACKGROUND 
Concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin 
increases the risk of upper gastrointestinal (GI) bleeding. Guidelines suggest avoiding certain 
drug combinations, yet little is known about the magnitude of their interactions.  
 
AIM 
We estimated the risk of upper GI bleeding during concomitant use of nonselective 
(ns)NSAIDs, cyclooxygenase -2 selective inhibitors (COX-2 inhibitors), and low-dose aspirin with 
other drugs. 
 
METHODS 
We performed a case series analysis of data from 114,835 patients with upper GI bleeding 
(930,888 person-years of follow-up) identified from 7 population-based health care databases 
(approximately 20 million subjects). Each patient served as his or her own control. Drug 
exposure was determined based on prescriptions of nsNSAIDs, COX-2 inhibitors, or low-dose 
aspirin, alone and in combination with other drugs that affect the risk of upper GI bleeding. 
We measured relative risk (incidence rate ratio [IRR] during drug exposure vs nonexposure) 
and excess risk due to concomitant drug exposure (relative excess risk due to interaction 
[RERI]). 
 
RESULTS 
Monotherapy with nsNSAIDs increased the risk of diagnosis of upper GI bleeding (IRR, 4.3) to a 
greater extent than monotherapy with COX-2 inhibitors (IRR, 2.9) or low-dose aspirin (IRR, 
3.1). Combination therapy generally increased the risk of upper GI bleeding; concomitant 
nsNSAID and corticosteroid therapies increased the IRR to the greatest extent (12.8) and also 
produced the greatest excess risk (RERI, 5.5). Concomitant use of nsNSAIDs and aldosterone 
antagonists produced an IRR for upper GI bleeding of 11.0 (RERI, 4.5). Excess risk from 
concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6, 
whereas that from use of COX-2 inhibitors with SSRIs was 1.9 and that for use of low-dose 
aspirin with SSRIs was 0.5. Excess risk of concomitant use of nsNSAIDs with anticoagulants was 
2.4, of COX-2 inhibitors with anticoagulants was 0.1, and of low-dose aspirin with 
anticoagulants was 1.9. 
 
CONCLUSION 
Based on a case series analysis, concomitant use of nsNSAIDs, COX-2 inhibitors, or low-dose 
aspirin with SSRIs significantly increases the risk of upper GI bleeding. Concomitant use of 
nsNSAIDs or low-dose aspirin, but not COX-2 inhibitors, with corticosteroids, aldosterone 
antagonists, or anticoagulants produces significant excess risk for upper GI bleeding.  
 
 
INTRODUCTION 
 
Upper gastrointestinal (GI) bleeding has a major impact on patients’ quality of life and public 
health care costs.344 Although great improvements in prevention and treatment of upper GI 
bleeding have been achieved in recent decades, upper GI bleeding-related morbidity and 
mortality remain substantial.70 Most previous studies have focused on risks associated with 
use of non-steroidal anti-inflammatory drugs (NSAIDs), which is one of the most common 
causes of upper GI bleeding. Clinical guidelines therefore recommend preventive strategies for 
at-risk patients treated with NSAIDs, including coprescription of proton pump inhibitors. 
Another preventive strategy is use of cyclo-oxygenase-2 selective inhibitors (COX-2 inhibitors), 
developed as a safer alternative to nonselective (ns)NSAIDs, especially among high-risk 
patients.11 
Use of low-dose aspirin is considered the standard of care for cardiovascular 
prevention. However, low-dose aspirin is also known to increase the risk of upper GI 
bleeding.73 The relative risk of upper GI bleeding associated with current use of low-dose 
aspirin compared with no use ranges from 1.6 to 4.0.73, 334, 345 Thus, coprescription of 
gastroprotective agents (GPAs) is also recommended for at-risk patients treated with low-dose 
aspirin as a key strategy to minimize upper gastrointestinal events.112 Adherence to preventive 
strategies in patients treated with low-dose aspirin is especially important given that an 
estimated 20% of these patients will also use NSAIDs and approximately 35% of the elderly 
population regularly uses low-dose aspirin.112  
Clinical guidelines suggest avoiding use of certain drugs in combination with 
nsNSAIDs as well as COX-2 inhibitors; these drugs include corticosteroids, anticoagulants, 
selective serotonin reuptake inhibitors (SSRIs), and antiplatelets.99 However, the concurrent 
use of NSAIDs with these other drugs has not been widely studied, and it remains unknown if, 
and to what extent, combinations of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin with 
specific other drug groups exert synergistic effects on the risk of upper GI bleeding. 
Understanding drug synergism is important in developing strategies to minimize the 
risk of upper GI bleeding, particularly in elderly patients who are at high risk for upper GI 
bleeding and are likely to use multiple drugs.120, 122 Therefore, we aimed to estimate the 
magnitude of interaction between nsNSAIDs, COX-2 inhibitors, or low-dose aspirin and specific 
drug groups reported to affect the risk of diagnosed upper GI bleeding. 
 
METHODS 
 
Data sources 
 
Data were obtained from a network of 7 electronic health record (EHR) databases from 3 
countries. The EU-ADR Project (Exploring and Understanding Adverse Drug Reactions by 
integrative mining of clinical records and biomedical knowledge) has successfully established a 
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platform that integrates data from various repositories of European EHRs for evaluation of 
drug safety.346 
We analyzed data from 3 primary care databases (Integrated Primary Care 
Information [IPCI, The Netherlands]; Health Search/CSD Longitudinal Patient Database [HSD, 
Italy]; and Pedianet [Italy]) and 4 administrative/claims databases (Aarhus University Hospital 
Database [Aarhus, Denmark], PHARMO Institute [PHARMO, The Netherlands], and the regional 
databases of Lombardy [UNIMIB, Italy] and Tuscany [ARS, Italy]). The characteristics and study 
periods of the databases are shown in Table 1. All of these databases have been extensively 
used in epidemiological studies.346-349  
Subjects can enter and may also leave the database at any time for several reasons 
(eg, death, moving out of the region, leave of practice). The primary care databases capture all 
prescriptions from general practitioners and some from secondary care (eg, repeat 
prescriptions). The study protocol was approved by the review board for all databases. 
 
Study Design 
 
The study population included all people registered in the database network with at least 1 
year of valid and continuous data. A self-controlled case series (SCCS) analysis was performed 
on all identified cases of upper GI bleeding. The SCCS is a case-only study (ie, control subjects 
are not included) in which the relative incidence of upper GI bleeding is estimated for exposed 
and nonexposed time in each case. 350, 351 Each case serves as its own control. The SCCS 
method assumes that all cases in the analysis should (1) have exposed and unexposed person-
time, (2) experience an upper GI bleeding, and (3) contribute follow-up time before and after 
the upper GI bleeding. The primary advantage of the SCCS is that it automatically adjusts for 
confounding factors that are fixed within subjects (ie, genetic factors, sex, chronic disease, or 
other comorbidity).  
 
Case definition 
 
From the study population, we identified all subjects who experienced an upper GI bleeding 
during follow-up by using pertinent disease codes from the different coding systems in each 
database.346 Upper GI bleeding was assessed using hospital discharge codes (in claims 
databases) or general practitioner diagnosis/recordings (in primary care databases). We 
included all codes indicating gastroduodenal ulcers and hemorrhages, melena and 
hematemesis. Codes for variceal bleeding specifically were not included. We only included 
codes corresponding to an acute upper GI bleeding, because for the SCCS the outcome should 
be an acute event with a clear disease onset. Supplementary Table 1 shows the corresponding 
codes for each coding system. A free-text search of clinical narratives was performed in IPCI 
and HSD.  
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platform that integrates data from various repositories of European EHRs for evaluation of 
drug safety.346 
We analyzed data from 3 primary care databases (Integrated Primary Care 
Information [IPCI, The Netherlands]; Health Search/CSD Longitudinal Patient Database [HSD, 
Italy]; and Pedianet [Italy]) and 4 administrative/claims databases (Aarhus University Hospital 
Database [Aarhus, Denmark], PHARMO Institute [PHARMO, The Netherlands], and the regional 
databases of Lombardy [UNIMIB, Italy] and Tuscany [ARS, Italy]). The characteristics and study 
periods of the databases are shown in Table 1. All of these databases have been extensively 
used in epidemiological studies.346-349  
Subjects can enter and may also leave the database at any time for several reasons 
(eg, death, moving out of the region, leave of practice). The primary care databases capture all 
prescriptions from general practitioners and some from secondary care (eg, repeat 
prescriptions). The study protocol was approved by the review board for all databases. 
 
Study Design 
 
The study population included all people registered in the database network with at least 1 
year of valid and continuous data. A self-controlled case series (SCCS) analysis was performed 
on all identified cases of upper GI bleeding. The SCCS is a case-only study (ie, control subjects 
are not included) in which the relative incidence of upper GI bleeding is estimated for exposed 
and nonexposed time in each case. 350, 351 Each case serves as its own control. The SCCS 
method assumes that all cases in the analysis should (1) have exposed and unexposed person-
time, (2) experience an upper GI bleeding, and (3) contribute follow-up time before and after 
the upper GI bleeding. The primary advantage of the SCCS is that it automatically adjusts for 
confounding factors that are fixed within subjects (ie, genetic factors, sex, chronic disease, or 
other comorbidity).  
 
Case definition 
 
From the study population, we identified all subjects who experienced an upper GI bleeding 
during follow-up by using pertinent disease codes from the different coding systems in each 
database.346 Upper GI bleeding was assessed using hospital discharge codes (in claims 
databases) or general practitioner diagnosis/recordings (in primary care databases). We 
included all codes indicating gastroduodenal ulcers and hemorrhages, melena and 
hematemesis. Codes for variceal bleeding specifically were not included. We only included 
codes corresponding to an acute upper GI bleeding, because for the SCCS the outcome should 
be an acute event with a clear disease onset. Supplementary Table 1 shows the corresponding 
codes for each coding system. A free-text search of clinical narratives was performed in IPCI 
and HSD.  
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A validation study was conducted in 4 of the databases used in the current study352 and 
showed a high concordance for International Classification of Diseases (ICD)-9 (positive 
predictive value [PPV] of 78% and 72%) and ICD-10 codes (PPV of 77%) that was not seen with 
the International Classification for Primary Care coding system (PPV of 21% for codes and free 
text only). 
 
Exposure definition 
 
We focused on concomitant use of nsNSAIDs, COX-2 inhibitors, and low-dose aspirin with 
other drugs reported to be associated with an increase or decrease in risk of upper GI 
bleeding. The drug groups of interest were as follows: (1) nsNSAIDs,73 (2) COX-2 inhibitors,353 
(3) low-dose aspirin,73, 349 (4) high-dose aspirin,354 (5) corticosteroids,72, 118, 211, 311, 334, 355 (6) 
SSRIs,356 (citalopram, fluoxetine and paroxetine were assessed individually) (7) GPAs,356, 357 (8) 
aldosterone antagonists,348, 358 (9) calcium channel blockers,359, 360 (10) anticoagulants,73, 119 (11) 
antiplatelets,73, 119 and (12) nitrates.73, 357 Drugs of interest were categorized according to the 
World Health Organization’s Anatomical Therapeutic Chemical (ATC) classification system.242 
Supplementary Table 2 shows the corresponding ATC codes. We created mutually exclusive 
exposure categories: no use of any drug of interest (reference group), use of only one drug of 
interest, or concurrent use of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin with one other 
drug of interest (Supplementary Figure 1). All other combinations of drugs of interest and 
combinations of >2 drugs were combined in a separate category. Fixed drug combinations 
were included in the corresponding drug combination group. Duration of exposure was 
calculated by dividing the total number of prescribed/dispensed pills by the number of pills per 
day or defined daily dosages. We assumed that all dispensed drugs were consumed. All 
exposed and unexposed person-time was therefore included in the analysis. Drug dose and 
frequency were not taken into account because such information is not consistently recorded 
in all databases. 
 
Main statistical analyses 
 
To estimate the relative incidence of upper GI bleeding, incidence rate ratios (IRRs) with 95% 
confidence intervals (CIs) were obtained using conditional Poisson regression by comparing 
the incidence rate of upper GI bleeding during periods of drug exposure with the incidence 
rate during all other observed time periods. Age-adjusted IRRs were calculated within each 
database and by pooling all data together (IRRp). To account for heterogeneity between the 
databases, pooling of data was also performed by a random effects meta-analytic model on 
the database-specific risk estimates resulting in an overall IRR. To estimate the magnitude of 
drug interaction (excess risk), the following measures were calculated: the relative excess risk 
due to interaction (RERI), the proportion attributable to interaction (AP), and the synergy 
index (S).361  
 
 
Interaction on an additive scale meant that the observed effect of the drug combination was 
larger than the sum of the effects of the drugs separately but less than multiplicative. If the IRR 
of the combination was more than the sum of the 2 drugs separately, interaction (at least on 
an additive scale) was present. Corresponding 95% CIs were also calculated for the RERI using 
the Hosmer–Lemeshow delta method.362 The estimated measure of the RERI, AP, or S itself 
does not provide any information on risk and cannot be interpreted in isolation. However, 
based on the relative risk, it can be concluded that an excess risk is present when the RERI is 
larger than 0 and the CIs around it do not cross 0. Additionally, it may be concluded that there 
is more excess risk with a RERI of 1 than with a RERI of 2 (see Supplementary Table 3 for more 
details). 
Population attributable risk (PAR) was calculated to estimate the proportion of upper 
GI bleeding in the general population that is attributable to concomitant use of drugs using the 
following formula: PAR= ( p* [IRR-1])]/(p*[IRR-1]+1).347 For this calculation drug utilization data 
from the participating databases (data not shown) were used to derive the prevalence of 
exposure (p) to which the IRR pertained.  
 
Sensitivity analyses 
 
Because increasing age confers additional risk of upper GI bleeding, analyses by stratifying on 
age (with a cut off of 60 and 70 years) and sex were conducted to investigate effect 
modification by age or sex. To explore the possibility of confounding by contraindication we 
performed a sensitivity analysis by truncating the drug exposure at time of event. A pooled 
analysis excluding the IPCI database was performed due to the low PPV in IPCI. 
 
RESULTS 
 
Risk of Upper GI bleeding with Drug Monotherapy 
 
In total 114,835 patients with upper GI bleeding (cases) with corresponding follow-up of 
930,888 person-years were included in the analysis (Table 1). For all drugs of interest, 
monotherapy showed a significant increased relative risk compared with no use of any of the 
drugs of interest. Monotherapy with nsNSAIDs was associated with an IRRp of 4.3 (95%CI, 4.1-
4.4), which is higher than monotherapy with either COX-2 inhibitors (IRRp, 2.9; 95%CI, 2.7-3.2) 
or low-dose aspirin (IRRp, 3.1; 95%CI, 2.9-3.2) (Table 2). The risk of diagnosed upper GI 
bleeding for all other drugs ranged between 1.6 for calcium channel blockers to 4.1 for 
corticosteroids (Table 2). IRRs were also estimated for 3 individual SSRIs and yielded an IRRp of 
2.0 (95%CI, 1.6-2.5) for fluoxetine, 2.3 (95% CI, 2.1-2.5) for citalopram and 1.9 (95%CI 1.7-2.2) 
for paroxetine, all similar to the IRRp for the overall SSRI class 2.1 (95% CI, 1.9-2.2). 
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Supplementary Table 4 shows the total duration of exposure to each drug and drug 
combination and Supplementary Table 5 shows the distribution of events across age groups 
and sex. 
 
Risk of Upper GI bleeding with Drug Combinations 
 
Generally, concomitant nsNSAID use with other drugs showed a higher risk for diagnosed 
upper GI bleeding compared with a combination with low-dose aspirin or COX-2 inhibitors 
(Table 2). To estimate the risk of diagnosed upper GI bleeding for drug combinations with 
nsNSAIDs, COX-2 inhibitors or low-dose aspirin, estimates of the separate drugs of interest 
were pooled. Combinations of any of the drugs of interest with nsNSAIDs yielded the highest 
IRR (6.9; 95%CI, 5.3-9.1), followed by combinations with low-dose aspirin (4.6; 95%CI, 3.6-6.0) 
and with COX-2 inhibitors (4.2; 95%CI, 3.0-5.9).  
Looking at separate drug classes, the highest risk of diagnosed upper GI bleeding was 
observed for the combination of nsNSAIDs and corticosteroids (IRRp, 12.8; 95%CI, 11.2-14.7), 
which was higher than the risk with use of low-dose aspirin and corticosteroids (IRRp, 8.4; 
95%CI, 7.1-9.8) or COX-2 inhibitors and corticosteroids (IRRp, 6.0; 95%CI, 4.3-8.3). Use of 
aldosterone antagonists with nsNSAIDs resulted in an IRRp of 11.0 (95%CI, 8.6-14.0), which 
was also higher than the combined use of aldosterone antagonists and low-dose aspirin (IRRp, 
5.0; 95%CI, 4.1-6.1) or that with COX-2 inhibitors (IRRp, 4.0; 95%CI, 2.1-7.8). 
The combination of anticoagulants with nsNSAIDs showed an IRRp of 8.7 (95%CI, 7.3-
10.4), which was higher than the combination of anticoagulants with low-dose aspirin (IRRp, 
6.9; 95%CI, 5.9-8.2) or that with COX-2 inhibitors (IRRp, 5.0; 95%CI, 3.2-7.8). Combinations 
with SSRIs were associated with a 5-, 6- and 7-fold increased risk for low-dose aspirin, COX-2 
inhibitors and nsNSAIDs, respectively. When using a meta-analytic approach by applying a 
random-effects model, substantial heterogeneity across databases was observed for some 
drug combinations but generally resulted in minor attenuations of the effects (Supplementary 
Table 6). 
 
Excess Risk 
 
Excess risk due to concomitant drug use, measured by additive interaction of nsNSAIDs/COX-2 
inhibitors/low-dose aspirin use with other drugs, is shown in Figure 1 and Supplementary 
Table 3. The highest excess risk was observed for the combination of nsNSAIDs and 
corticosteroids (RERI, 5.5; 95%CI, 3.7-7.3). Corticosteroids had significant interaction with low-
dose aspirin as well, but not with COX-2 inhibitors. Aldosterone antagonists showed significant 
interaction with nsNSAIDs (RERI, 4.5; 95%CI, 1.8-7.1) but not with low-dose aspirin or COX-2 
inhibitors. Anticoagulants showed significant interaction with nsNSAIDs and with low-dose 
aspirin but not with COX-2 inhibitors. Combinations of nsNSAIDs, COX-2 inhibitors or low-dose 
aspirin with GPAs or nitrates did not show excess NSAID-associated upper GI bleeding risk.  
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Supplementary Table 4 shows the total duration of exposure to each drug and drug 
combination and Supplementary Table 5 shows the distribution of events across age groups 
and sex. 
 
Risk of Upper GI bleeding with Drug Combinations 
 
Generally, concomitant nsNSAID use with other drugs showed a higher risk for diagnosed 
upper GI bleeding compared with a combination with low-dose aspirin or COX-2 inhibitors 
(Table 2). To estimate the risk of diagnosed upper GI bleeding for drug combinations with 
nsNSAIDs, COX-2 inhibitors or low-dose aspirin, estimates of the separate drugs of interest 
were pooled. Combinations of any of the drugs of interest with nsNSAIDs yielded the highest 
IRR (6.9; 95%CI, 5.3-9.1), followed by combinations with low-dose aspirin (4.6; 95%CI, 3.6-6.0) 
and with COX-2 inhibitors (4.2; 95%CI, 3.0-5.9).  
Looking at separate drug classes, the highest risk of diagnosed upper GI bleeding was 
observed for the combination of nsNSAIDs and corticosteroids (IRRp, 12.8; 95%CI, 11.2-14.7), 
which was higher than the risk with use of low-dose aspirin and corticosteroids (IRRp, 8.4; 
95%CI, 7.1-9.8) or COX-2 inhibitors and corticosteroids (IRRp, 6.0; 95%CI, 4.3-8.3). Use of 
aldosterone antagonists with nsNSAIDs resulted in an IRRp of 11.0 (95%CI, 8.6-14.0), which 
was also higher than the combined use of aldosterone antagonists and low-dose aspirin (IRRp, 
5.0; 95%CI, 4.1-6.1) or that with COX-2 inhibitors (IRRp, 4.0; 95%CI, 2.1-7.8). 
The combination of anticoagulants with nsNSAIDs showed an IRRp of 8.7 (95%CI, 7.3-
10.4), which was higher than the combination of anticoagulants with low-dose aspirin (IRRp, 
6.9; 95%CI, 5.9-8.2) or that with COX-2 inhibitors (IRRp, 5.0; 95%CI, 3.2-7.8). Combinations 
with SSRIs were associated with a 5-, 6- and 7-fold increased risk for low-dose aspirin, COX-2 
inhibitors and nsNSAIDs, respectively. When using a meta-analytic approach by applying a 
random-effects model, substantial heterogeneity across databases was observed for some 
drug combinations but generally resulted in minor attenuations of the effects (Supplementary 
Table 6). 
 
Excess Risk 
 
Excess risk due to concomitant drug use, measured by additive interaction of nsNSAIDs/COX-2 
inhibitors/low-dose aspirin use with other drugs, is shown in Figure 1 and Supplementary 
Table 3. The highest excess risk was observed for the combination of nsNSAIDs and 
corticosteroids (RERI, 5.5; 95%CI, 3.7-7.3). Corticosteroids had significant interaction with low-
dose aspirin as well, but not with COX-2 inhibitors. Aldosterone antagonists showed significant 
interaction with nsNSAIDs (RERI, 4.5; 95%CI, 1.8-7.1) but not with low-dose aspirin or COX-2 
inhibitors. Anticoagulants showed significant interaction with nsNSAIDs and with low-dose 
aspirin but not with COX-2 inhibitors. Combinations of nsNSAIDs, COX-2 inhibitors or low-dose 
aspirin with GPAs or nitrates did not show excess NSAID-associated upper GI bleeding risk.  
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Figure 1. Heat map of interaction of nonselective NSAIDs, COX-2 inhibitors and low-dose aspirin in combination 
with other drugs. 
 
Color intensity of the heat map is based on the Relative Excess Risk due to Interaction (RERI). Green represents no interaction, 
from yellow towards red represents presence and increasing strength of interaction. Nonselective NSAIDs (nsNSAIDs); COX-2 
selective inhibitors (COX-2 inhibitors); Not applicable (NA). 
 
Population Attributable Risk 
 
Based on an estimated 0.04% prevalence of nsNSAID use, the proportion of cases of upper GI 
bleeding in the general population attributable to nsNSAID monotherapy was 11.8 %. In other 
words, out of 100 people experiencing upper GI bleeding while exposed to nsNSAID 
monotherapy, 11.8% of these cases were attributable to nsNSAID monotherapy. The 
corresponding proportion attributable to corticosteroid monotherapy was 10.4% (estimated 
prevalence of corticosteroid use 0.04%), while the PAR for concurrent NSAID and 
corticosteroid use was 6.4%. The PAR for other drugs is shown in Supplementary Table 7. 
 
Sensitivity analyses 
 
Age stratification showed that subjects who were 60 years of age or older had higher IRRs of 
diagnosed upper GI bleeding than younger subjects (younger than 60 years) except for the 
combination of nsNSAIDs and anticoagulants and of COX-2 inhibitors with corticosteroids. No 
significant difference in risk between males and females subjects was observed. 
Sensitivity analyses with truncation of follow-up at the time of upper GI bleeding (to 
avoid confounding by contraindication) showed that the exposure pattern of the drugs (and in 
particular the nsNSAIDs) did not change after upper GI bleeding (Supplementary Figure 2). 
Corticosteroids 
Low-dose aspirin 
Anticoagulants 
SSRIs 
Aldosterone antagonists 
Antiplatelets 
Nitrates 
Calcium channel blockers 
       nsNSAIDs           selective COX-2      low-dose aspirin 
                                        inhibitors 
Gastroprotective agents 
      5.48  -0.02                  2.25 
      0.45   2.54 
      2.41   0.10                  1.87 
      1.62   1.86                  0.49 
      4.46  -1.15                  -0.31 
      1.50  -1.91                  1.70 
0.00    0.63                  -0.81 
      -0.39  -0.36                  -0.55 
      -0.98  -1.14                  -1.12 
 
 
When adjusting for acute myocardial infarction and anaphylactic shock, the results were 
similar (Supplementary Figure 3). When excluding IPCI from the main analysis, the results were 
also similar (Supplementary Figure 4). 
 
DISCUSSION 
 
We determined the magnitude of increased risk of diagnosed upper GI bleeding when 
nsNSAIDs, COX-2 inhibitors, and low-dose aspirin were combined with specific drug classes 
that may be independently associated with diagnosed upper GI bleeding. Although it may 
seem reasonable to assume synergistic effects with concurrent use of drugs that 
independently increase risk, these effects have rarely been investigated. To study the risk of 
diagnosed upper GI bleeding during use of specific drug combinations, it is essential to have a 
large number of data and an efficient study design. For this study, we used data from a huge 
network of European electronic health care databases, representing more than 20 million 
subjects. In addition, the SCCS is a suitable and efficient method to address the question of 
excess risk of upper GI bleeding with drug combinations while at the same time controlling for 
time-fixed confounding factors as well as confounding by indication. We observed that, 
overall, the risk of upper GI bleeding during concomitant use of drugs was significantly higher 
compared with what would have been expected based on the sum of the risk of the individual 
drugs. The magnitude of statistical additive interaction, which may be seen as a surrogate 
measure for biological synergism, was highest for the combination of nsNSAIDs with 
corticosteroids and the combination of nsNSAIDs with aldosterone antagonists. In line with 
previous studies, we observed that the risk of nsNSAID monotherapy was higher than that of 
monotherapy with low-dose aspirin or COX-2 inhibitors.72, 73 The risk of upper GI bleeding was 
always higher for drug combinations with nsNSAIDs than that for low-dose aspirin or COX-2 
inhibitors. 
Given that nsNSAIDs, COX-2 inhibitors, and low-dose aspirin are commonly 
consumed by elderly, with a self-reported prevalence of 35%,112 the observed risks in the 
current study emphasize the substantial risk of use of nsNSAIDs, COX-2 inhibitors, and low-
dose aspirin in the general population. This is especially true considering that elderly are 
inherently at higher risk due to physiological ageing mechanisms.121, 122  
 
Corticosteroids 
 
Interestingly, we observed that the risk of diagnosed upper GI bleeding with use of 
corticosteroid monotherapy was of the same magnitude as that with nsNSAID monotherapy. 
Previous studies have shown inconsistent results with respect to risk of upper GI bleeding with 
corticosteroids.118, 211, 355 Because nsNSAIDs are known to pose greater risk for inducing upper 
gastrointestinal ulcers compared with COX-2 inhibitors, interaction between corticosteroids 
and nsNSAIDs, but not with COX-2 inhibitors, was expected.117 The suggested 
pathophysiological mechanism behind this increased risk for corticosteroids is inhibition of 
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Color intensity of the heat map is based on the Relative Excess Risk due to Interaction (RERI). Green represents no interaction, 
from yellow towards red represents presence and increasing strength of interaction. Nonselective NSAIDs (nsNSAIDs); COX-2 
selective inhibitors (COX-2 inhibitors); Not applicable (NA). 
 
Population Attributable Risk 
 
Based on an estimated 0.04% prevalence of nsNSAID use, the proportion of cases of upper GI 
bleeding in the general population attributable to nsNSAID monotherapy was 11.8 %. In other 
words, out of 100 people experiencing upper GI bleeding while exposed to nsNSAID 
monotherapy, 11.8% of these cases were attributable to nsNSAID monotherapy. The 
corresponding proportion attributable to corticosteroid monotherapy was 10.4% (estimated 
prevalence of corticosteroid use 0.04%), while the PAR for concurrent NSAID and 
corticosteroid use was 6.4%. The PAR for other drugs is shown in Supplementary Table 7. 
 
Sensitivity analyses 
 
Age stratification showed that subjects who were 60 years of age or older had higher IRRs of 
diagnosed upper GI bleeding than younger subjects (younger than 60 years) except for the 
combination of nsNSAIDs and anticoagulants and of COX-2 inhibitors with corticosteroids. No 
significant difference in risk between males and females subjects was observed. 
Sensitivity analyses with truncation of follow-up at the time of upper GI bleeding (to 
avoid confounding by contraindication) showed that the exposure pattern of the drugs (and in 
particular the nsNSAIDs) did not change after upper GI bleeding (Supplementary Figure 2). 
Corticosteroids 
Low-dose aspirin 
Anticoagulants 
SSRIs 
Aldosterone antagonists 
Antiplatelets 
Nitrates 
Calcium channel blockers 
       nsNSAIDs           selective COX-2      low-dose aspirin 
                                        inhibitors 
Gastroprotective agents 
      5.48  -0.02                  2.25 
      0.45   2.54 
      2.41   0.10                  1.87 
      1.62   1.86                  0.49 
      4.46  -1.15                  -0.31 
      1.50  -1.91                  1.70 
0.00    0.63                  -0.81 
      -0.39  -0.36                  -0.55 
      -0.98  -1.14                  -1.12 
 
 
When adjusting for acute myocardial infarction and anaphylactic shock, the results were 
similar (Supplementary Figure 3). When excluding IPCI from the main analysis, the results were 
also similar (Supplementary Figure 4). 
 
DISCUSSION 
 
We determined the magnitude of increased risk of diagnosed upper GI bleeding when 
nsNSAIDs, COX-2 inhibitors, and low-dose aspirin were combined with specific drug classes 
that may be independently associated with diagnosed upper GI bleeding. Although it may 
seem reasonable to assume synergistic effects with concurrent use of drugs that 
independently increase risk, these effects have rarely been investigated. To study the risk of 
diagnosed upper GI bleeding during use of specific drug combinations, it is essential to have a 
large number of data and an efficient study design. For this study, we used data from a huge 
network of European electronic health care databases, representing more than 20 million 
subjects. In addition, the SCCS is a suitable and efficient method to address the question of 
excess risk of upper GI bleeding with drug combinations while at the same time controlling for 
time-fixed confounding factors as well as confounding by indication. We observed that, 
overall, the risk of upper GI bleeding during concomitant use of drugs was significantly higher 
compared with what would have been expected based on the sum of the risk of the individual 
drugs. The magnitude of statistical additive interaction, which may be seen as a surrogate 
measure for biological synergism, was highest for the combination of nsNSAIDs with 
corticosteroids and the combination of nsNSAIDs with aldosterone antagonists. In line with 
previous studies, we observed that the risk of nsNSAID monotherapy was higher than that of 
monotherapy with low-dose aspirin or COX-2 inhibitors.72, 73 The risk of upper GI bleeding was 
always higher for drug combinations with nsNSAIDs than that for low-dose aspirin or COX-2 
inhibitors. 
Given that nsNSAIDs, COX-2 inhibitors, and low-dose aspirin are commonly 
consumed by elderly, with a self-reported prevalence of 35%,112 the observed risks in the 
current study emphasize the substantial risk of use of nsNSAIDs, COX-2 inhibitors, and low-
dose aspirin in the general population. This is especially true considering that elderly are 
inherently at higher risk due to physiological ageing mechanisms.121, 122  
 
Corticosteroids 
 
Interestingly, we observed that the risk of diagnosed upper GI bleeding with use of 
corticosteroid monotherapy was of the same magnitude as that with nsNSAID monotherapy. 
Previous studies have shown inconsistent results with respect to risk of upper GI bleeding with 
corticosteroids.118, 211, 355 Because nsNSAIDs are known to pose greater risk for inducing upper 
gastrointestinal ulcers compared with COX-2 inhibitors, interaction between corticosteroids 
and nsNSAIDs, but not with COX-2 inhibitors, was expected.117 The suggested 
pathophysiological mechanism behind this increased risk for corticosteroids is inhibition of 
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ulcer healing.120 Previous studies estimated the magnitude of this risk to range from 9-fold to 
12-fold,72, 117, 118, 311, 355 although drug interaction between corticosteroids and nsNSAIDs was 
not consistently observed.355 Aside from the small numbers of concomitant users of nsNSAIDs 
and corticosteroids in previous studies,72, 118, 211, 311 there were also differences in outcome 
definitions and reference categories used (varying from no drug use in the past 7 days355 to 
180 days72). According to guidelines, corticosteroids should be considered an independent risk 
factor for upper GI bleeding and gastroprotective measures should be prescribed to patients 
treated with corticosteroids.99 To translate the observed risks to the general population, we 
estimated the population attributable risk (PAR) due to drug use. The PAR was 6.4% for 
concurrent use of nsNSAIDs and corticosteroids, 11.8% for nsNSAID monotherapy, and 10.4% 
for corticosteroid monotherapy. This implies that the proportion of upper GI bleeding in the 
general population attributable to the previously mentioned therapies was high, given the 
assumption that the association between drug use and occurrence of upper GI bleeding is 
causal. Although this can be reduced by correct use of gastroprotection, future studies should 
investigate the risk of a combination of corticosteroids and nsNSAIDs with gastroprotective 
agents compared with a combination of corticosteroids and COX-2 inhibitors. 
 
Selective serotonin reuptake inhibitors 
 
Selective serotonin reuptake inhibitors (SSRIs) showed statistically significant interaction with 
nsNSAIDs and COX-2 inhibitors but not with low-dose aspirin. From a biological point of view, 
this interaction seems plausible because SSRIs decrease the serotonin level, resulting in 
impaired thrombocyte aggregation and an increased risk of bleeding in general, including 
upper GI bleeding. Based on this mechanism, NSAIDs, and low-dose aspirin to lesser extent,363, 
364 are suspected to produce synergism with SSRIs. Although previous studies report an 
increased risk between 2.6-fold and 16-fold for upper GI bleeding with use of SSRIs and NSAIDs 
when compared with drug monotherapy,363-365 others could not show interaction.356, 365 
However, these were not performed primarily on NSAID users,364 did not control for important 
confounders363, 364 and did not create mutually exclusive drug exposure groups.363 
 
Aldosterone antagonists 
 
The risk of aldosterone antagonists concurrently used with nsNSAIDs was higher than when 
used with low-dose aspirin or COX-2 inhibitors. Earlier, case reports indicated a possible 
association between aldosterone antagonists and upper GI bleeding or upper GI ulcers.324 
More recently, case-control studies confirmed this association.348, 358 The potential mechanism 
may be related to impaired healing of gastric and duodenal erosions due to inhibition of 
fibrous tissue formation.348  
 
 
 
 
 
Anticoagulants and antiplatelets 
 
Use of anticoagulants is an acknowledged risk factor for upper GI bleeding, with previous 
studies showing risks from 5.3-fold to 6.5-fold for concomitant use of anticoagulants with low-
dose aspirin,119, 353 4.6-fold with COX-2 inhibitors,353 and up to 19-fold with nsNSAIDs.73 In the 
current study anticoagulants showed a higher risk when combined with low-dose aspirin than 
with nsNSAIDs or COX-2 inhibitors. The difference between these findings and previous studies 
may rely on less stringent control for confounders in previous studies than in the current 
study; furthermore, with the SCCS all within-person confounders that are fixed over time are 
immediately dealt with. In line with others, concomitant use of low-dose aspirin eliminates the 
presumed benefit of COX-2 inhibitors over nsNSAIDs on the risk of upper GI adverse events.10, 
73, 327, 340 
 
Gastroprotective agents 
 
The increased risk of diagnosed upper GI bleeding observed with the concomitant use of 
nsNSAIDs, COX-2 inhibitors, or low-dose aspirin with GPAs seems counterintuitive; however, 
no interaction was observed for any of these drug combinations. The increased risk is thus 
more likely explained by the phenomenon of “channeling”, in which high-risk patients receive 
concurrent prescriptions for GPAs whereas low-risk patients do not. Another explanation is 
protopathic bias, because GPAs might be given as treatment for first symptoms of upper GI 
bleeding.366  
 
Age-Related COX Enzyme selectivity 
 
As expected, the risk of diagnosed upper GI bleeding with use of the drugs of interest 
(monotherapy), except antiplatelets, was lower for subjects younger than 60 years of age than 
for subjects older than 60 years of age. Surprisingly, the difference in risk between younger 
and older subjects was larger for drug combinations with COX-2 inhibitors than for 
combinations with nsNSAIDs. Application of a cutoff level of 70 years of age did not yield 
different results. However, using an age cutoff of 70 years showed excess risk for the 
combination of COX-2 inhibitors and corticosteroids, whereas this was not present with an age 
cutoff of 60 years. In elderly subjects, prostaglandin-levels decreased due to decreased 
conversion of arachidonic acid to prostaglandin, resulting in an increased risk of upper GI 
bleeding. This partially accounts for the recommendation to use gastroprotective measures in 
elderly patients.99 We hypothesize that COX enzyme selectivity with aging might explain the 
difference in drug interaction between nsNSAIDs and COX-2 inhibitors. In animal studies, older 
rats expressed different COX enzyme mRNA than younger rats and an impaired response of 
prostaglandin synthesis to irritants with older age was shown.120 In humans, higher basal acid 
output in the stomach among elderly patients121 results in lower mucosal prostaglandin 
concentrations in the stomach and duodenum.367 However, these observations were related 
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cutoff of 60 years. In elderly subjects, prostaglandin-levels decreased due to decreased 
conversion of arachidonic acid to prostaglandin, resulting in an increased risk of upper GI 
bleeding. This partially accounts for the recommendation to use gastroprotective measures in 
elderly patients.99 We hypothesize that COX enzyme selectivity with aging might explain the 
difference in drug interaction between nsNSAIDs and COX-2 inhibitors. In animal studies, older 
rats expressed different COX enzyme mRNA than younger rats and an impaired response of 
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to the COX-1 enzyme and do not explain our findings. As the SCCS, by definition, controls for 
confounders fixed within-person and the baseline risk, this also does not explain the difference 
between younger and older subjects for COX-2 inhibitor combinations in the current study. 
Future studies are needed to elucidate these findings. 
 
Strengths and limitations 
 
A major strength of the current study is that while previous studies reported data from single 
centers73 or single databases, 118-120, 211, 311, 348, 353, 356, 363-365 we performed a multi-database study 
to increase the power for studying the risk of upper GI bleeding due to drug synergism of 
relatively uncommon drug combinations. Additionally, we specifically looked at drug 
combinations of low-dose aspirin, nsNSAIDs and COX-2 inhibitors separately.349 
However, we acknowledge the following limitations. A key assumption of the SCCS is 
that the exposure distribution within the observation period and the observation period itself 
must be independent of the time of the event. This assumption could have been violated, 
because the standard of care considers use of an nsNSAID without gastroprotection as 
relatively contraindicated after occurrence of upper GI bleeding. However, sensitivity analyses 
involving truncation of follow-up at the time of the event showed that drug exposure of 
nsNSAIDs did not change after the event (ie, results obtained were similar to those from the 
original analysis), meaning that confounding by contraindication was unlikely to explain the 
findings (Supplementary Figure 2). The health condition of a subject may vary over time at all 
phases of follow-up. Nevertheless, many chronic conditions, such as type 2 diabetes mellitus, 
hypertension, and peripheral vascular disease, are relatively stable diseases and vary little over 
time. We have no reason to believe that this will influence the estimates. The sensitivity 
analysis adjusting for acute myocardial infarction and anaphylactic shock did not yield 
different estimates as compared with the main analysis (Supplementary Figure 3). In addition, 
the age of a subject increases during follow-up, and given that older subjects are at higher risk 
than when at a younger age, we also adjusted for age in the analysis. Residual confounding 
due to an underlying clinical condition that led to a drug prescription, although unlikely, 
cannot be ruled out. 
Misclassification of exposure time of NSAIDs could have occurred, because NSAIDs 
are often used intermittently rather than continuously, although this is probably true more for 
over-the-counter use of NSAIDs. Over-the-counter use of NSAIDs is not captured in EHR 
databases and could have led to a potential underestimation of use. However, the proportion 
of NSAIDs used over-the-counter is limited given that prescribed NSAIDs are reimbursed 
whereas over-the-counter drugs are not. Although information on drug use differed between 
dispensing and prescribing data, patterns of use of NSAID classes varied among different 
countries but were similar among different databases in the same country.346 In addition, we 
defined nonexposure as no use of any of the drugs of interest instead of no use of any drug. 
We mitigated misclassification of nonexposure by restricting the analysis to drugs that have 
been reported to significantly increase or decrease the risk of upper GI bleeding. We used a 
 
 
rather broad definition of upper GI bleeding, including all gastroduodenal ulcers and 
hemorrhages, which may have led to less severe cases of upper GI bleeding in the primary care 
databases compared with administrative databases. A validation study was performed in 4 
databases. For this purpose, a sample of upper GI bleeding cases was manually validated by 
medical chart review to characterize and document any outcome misclassification related to 
drug- associated upper GI bleeding. This showed that misclassification was uncommon and did 
not affect the magnitude of risk estimates.352 Second, when excluding the data set with the 
lowest PPV for diagnosis of upper GI bleeding in the current study, the estimates were not 
different from the main analysis. In addition, incidence rates of upper GI bleeding in these 
databases did not differ substantially across European countries and are in accordance with 
literature.346 Variceal bleeding was not included as part of the definition of upper GI bleeding. 
However, we cannot rule out that variceal bleeding may have been wrongly coded as a code 
more specific for upper GI bleeding than variceal bleeding. 
Nevertheless, non-differential misclassification cannot be ruled out and may have 
resulted in an underestimation of the true estimates. Finally, we did not take any carry-over 
effect or dose of drug exposure into account, which potentially limits the generalizability 
concerning causality of the associations.  
The SCCS assumes that observation periods should be independent of event times, 
which may be violated if subjects die quickly after the event. By applying an alternative 
method368 in one database taking this assumption into account by weighting the post-event 
periods, the estimates remained within the 95% confidence limits of the original analysis. 
When estimating the magnitude of interaction, the presence and direction depends 
on the scale that is used: either additive or multiplicative interaction. In the current study, 
multiplicative interaction was only observed for the combination of low-dose aspirin and 
antiplatelets. However, statistical interaction does not directly imply biological interaction. 361  
In conclusion, concomitant use of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin 
with SSRIs is associated with a significantly increased risk of diagnosed upper GI bleeding. 
Concomitant use of nsNSAIDs or low-dose aspirin, but not COX-2 inhibitors, with 
corticosteroids, aldosterone antagonists or anticoagulants were associated with an increased 
and excess risk of upper GI bleeding. These findings may help clinicians in tailoring therapy to 
minimize upper GI bleeding adverse events, and are especially valuable in the elderly who are 
likely to use multiple drugs concurrently. 
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In conclusion, concomitant use of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin 
with SSRIs is associated with a significantly increased risk of diagnosed upper GI bleeding. 
Concomitant use of nsNSAIDs or low-dose aspirin, but not COX-2 inhibitors, with 
corticosteroids, aldosterone antagonists or anticoagulants were associated with an increased 
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SUPPLEMENTARY MATERIAL 
 
 
Supplementary Table 1. Definition of codes of Upper GI Bleeding among different coding systems. 
 
ICD-9 CM 
(ARS, HSD, Pedianet, PHARMO, UNIMIB) 
ICD-10 
(for Aarhus) 
ICPC 
(for IPCI) 
531.00/ 
531.01 
Gastric ulcer, Acute with 
hemorrhage 
K25.0 Gastric ulcer, Acute with 
hemorrhage 
  
531.10 Gastric ulcer, Acute with 
perforation 
K25.1 Gastric ulcer, Acute with 
perforation 
  
531.20/531.21 Gastric ulcer, Acute with 
hemorrhage and perforation 
K25.2 Gastric ulcer, Acute with both 
hemorrhage and perforation 
  
532.00/532.01 Duodenal ulcer, Acute with 
hemorrhage 
K26.0 Duodenal ulcer, Acute with 
hemorrhage 
D85 Duodenal 
ulcer 
532.10 Duodenal ulcer, Acute with 
perforation 
K26.1 Duodenal ulcer, Acute with 
perforation 
  
532.20 Duodenal ulcer, Acute with 
hemorrhage and perforation 
K26.2 Duodenal ulcer, Acute with 
both hemorrhage and 
perforation 
  
533.00 Peptic ulcer, site unspecified, 
Acute with hemorrhage 
K27.0 Peptic ulcer, site unspecified, 
Acute with hemorrhage 
D86 Peptic ulcer, 
other 
533.10 Peptic ulcer, site unspecified, 
Acute with perforation 
K27.1 Peptic ulcer, site unspecified, 
Acute with perforation 
  
533.20 Peptic ulcer, site unspecified, 
Acute with hemorrhage and 
perforation 
K27.2 Peptic ulcer, site unspecified, 
Acute with both hemorrhage 
and perforation 
  
534.00/534.01 Gastrojejunal ulcer, Acute with 
hemorrhage 
K28.0 Gastrojejunal ulcer, Acute with 
hemorrhage 
  
534.10 Gastrojejunal ulcer, Acute with 
perforation 
K28.1 Gastrojejunal ulcer, Acute with 
perforation 
  
534.20/534.21 Gastrojejunal ulcer, Acute with 
hemorrhage and perforation 
K28.2 Gastrojejunal ulcer, Acute with 
both hemorrhage and 
perforation 
  
535.01 Acute gastritis, with hemorrhage K29.0 Acute hemorrhagic gastritis   
535.11 Atrophic gastritis, with 
hemorrhage 
    
535.41 Other specified gastritis, with 
hemorrhage 
    
535.51 Unspecified gastritis and 
gastroduodenitis, with 
hemorrhage 
    
578.0 Hematemesis, Vomiting of blood K92.0 Hematemesis D15 Hematemesis 
578.1 Blood in stool, Melena K92.1 Melena D14 Melena 
578.9 Hemorrhage of gastrointestinal 
tract, unspecified 
K92.2 Gastrointestinal hemorrhage, 
unspecified 
  
 
Abbreviations: International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM); International Classification 
of Diseases, 10th Revision (ICD-10); International Classification for Primary Care (ICPC). 
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Supplementary Table 2. Corresponding anatomical therapeutic chemical (ATC)-codes for drug groups of 
interest.99 
 
Drug group ATC-codes*  
nsNSAIDs M01AB, M01AC, M01AE, M01AG, M01AX 
COX-2 inhibitors M01AH 
Low-dose aspirin B01AC06 
High-dose aspirin N02BA01, N02BA15 
Corticosteroids H02AB 
Selective serotonin reuptake inhibitors N06AB 
Gastroprotective agents A02BC, A02BA, A02BB01 
Aldosterone antagonists C03DA01, C03DA02, C03DA03, C03DA04 
Calcium channel blockers 
C08CA, C08CX01, C08DA01, C08DA02, C08DB01, C08EA01, 
C08EA02, C08EX01, C08EX02 
Anticoagulantia B01AA, B01AB 
Antiplatelets B01AC, excluding B01AC06 
Nitrates 
C01DA02, C01DA04, C01DA05, C01DA07, C01DA08, 
C01DA09, C01DA13, C01DA14 
 
* Including all ATC-codes belonging to this drug group.  
 
 
 
Supplementary Table 3. Additive interaction measures for drug combinations of nsNSAIDs, low-dose aspirin and 
COX-2 inhibitors with other drugs. 
 
  RERI (95% CI) AP  Synergy index 
 nsNSAIDs + LDA 0.45 (-0.27 to 1.18) 0.07 1.09 
 nsNSAIDs + Corticosteroids 5.48 (3.71 to 7.26) 0.43 1.87 
 nsNSAIDs + SSRIs 1.62 (0.58 to 2.66) 0.23 1.38 
 nsNSAIDs + Gastroprotective agents -0.98 (-1.33 to -0.62) -0.25 0.75 
 nsNSAIDs + Aldosterone antagonists 4.46 (1.79 to 7.13) 0.41 1.81 
 nsNSAIDs + Calcium channel 
blockers 
-0.39 (-0.90 to 0.13) -0.09 0.90 
 nsNSAIDs + Anticoagulants 2.41 (0.89 to 3.94) 0.28 1.46 
 nsNSAIDs + Antiplatelets* 1.50 (0.03 to 2.97) 0.23 1.37 
 nsNSAIDs + Nitrates 0.00 (-0.93 to 0.93) 0.00 0.10 
 COX-2 inhibitors + LDA 2.54 (1.13 to 3.94) 0.34 1.64 
 COX-2 inhibitors + Corticosteroids -0.02 (-2.03 to 1.99) -0.00 0.10 
 COX-2 inhibitors + SSRIs 1.86 (0.28 to 3.44) 0.32 1.63 
 COX-2 inhibitors + Gastroprotective 
agents 
-1.14 (-1.69 to -0.59) -0.48 0.55 
 COX-2 inhibitors + Aldosterone 
antagonists 
-1.15 (-3.84 to 1.53) -0.29 0.72 
 COX-2 inhibitors + Calcium channel 
blockers 
-0.36 (-1.12 to 0.41) -0.11 0.86 
 COX-2 inhibitors + Anticoagulants 0.10 (-2.15 to 2.34) 0.02 1.03 
 COX-2 inhibitors + Antiplatelets -1.91 (-3.13 to -0.69) -1.10 0.28 
 COX-2 inhibitors + Nitrates 0.63 (-0.87 to 2.14) 0.12 1.18 
 LDA + Corticosteroids 2.25 (0.91 to 3.59) 0.26 1.44 
 LDA + SSRIs 0.49 (-0.05 to 1.03) 0.10 1.16 
 LDA + Gastroprotective agents -1.12 (-1.37 to -0.88) -0.44 0.58 
 LDA + Aldosterone antagonists -0.31 (-1.30 to 0.67) -0.06 0.93 
 LDA + Calcium channel blockers -0.55 (-0.79 to -0.32) -0.18 0.79 
 LDA + Anticoagulants 1.87 (0.70 to 3.05) 0.27 1.46 
 LDA + Antiplatelets* 1.70 (0.85 to 2.56) 0.31 1.61 
 LDA + Nitrates -0.81 (-1.13 to -0.50) -0.21 0.77 
 
In Bold are drug-combinations where additive interaction is significant based on 95% CIs of RERI not crossing 0. 
Abbreviations: Relative Excess risk due to interaction (RERI); Proportion attributable to interaction (AP); Nonselective NSAIDs 
(nsNSAIDs); COX-2 selective inhibitors (COX-2 inhibitors); Low-dose aspirin (LDA); Oral steroids (steroids); Selective serotonin 
reuptake inhibitors (SSRIs). *Antiplatelets excluding low-dose aspirin. 
RERI = RR11 - RR10 - RR01 + 1  ;  AP= RERI/RR11.  
RERI or AP = 0: means no interaction. RERI or AP < 0 means negative interaction or less than additive interaction. RERI or AP > 0: 
means positive interaction or more than additive interaction. R01 and R10 represent relative risk of upper GI bleeding for each 
drug separately; RR11 represents relative risk of upper GI bleeding during combination therapy. 
95% CIs of RERI is calculated based on the variance and covariance of the separate estimates and combined drug estimate. 
Synergy index = (RR11 - 1) / ( (RR10 - 1) + (RR01 - 1) )  
Synergy index = 1: means no interaction. Synergy index < 1: means negative interaction or less than additive interaction. Synergy 
index > 1: means positive interaction or more than additive interaction. 
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Supplementary Table 2. Corresponding anatomical therapeutic chemical (ATC)-codes for drug groups of 
interest.99 
 
Drug group ATC-codes*  
nsNSAIDs M01AB, M01AC, M01AE, M01AG, M01AX 
COX-2 inhibitors M01AH 
Low-dose aspirin B01AC06 
High-dose aspirin N02BA01, N02BA15 
Corticosteroids H02AB 
Selective serotonin reuptake inhibitors N06AB 
Gastroprotective agents A02BC, A02BA, A02BB01 
Aldosterone antagonists C03DA01, C03DA02, C03DA03, C03DA04 
Calcium channel blockers 
C08CA, C08CX01, C08DA01, C08DA02, C08DB01, C08EA01, 
C08EA02, C08EX01, C08EX02 
Anticoagulantia B01AA, B01AB 
Antiplatelets B01AC, excluding B01AC06 
Nitrates 
C01DA02, C01DA04, C01DA05, C01DA07, C01DA08, 
C01DA09, C01DA13, C01DA14 
 
* Including all ATC-codes belonging to this drug group.  
 
 
 
Supplementary Table 3. Additive interaction measures for drug combinations of nsNSAIDs, low-dose aspirin and 
COX-2 inhibitors with other drugs. 
 
  RERI (95% CI) AP  Synergy index 
 nsNSAIDs + LDA 0.45 (-0.27 to 1.18) 0.07 1.09 
 nsNSAIDs + Corticosteroids 5.48 (3.71 to 7.26) 0.43 1.87 
 nsNSAIDs + SSRIs 1.62 (0.58 to 2.66) 0.23 1.38 
 nsNSAIDs + Gastroprotective agents -0.98 (-1.33 to -0.62) -0.25 0.75 
 nsNSAIDs + Aldosterone antagonists 4.46 (1.79 to 7.13) 0.41 1.81 
 nsNSAIDs + Calcium channel 
blockers 
-0.39 (-0.90 to 0.13) -0.09 0.90 
 nsNSAIDs + Anticoagulants 2.41 (0.89 to 3.94) 0.28 1.46 
 nsNSAIDs + Antiplatelets* 1.50 (0.03 to 2.97) 0.23 1.37 
 nsNSAIDs + Nitrates 0.00 (-0.93 to 0.93) 0.00 0.10 
 COX-2 inhibitors + LDA 2.54 (1.13 to 3.94) 0.34 1.64 
 COX-2 inhibitors + Corticosteroids -0.02 (-2.03 to 1.99) -0.00 0.10 
 COX-2 inhibitors + SSRIs 1.86 (0.28 to 3.44) 0.32 1.63 
 COX-2 inhibitors + Gastroprotective 
agents 
-1.14 (-1.69 to -0.59) -0.48 0.55 
 COX-2 inhibitors + Aldosterone 
antagonists 
-1.15 (-3.84 to 1.53) -0.29 0.72 
 COX-2 inhibitors + Calcium channel 
blockers 
-0.36 (-1.12 to 0.41) -0.11 0.86 
 COX-2 inhibitors + Anticoagulants 0.10 (-2.15 to 2.34) 0.02 1.03 
 COX-2 inhibitors + Antiplatelets -1.91 (-3.13 to -0.69) -1.10 0.28 
 COX-2 inhibitors + Nitrates 0.63 (-0.87 to 2.14) 0.12 1.18 
 LDA + Corticosteroids 2.25 (0.91 to 3.59) 0.26 1.44 
 LDA + SSRIs 0.49 (-0.05 to 1.03) 0.10 1.16 
 LDA + Gastroprotective agents -1.12 (-1.37 to -0.88) -0.44 0.58 
 LDA + Aldosterone antagonists -0.31 (-1.30 to 0.67) -0.06 0.93 
 LDA + Calcium channel blockers -0.55 (-0.79 to -0.32) -0.18 0.79 
 LDA + Anticoagulants 1.87 (0.70 to 3.05) 0.27 1.46 
 LDA + Antiplatelets* 1.70 (0.85 to 2.56) 0.31 1.61 
 LDA + Nitrates -0.81 (-1.13 to -0.50) -0.21 0.77 
 
In Bold are drug-combinations where additive interaction is significant based on 95% CIs of RERI not crossing 0. 
Abbreviations: Relative Excess risk due to interaction (RERI); Proportion attributable to interaction (AP); Nonselective NSAIDs 
(nsNSAIDs); COX-2 selective inhibitors (COX-2 inhibitors); Low-dose aspirin (LDA); Oral steroids (steroids); Selective serotonin 
reuptake inhibitors (SSRIs). *Antiplatelets excluding low-dose aspirin. 
RERI = RR11 - RR10 - RR01 + 1  ;  AP= RERI/RR11.  
RERI or AP = 0: means no interaction. RERI or AP < 0 means negative interaction or less than additive interaction. RERI or AP > 0: 
means positive interaction or more than additive interaction. R01 and R10 represent relative risk of upper GI bleeding for each 
drug separately; RR11 represents relative risk of upper GI bleeding during combination therapy. 
95% CIs of RERI is calculated based on the variance and covariance of the separate estimates and combined drug estimate. 
Synergy index = (RR11 - 1) / ( (RR10 - 1) + (RR01 - 1) )  
Synergy index = 1: means no interaction. Synergy index < 1: means negative interaction or less than additive interaction. Synergy 
index > 1: means positive interaction or more than additive interaction. 
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Supplementary Table 5. Distribution of upper GI bleeding cases per gender across age categories.  
 
Age range (year) 
Number of upper GI bleeding 
cases 
Number of upper GI 
bleeding cases 
Female Male 
Total 51,440 63,395 
0-4 813 1,085 
5-9 329 408 
10-14 237 327 
15-19 410 425 
20-24 593 705 
25-29 687 893 
30-34 781 1,339 
35-39 1,037 1,835 
40-44 1,288 2,392 
45-49 1,512 2,830 
50-54 1,892 3,876 
55-59 2,349 4,755 
60-64 3,042 5,978 
65-69 4,071 7,366 
70-74 5,551 8,380 
75-79 7,723 8,556 
80-84 8,267 6,643 
≥85 10,858 5,602 
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Supplementary Table 5. Distribution of upper GI bleeding cases per gender across age categories.  
 
Age range (year) 
Number of upper GI bleeding 
cases 
Number of upper GI 
bleeding cases 
Female Male 
Total 51,440 63,395 
0-4 813 1,085 
5-9 329 408 
10-14 237 327 
15-19 410 425 
20-24 593 705 
25-29 687 893 
30-34 781 1,339 
35-39 1,037 1,835 
40-44 1,288 2,392 
45-49 1,512 2,830 
50-54 1,892 3,876 
55-59 2,349 4,755 
60-64 3,042 5,978 
65-69 4,071 7,366 
70-74 5,551 8,380 
75-79 7,723 8,556 
80-84 8,267 6,643 
≥85 10,858 5,602 
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Supplementary Figure 1. Classification of drug prescriptions into the drug categories. 
 
GI, gastrointestinal; nsNSAID, nonselective NSAID. 
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Supplementary Figure 2. Explanation of Sensitivity analysis with observation time truncated at time of event. 
Observed Incidence rate ratios of drug monotherapy for the main analysis in SCCS and sensitivity analysis. 
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initial estimate. These analyses implicate that the exposure of for instance nsNSAIDs did not change significantly after the event, 
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TO THE EDITOR: 
 
We read with great interest the thorough review and meta-analysis by Tong et al.369 about 
microscopic colitis (MC). Their study summarizes evidence from epidemiological studies on MC 
incidence and drug-associations. They report incidence rates from different countries in 
different time periods. They conclude that the overall incidence of MC increases with age, is 
higher in females than males and is comparable to the incidence of inflammatory bowel 
disease. Differences in study settings, geography, source population and diagnosis verification 
likely contributed to heterogeneity of the results. Nevertheless, MC incidences appear to have 
increased over time and proton pump inhibitors as well as selective serotonin reuptake 
inhibitors were associated with an increased risk of MC. As the authors point out, clinical 
awareness, more liberal use of colonoscopy, and routine random biopsy sampling in normal 
colonoscopies may have distorted the estimation of the ‘true’ incidence of the disease. These 
types of detection and diagnostic biases370 are, however, difficult to account for in incidence 
studies. A possible solution to give insight in such detection bias is to calculate the incidence of 
the disease in relation to the number of diagnostic procedures. In a cohort study using data 
from a primary care database containing electronic medical records of 1.6 million subjects in 
the Netherlands, we identified 210 incident, histologically-verified, MC cases between 2003 
and 2013. We calculated the rate of MC both over the number of person-years (PY) as most 
studies do, but also over the number of index colonoscopies, not considering follow-up 
colonoscopies. An increase in incidence per PY was seen that tapered off in 2011 (Figure 1). 
There was a substantial increase in total number of colonoscopies over this period (from 62 
colonoscopies per 10,000 PY in 2003 to 283 in 2013). The rate of MC lowered when based on 
the number of colonoscopies from 5.6 per 1,000 colonoscopies in 2003 to 0.9 in 2013 (Figure 
2). 
Our findings thus suggest that the actual incidence of MC remained fairly stable 
during a 10-year period in the Netherlands, and that increases that may be seen on the 
population level are due to increasing rates of colonoscopies. These findings contrast with 
previous studies as summarized by Tong et al.369 This contrast can explained by the fact that 
the majority of previous studies did not correct for increases in the number of colonoscopy 
procedures, and therefore ability to detect MC, over time. 
 
 
 
 
Figure 1. Incidence rate with 95% Confidence Intervals of Microscopic Colitis per 100,000 Person-Years. 
 
Figure 2. Rate with 95% Confidence Intervals of Microscopic Colitis per 1,000 diagnostic colonoscopies. 
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ABSTRACT 
 
BACKGROUND 
Microscopic colitis (MC) is characterized by chronic watery diarrhea. Recently several drugs 
were reported to increase the risk of MC. However, studies lacked a clear exposure definition, 
did not address duration-relationships and did not take important biases into account. 
 
AIM 
We estimated the risk of MC during drug use. 
 
METHODS  
Population-based nested case-control study using a Dutch primary care database (1999-2013). 
Incident microscopic colitis cases (aged ≥18 years) were matched to: 1) community-based, and 
2) colonoscopy-negative controls on age, sex and primary care practice. Drug use was assessed 
within 1 and 2 years prior to index date. Adjusted odds ratios (OR) were calculated by 
conditional logistic regression. 
 
RESULTS 
From the source population of 1,458,410 subjects; 218 cases were matched to 15,045 
community controls and 475 colonoscopy negative controls. Current use (≤3 months) of 
proton pump inhibitors (PPIs), NSAIDs, selective serotonin reuptake inhibitors, low-dose 
aspirin, ACE-inhibitors and beta-blockers significantly increased the risk of microscopic colitis 
compared to never use in community controls. Adjusted ORs ranged from 2.5 (95%CI: 1.5-4.2) 
for ACE-inhibitors to 7.3 (95%CI: 4.5-12.1) for PPIs in the year prior to index date. After 
accounting for diagnostic delay, only use of NSAIDs, PPIs, low-dose aspirin and ACE-inhibitors 
increased risk of MC. Compared to colonoscopy controls, only use of PPIs (ORadjusted 10.6, 
1.8-64.2) and NSAIDs (ORadjusted 5.6, 1.2-27.0) increased the risk of MC. 
 
CONCLUSION 
NSAIDs and PPIs are associated with an increased risk of MC. The association of MC with use of 
the other drugs is probably explained by worsening of diarrhea/symptoms rather than 
increasing the risk of MC itself. 
 
  
 
 
INTRODUCTION 
 
Microscopic colitis (MC) is a condition characterized by chronic watery diarrhea, normal 
radiological and endoscopic appearance and microscopic inflammation of the colon. It is a rare 
disease with an incidence around 5 to 8.6 cases per 100,000 person-years. 371, 372 MC includes 
two distinct entities, namely lymphocytic colitis and collagenous colitis. They differ in 
histopathological features: collagenous colitis is characterized by a subepithelial collagen band 
adjacent to the basal membrane, while lymphocytic colitis is characterized by the presence of 
an inflammatory infiltrate in the lamina propria. The etiology of MC is largely unknown, but 
risk factors include autoimmune diseases such as rheumatoid arthritis and celiac disease.373-375 
MC is more prevalent in elderly, particularly among females aged 60 years and over.372, 376 
Parallel to this increase in incidence of MC is the increase in polypharmacy in elderly. Several 
drugs have been reported to be associated with the onset of MC. These drugs include selective 
serotonin reuptake inhibitors (SSRIs), 377 non-steroidal anti-inflammatory drugs (NSAIDs), 377 
and proton pump inhibitors (PPIs). 378 One of the proposed mechanisms of drug-associated MC 
is triggering factors of colonic inflammation in a genetically predisposed individual. Both 
NSAIDs and PPIs have been reported to affect the bowel integrity and colonic permeability. 9, 
83-88 Subsequently, luminal antigens can more easily enter the lamina propria and elicit an 
immune and inflammatory reaction.83 Another mechanism by which PPIs could lead to MC is 
alteration of the colonic intestinal flora through acid inhibition and thereby promoting colonic 
microbial growth. 210, 379 
On the other hand, drugs may also be implicated in the development or worsening of 
diarrhea in a patient with a pre-existing, undiagnosed, MC. In other words, the drug itself may 
not induce MC, but rather the underlying disease or indication to receive the drug. Previous 
studies assessing the association between drug intake and MC have not been able to take 
confounding-by-indication (i.e., the indication to receive the drug) into account. Additionally, 
such studies were limited by small sample size, lack of clear drug exposure definitions, and lack 
of duration analyses. 378 The aim of this study was to assess the risk of MC during use of 
various drugs in a population-based nested case-control study. 
 
METHODS 
 
Data sources 
 
A population-based general practice electronic healthcare record database, the Integrated 
Primary Care Information database (IPCI) from the Netherlands (NL) was used as data source. 
This database contains prospectively collected routine care data representing real-life 
practice.238 In the Netherlands, all citizens are registered with a general practitioner (GP), who 
acts as a gatekeeper to secondary and tertiary medical care. IPCI contains >1.5 million active 
patients from 340 GP practices. For each individual patient all relevant medical information 
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Primary Care Information database (IPCI) from the Netherlands (NL) was used as data source. 
This database contains prospectively collected routine care data representing real-life 
practice.238 In the Netherlands, all citizens are registered with a general practitioner (GP), who 
acts as a gatekeeper to secondary and tertiary medical care. IPCI contains >1.5 million active 
patients from 340 GP practices. For each individual patient all relevant medical information 
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from primary and secondary care is documented in the electronic record. This includes 
information on medical diagnoses, discharge summaries, demographics, GP notes and drug 
prescriptions. In IPCI the International Classification for Primary Care240 system is used for 
coding of medical diagnosis and symptoms. Information on drug use is coded according to the 
World Health Organization’s Anatomical Therapeutic Chemical (ATC) classification . IPCI has 
been extensively used in pharmaco-epidemiological studies.117, 243 In previous studies, the 
characteristics and incidence/prevalence of diseases such as upper gastrointestinal bleeding, 
Barrett’s esophagus were shown to be consistent with other literature.346, 380, 381 The study 
protocol was approved by the IPCI Scientific and Ethical Advisory Board. 
 
Study Design and Population 
 
A nested case-control study was conducted. The source population consisted of all subjects 
aged ≥ 18 years who were registered with one of the general practitioners and contributed 
data between January 1st 1999 and March 31st 2012 and had at least 1 year of valid data in the 
database. This one year run-in period was used to distinguish between incident and prevalent 
cases of MC. 
 
Cases and control selection 
 
MC cases were identified via key word search within the free-text narratives in the electronic 
medical records and were included when: 1) a record of MC diagnosis; and 2) additional 
evidence consisting of histology report confirming MC diagnosis were present. Only incident 
MC cases (i.e. newly diagnosed cases) were considered for the study. The index date (date to 
which we make reference for exposure assessment) was defined as the first date of recorded 
symptoms leading to the diagnosis of MC. Subjects with a diagnosis of colorectal cancer were 
excluded. Due to the availability of the medical history of each patient, we could review on 
which date symptoms related to microscopic diagnosis started. 
Two control groups were considered for the analysis; 1) community-based controls 
(i.e., from the source population); and 2) colonoscopy controls (i.e., those who had undergone 
a colonoscopy without signs or histology of MC). We matched by incidence density sampling 
on age (+/- 1 year), GP practice and sex. For the colonoscopy controls the date of colonoscopy 
was within 6 months of the date of the corresponding case in order to rule out any effect that 
could be time-related. We matched on GP practice, in order to take any referral bias or 
prescribing preference from GPs into account.  
 
Drug Exposure 
 
Drugs of interest were those that previously have been reported to be associated with (either 
increased or decreased) risk of MC: 1) NSAIDs (including high-dose aspirin; >325 mg of aspirin 
per day) 377, 2) PPIs 378, 382, 3) statins 377, 4) SSRIs 377, 5) low-dose aspirin (up to 325 mg/day) 382, 
 
 
6) angiotensin converting enzyme (ACE)-inhibitors 377, 378 and 7) beta-blockers.382 Analyses with 
respect to individual types of NSAIDs and PPIs were conducted including assessment of 
heterogeneity between individual estimates. 
We considered several risk periods of drug exposure because of the possibility of 
delay between disease onset to first time that symptoms are recorded. The different risk 
periods were as follows: within 1 year prior to the index date (A) and within 2 years prior to 
the index date (B) while excluding the last year before index date. In risk period B the first year 
prior to index date was not considered for exposure assessment in order to account for a 
potential lag-time in recorded symptoms (i.e. assuming there could be a difference of one year 
between actual start of the disease and first date of recorded symptoms). It would actually be 
the same as risk period A but moving back the index date to 1 year prior to the recorded 
symptom onset. For risk period B, at least 2 year of valid data should be available. 
Subsequently we divided exposure time into the following mutually exclusive groups: current 
use (≤3 months), past use (3-12 months prior to index date) and never use (no drug in 12 
months prior to index date). In Figure 1 the considered exposure groups for the different risk 
periods are depicted. 
 
Figure 1. Risk periods used for exposure assessment. 
 
Covariates 
 
We considered as risk factors for MC those that have been reported previously in the 
literature: celiac disease 373, 375, 382; inflammatory bowel disease 375; rheumatoid arthritis 374; 
hypothyroid disease 375; polyarthritis 375, 382; and diabetes mellitus type 2.374 As a quality check 
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we analyzed the incidence of the covariables in the source population of the database and 
found that the incidence rates were similar to rates reported in the literature. For instance, we 
found an overall incidence of polymyalgia rheumatica of 54.3 per 100,000 person-years, which 
is in line with the reported incidence rates in Denmark (41.3 and 68.3/100,000 person years) 
and Sweden (50.0/100,000 person years). 383 
 
Statistical analysis 
 
Incidence rates of MC were calculated by dividing the number of incident (i.e., newly-
diagnosed) MC cases by the number of person-years at risk. The incidence rates (IR) of MC 
were also calculated in relation to the number of colonoscopies performed, in order to 
account for detection bias. Baseline characteristics of cases and controls were described and 
compared using univariable conditional logistic regression. To estimate the risk for MC for use 
of the drugs of interest, matched and adjusted odds ratios (OR) with 95% confidence intervals 
(CIs) were calculated using conditional logistic regression. Identification of confounders was 
performed by entering each potential confounder into the model one by one. Confounders 
were kept into the model if the risk estimate for the drug exposure changed more than 10%.384 
Duration analyses in the different risk periods were conducted according to the above 
specified categories. Dose effects were analysed by the cumulative amount of prescribed drug 
during the exposure period and expressed as the total amount of recommended defined daily 
dose (DDD) . Categories of DDDs were divided in 0 DDD; 1-7 DDDs; 8-15 DDDs and >15 DDDs 
for NSAIDs and in 0 DDD; 1-29 DDDs; 30-90 DDDs and >90 DDDs for PPIs, statins, SSRIs, ACE-
inhibitors and beta-blockers. 
 
Sensitivity analysis 
 
As sensitivity analysis we excluded the unspecified types of MC, in order to rule out any 
misclassification of MC cases. Secondly, we performed subgroup analyses by type of MC 
(collagenous or lymphocytic colitis). Effect modification by sex and age group (≤ 45 years; >45 
years) was explored by multiplicative interaction. 
 
RESULTS 
 
Study population 
 
In the source population of 1,458,410 subjects we identified 218 incident MC cases 
(lymphocytic colitis 70, collagenous colitis 92, and unspecified 56). This yielded an IR of 
5.1/100,000 PYs for MC overall; 2.1/100,000 PYS for collagenous colitis; 1.6/100,000 PYS for 
lymphocytic colitis and 1.3/100,000 PYs for unspecified MC. The incidence rate of MC was 3.3 
per 1,000 colonoscopies. The 218 incident MC cases (who had at least 1 year of risk period 
assessment) were matched to 15,045 community controls. The median number of controls 
 
 
was 54 per case (interquartile range: 32-93). When including only cases with at least 2 years of 
valid data before index date, 138 cases were retained who were matched to 9,160 community 
controls. For 148 cases we could match at least one colonoscopy control from the same GP 
practice (n=475) for a 1 year risk period assessment, and 95 cases to 296 colonoscopy controls 
for a 2 year risk period assessment. Characteristics of the cases on date of diagnosis and 
matched controls on index date are shown in Table 1. Among cases occurrence of celiac 
disease, inflammatory bowel disease or rheumatoid arthritis was more frequent than among 
controls.  
 
Characteristics of drug exposure 
 
Characteristics of drug exposure in the different risk periods are described for cases and 
community and colonoscopy controls in Table 2. Most frequently used drugs were NSAIDs and 
proton pump inhibitors (PPIs) in the 1 and 2 year risk periods, both among cases and 
community controls, with the exception of beta-blockers, which were more often used than 
NSAIDs by cases in the 1 year risk period. Similar exposure prevalences of the drugs were seen 
for colonoscopy controls as with community controls (Table 2). 
 
Risk of microscopic colitis compared to community controls 
 
To determine the risk of MC in association with use of drugs, a nested case-control study was 
conducted. When looking at the 1 year risk period (within 1 year prior to index date), current 
use (within 3 months of index date) of NSAIDs, PPIs, statins, SSRIs, low-dose aspirin, ACE-
inhibitors and beta-blockers all significantly increased the risk of MC compared to never use. 
When adjusting for important confounders, current use of NSAIDs, PPIs, SSRIs, low-dose 
aspirin, ACE-inhibitors and beta-blockers remained associated with an increased risk of MC, 
ranging between 2.5 for ACE-inhibitors and 7.3 for PPIs (Table 3A, Supplementary Figure 1A 
and B). When taking diagnostic delay into account (by taking out the year directly prior to 
index date and looking in the year 1 to 2 years prior to index date), all drugs substantially 
increased the risk of MC in the matched analysis (Table 3A). However, adjustment for 
confounders resulted in elevated risks only for current use of NSAIDs, PPIs, low-dose aspirin 
and ACE-inhibitors (Table 3A, Supplementary Figure 1A and B), ranging between 2.3- and 8.3-
fold for ACE-inhibitors and NSAIDs, respectively. Diclofenac was the most commonly used 
NSAID followed by ibuprofen. Omeprazole was the most frequently used PPI. Results regarding 
individual types of NSAIDs and PPIs are shown in Supplementary Figures 3 and Figures 4. No 
heterogeneity was seen between individual NSAIDs and PPIs. Analyses of dose effects are 
shown in Supplementary Table 1A.   
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Table 1. Characteristics of cases and controls on index date. 
 
  
COMMUNITY CONTROLS 
1 year risk period* 2 year risk period# 
  Case Control Case Control 
 Characteristics N (%) N (%) N (%) N (%) 
Total 218 (100) 15,045 (100) 138 (100) 9,160 (100) 
Median no. of controls (IQR) 53.5 (32-93)   53 (33-85)   
Type microscopic colitis  
Collagenous colitis 92 (42.2)   59 (42.8)   
Lymphocytic colitis 70 (32.1)   42 (30.4)   
Not specified 56 (25.7)   37 (26.8)   
Sex  
male 58 (26.6) 3,898 (25.9) 39 (28.3) 2,525 (27.6) 
female 160 (73.4) 11,147 (74.1) 99 (71.7) 6,635 (72.4) 
Mean age at index date (SD) 45.1 (2.1) 45.2 (2.0) 45.3 (2.1) 45.2 (2.1) 
Median age at index date (IQR) 45.6 (44.4-46.6) 45.7 (44.4-46.7) 45.7 (44.6-46.7) 45.7 (44.5-46.7) 
Age group (years)  
<40 12 (5.5) 715 (4.8) 9 (6.5) 606 (6.6) 
40-45 68 (31.2) 4,788 (31.8) 37 (26.8) 2,666 (29.1) 
>45 138 (63.3) 9,542 (63.4) 92 (66.7) 5,888 (64.3) 
Celiac Disease yes 13 (6) 46 (0.3) 9 (6.5) 35 (0.4) 
Inflammatory Bowel Disease yes 38 (17.4) 60 (0.4) 28 (20.3) 50 (0.5) 
Hypothyroid Disease  yes 13 (6) 388 (2.6) 1 (0.7) 2 (0) 
Polyarthritis yes 2 (0.9) 21 (0.1) 1 (0.7) 24 (0.3) 
Rheumatoid Arthritis yes 5 (2.3) 148 (1.0) 9 (6.5) 129 (1.4) 
Diabetes Mellitus T2  yes 7 (3.2) 601 (4.0) 5 (3.6) 491 (5.4) 
Index year  
1999 1 (0.5) 11 (0.1) 0 (0) 0 (0) 
2000 0 (0) 0 (0) 0 (0) 0 (0) 
2001 0 (0) 0 (0) 0 (0) 0 (0) 
2002 1 (0.5) 49 (0.3) 1 (0.7) 49 (0.5) 
2003 3 (1.4) 168 (1.1) 2 (1.4) 139 (1.5) 
2004 6 (2.8) 457 (3) 5 (3.6) 388 (4.2) 
2005 2 (0.9) 75 (0.5) 2 (1.4) 75 (0.8) 
2006 1 (0.5) 27 (0.2) 0 (0) 0 (0) 
2007 5 (2.3) 212 (1.4) 1 (0.7) 54 (0.6) 
2008 14 (6.4) 1,247 (8.3) 4 (2.9) 485 (5.3) 
2009 32 (14.7) 2,163 (14.4) 21 (15.2) 1,359 (14.8) 
2010 47 (21.6) 2,835 (18.8) 31 (22.5) 1,716 (18.7) 
2011 55 (25.2) 3,995 (26.6) 37 (26.8) 2,502 (27.3) 
2012 50 (22.9) 3,762 (25.0) 33 (23.9) 2,349 (25.6) 
2013 1 (0.5) 44 (0.3) 1 (0.7) 44 (0.5) 
 
* 1 year risk period (A): assessment of characteristics for the cases and controls that are included in the analysis with a 1 year risk 
period assessment available. See Figure 1, risk period (A). # 2 year risk period (B): assessment of characteristics for the cases and 
controls that are included in the analysis with 2 year valid data available. See Figure 1, risk period (B). 
IQR, interquartile range; SD, standard deviation. Matching factors: age, GP practice, sex, date of diagnosis (for cases). Values in 
bold represent non-significant different proportions between matched cases and controls. 
 
 
Table 1. Characteristics of cases and controls on index date (continued). 
 
  
COLONOSCOPY CONTROLS 
1 year risk period* 2 year risk period# 
  Case Control Case Control 
 Characteristics N (%) N (%) N (%) N (%) 
Total 148 (100) 475 (100) 95 (100) 296 (100) 
Median no. of controls (IQR) 2 (1-4)   2 (1-4) 
Type microscopic colitis  
Collagenous colitis 61 (41.2)   29 (30.5) 
Lymphocytic colitis 48 (32.4)   31 (32.6) 
Not specified 39 (26.4)   25 (26.3) 
Sex  
male 32 (21.6) 100 (21.1) 24 (25.3) 81 (27.4) 
female 116 (78.4) 375 (78.9) 71 (74.7) 215 (72.6) 
Mean age at index date (SD) 45.3 (2.0) 45.7 (1.7) 45.4 (1.9) 45.6 (1.8) 
Median age at index date (IQR) 45.7 (44.6-46.6) 46.1 (45.0-46.8) 45.7 (44.6-46.6) 46.2 (45.0-46.7) 
Age group (years) 
<40 5 (3.4) 12 (2.5) 4 (4.2) 11 (3.7) 
40-45 47 (31.8) 126 (26.5) 29 (30.5) 79 (26.7) 
>45 96 (64.9) 337 (70.9) 62 (65.3) 206 (69.6) 
Celiac Disease yes 9 (6.1) 17 (3.6) 6 (6.3) 6 (2) 
Inflammatory Bowel Disease yes 23 (15.5) 13 (2.7) 16 (16.8) 10 (3.4) 
Hypothyroid Disease  yes 12 (8.1) 31 (6.5) 1 (1.1) 0 (0) 
Polyarthritis yes 2 (1.4) 0 (0) 1 (1.1) 1 (0.3) 
Rheumatoid Arthritis yes 3 (2) 8 (1.7) 5 (5.3) 6 (2.0) 
Diabetes Mellitus T2  yes 6 (4.1) 20 (4.2) 5 (5.3) 15 (5.1) 
Index year  
1999 1 (0.7) 1 (0.2) 0 (0) 0 (0) 
2000 0 (0) 0 (0) 0 (0) 0 (0) 
2001 0 (0) 0 (0) 0 (0) 0 (0) 
2002 1 (0.7) 1 (0.2) 1 (1.1) 1 (0.3) 
2003 0 (0) 0 (0) 0 (0) 0 (0) 
2004 3 (2) 10 (2.1) 3 (3.2) 10 (3.4) 
2005 1 (0.7) 1 (0.2) 1 (1.1) 1 (0.3) 
2006 0 (0) 0 (0) 0 (0) 0 (0) 
2007 2 (1.4) 5 (1.1) 1 (1.1) 4 (1.4) 
2008 8 (5.4) 17 (3.6) 3 (3.2) 8 (2.7) 
2009 22 (14.9) 54 (11.4) 15 (15.8) 31 (10.5) 
2010 36 (24.3) 102 (21.5) 21 (22.1) 68 (23.0) 
2011 39 (26.4) 137 (28.8) 27 (28.4) 90 (30.4) 
2012 34 (23.0) 144 (30.3) 22 (23.2) 80 (27.0) 
2013 1 (0.7) 3 (0.6) 1 (1.1) 3 (1) 
 
* 1 year risk period (A): assessment of characteristics for the cases and controls that are included in the analysis with a 1 year risk 
period assessment available. See Figure 1, risk period (A). # 2 year risk period (B): assessment of characteristics for the cases and 
controls that are included in the analysis with 2 year valid data available. See Figure 1, risk period (B). IQR, interquartile range; 
SD, standard deviation. Matching factors: age, GP practice, sex, date of diagnosis (for cases). Values in bold represent non-
significant different proportions between matched cases and controls. 
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2001 0 (0) 0 (0) 0 (0) 0 (0) 
2002 1 (0.5) 49 (0.3) 1 (0.7) 49 (0.5) 
2003 3 (1.4) 168 (1.1) 2 (1.4) 139 (1.5) 
2004 6 (2.8) 457 (3) 5 (3.6) 388 (4.2) 
2005 2 (0.9) 75 (0.5) 2 (1.4) 75 (0.8) 
2006 1 (0.5) 27 (0.2) 0 (0) 0 (0) 
2007 5 (2.3) 212 (1.4) 1 (0.7) 54 (0.6) 
2008 14 (6.4) 1,247 (8.3) 4 (2.9) 485 (5.3) 
2009 32 (14.7) 2,163 (14.4) 21 (15.2) 1,359 (14.8) 
2010 47 (21.6) 2,835 (18.8) 31 (22.5) 1,716 (18.7) 
2011 55 (25.2) 3,995 (26.6) 37 (26.8) 2,502 (27.3) 
2012 50 (22.9) 3,762 (25.0) 33 (23.9) 2,349 (25.6) 
2013 1 (0.5) 44 (0.3) 1 (0.7) 44 (0.5) 
 
* 1 year risk period (A): assessment of characteristics for the cases and controls that are included in the analysis with a 1 year risk 
period assessment available. See Figure 1, risk period (A). # 2 year risk period (B): assessment of characteristics for the cases and 
controls that are included in the analysis with 2 year valid data available. See Figure 1, risk period (B). 
IQR, interquartile range; SD, standard deviation. Matching factors: age, GP practice, sex, date of diagnosis (for cases). Values in 
bold represent non-significant different proportions between matched cases and controls. 
 
 
Table 1. Characteristics of cases and controls on index date (continued). 
 
  
COLONOSCOPY CONTROLS 
1 year risk period* 2 year risk period# 
  Case Control Case Control 
 Characteristics N (%) N (%) N (%) N (%) 
Total 148 (100) 475 (100) 95 (100) 296 (100) 
Median no. of controls (IQR) 2 (1-4)   2 (1-4) 
Type microscopic colitis  
Collagenous colitis 61 (41.2)   29 (30.5) 
Lymphocytic colitis 48 (32.4)   31 (32.6) 
Not specified 39 (26.4)   25 (26.3) 
Sex  
male 32 (21.6) 100 (21.1) 24 (25.3) 81 (27.4) 
female 116 (78.4) 375 (78.9) 71 (74.7) 215 (72.6) 
Mean age at index date (SD) 45.3 (2.0) 45.7 (1.7) 45.4 (1.9) 45.6 (1.8) 
Median age at index date (IQR) 45.7 (44.6-46.6) 46.1 (45.0-46.8) 45.7 (44.6-46.6) 46.2 (45.0-46.7) 
Age group (years) 
<40 5 (3.4) 12 (2.5) 4 (4.2) 11 (3.7) 
40-45 47 (31.8) 126 (26.5) 29 (30.5) 79 (26.7) 
>45 96 (64.9) 337 (70.9) 62 (65.3) 206 (69.6) 
Celiac Disease yes 9 (6.1) 17 (3.6) 6 (6.3) 6 (2) 
Inflammatory Bowel Disease yes 23 (15.5) 13 (2.7) 16 (16.8) 10 (3.4) 
Hypothyroid Disease  yes 12 (8.1) 31 (6.5) 1 (1.1) 0 (0) 
Polyarthritis yes 2 (1.4) 0 (0) 1 (1.1) 1 (0.3) 
Rheumatoid Arthritis yes 3 (2) 8 (1.7) 5 (5.3) 6 (2.0) 
Diabetes Mellitus T2  yes 6 (4.1) 20 (4.2) 5 (5.3) 15 (5.1) 
Index year  
1999 1 (0.7) 1 (0.2) 0 (0) 0 (0) 
2000 0 (0) 0 (0) 0 (0) 0 (0) 
2001 0 (0) 0 (0) 0 (0) 0 (0) 
2002 1 (0.7) 1 (0.2) 1 (1.1) 1 (0.3) 
2003 0 (0) 0 (0) 0 (0) 0 (0) 
2004 3 (2) 10 (2.1) 3 (3.2) 10 (3.4) 
2005 1 (0.7) 1 (0.2) 1 (1.1) 1 (0.3) 
2006 0 (0) 0 (0) 0 (0) 0 (0) 
2007 2 (1.4) 5 (1.1) 1 (1.1) 4 (1.4) 
2008 8 (5.4) 17 (3.6) 3 (3.2) 8 (2.7) 
2009 22 (14.9) 54 (11.4) 15 (15.8) 31 (10.5) 
2010 36 (24.3) 102 (21.5) 21 (22.1) 68 (23.0) 
2011 39 (26.4) 137 (28.8) 27 (28.4) 90 (30.4) 
2012 34 (23.0) 144 (30.3) 22 (23.2) 80 (27.0) 
2013 1 (0.7) 3 (0.6) 1 (1.1) 3 (1) 
 
* 1 year risk period (A): assessment of characteristics for the cases and controls that are included in the analysis with a 1 year risk 
period assessment available. See Figure 1, risk period (A). # 2 year risk period (B): assessment of characteristics for the cases and 
controls that are included in the analysis with 2 year valid data available. See Figure 1, risk period (B). IQR, interquartile range; 
SD, standard deviation. Matching factors: age, GP practice, sex, date of diagnosis (for cases). Values in bold represent non-
significant different proportions between matched cases and controls. 
	 Drugs	and	risk	of	microscopic	colitis	|	173  172	|	Chapter	5.2
 
 
Table 2. Exposure characteristics of cases and controls. 
 
COMMUNITY CONTROLS 
Within 1 year before index date #  Within 2 years before index date 
including 1 year lag-time‡ 
  Case Control  Case Control 
  N (%) N (%)  N (%) N (%) 
 Total Number 218 (100) 15,045 (100)  138 (100) 9,160 (100) 
Use of NSAIDs:     
Never use (>12 mo) 175 (80) 14,597 (97)  103 (75) 8,889 (97) 
Past use (3-12 mo) 16 (7.3) 237 (1.6)  11 (8) 169 (1.8) 
Current use (<3 mo) 27 (12) 211 (1.4)  24 (17) 102 (1.1) 
Use of PPIs:     
Never use (>12 mo) 126 (58) 14,538 (97)  93 (67) 8,880 (97) 
Past use (3-12 mo) 26 (12) 139 (0.9)  9 (6.5) 93 (1.0) 
Current use (<3 mo) 66 (30) 368 (2.4)  36 (26) 187 (2.0) 
Use of Statins:     
Never use (>12 mo) 176 (81) 14,683 (98)  108 (78) 8,952 (98) 
Past use (3-12 mo) 3 (1.4) 31 (0.2)  8 (5.8) 40 (0.4) 
Current use (<3 mo) 39 (18) 331 (2.2)  22 (16) 168 (1.8) 
Use of SSRIs:     
Never use (>12 mo) 195 (89) 14,940 (99)  127 (92) 9,100 (99) 
Past use (3-12 mo) 3 (1.4) 15 (0.1)  3 (2.2) 13 (0.1) 
Current use (<3 mo) 20 (9.2) 90 (0.6)  8 (5.8) 47 (0.5) 
Use of Low-dose Aspirin:     
Never use (>12 mo) 183 (84) 14,936 (99)  118 (86) 9,101 (99) 
Past use (3-12 mo) 3 (1.4) 7 (0.05)  0 (0) 10 (0.1) 
Current use (<3 mo) 32 (15) 102 (0.7)  20 (14) 49 (0.5) 
Use of ACE-inhibitors:     
Never use (>12 mo) 187 (86) 14,821 (99)  118 (86) 9,030 (99) 
Past use (3-12 mo) 1 (0.5) 18 (0.1)  6 (4.3) 23 (0.3) 
Current use (<3 mo) 30 (14) 206 (1.4)  14 (10) 107 (1.2) 
Use of Beta-blockers:     
Never use (>12 mo) 169 (78) 14,672 (98)  108 (78) 8,933 (98) 
Past use (3-12 mo) 2 (0.9) 25 (0.2)  3 (2.2) 47 (0.5) 
Current use (<3 mo) 47 (22) 348 (2.3)  27 (20) 180 (2) 
 
* For 2 year exposure period: current use (< 3 months), recent use (3-12 months), past use (12-24 months), never use (> 24 
months). 
# 1 year risk period (A): assessment of exposure characteristics for the cases and controls that are included in the analysis with a 
1 year risk period assessment available. See Figure 1, risk period (A). 
‡ 2 year risk period (B) : assessment of exposure characteristics for the cases and controls that are included in the analysis with 2 
year valid data available, but excluding the 1 year prior to index date, thus including a 1 year lag-time. See Figure 1, risk period 
(B). 
  
 
 
Table 2. Exposure characteristics of cases and controls (continued). 
 
COLONOSCOPY CONTROLS 
Within 1 year before index date#  Within 2 years before index date 
excluding the 1 year prior to index date‡ 
  Case Control  Case Control 
  N (%) N (%)  N (%) N (%) 
 Total Number 148 (100) 475 (100)  95 (100) 296 (100) 
Use of NSAIDs:      
Never use (>12 mo) 121 (82) 455 (96)  69 (73) 282 (95) 
Past use (3-12 mo) 11 (7.4) 6 (1.3)  11 (12) 10 (3.4) 
Current use (<3 mo) 16 (11) 14 (2.9)  15 (16) 4 (1.4) 
Use of PPIs:      
Never use (>12 mo) 83 (56) 441 (93)  62 (65) 289 (98) 
Past use (3-12 mo) 23 (16) 4 (0.8)  7 (7.4) 4 (1.4) 
Current use (<3 mo) 42 (28) 30 (6.3)  26 (27) 3 (1) 
Use of Statins:      
Never use (>12 mo) 120 (81) 455 (96)  75 (79) 284 (96) 
Past use (3-12 mo) 3 (2.0) 2 (0.4)  5 (5.3) 3 (1.0) 
Current use (<3 mo) 25 (17) 18 (3.8)  15 (16) 9 (3) 
Use of SSRIs:      
Never use (>12 mo) 131 (89) 475 (100)  87 (92) 296 (100) 
Past use (3-12 mo) 2 (1.4) 0 (0)  3 (3.2) 0 (0) 
Current use (<3 mo) 15 (10) 0 (0)  5 (5.3) 0 (0) 
Use of Low-dose Aspirin:     
Never use (>12 mo) 125 (84) 472 (99)  83 (87) 295 (99.7) 
Past use (3-12 mo) 3 (2) 0 (0)  0 (0) 0 (0) 
Current use (<3 mo) 20 (14) 3 (0.6)  12 (13) 1 (0.3) 
Use of ACE-inhibitors:     
Never use (>12 mo) 126 (85) 457 (96)  80 (84) 286 (97) 
Past use (3-12 mo) 1 (0.7) 0 (0)  5 (5.3) 2 (0.7) 
Current use (<3 mo) 21 (14) 18 (3.8)  10 (11) 8 (2.7) 
Use of Beta-blockers:      
Never use (>12 mo) 117 (79) 467 (98)  74 (78) 291 (98) 
Past use (3-12 mo) 0 (0) 0 (0)  1 (1.1) 2 (0.7) 
Current use (<3 mo) 31 (21) 8 (1.7)  20 (21) 3 (1) 
 
* For 2 year exposure period: current use (< 3 months), recent use (3-12 months), past use (12-24 months), never use (> 24 
months). 
# 1 year risk period (A): assessment of exposure characteristics for the cases and controls that are included in the analysis with a 
1 year risk period assessment available. See Figure 1, risk period (A). 
‡ 2 year risk period (B) : assessment of exposure characteristics for the cases and controls that are included in the analysis with 2 
year valid data available, but excluding the 1 year prior to index date, thus including a 1 year lag-time. See Figure 1, risk period 
(B). 
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Table 2. Exposure characteristics of cases and controls. 
 
COMMUNITY CONTROLS 
Within 1 year before index date #  Within 2 years before index date 
including 1 year lag-time‡ 
  Case Control  Case Control 
  N (%) N (%)  N (%) N (%) 
 Total Number 218 (100) 15,045 (100)  138 (100) 9,160 (100) 
Use of NSAIDs:     
Never use (>12 mo) 175 (80) 14,597 (97)  103 (75) 8,889 (97) 
Past use (3-12 mo) 16 (7.3) 237 (1.6)  11 (8) 169 (1.8) 
Current use (<3 mo) 27 (12) 211 (1.4)  24 (17) 102 (1.1) 
Use of PPIs:     
Never use (>12 mo) 126 (58) 14,538 (97)  93 (67) 8,880 (97) 
Past use (3-12 mo) 26 (12) 139 (0.9)  9 (6.5) 93 (1.0) 
Current use (<3 mo) 66 (30) 368 (2.4)  36 (26) 187 (2.0) 
Use of Statins:     
Never use (>12 mo) 176 (81) 14,683 (98)  108 (78) 8,952 (98) 
Past use (3-12 mo) 3 (1.4) 31 (0.2)  8 (5.8) 40 (0.4) 
Current use (<3 mo) 39 (18) 331 (2.2)  22 (16) 168 (1.8) 
Use of SSRIs:     
Never use (>12 mo) 195 (89) 14,940 (99)  127 (92) 9,100 (99) 
Past use (3-12 mo) 3 (1.4) 15 (0.1)  3 (2.2) 13 (0.1) 
Current use (<3 mo) 20 (9.2) 90 (0.6)  8 (5.8) 47 (0.5) 
Use of Low-dose Aspirin:     
Never use (>12 mo) 183 (84) 14,936 (99)  118 (86) 9,101 (99) 
Past use (3-12 mo) 3 (1.4) 7 (0.05)  0 (0) 10 (0.1) 
Current use (<3 mo) 32 (15) 102 (0.7)  20 (14) 49 (0.5) 
Use of ACE-inhibitors:     
Never use (>12 mo) 187 (86) 14,821 (99)  118 (86) 9,030 (99) 
Past use (3-12 mo) 1 (0.5) 18 (0.1)  6 (4.3) 23 (0.3) 
Current use (<3 mo) 30 (14) 206 (1.4)  14 (10) 107 (1.2) 
Use of Beta-blockers:     
Never use (>12 mo) 169 (78) 14,672 (98)  108 (78) 8,933 (98) 
Past use (3-12 mo) 2 (0.9) 25 (0.2)  3 (2.2) 47 (0.5) 
Current use (<3 mo) 47 (22) 348 (2.3)  27 (20) 180 (2) 
 
* For 2 year exposure period: current use (< 3 months), recent use (3-12 months), past use (12-24 months), never use (> 24 
months). 
# 1 year risk period (A): assessment of exposure characteristics for the cases and controls that are included in the analysis with a 
1 year risk period assessment available. See Figure 1, risk period (A). 
‡ 2 year risk period (B) : assessment of exposure characteristics for the cases and controls that are included in the analysis with 2 
year valid data available, but excluding the 1 year prior to index date, thus including a 1 year lag-time. See Figure 1, risk period 
(B). 
  
 
 
Table 2. Exposure characteristics of cases and controls (continued). 
 
COLONOSCOPY CONTROLS 
Within 1 year before index date#  Within 2 years before index date 
excluding the 1 year prior to index date‡ 
  Case Control  Case Control 
  N (%) N (%)  N (%) N (%) 
 Total Number 148 (100) 475 (100)  95 (100) 296 (100) 
Use of NSAIDs:      
Never use (>12 mo) 121 (82) 455 (96)  69 (73) 282 (95) 
Past use (3-12 mo) 11 (7.4) 6 (1.3)  11 (12) 10 (3.4) 
Current use (<3 mo) 16 (11) 14 (2.9)  15 (16) 4 (1.4) 
Use of PPIs:      
Never use (>12 mo) 83 (56) 441 (93)  62 (65) 289 (98) 
Past use (3-12 mo) 23 (16) 4 (0.8)  7 (7.4) 4 (1.4) 
Current use (<3 mo) 42 (28) 30 (6.3)  26 (27) 3 (1) 
Use of Statins:      
Never use (>12 mo) 120 (81) 455 (96)  75 (79) 284 (96) 
Past use (3-12 mo) 3 (2.0) 2 (0.4)  5 (5.3) 3 (1.0) 
Current use (<3 mo) 25 (17) 18 (3.8)  15 (16) 9 (3) 
Use of SSRIs:      
Never use (>12 mo) 131 (89) 475 (100)  87 (92) 296 (100) 
Past use (3-12 mo) 2 (1.4) 0 (0)  3 (3.2) 0 (0) 
Current use (<3 mo) 15 (10) 0 (0)  5 (5.3) 0 (0) 
Use of Low-dose Aspirin:     
Never use (>12 mo) 125 (84) 472 (99)  83 (87) 295 (99.7) 
Past use (3-12 mo) 3 (2) 0 (0)  0 (0) 0 (0) 
Current use (<3 mo) 20 (14) 3 (0.6)  12 (13) 1 (0.3) 
Use of ACE-inhibitors:     
Never use (>12 mo) 126 (85) 457 (96)  80 (84) 286 (97) 
Past use (3-12 mo) 1 (0.7) 0 (0)  5 (5.3) 2 (0.7) 
Current use (<3 mo) 21 (14) 18 (3.8)  10 (11) 8 (2.7) 
Use of Beta-blockers:      
Never use (>12 mo) 117 (79) 467 (98)  74 (78) 291 (98) 
Past use (3-12 mo) 0 (0) 0 (0)  1 (1.1) 2 (0.7) 
Current use (<3 mo) 31 (21) 8 (1.7)  20 (21) 3 (1) 
 
* For 2 year exposure period: current use (< 3 months), recent use (3-12 months), past use (12-24 months), never use (> 24 
months). 
# 1 year risk period (A): assessment of exposure characteristics for the cases and controls that are included in the analysis with a 
1 year risk period assessment available. See Figure 1, risk period (A). 
‡ 2 year risk period (B) : assessment of exposure characteristics for the cases and controls that are included in the analysis with 2 
year valid data available, but excluding the 1 year prior to index date, thus including a 1 year lag-time. See Figure 1, risk period 
(B). 
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Higher cumulative doses of NSAIDs (>15 DDDs), SSRIs (30-90 DDDS; and >90 DDDs) and 
moderate to medium cumulative doses of beta-blockers (1-29 DDDs; 30-90 DDDs) were 
associated with an increased risk of MC in the 1 year risk period. In the 2 year risk period when 
only looking at the first year, all cumulative doses of NSAIDs were associated with an increased 
risk of MC, with the highest estimate for the highest cumulative dose (> 90 DDDs: ORa 10.8; 
95% CI: 5.0-23.4). In this risk period all doses of ACE-inhibitors, between 30-90 DDDs of statins, 
the highest cumulative dose (>90 DDDs) of SSRIs and between 1-29 DDDs of beta-blockers 
were associated with MC. For PPIs all dose categories were associated with increase in risk of 
MC, although no dose-response effect with increasing risk estimates over higher dose 
categories was seen. 
 
Risk of microscopic colitis compared to colonoscopy controls 
 
By using a control group consisting of subjects who underwent a colonoscopy that was 
negative for MC or colorectal cancer, the potential impact of confounding-by-indication and 
diagnostic bias were taken into account. Looking at the 1 year risk period, adjusted odds ratios 
were only significantly increased for current use of PPIs (ORa 4.4; 95%CI: 1.6-12.1), low-dose 
aspirin (ORa 17.6; 95%CI: 1.9-165.9), and beta-blockers (ORa 5.8; 95%CI: 1.6-21.1) (Table 3B, 
Supplementary Figure 2A and B). No controls were exposed to SSRIs and thus no ORs for SSRI 
use could be calculated. When taking diagnostic delay (by looking at the period 1 to 2 years 
prior to index date and not in the 1 year prior to index date) into account, only current use of 
PPIs (ORa 10.6; 95%CI: 1.8-64.2) and NSAIDs (ORa 5.6; 95%CI: 1.2-27.0) remained to 
significantly increase the risk of MC. Results regarding individual types of NSAIDs and PPIs are 
shown in Supplementary Figures 3 and Figures 4. Heterogeneity for PPIs was seen for risk 
period B (p=0.022), but not for risk period A (p=0.0622). Analyses of dose effects for PPIs 
indicate that a higher cumulative dose was associated with a significant increased risk of MC in 
the 1 year risk period and was borderline significant for the 2 year risk period (Supplementary 
Table 1B). For NSAIDs, only the highest cumulative dose (>15 DDDs) was associated with MC in 
the 2 year risk period (ORa 5.7; 95%CI: 1.3-25.4). 
 
Sensitivity analysis 
 
When excluding the MC cases with unspecified type of MC, results were similar to the initial 
analyses (data not shown). Also, when stratifying the analyses by type of MC, results did not 
change substantially (data not shown). Odds ratios were higher for collagenous colitis than 
lymphocytic colitis during current use of PPIs. No significant effect modification by sex or age 
was observed on a multiplicative scale (data not shown). 
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Higher cumulative doses of NSAIDs (>15 DDDs), SSRIs (30-90 DDDS; and >90 DDDs) and 
moderate to medium cumulative doses of beta-blockers (1-29 DDDs; 30-90 DDDs) were 
associated with an increased risk of MC in the 1 year risk period. In the 2 year risk period when 
only looking at the first year, all cumulative doses of NSAIDs were associated with an increased 
risk of MC, with the highest estimate for the highest cumulative dose (> 90 DDDs: ORa 10.8; 
95% CI: 5.0-23.4). In this risk period all doses of ACE-inhibitors, between 30-90 DDDs of statins, 
the highest cumulative dose (>90 DDDs) of SSRIs and between 1-29 DDDs of beta-blockers 
were associated with MC. For PPIs all dose categories were associated with increase in risk of 
MC, although no dose-response effect with increasing risk estimates over higher dose 
categories was seen. 
 
Risk of microscopic colitis compared to colonoscopy controls 
 
By using a control group consisting of subjects who underwent a colonoscopy that was 
negative for MC or colorectal cancer, the potential impact of confounding-by-indication and 
diagnostic bias were taken into account. Looking at the 1 year risk period, adjusted odds ratios 
were only significantly increased for current use of PPIs (ORa 4.4; 95%CI: 1.6-12.1), low-dose 
aspirin (ORa 17.6; 95%CI: 1.9-165.9), and beta-blockers (ORa 5.8; 95%CI: 1.6-21.1) (Table 3B, 
Supplementary Figure 2A and B). No controls were exposed to SSRIs and thus no ORs for SSRI 
use could be calculated. When taking diagnostic delay (by looking at the period 1 to 2 years 
prior to index date and not in the 1 year prior to index date) into account, only current use of 
PPIs (ORa 10.6; 95%CI: 1.8-64.2) and NSAIDs (ORa 5.6; 95%CI: 1.2-27.0) remained to 
significantly increase the risk of MC. Results regarding individual types of NSAIDs and PPIs are 
shown in Supplementary Figures 3 and Figures 4. Heterogeneity for PPIs was seen for risk 
period B (p=0.022), but not for risk period A (p=0.0622). Analyses of dose effects for PPIs 
indicate that a higher cumulative dose was associated with a significant increased risk of MC in 
the 1 year risk period and was borderline significant for the 2 year risk period (Supplementary 
Table 1B). For NSAIDs, only the highest cumulative dose (>15 DDDs) was associated with MC in 
the 2 year risk period (ORa 5.7; 95%CI: 1.3-25.4). 
 
Sensitivity analysis 
 
When excluding the MC cases with unspecified type of MC, results were similar to the initial 
analyses (data not shown). Also, when stratifying the analyses by type of MC, results did not 
change substantially (data not shown). Odds ratios were higher for collagenous colitis than 
lymphocytic colitis during current use of PPIs. No significant effect modification by sex or age 
was observed on a multiplicative scale (data not shown). 
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DISCUSSION 
 
In this population-based nested case-control study use of NSAIDs, proton pump inhibitors, 
selective serotonin reuptake inhibitors, low-dose aspirin, ACE-inhibitors or beta-blockers were 
associated with an increased risk of MC. However, when taking confounding-by-indication, 
diagnostic delay and diagnostic bias into account (by comparing with subjects who have had a 
colonoscopy negative for colorectal cancer and MC), only PPIs and NSAIDs significantly 
increased the risk of MC. This finding was supported by dose analyses showing increasing 
estimates with higher cumulative doses used. 
 Different studies were done prior to this study with contradicting results. Regarding 
NSAIDs, an unmatched case control study compared the frequency of use of several drugs in 
patients with chronic watery diarrhea, but not MC, to that in patients attending an outpatient 
surgery unit.377 This study suggested that NSAIDs, SSRIs and statins were significantly 
associated with chronic watery diarrhea.377 Our results are well in line with this, as we showed 
that only PPIs, NSAIDs and low-dose aspirin increased the risk of MC when compared to 
colonoscopy controls. The apparent increased MC risk with use of ACE-inhibitors, beta-
blockers, SSRIs and statins in that study is probably an artifact.377 In the current study, these 
drugs did not increase the risk of MC when compared to community controls. They increase 
the likelihood of undergoing a colonoscopy by, for instance, inducing abdominal symptoms, 
increasing stool frequency or worsening diarrhea. In addition, NSAIDs are indicated for 
treatment of arthralgias, which often accompany MC. Thus, subjects with arthralgia may be 
more likely to undergo colonoscopy and be diagnosed with MC. Our results are in line with a 
recent Danish case-control study.385 This study is however limited by the fact they classified 
having only 1 filled prescription in the year prior to MC diagnosis as being exposed to the drug, 
which may predispose to misclassification of exposure. No distinction was made between 
current users and past users, while filling more than only 1 prescription would provide a more 
robust investigation of the exposure.385 Although the association between NSAIDs and MC may 
be explained by the underlying co-morbid disease, current use of NSAIDs in our population 
remained associated with an increased risk of MC even when we adjusted for concomitant 
exposure, polyarthritis and rheumatoid arthritis. Thus, it is unlikely that the indication of 
NSAID could explain the association between NSAIDs and MC as observed in the current study. 
This observation is supported by previous reports.377, 378, 386 Also, in our study NSAIDs still 
increased the risk of MC up to 6-fold when taking diagnostic delay and diagnostic bias into 
consideration. Furthermore, the association was supported by the dose analysis providing 
increasing risk estimates with higher cumulative doses of NSAIDs used. To examine whether 
the risk of MC was different for individual types of NSAIDs we conducted analyses for 
individual NSAIDs. Diclofenac was the most commonly used NSAID and accounted for 52% to 
67% of NSAIDs used by cases. Because fewer exposed cases could be matched to colonoscopy-
negative controls, the study had insufficient power to estimate a risk estimate for each 
individual NSAID. The results on individual NSAIDs should thus be interpreted with caution. 
Physiologically the association can be explained by loosening the colonic paracellular 
	 Drugs	and	risk	of	microscopic	colitis	|	177 
5
 
 
Ta
bl
e 
3B
. R
isk
 o
f M
ic
ro
sc
op
ic
 c
ol
iti
s,
 c
as
es
 c
om
pa
re
d 
to
 c
ol
on
os
co
py
 c
on
tr
ol
s.
 
  
W
ith
in
 1
 y
ea
r b
ef
or
e 
in
de
x 
da
te
 †
 
W
ith
in
 2
 y
ea
rs
 b
ef
or
e 
in
de
x 
da
te
 e
xc
l t
he
 1
 y
ea
r p
rio
r t
o 
in
de
x 
da
te
 ‡
 
  
O
Rm
at
ch
ed
  
(9
5%
 C
I) 
P-
va
lu
e 
O
Ra
dj
# 
 
(9
5%
 C
I) 
P-
va
lu
e 
O
Rm
at
ch
ed
  
(9
5%
 C
I) 
P-
va
lu
e 
O
Ra
dj
# 
 
(9
5%
 C
I) 
P-
va
lu
e 
 U
se
 o
f N
SA
ID
s:
 
 
 
 
 
 
 
 
N
ev
er
 u
se
 (>
12
 m
o)
 
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
Pa
st
 u
se
 (3
-1
2 
m
o)
 
6.
7 
(2
.1
-2
0.
7)
 
0.
00
1 
12
.4
 (1
.7
-9
3.
1)
 
0.
01
4 
4.
0 
(1
.4
-1
1.
2)
 
0.
00
9 
1.
7 
(0
.3
-9
.2
) 
0.
55
2 
Cu
rr
en
t u
se
 (<
3 
m
o)
 
3.
4 
(1
.4
-7
.9
) 
0.
00
5 
0.
8 
(0
.2
-2
.7
) 
0.
71
8 
12
.0
 (3
.7
-3
8.
6)
 
<0
.0
01
 
5.
6 
(1
.2
-2
7.
0)
 
0.
03
1 
U
se
 o
f P
PI
s:
 
 
 
 
 
 
 
 
N
ev
er
 u
se
 (>
12
 m
o)
 
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
Pa
st
 u
se
 (3
-1
2 
m
o)
 
19
.7
 (6
.3
-6
1.
5)
 
<0
.0
01
 
16
.8
 (4
.2
-6
6.
7)
 
<0
.0
01
 
4.
. (
1.
1-
16
.6
) 
0.
03
6 
0.
6 
(0
.1
-6
.7
) 
0.
64
5 
Cu
rr
en
t u
se
 (<
3 
m
o)
 
9.
8 
(4
.7
-2
0.
3)
 
<0
.0
01
 
4.
4 
(1
.6
-1
2.
1)
 
0.
00
5 
41
.1
 (9
.5
-1
78
.9
) 
<0
.0
01
 
10
.6
 (1
.8
-6
4.
2)
 
0.
01
0 
U
se
 o
f S
ta
tin
s:
 
 
 
 
 
 
 
 
N
ev
er
 u
se
 (>
12
 m
o)
 
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
Pa
st
 u
se
 (3
-1
2 
m
o)
 
N
A 
N
A 
10
.6
 (2
.2
-5
1.
1)
 
0.
00
3 
3.
2 
(0
.1
-1
24
.2
) 
0.
53
0 
Cu
rr
en
t u
se
 (<
3 
m
o)
 
10
.7
 (4
.3
-2
6.
4)
 
<0
.0
01
 
1.
1 
(0
.3
-4
.3
) 
0.
93
4 
12
.6
 (3
.7
-4
2.
5)
 
<0
.0
01
 
1.
1 
(0
.1
-8
.5
) 
0.
92
4 
U
se
 o
f L
ow
-d
os
e 
As
pi
rin
: 
 
 
 
 
 
 
 
N
ev
er
 u
se
 (>
12
 m
o)
 
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
Pa
st
 u
se
 (3
-1
2 
m
o)
 
N
A 
N
A 
N
A 
N
A 
Cu
rr
en
t u
se
 (<
3 
m
o)
 
30
.7
 (6
.8
-1
37
.6
) 
<0
.0
01
 
17
.6
 (1
.9
-1
65
.9
) 
<0
.0
01
 
46
.7
 (5
.8
-3
75
.3
) 
<0
.0
01
 
N
A 
U
se
 o
f A
CE
-in
hi
bi
to
rs
: 
 
 
 
 
 
 
 
N
ev
er
 u
se
 (>
12
 m
o)
 
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
Pa
st
 u
se
 (3
-1
2 
m
o)
 
N
A 
N
A 
10
.3
 (1
.7
-6
1.
8)
 
0.
01
1 
N
A 
Cu
rr
en
t u
se
 (<
3 
m
o)
 
6.
7 
(2
.9
-1
5.
19
) 
<0
.0
01
 
2.
2 
(0
.6
-7
.7
) 
0.
23
6 
12
.9
 (3
.3
-5
0.
8)
 
<0
.0
01
 
2.
4 
(0
.2
-3
6.
7)
 
0.
51
8 
U
se
 o
f B
et
a-
bl
oc
ke
rs
: 
 
 
 
 
 
 
 
N
ev
er
 u
se
 (>
12
 m
o)
 
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
1 
(r
ef
) 
  
Pa
st
 u
se
 (3
-1
2 
m
o)
 
N
A 
N
A 
4.
2 
(0
.3
-5
8.
7)
 
0.
28
3 
1.
7 
(0
.1
-5
2.
7)
 
0.
77
4 
Cu
rr
en
t u
se
 (<
3 
m
o)
 
16
.5
 (6
.2
-4
3.
8)
 
<0
.0
01
 
5.
8 
(1
.6
-2
1.
1)
 
0.
00
8 
53
.1
 (6
.9
-4
05
.7
) 
<0
.0
01
 
7.
8 
(0
.7
-8
2.
8)
 
0.
08
7 
 # 
Ad
ju
st
ed
 fo
r c
on
co
m
ita
nt
 u
se
 o
f N
SA
ID
s, 
PP
Is
, s
ta
tin
s, 
SS
RI
s, 
lo
w
-d
os
e 
as
pi
rin
, A
CE
-in
hi
bi
to
rs
, b
et
a-
bl
oc
ke
rs
; c
el
ia
c d
ise
as
e;
 in
fla
m
m
at
or
y 
bo
w
el
 d
ise
as
e;
 h
yp
ot
hy
ro
id
 d
ise
as
e;
 p
ol
ya
rt
hr
iti
s;
 
rh
eu
m
at
oi
d 
ar
th
rit
is 
an
d 
ty
pe
 2
 d
ia
be
te
s m
el
lit
us
. †
 1
 y
ea
r r
isk
 p
er
io
d 
(A
): 
O
dd
s r
at
io
s f
ro
m
 th
e 
an
al
ys
is 
w
ith
 a
 1
 y
ea
r r
isk
 p
er
io
d 
as
se
ss
m
en
t a
va
ila
bl
e.
 S
ee
 F
ig
ur
e 
1,
 ri
sk
 p
er
io
d 
(A
). 
‡ 
2 
ye
ar
 ri
sk
 
pe
rio
d 
(B
) :
 O
dd
s r
at
io
s f
ro
m
 th
e 
an
al
ys
is 
w
ith
 2
 y
ea
r v
al
id
 d
at
a 
av
ai
la
bl
e,
 b
ut
 e
xc
lu
di
ng
 th
e 
1 
ye
ar
 p
rio
r t
o 
in
de
x 
da
te
, t
hu
s i
nc
lu
di
ng
 a
 1
 y
ea
r l
ag
-t
im
e.
 S
ee
 F
ig
ur
e 
1,
 ri
sk
 p
er
io
d 
(B
). 
M
o,
 m
on
th
s;
 
SS
RI
s, 
se
le
ct
iv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
bi
to
rs
. 
 
 
DISCUSSION 
 
In this population-based nested case-control study use of NSAIDs, proton pump inhibitors, 
selective serotonin reuptake inhibitors, low-dose aspirin, ACE-inhibitors or beta-blockers were 
associated with an increased risk of MC. However, when taking confounding-by-indication, 
diagnostic delay and diagnostic bias into account (by comparing with subjects who have had a 
colonoscopy negative for colorectal cancer and MC), only PPIs and NSAIDs significantly 
increased the risk of MC. This finding was supported by dose analyses showing increasing 
estimates with higher cumulative doses used. 
 Different studies were done prior to this study with contradicting results. Regarding 
NSAIDs, an unmatched case control study compared the frequency of use of several drugs in 
patients with chronic watery diarrhea, but not MC, to that in patients attending an outpatient 
surgery unit.377 This study suggested that NSAIDs, SSRIs and statins were significantly 
associated with chronic watery diarrhea.377 Our results are well in line with this, as we showed 
that only PPIs, NSAIDs and low-dose aspirin increased the risk of MC when compared to 
colonoscopy controls. The apparent increased MC risk with use of ACE-inhibitors, beta-
blockers, SSRIs and statins in that study is probably an artifact.377 In the current study, these 
drugs did not increase the risk of MC when compared to community controls. They increase 
the likelihood of undergoing a colonoscopy by, for instance, inducing abdominal symptoms, 
increasing stool frequency or worsening diarrhea. In addition, NSAIDs are indicated for 
treatment of arthralgias, which often accompany MC. Thus, subjects with arthralgia may be 
more likely to undergo colonoscopy and be diagnosed with MC. Our results are in line with a 
recent Danish case-control study.385 This study is however limited by the fact they classified 
having only 1 filled prescription in the year prior to MC diagnosis as being exposed to the drug, 
which may predispose to misclassification of exposure. No distinction was made between 
current users and past users, while filling more than only 1 prescription would provide a more 
robust investigation of the exposure.385 Although the association between NSAIDs and MC may 
be explained by the underlying co-morbid disease, current use of NSAIDs in our population 
remained associated with an increased risk of MC even when we adjusted for concomitant 
exposure, polyarthritis and rheumatoid arthritis. Thus, it is unlikely that the indication of 
NSAID could explain the association between NSAIDs and MC as observed in the current study. 
This observation is supported by previous reports.377, 378, 386 Also, in our study NSAIDs still 
increased the risk of MC up to 6-fold when taking diagnostic delay and diagnostic bias into 
consideration. Furthermore, the association was supported by the dose analysis providing 
increasing risk estimates with higher cumulative doses of NSAIDs used. To examine whether 
the risk of MC was different for individual types of NSAIDs we conducted analyses for 
individual NSAIDs. Diclofenac was the most commonly used NSAID and accounted for 52% to 
67% of NSAIDs used by cases. Because fewer exposed cases could be matched to colonoscopy-
negative controls, the study had insufficient power to estimate a risk estimate for each 
individual NSAID. The results on individual NSAIDs should thus be interpreted with caution. 
Physiologically the association can be explained by loosening the colonic paracellular 
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permeability,85 inducing lower gastrointestinal (GI) bleeding9, 86 and affecting the bowel 
integrity.84 Subsequently, luminal antigens can more easily enter the lamina propria and elicit 
an immune and inflammatory reaction. Therefore we suggest that NSAIDs should be avoided 
in patients at risk of developing MC. To the best of our knowledge, no clinical decision models 
are available to weigh the benefits and risks of NSAIDs including MC as adverse event. A 
balanced decision should be based on clinical knowledge and the preference of the patient. 
 
Proton Pump Inhibitors 
 
The recent Danish study also noted the association between PPIs and MC, regardless of having 
had colonic biopsies.385 Again, though they applied a second control group, the exposure 
definition was rather broad with only 1 filled prescription required to being classified as 
exposed to the drug.385 Also, they relied on the MC diagnosis date385 rather than the start of 
symptoms of MC as we could verify in the medical records. A previous case-control study from 
the Netherlands showed that use of PPIs was associated with an increased risk of MC.378 
However, this study may have suffered from selection bias, as cases were retrieved from a 
secondary and tertiary hospital, while controls were selected from the general population.378 
Another case-control study on 26 cases found contrasting results with no increased risk of MC 
with PPI use. This study may be limited by its sample size and by lack of adjustment for 
NSAIDs, which are often concomitantly used with PPIs.387 As is shown in our study, substantial 
confounding-by-indication is present as the risk of MC for current use of PPIs in the 1 year risk 
period decreased from 7.3-fold to 4.4-fold when using colonoscopy controls instead of 
community controls. Similar to NSAIDs, we investigated the risk of MC for different individual 
PPIs. Omeprazole was the predominant PPI used and accounted for 59% to 67% of PPIs used 
by cases. There have been several case-series published on PPI-induced MC388, 389 but the 
underlying pathophysiological mechanism remains poorly understood. Experimental studies 
have shown the influence of PPIs on intestinal permeability, inducing smooth muscle 
relaxation and inhibiting contractile activity.83, 87, 88 The effect on the contractile activity system 
may also affect the actinomyosin cytoskeleton, resulting in conformational changes in the 
cytoskeleton of epithelial cells and subsequent alterations in the function of tight junctions.83, 
87, 88 PPIs also affect the colonic intestinal flora, thereby increasing the risk of bacterial 
intestinal infections. Evidence on this topic until now, however, is scarce.210, 379 
 
Beta-blockers and ACE-inhibitors 
 
Our observation that beta-blockers and ACE-inhibitors were associated with MC compared to 
community controls, but not compared to colonoscopy controls could be explained by two 
reasons. First, the association between beta-blockers and ACE-inhibitors is true, but could not 
be confirmed in the comparison with the colonoscopy controls due to smaller sample size. 
Second, the association is false and likely due to confounding-by-indication, for instance 
subjects on drugs may be more closely monitored. There is some evidence on a 
 
 
pathophysiological mechanism by which beta-blockers augment small intestinal transit by 
increasing the propulsive force associated with small intestinal contractions.390, 391 To which 
extent these effects result in increased bowel frequency and stool consistency has not been 
studied. 
 
Selective serotonin reuptake inhibitors 
 
We demonstrated that SSRIs increased the risk of MC when compared to community controls, 
but not when compared to colonoscopy controls. This could be explained by confounding-by-
indication, in particular since diarrhea is a known side effect of SSRI use.392 
 
Strengths and limitations 
 
Strengths of the current study include the population-based setting based of the electronic 
medical records, which allowed to identify all potential MC cases while matching to 
community controls and colonoscopy-negative controls. By doing so, we mitigated against 
selection bias as the cases and controls were derived from the same source population. In this 
context, the odds ratio may be interpreted directly as the relative risk.393, 394 Second, by 
applying different risk periods, from 1 year up to 2 years prior to the index date, we corrected 
for any diagnostic delay of MC, which may take up to several months. This is demonstrated by 
the fact that exposure closer to index date (<3 months) yielded higher risks of MC than 
exposure longer before (>12 months). This could be due to an actual risk increase, but is more 
likely affected by lag-time bias. We also chose the date of first symptoms leading to the MC 
diagnosis as index date in order to avoid any misclassification of the exposure in the risk 
periods. 
 We acknowledge the following limitations. First, MC is a specialist confirmed 
diagnosis, meaning that in a GP database underreporting of MC could have occurred. We 
assumed that all relevant medical information on a microscopic diagnosis is recorded by the 
GP. However, this may not hold true entirely and we may have missed some MC cases. 
Nevertheless, we extensively reviewed the medical records of all MC cases included in the 
current study to ensure that the MC cases included in the study had histological confirmation 
of the diagnosis. Misclassification of MC is therefore unlikely, but if present it will be non-
differential and will have resulted in more conservative, but unbiased estimates. Additionally, 
by excluding the unspecified MC cases we performed sensitivity analyses which yielded similar 
results as the initial analyses. When stratifying by type of MC, we found similar results as for 
the main analysis. However, caution should be taken when interpreting the findings on the risk 
of collagenous and lymphocytic colitis separately by use of drugs, as the subgroup analyses 
were based on small numbers. We included two control groups, which both have their 
limitations. The colonoscopy group had a clinical indication to undergo this procedure, which 
you can see as a test-negative control group, however this is similarly so for the cases. 
Confounding for ‘indication’ is actually reduced in such a control group. Colonoscopies were 
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in patients at risk of developing MC. To the best of our knowledge, no clinical decision models 
are available to weigh the benefits and risks of NSAIDs including MC as adverse event. A 
balanced decision should be based on clinical knowledge and the preference of the patient. 
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definition was rather broad with only 1 filled prescription required to being classified as 
exposed to the drug.385 Also, they relied on the MC diagnosis date385 rather than the start of 
symptoms of MC as we could verify in the medical records. A previous case-control study from 
the Netherlands showed that use of PPIs was associated with an increased risk of MC.378 
However, this study may have suffered from selection bias, as cases were retrieved from a 
secondary and tertiary hospital, while controls were selected from the general population.378 
Another case-control study on 26 cases found contrasting results with no increased risk of MC 
with PPI use. This study may be limited by its sample size and by lack of adjustment for 
NSAIDs, which are often concomitantly used with PPIs.387 As is shown in our study, substantial 
confounding-by-indication is present as the risk of MC for current use of PPIs in the 1 year risk 
period decreased from 7.3-fold to 4.4-fold when using colonoscopy controls instead of 
community controls. Similar to NSAIDs, we investigated the risk of MC for different individual 
PPIs. Omeprazole was the predominant PPI used and accounted for 59% to 67% of PPIs used 
by cases. There have been several case-series published on PPI-induced MC388, 389 but the 
underlying pathophysiological mechanism remains poorly understood. Experimental studies 
have shown the influence of PPIs on intestinal permeability, inducing smooth muscle 
relaxation and inhibiting contractile activity.83, 87, 88 The effect on the contractile activity system 
may also affect the actinomyosin cytoskeleton, resulting in conformational changes in the 
cytoskeleton of epithelial cells and subsequent alterations in the function of tight junctions.83, 
87, 88 PPIs also affect the colonic intestinal flora, thereby increasing the risk of bacterial 
intestinal infections. Evidence on this topic until now, however, is scarce.210, 379 
 
Beta-blockers and ACE-inhibitors 
 
Our observation that beta-blockers and ACE-inhibitors were associated with MC compared to 
community controls, but not compared to colonoscopy controls could be explained by two 
reasons. First, the association between beta-blockers and ACE-inhibitors is true, but could not 
be confirmed in the comparison with the colonoscopy controls due to smaller sample size. 
Second, the association is false and likely due to confounding-by-indication, for instance 
subjects on drugs may be more closely monitored. There is some evidence on a 
 
 
pathophysiological mechanism by which beta-blockers augment small intestinal transit by 
increasing the propulsive force associated with small intestinal contractions.390, 391 To which 
extent these effects result in increased bowel frequency and stool consistency has not been 
studied. 
 
Selective serotonin reuptake inhibitors 
 
We demonstrated that SSRIs increased the risk of MC when compared to community controls, 
but not when compared to colonoscopy controls. This could be explained by confounding-by-
indication, in particular since diarrhea is a known side effect of SSRI use.392 
 
Strengths and limitations 
 
Strengths of the current study include the population-based setting based of the electronic 
medical records, which allowed to identify all potential MC cases while matching to 
community controls and colonoscopy-negative controls. By doing so, we mitigated against 
selection bias as the cases and controls were derived from the same source population. In this 
context, the odds ratio may be interpreted directly as the relative risk.393, 394 Second, by 
applying different risk periods, from 1 year up to 2 years prior to the index date, we corrected 
for any diagnostic delay of MC, which may take up to several months. This is demonstrated by 
the fact that exposure closer to index date (<3 months) yielded higher risks of MC than 
exposure longer before (>12 months). This could be due to an actual risk increase, but is more 
likely affected by lag-time bias. We also chose the date of first symptoms leading to the MC 
diagnosis as index date in order to avoid any misclassification of the exposure in the risk 
periods. 
 We acknowledge the following limitations. First, MC is a specialist confirmed 
diagnosis, meaning that in a GP database underreporting of MC could have occurred. We 
assumed that all relevant medical information on a microscopic diagnosis is recorded by the 
GP. However, this may not hold true entirely and we may have missed some MC cases. 
Nevertheless, we extensively reviewed the medical records of all MC cases included in the 
current study to ensure that the MC cases included in the study had histological confirmation 
of the diagnosis. Misclassification of MC is therefore unlikely, but if present it will be non-
differential and will have resulted in more conservative, but unbiased estimates. Additionally, 
by excluding the unspecified MC cases we performed sensitivity analyses which yielded similar 
results as the initial analyses. When stratifying by type of MC, we found similar results as for 
the main analysis. However, caution should be taken when interpreting the findings on the risk 
of collagenous and lymphocytic colitis separately by use of drugs, as the subgroup analyses 
were based on small numbers. We included two control groups, which both have their 
limitations. The colonoscopy group had a clinical indication to undergo this procedure, which 
you can see as a test-negative control group, however this is similarly so for the cases. 
Confounding for ‘indication’ is actually reduced in such a control group. Colonoscopies were 
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performed for the complete range of clinical indications, including colorectal cancer screening. 
However, results from analyses are consistent across the control groups, which strengthen the 
results and provide consistent evidence that NSAIDs and PPIs are associated with MC. Also, in 
the more recent years clinicians became more aware of MC. The majority of cases was 
diagnosed after 2006. This has an effect on the sample size, but was unlikely to provide 
spurious or biased associations since cases and controls were matched on calendar time. 
Second, information on other potential confounders such as smoking status and alcohol use is 
likely to be underreported in the database and was therefore not considered in the analysis. 
This may have resulted in residual confounding. Thirdly, the date of onset of disease could 
have been misclassified. Although we tried to mitigate against misspecification of the risk 
window by using the date of onset of symptoms as index date, we cannot account for patients 
delay between actual start of symptoms and recording of symptoms by the GP. Yet, in order to 
account for diagnostic delay, we applied two different risk periods in the current study. Fourth, 
we only observed that NSAIDs and PPIs were associated with MC. However, due to the smaller 
sample size, particularly in the risk period of 2 years while excluding the last year prior to index 
date, we cannot rule out that due to power issues we did not observe an association for the 
other drugs.  
 In conclusion, non-steroidal anti-inflammatory drugs and proton pump inhibitors 
significantly increased the risk of MC, even after taking diagnostic bias and diagnostic delay 
into account. Use of selective serotonin reuptake inhibitors, low-dose aspirin, beta-blockers 
and ACE-inhibitors were associated with increased risk of MC when compared to community 
controls, but not compared to colonoscopy negative controls. We suggest that the association 
between SSRIs, low-dose aspirin, beta-blockers, ACE-inhibitors and MC in community controls 
could be due to worsening of diarrhea or symptoms in patients with underlying colonic disease 
requiring colonoscopy rather than increasing the risk of MC itself. 
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significantly increased the risk of MC, even after taking diagnostic bias and diagnostic delay 
into account. Use of selective serotonin reuptake inhibitors, low-dose aspirin, beta-blockers 
and ACE-inhibitors were associated with increased risk of MC when compared to community 
controls, but not compared to colonoscopy negative controls. We suggest that the association 
between SSRIs, low-dose aspirin, beta-blockers, ACE-inhibitors and MC in community controls 
could be due to worsening of diarrhea or symptoms in patients with underlying colonic disease 
requiring colonoscopy rather than increasing the risk of MC itself. 
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Supplementary Figure 1A and 1B. Risk of microscopic colitis compared to community and colonoscopy controls 
in risk period 1 year prior to index date (risk period A). 
 
# Adjusted for concomitant use of NSAIDs, PPIs, statins, SSRIs, low-dose aspirin, ACE-inhibitors, beta-blockers; celiac disease; 
inflammatory bowel disease; hypothyroid disease; polyarthritis; rheumatoid arthritis and type 2 diabetes mellitus. 
Risk period (A): Odds ratios from the analysis 1 year prior to index date. See Figure 1, risk period (A). 
Mo, months; SSRIs, selective serotonin reuptake inhibitors.  
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Supplementary Figure 2A and 2B. Risk of microscopic colitis compared to community and colonoscopy controls 
in risk period within 2 years before index date, while excluding the 1 year prior to index date (risk period B). 
 
# Adjusted for concomitant use of NSAIDs, PPIs, statins, SSRIs, low-dose aspirin, ACE-inhibitors, beta-blockers; celiac disease; 
inflammatory bowel disease; hypothyroid disease; polyarthritis; rheumatoid arthritis and type 2 diabetes mellitus. 
Risk period (B): Odds ratios from the analysis within 2 years before index date while excluding the year prior to index date.  See 
Figure 1, risk period (B). 
Mo, months; SSRIs, selective serotonin reuptake inhibitors.  
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# Adjusted for concomitant use of NSAIDs, PPIs, statins, SSRIs, low-dose aspirin, ACE-inhibitors, beta-blockers; celiac disease; 
inflammatory bowel disease; hypothyroid disease; polyarthritis; rheumatoid arthritis and type 2 diabetes mellitus. 
Risk period (B): Odds ratios from the analysis within 2 years before index date while excluding the year prior to index date.  See 
Figure 1, risk period (B). 
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Supplementary Figure 3A and 3B. Risk of Microscopic colitis for individual types of NSAIDs, cases compared to 
community and colonoscopy controls.  
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Supplementary Figure 4A and 4B. Risk of Microscopic colitis for individual types of PPIs, cases compared to 
community and colonoscopy controls. 
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ABSTRACT  
 
BACKGROUND 
Microscopic colitis (MC) is a disease characterized by chronic watery diarrhea. Affected tissue 
has a normal endoscopic appearance but microscopic inflammation. It is unknown whether 
this increases the risk for colorectal neoplasia. 
 
AIM 
We assessed the incidence of non-adenomatous polyps, adenomas and colorectal cancer 
(CRC) in patients with MC. 
 
METHODS 
Cohort study using nationwide population-based databases in Denmark and the Netherlands. 
We identified all adults (aged ≥18 years) newly diagnosed with MC and followed them until 
first occurrence of a polyp, adenoma, or CRC, or death during the study period (1991-2014). 
Standardized incidence ratios (SIRs) were used to compare the incidence of these occurrences 
in MC patients and in the general population. Absolute risks of the outcomes after MC 
diagnosis were calculated using Kaplan-Meier analysis. 
 
RESULTS 
We identified 13,061 incident MC cases in Denmark and 7,770 cases in the Netherlands. In the 
Danish cohort, 1,976 (15.1%) patients developed a non-adenomatous polyp, 1,039 (8.0%) 
developed an adenoma, and 111 (0.8%) were diagnosed with CRC. In the Dutch cohort 1,005 
(12.9%) patients developed a polyp, 687 (8.8%) developed an adenoma, and 91 (1.2%) were 
diagnosed with CRC. The SIR for CRC was 0.90 (95% CI: 0.74-1.09) in Denmark and 0.83 (95% 
CI: 0.75-0.89) in the Netherlands. Within the first year after MC diagnosis, the SIR was 2.23 
(95% CI: 1.68-2.91) in Denmark and 2.74 (95% CI: 1.89-4.43) in the Netherlands, and then 
decreased in both countries. The absolute 10-year risk of CRC was 1.3%-1.4%. 
 
CONCLUSION 
The risk of developing CRC 10 years after incident MC diagnosis is small. The high rate of non-
adenomatous polyps and adenomas in the first year following MC diagnosis is probably due to 
heightened diagnostic efforts, with associated removal of polyps and treatment leading to a 
lower rate of CRC in subsequent years.  
 
 
INTRODUCTION 
 
Microscopic colitis (MC) is disease characterized by chronic watery diarrhea. Affected colonic 
mucosa has a normal endoscopic appearance but microscopic inflammation.371, 372, 395 MC 
includes two distinct entities: lymphocytic colitis (LC) and collagenous colitis (CC). The causes 
of the disease are largely unknown. Risk factors include autoimmune diseases.373-375 Use of 
certain drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump 
inhibitors (PPIs) also has been associated with MC risk.396 
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strategies should be considered, as recommended for other forms of IBD.398, 399 
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among 647 MC cases compared to age and gender-matched patients without MC that 
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should be interpreted with caution, as CRC was diagnosed before or concurrently with MC. 
The study could not discern whether the MC patients were at higher risk due to chronic 
colonic inflammation.400 Two other retrospective studies detected no increased CRC risk after 
a CC diagnosis.401, 402 A Canadian cohort study including 164 incident MC cases reported only 
on CRC occurrence before an MC diagnosis.403 
This study assessed the risk of non-adenomatous polyps, adenomas, and CRC in 
patients diagnosed with MC, using data from large populations, with long follow-up. 
 
METHODS 
 
We conducted a nationwide historical cohort study in Denmark and the Netherlands to 
compare the observed number of non-adenomatous polyps, adenomas and CRC diagnosed in 
MC patients with the number expected in the general population. 
 
Data sources 
 
In Denmark, the Danish Civil Registration System (DCRS) assigns a personal identifier to each 
Danish resident at birth or upon immigration, and also monitors mortality and emigration. The 
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hospitals.405 406 In 1995, hospital outpatient clinic visits were added to its database, accounting 
for essentially all specialist gastroenterology and cancer care in Denmark. DNPR data elements 
include patients’ civil registration number, dates of hospital admission and discharge, surgical 
procedures, and up to 20 discharge diagnoses for each hospitalization. All inpatient stays and 
outpatient hospital visits are assigned diagnoses coded according to the International 
Classification of Diseases, Eighth Revision (ICD-8) until the end of 1993 and Tenth Revision 
(ICD-10) thereafter.323 We obtained information on CRC diagnoses from the DNPR. The Danish 
Pathology Registry (DPR), established in 1990, provided results of pathological examinations of 
MC, non-adenomatous polyps and adenomas. Since 1997 all pathology departments in 
Denmark have been required to submit their pathology reports to the DPR. Diagnoses are 
coded according to a Danish version of the Systematized Nomenclature of Medicine 
(SNOMED).257 Previous studies of gastrointestinal diseases have documented the accuracy of 
these data sources.407 
In the Netherlands all histopathology and cytopathology reports are collected in the 
PALGA database, which encompasses all 55 pathology laboratories in the country.408 Since 
1991, PALGA has had nationwide coverage and currently includes >42 million reports from 
nearly 10 million patients. Each report contains encrypted patient information, a portion of 
the original pathology report, and diagnostic codes similar to the SNOMED codes issued by the 
College of American Pathologists.409 A limitation is that the number and location of biopsies 
and the indication for performing an endoscopic procedure are not uniformly recorded. 
However, each pathology report can be traced to an individual patient with a unique identifier, 
allowing follow-up of subsequent histology.410 In the current study, information on cases of 
MC, non-adenomatous polyps, adenomas, CRC, and celiac disease was extracted from the 
PALGA database. 
 
Study population 
 
In both countries, we identified a cohort of adults (aged ≥18 years) with an incident diagnosis 
of microscopic colitis recorded during the study period (January 1, 1990 - December 31, 2014). 
MC patients were excluded from the cohort if they had been diagnosed with CRC or another 
gastrointestinal cancer before their MC diagnosis. A previous Danish study has documented 
the validity of SNOMED codes for identifying MC.411 In the Netherlands MC diagnoses were 
verified through review of pathology reports, as previously described.412 MC was classified as 
lymphocytic, collagenous, or ‘unspecified’ when no further information on subtype was 
available. 
For each patient in the MC cohorts, follow-up started on the date of first MC 
diagnosis and ended upon the diagnosis of non-adenomatous polyps, adenomas, or CRC, 
death, emigration, or end of the study period, whichever came first. Since only pathology 
reports were available in PALGA, the date of death was not known for each subject. In order to 
censor person-time and to avoid overestimating the denominator, we assumed a life 
expectancy similar to that of the general Dutch population. 
 
 
Outcomes 
 
Three outcomes were evaluated in the study: non-adenomatous polyps, adenomas, and CRC. 
We considered non-adenomatous polyps and adenomas as separate outcomes because of 
their different malignant potential. In case of multiple lesions, only the most advanced lesion 
was recorded. 
 
Statistical Analysis 
 
We described the characteristics of the MC cohorts in the two countries. To compare the risk 
of non-adenomatous polyps, adenomas, and cancer in the MC cohorts with that in the general 
population, we calculated standardized incidence ratios (SIRs) by dividing the observed 
number of cases by the expected number of cases.413 In Denmark the number of expected 
cases was based on calculated reference incidence rates from a nationwide database. In The 
Netherlands, it was derived from Globocan.414 Confidence intervals (95% CI) were computed 
based on the assumption that the observed number of cases followed a Poisson distribution. 
Numerators and denominators were stratified by sex, time from first recorded MC diagnosis 
(≤1 or > 1 year), age at MC diagnosis, and calendar year of MC diagnosis. We used Kaplan-
Meier analysis to calculate the absolute (cumulative) risk of non-adenomatous polyps, 
adenomas, and CRC occurring within 10 years following diagnosis of MC. Kaplan-Meier analysis 
was stratified by sex, type of MC and age. 
As only a subset of the general population undergoes colonoscopy, comparison of 
the study cohorts with the general population may be biased. We therefore performed 
sensitivity analyses in which we classified MC patients on their histology reports on the date of 
MC diagnosis. This means that we classified MC patients at time of MC diagnosis as (1) being 
free of non-adenomatous polyps or adenomas, (2) having a non-adenomatous polyp, and (3) 
having an adenoma. We then calculated the progression to and incidence rates (IRs) of 
outcomes in these three groups during follow-up and compared them with rates in 
populations undergoing colorectal screening (Supplementary Table 2).415-421  
All statistical analyses were performed using SAS version 9.2. The study protocol was 
approved by the Danish Protection Agency (2011-41-5913) and by the PALGA Review Board. 
 
RESULTS 
 
We identified 13,275 subjects with incident MC in Denmark. After exclusion of patients with 
CRC (n=193, 1.5%) or other GI cancers (n=21, 0.2%) before or at the time of MC diagnosis, 
13,061 subjects with incident MC remained and were followed for a median duration of 3.6 
years (Table 1). The majority of subjects was female (71%) and median age at MC diagnosis 
was 66.3 years (interquartile range (IQR): 56.4-75.5 years). In the Netherlands, we identified 
10,826 potential MC cases, of whom 7,896 were classified as incident MC cases and the 
remaining 2,930 patients did not have microscopic colitis. We excluded 126 patients with a 
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history of cancer before cohort entry (n=104, 1.3%; of these, CRC: n=22; 0.3%; other GI 
cancer), resulting in 7,770 incident MC patients who were followed for a median duration of 
7.2 years. The median age was 61 years (IQR: 49-71) and the majority (73%) was female.  
Among patients with incident MC in Denmark, we observed 937 patients with non-
adenomatous polyps, of whom 154 were diagnosed at time of MC diagnosis; 1,039 with 
adenomas, of whom 24 at time of MC diagnosis; and 111 with CRC (Table 2). In the 
Netherlands, we observed 318 patients with non-adenomatous polyps, of whom 196 at time 
of MC diagnosis; 687 with adenomas of whom 388 at time of MC diagnosis; and 91 with CRC. 
 
Table 2. Number of incident outcomes in microscopic colitis patients in Denmark and the Netherlands. 
 
Denmark the Netherlands 
N (%) N (%) 
MC all Total MC 13,061 (100) 7,770 (100) 
Non-adenomatous polyps 937 (7.2) 318 (4.1) 
Adenomas 1,039 (8.0) 687 (8.8) 
Colorectal cancer 111 (0.8) 91 (1.2) 
Collagenous Total Collagenous 7,257 (100) 4,320 (100) 
Non-adenomatous polyps 449 (6.2) 167 (3.9) 
Adenomas 512 (7.1) 329 (7.6) 
Colorectal cancer 70 (1.0) 51 (1.2) 
Lymphocytic Total Lymphocytic 5,335 (100) 2,629 (100) 
Non-adenomatous polyps 455 (8.5) 130 (4.9) 
Adenomas 494 (9.3) 283 (10.8) 
Colorectal cancer 39 (0.7) 28 (1.1) 
Unspecified Total Unspecified 469 (100) 821 (100) 
Non-adenomatous polyps 33 (7.0) 21 (2.6) 
Adenomas 33 (7.0) 75 (9.1) 
Colorectal cancer 3 (0.6) 12 (1.5) 
 
MC, microscopic colitis 
 
In Denmark, rates of non-adenomatous polyps and adenomas in the general population were 
available as reference, allowing estimation of standardized incidence ratios (SIRs) for these 
outcomes. SIRs for non-adenomatous polyps and adenomas were significantly increased 
(Supplementary Table 1). 
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history of cancer before cohort entry (n=104, 1.3%; of these, CRC: n=22; 0.3%; other GI 
cancer), resulting in 7,770 incident MC patients who were followed for a median duration of 
7.2 years. The median age was 61 years (IQR: 49-71) and the majority (73%) was female.  
Among patients with incident MC in Denmark, we observed 937 patients with non-
adenomatous polyps, of whom 154 were diagnosed at time of MC diagnosis; 1,039 with 
adenomas, of whom 24 at time of MC diagnosis; and 111 with CRC (Table 2). In the 
Netherlands, we observed 318 patients with non-adenomatous polyps, of whom 196 at time 
of MC diagnosis; 687 with adenomas of whom 388 at time of MC diagnosis; and 91 with CRC. 
 
Table 2. Number of incident outcomes in microscopic colitis patients in Denmark and the Netherlands. 
 
Denmark the Netherlands 
N (%) N (%) 
MC all Total MC 13,061 (100) 7,770 (100) 
Non-adenomatous polyps 937 (7.2) 318 (4.1) 
Adenomas 1,039 (8.0) 687 (8.8) 
Colorectal cancer 111 (0.8) 91 (1.2) 
Collagenous Total Collagenous 7,257 (100) 4,320 (100) 
Non-adenomatous polyps 449 (6.2) 167 (3.9) 
Adenomas 512 (7.1) 329 (7.6) 
Colorectal cancer 70 (1.0) 51 (1.2) 
Lymphocytic Total Lymphocytic 5,335 (100) 2,629 (100) 
Non-adenomatous polyps 455 (8.5) 130 (4.9) 
Adenomas 494 (9.3) 283 (10.8) 
Colorectal cancer 39 (0.7) 28 (1.1) 
Unspecified Total Unspecified 469 (100) 821 (100) 
Non-adenomatous polyps 33 (7.0) 21 (2.6) 
Adenomas 33 (7.0) 75 (9.1) 
Colorectal cancer 3 (0.6) 12 (1.5) 
 
MC, microscopic colitis 
 
In Denmark, rates of non-adenomatous polyps and adenomas in the general population were 
available as reference, allowing estimation of standardized incidence ratios (SIRs) for these 
outcomes. SIRs for non-adenomatous polyps and adenomas were significantly increased 
(Supplementary Table 1). 
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The incidence rate (IR) of CRC among patients with incident MC was 190.1 per 100,000 person-
years in Denmark and 145.0 per 100,000 person-years in the Netherlands (Table 3). 
Comparison of the observed number of CRC cases with the country-specific incidence rate of 
CRC in the general population yielded SIRs of 0.90 (95% CI: 0.74-1.09) in Denmark and 0.83 
(95% CI: 0.75-0.89) in the Netherlands. The IR of CRC was particularly high during the first year 
after MC diagnosis, resulting in increased SIRs in both Denmark and the Netherlands. 
Following the first year, the incidence of CRC was lower and the SIR was decreased. The SIR 
was higher when MC was diagnosed at a younger age. No consistent pattern was observed 
over calendar time. 
 
Table 3. Risk of colorectal cancer among MC patients in Denmark and the Netherlands compared to the Danish 
and Dutch general populations. 
 
  Denmark 
  Observed N Expected N Crude IR* SIR 95% CI 
Total 111 122.9 190.1 0.90 (0.74-1.09) 
Sex      
 Male 42 41.8 262.3 1.00 (0.72-1.36) 
 Female 69 81.1 162.8 0.85 (0.66-1.08) 
Follow-up time      
 <= 1 year 55 24.6 460.2 2.23 (1.68-2.91) 
 >1 year 56 98.3 120.6 0.57 (0.43-0.74) 
Age at MC Dx      
 18-39 1 0.4 20.7 2.61 (0.07-14.52) 
 40-59 21 16.4 110.7 1.28 (0.79-1.95) 
 60-74 46 61.2 195.4 0.75 (0.55-1.00) 
 75+ 43 44.9 388.6 0.96 (0.69-1.29) 
Age at CRC Dx      
 18-39 1 0.1 31.1 8.51 (0.22-47.38) 
 40-59 13 7.6 89.0 1.70 (0.91-2.91) 
 60-74 46 51.5 186.5 0.89 (0.65-1.19) 
 75+ 51 63.7 320.7 0.80 (0.60-1.05) 
Year of CRC Dx      
 1990-1999# 9 2.1 665.3 4.21 (1.93-7.99) 
 2000-2009 55 61.4 179.9 0.90 (0.68-1.17) 
 2010-2014 47 59.5 177.6 0.79 (0.58-1.05) 
Type of MC      
 Collagenous 70 72.6 210.5 0.96 (0.75-1.22) 
 Lymphocytic 38 45.3 166.5 0.84 (0.59-1.15) 
 
IR, incidence rate; PYs, person-years; SIR, standardized incidence ratio; 95%CI, 95% Confidence Intervals; Dx, diagnosis. 
# in Denmark the period was 1995-1999.* Crude IR per 100,000 Person-Years. 
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The incidence rate (IR) of CRC among patients with incident MC was 190.1 per 100,000 person-
years in Denmark and 145.0 per 100,000 person-years in the Netherlands (Table 3). 
Comparison of the observed number of CRC cases with the country-specific incidence rate of 
CRC in the general population yielded SIRs of 0.90 (95% CI: 0.74-1.09) in Denmark and 0.83 
(95% CI: 0.75-0.89) in the Netherlands. The IR of CRC was particularly high during the first year 
after MC diagnosis, resulting in increased SIRs in both Denmark and the Netherlands. 
Following the first year, the incidence of CRC was lower and the SIR was decreased. The SIR 
was higher when MC was diagnosed at a younger age. No consistent pattern was observed 
over calendar time. 
 
Table 3. Risk of colorectal cancer among MC patients in Denmark and the Netherlands compared to the Danish 
and Dutch general populations. 
 
  Denmark 
  Observed N Expected N Crude IR* SIR 95% CI 
Total 111 122.9 190.1 0.90 (0.74-1.09) 
Sex      
 Male 42 41.8 262.3 1.00 (0.72-1.36) 
 Female 69 81.1 162.8 0.85 (0.66-1.08) 
Follow-up time      
 <= 1 year 55 24.6 460.2 2.23 (1.68-2.91) 
 >1 year 56 98.3 120.6 0.57 (0.43-0.74) 
Age at MC Dx      
 18-39 1 0.4 20.7 2.61 (0.07-14.52) 
 40-59 21 16.4 110.7 1.28 (0.79-1.95) 
 60-74 46 61.2 195.4 0.75 (0.55-1.00) 
 75+ 43 44.9 388.6 0.96 (0.69-1.29) 
Age at CRC Dx      
 18-39 1 0.1 31.1 8.51 (0.22-47.38) 
 40-59 13 7.6 89.0 1.70 (0.91-2.91) 
 60-74 46 51.5 186.5 0.89 (0.65-1.19) 
 75+ 51 63.7 320.7 0.80 (0.60-1.05) 
Year of CRC Dx      
 1990-1999# 9 2.1 665.3 4.21 (1.93-7.99) 
 2000-2009 55 61.4 179.9 0.90 (0.68-1.17) 
 2010-2014 47 59.5 177.6 0.79 (0.58-1.05) 
Type of MC      
 Collagenous 70 72.6 210.5 0.96 (0.75-1.22) 
 Lymphocytic 38 45.3 166.5 0.84 (0.59-1.15) 
 
IR, incidence rate; PYs, person-years; SIR, standardized incidence ratio; 95%CI, 95% Confidence Intervals; Dx, diagnosis. 
# in Denmark the period was 1995-1999.* Crude IR per 100,000 Person-Years. 
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Table 3. Risk of colorectal cancer among MC patients in Denmark and the Netherlands compared to the Danish 
and Dutch general populations (continued). 
 
  The Netherlands 
  Observed N Expected N Crude IR* SIR 95% CI 
Total 91 109.9 145.0 0.83 (0.75-0.89) 
Sex      
 Male 27 35.9 157.3 0.75 (0.59-0.86) 
 Female 64 66.3 140.3 0.96 (0.89-0.99) 
Follow-up time      
 <= 1 year 35 12.8 499.0 2.74 (1.89-4.43) 
 >1 year 56 90.9 116.0 0.62 (0.51-0.71) 
Age at MC Dx      
 18-39 1 0.4 17.8 2.40 (1.08-25.92) 
 40-59 24 9.7 117.6 2.47 (1.66-4.24) 
 60-74 46 49.8 205.7 0.92 (0.82-0.97) 
 75+ 20 58.1 139.1 0.34 (0.24-0.47) 
Age at CRC Dx      
 18-39 1 0.4 17.8 2.40 (1.08-25.92) 
 40-59 19 9.7 93.1 1.95 (1.40-3.28) 
 60-74 34 49.8 152.0 0.68 (0.54-0.80) 
 75+ 37 58.1 257.4 0.64 (0.51-0.75) 
Year of CRC Dx      
 1990-1999# 29 30.6 168.8 0.95 (0.81-0.99) 
 2000-2009 45 58.7 146.6 0.77 (0.64-0.86) 
 2010-2014 17 13.7 258.4 1.24 (1.08-1.76) 
Type of MC      
 Collagenous 51 68.6 131.6 0.74 (0.63-0.83) 
 Lymphocytic 28 30.2 163.9 0.93 (0.78-0.98) 
 
IR, incidence rate; PYs, person-years; SIR, standardized incidence ratio; 95%CI, 95% Confidence Intervals; Dx, diagnosis. 
# in Denmark the period was 1995-1999.* Crude IR per 100,000 Person-Years. 
 
The cumulative risk of CRC 1 year after MC diagnosis was 0.4% (95% CI: 0.3%-0.6%) in 
Denmark and 0.5% (95% CI: 0.3%-0.6%) in the Netherlands (Table 4) and was higher in patients 
diagnosed with MC after age 60 years compared to patients diagnosed before age 60 years (p 
log-rank <0.0001 in both Denmark and the Netherlands). Absolute risks did not differ by sex, 
type of MC, or history of celiac disease. 
 
  
 
 
Table 4. Cumulative risks of colorectal neoplasia in Microscopic Colitis patients Denmark and the Netherlands. 
 
Denmark the Netherlands 
MC all MC all 
Cumulative risk (%) 95% CI Cumulative risk (%) 95% CI 
Non-adenomatous polyps 1 year 5.4 5.0-5.8 2.8 2.5-3.2 
5 years 7.2 6.8-7.7 3.5 3.1-4.0 
10 years 8.9 8.3-9.6 4.4 3.9-4.9 
Adenomas 1 year 6.4 6.0-6.8 5.5 5.0-6.0 
5 years 8.0 7.5-8.5 7.1 6.6-7.7 
10 years 9.6 8.9-10.2 9.5 8.8-10.2 
Colorectal  1 year 0.5 0.4-0.6 0.5 0.3-0.6 
Cancer 5 years 0.8 0.7-1.0 0.9 0.7-1.1 
10 years 1.4 1.1-1.7 1.4 1.1-1.8 
 
95% CI, 95% confidence interval 
 
In the Kaplan-Meier analyses for non-adenomatous polyps, the cumulative risk differed by 
type of MC (log-rank p=0.0009), with higher risk for lymphocytic colitis than for collagenous or 
unspecified colitis. The risk did not differ by sex or age. For adenomas, the cumulative risk was 
6.4% in Denmark and 5.5% in the Netherlands during the first year after MC diagnosis. Five 
years after diagnosis, it was 8.0% in Denmark and 7.1% in the Netherlands. These risks differed 
by sex, type of MC, and age (all log-rank p<0.0001), with higher risks for males, presence of 
lymphocytic colitis, and age 60 years or older. 
 
In sensitivity analyses we classified the MC groups based on their index histology at cohort 
entry [presence/absence of non-adenomatous polyp(s) and adenoma(s)]. In Denmark 12,883 
subjects and in the Netherlands 7,186 subjects had no polyps or adenomas at baseline. Among 
these subjects, 1,005 (7.8%) in Denmark and 292 (4.1%) in the Netherlands developed an 
adenoma, and 107 (0.8%) in Denmark and 88 (1.2%) in the Netherlands developed CRC after 
median follow-up of 3.6 and 2.2 years, respectively. This yielded an incidence rate of CRC of 
1.9 (95%CI: 1.5-2.2) per 1,000 person-years in Denmark and 1.5 (95%CI: 1.2-1.8) per 1,000 
person-years in the Netherlands. In Denmark, 154 MC subjects had a non-adenomatous polyp 
and 24 MC subjects had an adenoma at baseline. Three (2%) of the subjects with a non-
adenomatous polyp and 1 (4.2%) with an adenoma developed CRC during follow-up. In the 
Netherlands, among subjects with a non-adenomatous polyp or adenoma at baseline 2 (1.4%) 
and 1 (0.3%) were diagnosed with CRCs after median follow-up of 2.9 and 0.2 years, 
respectively (Table 5). Our sensitivity analysis showed that incidence of CRC was higher in MC 
subjects with a non-adenomatous polyp or adenoma at baseline compared to MC subjects 
without these baseline findings. 
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Table 3. Risk of colorectal cancer among MC patients in Denmark and the Netherlands compared to the Danish 
and Dutch general populations (continued). 
 
  The Netherlands 
  Observed N Expected N Crude IR* SIR 95% CI 
Total 91 109.9 145.0 0.83 (0.75-0.89) 
Sex      
 Male 27 35.9 157.3 0.75 (0.59-0.86) 
 Female 64 66.3 140.3 0.96 (0.89-0.99) 
Follow-up time      
 <= 1 year 35 12.8 499.0 2.74 (1.89-4.43) 
 >1 year 56 90.9 116.0 0.62 (0.51-0.71) 
Age at MC Dx      
 18-39 1 0.4 17.8 2.40 (1.08-25.92) 
 40-59 24 9.7 117.6 2.47 (1.66-4.24) 
 60-74 46 49.8 205.7 0.92 (0.82-0.97) 
 75+ 20 58.1 139.1 0.34 (0.24-0.47) 
Age at CRC Dx      
 18-39 1 0.4 17.8 2.40 (1.08-25.92) 
 40-59 19 9.7 93.1 1.95 (1.40-3.28) 
 60-74 34 49.8 152.0 0.68 (0.54-0.80) 
 75+ 37 58.1 257.4 0.64 (0.51-0.75) 
Year of CRC Dx      
 1990-1999# 29 30.6 168.8 0.95 (0.81-0.99) 
 2000-2009 45 58.7 146.6 0.77 (0.64-0.86) 
 2010-2014 17 13.7 258.4 1.24 (1.08-1.76) 
Type of MC      
 Collagenous 51 68.6 131.6 0.74 (0.63-0.83) 
 Lymphocytic 28 30.2 163.9 0.93 (0.78-0.98) 
 
IR, incidence rate; PYs, person-years; SIR, standardized incidence ratio; 95%CI, 95% Confidence Intervals; Dx, diagnosis. 
# in Denmark the period was 1995-1999.* Crude IR per 100,000 Person-Years. 
 
The cumulative risk of CRC 1 year after MC diagnosis was 0.4% (95% CI: 0.3%-0.6%) in 
Denmark and 0.5% (95% CI: 0.3%-0.6%) in the Netherlands (Table 4) and was higher in patients 
diagnosed with MC after age 60 years compared to patients diagnosed before age 60 years (p 
log-rank <0.0001 in both Denmark and the Netherlands). Absolute risks did not differ by sex, 
type of MC, or history of celiac disease. 
 
  
 
 
Table 4. Cumulative risks of colorectal neoplasia in Microscopic Colitis patients Denmark and the Netherlands. 
 
Denmark the Netherlands 
MC all MC all 
Cumulative risk (%) 95% CI Cumulative risk (%) 95% CI 
Non-adenomatous polyps 1 year 5.4 5.0-5.8 2.8 2.5-3.2 
5 years 7.2 6.8-7.7 3.5 3.1-4.0 
10 years 8.9 8.3-9.6 4.4 3.9-4.9 
Adenomas 1 year 6.4 6.0-6.8 5.5 5.0-6.0 
5 years 8.0 7.5-8.5 7.1 6.6-7.7 
10 years 9.6 8.9-10.2 9.5 8.8-10.2 
Colorectal  1 year 0.5 0.4-0.6 0.5 0.3-0.6 
Cancer 5 years 0.8 0.7-1.0 0.9 0.7-1.1 
10 years 1.4 1.1-1.7 1.4 1.1-1.8 
 
95% CI, 95% confidence interval 
 
In the Kaplan-Meier analyses for non-adenomatous polyps, the cumulative risk differed by 
type of MC (log-rank p=0.0009), with higher risk for lymphocytic colitis than for collagenous or 
unspecified colitis. The risk did not differ by sex or age. For adenomas, the cumulative risk was 
6.4% in Denmark and 5.5% in the Netherlands during the first year after MC diagnosis. Five 
years after diagnosis, it was 8.0% in Denmark and 7.1% in the Netherlands. These risks differed 
by sex, type of MC, and age (all log-rank p<0.0001), with higher risks for males, presence of 
lymphocytic colitis, and age 60 years or older. 
 
In sensitivity analyses we classified the MC groups based on their index histology at cohort 
entry [presence/absence of non-adenomatous polyp(s) and adenoma(s)]. In Denmark 12,883 
subjects and in the Netherlands 7,186 subjects had no polyps or adenomas at baseline. Among 
these subjects, 1,005 (7.8%) in Denmark and 292 (4.1%) in the Netherlands developed an 
adenoma, and 107 (0.8%) in Denmark and 88 (1.2%) in the Netherlands developed CRC after 
median follow-up of 3.6 and 2.2 years, respectively. This yielded an incidence rate of CRC of 
1.9 (95%CI: 1.5-2.2) per 1,000 person-years in Denmark and 1.5 (95%CI: 1.2-1.8) per 1,000 
person-years in the Netherlands. In Denmark, 154 MC subjects had a non-adenomatous polyp 
and 24 MC subjects had an adenoma at baseline. Three (2%) of the subjects with a non-
adenomatous polyp and 1 (4.2%) with an adenoma developed CRC during follow-up. In the 
Netherlands, among subjects with a non-adenomatous polyp or adenoma at baseline 2 (1.4%) 
and 1 (0.3%) were diagnosed with CRCs after median follow-up of 2.9 and 0.2 years, 
respectively (Table 5). Our sensitivity analysis showed that incidence of CRC was higher in MC 
subjects with a non-adenomatous polyp or adenoma at baseline compared to MC subjects 
without these baseline findings. 
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DISCUSSION 
 
This population-based nationwide study in Denmark and the Netherlands found a high 
incidence of non-adenomatous polyps and adenomas during the first year after diagnosis of 
MC, both in in terms of cumulative risk and compared with the general population. CRC risk 
was approximately 0.4% in the first year after MC diagnosis, with a much higher incidence 
than in the general population. However, CRC incidence was lower among MC patients than 
among the general population starting one year after MC diagnosis. This suggests that a MC 
diagnosis may lead to better follow-up and treatment for non-adenomatous polyps and 
adenomas during the year after diagnosis, subsequently resulting in a lower rate of CRC.  
This is the first study to assess the risk of CRC after a MC diagnosis. Because previous 
studies focused on CRC detection before or at the same time as a MC diagnosis,400-403, 422 they 
were unable to establish a potential causal effect of MC-associated inflammation on colorectal 
carcinogenesis. A recent case-control study concluded that chronic inflammatory conditions of 
the colon, including MC, were associated with a decreased prevalence of non-adenomatous 
polyps and adenomas.342 While these findings seem contradictory to our results, the study 
addressed a different question. It compared the prevalence of non-adenomatous polyps and 
adenomas detected during colonoscopy among patients concurrently diagnosed with MC and 
among patients not concurrently diagnosed with MC.409 In contrast, we examined the 
occurrence of non-adenomatous polyps, adenomas, and CRC in patients with MC after MC 
diagnosis. In the current study, the frequency of non-adenomatous polyps and adenomas 
detected at time of the colonoscopy that led to a MC diagnosis in The Netherlands was 7.5%, 
while the proportion of MC subjects diagnosed with a non-adenomatous polyp or adenoma in 
the case-control study was comparable at 8.5%.342 We found that patients diagnosed with MC 
are more likely to be diagnosed subsequently with non-adenomatous polyps and adenomas 
than persons in the general population. This finding may be explained in part by enhanced 
diagnostic surveillance and an associated increased chance for diagnosis, a phenomenon also 
seen with other diseases.407, 423, 424 Our study subjects underwent a colonoscopy for MC 
complaints, and by having a colonoscopy they were more likely to be diagnosed with non-
adenomatous polyps, adenomas, or CRC than persons without MC symptoms particularly in 
the event of follow-up colonoscopies.425  
In our sensitivity analysis we did not observe more adenomas or CRC in the MC 
cohort than in other screening populations (Supplementary Table 2). In accordance with 
studies assessing outcomes at first colonoscopy screening 415, 416, 419, 426 and at surveillance 
colonoscopy following a previous colorectal adenoma,420, 421 we found that 1.3% of MC 
subjects in the Netherlands and 1.5% of subjects in Denmark had a concurrent diagnosis of 
CRC at baseline; we subsequently excluded these patients to identify incident CRC cases. In our 
study population the incidence rate of CRC in Denmark and in the Netherlands was in line with 
the incidence rate reported in other studies, ranging between 0.6 to 1.5 per 1,000 person-
years.415, 421, 426, 427 We found that patients who developed CRC during follow-up were generally 
older at time of their MC diagnosis than patients who did not develop CRC.  
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DISCUSSION 
 
This population-based nationwide study in Denmark and the Netherlands found a high 
incidence of non-adenomatous polyps and adenomas during the first year after diagnosis of 
MC, both in in terms of cumulative risk and compared with the general population. CRC risk 
was approximately 0.4% in the first year after MC diagnosis, with a much higher incidence 
than in the general population. However, CRC incidence was lower among MC patients than 
among the general population starting one year after MC diagnosis. This suggests that a MC 
diagnosis may lead to better follow-up and treatment for non-adenomatous polyps and 
adenomas during the year after diagnosis, subsequently resulting in a lower rate of CRC.  
This is the first study to assess the risk of CRC after a MC diagnosis. Because previous 
studies focused on CRC detection before or at the same time as a MC diagnosis,400-403, 422 they 
were unable to establish a potential causal effect of MC-associated inflammation on colorectal 
carcinogenesis. A recent case-control study concluded that chronic inflammatory conditions of 
the colon, including MC, were associated with a decreased prevalence of non-adenomatous 
polyps and adenomas.342 While these findings seem contradictory to our results, the study 
addressed a different question. It compared the prevalence of non-adenomatous polyps and 
adenomas detected during colonoscopy among patients concurrently diagnosed with MC and 
among patients not concurrently diagnosed with MC.409 In contrast, we examined the 
occurrence of non-adenomatous polyps, adenomas, and CRC in patients with MC after MC 
diagnosis. In the current study, the frequency of non-adenomatous polyps and adenomas 
detected at time of the colonoscopy that led to a MC diagnosis in The Netherlands was 7.5%, 
while the proportion of MC subjects diagnosed with a non-adenomatous polyp or adenoma in 
the case-control study was comparable at 8.5%.342 We found that patients diagnosed with MC 
are more likely to be diagnosed subsequently with non-adenomatous polyps and adenomas 
than persons in the general population. This finding may be explained in part by enhanced 
diagnostic surveillance and an associated increased chance for diagnosis, a phenomenon also 
seen with other diseases.407, 423, 424 Our study subjects underwent a colonoscopy for MC 
complaints, and by having a colonoscopy they were more likely to be diagnosed with non-
adenomatous polyps, adenomas, or CRC than persons without MC symptoms particularly in 
the event of follow-up colonoscopies.425  
In our sensitivity analysis we did not observe more adenomas or CRC in the MC 
cohort than in other screening populations (Supplementary Table 2). In accordance with 
studies assessing outcomes at first colonoscopy screening 415, 416, 419, 426 and at surveillance 
colonoscopy following a previous colorectal adenoma,420, 421 we found that 1.3% of MC 
subjects in the Netherlands and 1.5% of subjects in Denmark had a concurrent diagnosis of 
CRC at baseline; we subsequently excluded these patients to identify incident CRC cases. In our 
study population the incidence rate of CRC in Denmark and in the Netherlands was in line with 
the incidence rate reported in other studies, ranging between 0.6 to 1.5 per 1,000 person-
years.415, 421, 426, 427 We found that patients who developed CRC during follow-up were generally 
older at time of their MC diagnosis than patients who did not develop CRC.  
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As well, the time to CRC for patients with MC was relatively short after cohort entry (median 
3.6 years in Denmark and 2.2 years in the Netherlands). This suggests that a neoplastic lesion 
could have been missed or incompletely removed at initial scopy that resulted in the MC 
diagnosis. This may be evidence that other factors, such as age, diagnostic bias, and clinical 
awareness contributed to the peak in CRC incidence during the first year following MC 
diagnosis. 
Importantly, we observed that MC patients were more likely to be diagnosed with 
non-adenomatous polyps and adenomas more than a year following a MC diagnosis. This 
supports the hypothesis that inflammation associated with MC produces structural cell 
changes leading to precancerous lesions. The length of time between progression of neoplastic 
polyps to CRC and the relatively short follow-up period in our study (median of 3.6 and 7.2 
years in the Danish and Dutch cohorts, respectively) limited our ability to identify any 
association with increased CRC risk in the long-term. Our findings are in accordance with 
reports in the literature showing a higher risk of CRC among males and older persons.428 This 
provides reassurance about the validity of our data and results. 
Notably, we observed a decreased risk of CRC more than 1 year after MC diagnosis. 
This could be explained by several factors. Now, and especially in the early years, a substantial 
group of MC patients are treated with 5-aminosalicylic acid (5-ASA) compounds, sometimes 
for many years. Though still controversial, it has been suggested that 5-ASA may affect tumour 
growth and survival and thus may protect against development of CRC.429, 430 Another 
explanation could be that colonoscopies conducted for symptoms of MC lead to the detection 
of CRC precursor lesions, subsequent surveillance colonoscopies in time and thus prevents 
subsequent CRC development.275 
Apart from the increased and prolonged duration of colonic inflammation in MC 
patients, observed associations may be explained by shared or common risk factors for MC, 
non-adenomatous polyps, adenomas, and CRC. Prior studies have suggested that some 
lymphoproliferative diseases and malignancies are more frequent in patients with celiac 
disease, including malignant lymphoma and intestinal cancers.241, 431, 432 As about 10% of MC 
patients have celiac disease and 33% of celiac disease patients have histological characteristics 
consistent with MC,373 there may be a differential risk of non-adenomatous polyps, adenomas, 
and CRC in MC patients with versus without celiac disease. We did not observe a significantly 
different CRC risk in the presence/absence of celiac disease, though our analysis may have 
been limited by the small number of patients in these strata. 
Strengths of the study are its large scale and use of nationwide population-based 
data sources to identify microscopic colitis patients, mitigating selection bias. Through follow-
up of patients using population-based registries, we were able to calculate the risk of non-
adenomatous polyps, adenomas, and CRC after MC diagnosis. 
Our study has several limitations. First, using the general population as the reference 
population could lead to Berkson’s bias. We tried to mitigate such bias by also comparing the 
proportion and rates of the outcomes in our study population with those in screening 
populations that underwent colonoscopy. Second, diagnoses of MC and colorectal outcomes 
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As well, the time to CRC for patients with MC was relatively short after cohort entry (median 
3.6 years in Denmark and 2.2 years in the Netherlands). This suggests that a neoplastic lesion 
could have been missed or incompletely removed at initial scopy that resulted in the MC 
diagnosis. This may be evidence that other factors, such as age, diagnostic bias, and clinical 
awareness contributed to the peak in CRC incidence during the first year following MC 
diagnosis. 
Importantly, we observed that MC patients were more likely to be diagnosed with 
non-adenomatous polyps and adenomas more than a year following a MC diagnosis. This 
supports the hypothesis that inflammation associated with MC produces structural cell 
changes leading to precancerous lesions. The length of time between progression of neoplastic 
polyps to CRC and the relatively short follow-up period in our study (median of 3.6 and 7.2 
years in the Danish and Dutch cohorts, respectively) limited our ability to identify any 
association with increased CRC risk in the long-term. Our findings are in accordance with 
reports in the literature showing a higher risk of CRC among males and older persons.428 This 
provides reassurance about the validity of our data and results. 
Notably, we observed a decreased risk of CRC more than 1 year after MC diagnosis. 
This could be explained by several factors. Now, and especially in the early years, a substantial 
group of MC patients are treated with 5-aminosalicylic acid (5-ASA) compounds, sometimes 
for many years. Though still controversial, it has been suggested that 5-ASA may affect tumour 
growth and survival and thus may protect against development of CRC.429, 430 Another 
explanation could be that colonoscopies conducted for symptoms of MC lead to the detection 
of CRC precursor lesions, subsequent surveillance colonoscopies in time and thus prevents 
subsequent CRC development.275 
Apart from the increased and prolonged duration of colonic inflammation in MC 
patients, observed associations may be explained by shared or common risk factors for MC, 
non-adenomatous polyps, adenomas, and CRC. Prior studies have suggested that some 
lymphoproliferative diseases and malignancies are more frequent in patients with celiac 
disease, including malignant lymphoma and intestinal cancers.241, 431, 432 As about 10% of MC 
patients have celiac disease and 33% of celiac disease patients have histological characteristics 
consistent with MC,373 there may be a differential risk of non-adenomatous polyps, adenomas, 
and CRC in MC patients with versus without celiac disease. We did not observe a significantly 
different CRC risk in the presence/absence of celiac disease, though our analysis may have 
been limited by the small number of patients in these strata. 
Strengths of the study are its large scale and use of nationwide population-based 
data sources to identify microscopic colitis patients, mitigating selection bias. Through follow-
up of patients using population-based registries, we were able to calculate the risk of non-
adenomatous polyps, adenomas, and CRC after MC diagnosis. 
Our study has several limitations. First, using the general population as the reference 
population could lead to Berkson’s bias. We tried to mitigate such bias by also comparing the 
proportion and rates of the outcomes in our study population with those in screening 
populations that underwent colonoscopy. Second, diagnoses of MC and colorectal outcomes 
	 Colorectal	neoplasia	in	microscopic	colitis	|	205  204	|	Chapter	5.3
 
 
could have been subject to misclassification. However, the pathology codes used to identify 
the cancers are registered prospectively for pathologically confirmed diseases assuming that 
patients underwent colonoscopy with biopsies at that moment. The positive predictive value 
for CRC in the DNRP and DCR has been found to be 88.9%.433 In the Dutch database we 
reviewed the pathology reports of all patients in order to verify the diagnoses of MC and 
outcomes. A third concern is that left censoring of MC diagnosis could have occurred, resulting 
in the classification of patients as incident cases when they were actually prevalent cases. This 
could lead to overestimation of cancer risk. However, since cancer is rare and takes decades to 
progress to overt disease, overestimation is unlikely. Fourth, we lacked information on CRC 
stage. This may have confounded our results, as detection bias could have led to earlier 
diagnosis and earlier CRC stage in MC patients compared to the reference populations. 
In conclusion, patients newly diagnosed with microscopic colitis were not at 
increased risk of CRC one or more years after their diagnosis, compared to the general 
population in Denmark and the Netherlands. The high observed incidence of non-
adenomatous polyps, adenomas, and CRC, particularly in the first year following MC diagnosis, 
was probably due to surveillance bias, with better screening and treatment for precursor 
lesions leading to a lower rate of CRC. 
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Supplementary Table 1. Standardized incidence ratio of non-adenomatous polyps and adenomas among 
microscopic colitis patients in Denmark compared to the Danish general population. 
 
  Colorectal Polyps Colorectal Adenomas 
  Observed Expected SIR 95%CI Observed Expected SIR 95%CI 
Total 939 156.2 6.01 5.63-6.41 1040 209.2 4.97 4.67-5.28 
Sex   
 Male 330 49.2 6.71 6.00-7.47 455 72.8 6.25 5.69-6.85 
 Female 609 107.0 5.69 5.25-6.16 585 136.4 4.29 3.95-4.65 
Time in follow-up   
 <= 1 year 698 31.7 22.05 20.45-23.75 833 41.2 20.22 18.87-21.64 
 >1 year 241 124.6 1.93 1.70-2.20 207 168.0 1.23 1.07-1.41 
Age at MC diagnosis   
 18-39 25 2.6 23.37 15.12-34.49 14 0.6 21.68 11.84-36.38 
 40-59 255 41.8 10.01 8.82-11.32 199 24.7 8.05 6.97-9.25 
 60-74 466 80.8 5.71 5.20-6.25 521 105.5 4.94 4.53-5.38 
 75+ 193 31.0 4.02 3.47-4.62 306 78.4 3.90 3.48-4.37 
Type of MC*   
 Collagenous  449 91.1 4.93 4.48-5.41 512 122.1 4.19 3.84-4.57 
 Lymphocytic 457 58.8 7.78 7.08-8.52 495 78.7 6.29 5.75-6.87 
Year of CRC Diagnosis   
 1995-1999 34 1.9 17.59 12.18-24.58 27 1.9 14.35 9.45-20.87 
 2000-2009 522 79.7 6.55 6.00-7.14 555 100.4 5.53 5.08-6.01 
 2010-2012 383 74.6 5.14 4.63-5.68 458 107.0 4.28 3.90-4.69 
 
* Numbers do not add up to Total Number of events as MC types were classified into Collagenous, Lymphocytic and Unspecified.  
Abbreviations: SIR, standardized incidence ratio; 95%CI, 95% Confidence Intervals. 
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Supplementary Table 1. Standardized incidence ratio of non-adenomatous polyps and adenomas among 
microscopic colitis patients in Denmark compared to the Danish general population. 
 
  Colorectal Polyps Colorectal Adenomas 
  Observed Expected SIR 95%CI Observed Expected SIR 95%CI 
Total 939 156.2 6.01 5.63-6.41 1040 209.2 4.97 4.67-5.28 
Sex   
 Male 330 49.2 6.71 6.00-7.47 455 72.8 6.25 5.69-6.85 
 Female 609 107.0 5.69 5.25-6.16 585 136.4 4.29 3.95-4.65 
Time in follow-up   
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 >1 year 241 124.6 1.93 1.70-2.20 207 168.0 1.23 1.07-1.41 
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 18-39 25 2.6 23.37 15.12-34.49 14 0.6 21.68 11.84-36.38 
 40-59 255 41.8 10.01 8.82-11.32 199 24.7 8.05 6.97-9.25 
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 Collagenous  449 91.1 4.93 4.48-5.41 512 122.1 4.19 3.84-4.57 
 Lymphocytic 457 58.8 7.78 7.08-8.52 495 78.7 6.29 5.75-6.87 
Year of CRC Diagnosis   
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* Numbers do not add up to Total Number of events as MC types were classified into Collagenous, Lymphocytic and Unspecified.  
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ABSTRACT  
 
BACKGROUND 
Use of selective COX-2 non-steroidal anti-inflammatory drugs (NSAIDs) has been associated 
with an increase in the risk of acute myocardial infarction (AMI), but the magnitude of risk is 
unknown for individual nonselective NSAIDs. 
 
METHODS 
A case-control study was performed nested in a cohort of new NSAID users ≥18 years (1999-
2011) matching cases to a maximum of 100 controls on database, sex, age, and AMI diagnosis 
date. Data were retrieved from six healthcare databases using the same protocol and data 
transformations: IPCI, PHARMO (Netherlands); SISR, OSSIFF (Italy); GePaRD (Germany) and 
THIN (United Kingdom). Adjusted odds ratios (ORs) were estimated per database comparing 
current use of NSAIDs to past use. Pooling was done by a random effects model (ORmeta) and 
unweighted pooling (ORpooled). 
 
RESULTS 
In a cohort of 8.5 million new NSAID users 79,553 AMI cases were identified. The risk was 
significantly elevated for current use of ketorolac (ORmeta 2.06; 95%CI: 1.83-2.32, ORpooled 
1.80; 95%CI: 1.49-2.18) followed in descending order by indometacin, etoricoxib, rofecoxib, 
diclofenac, fixed combination of diclofenac with misoprostol, piroxicam, ibuprofen, naproxen, 
celecoxib, meloxicam, nimesulide and ketoprofen (ORmeta 1.12; 95%CI: 1.03-1.22, ORpooled 
1.00; 95%CI: 0.86-1.16). For other NSAIDs there was no significantly increased risk, amongst 
those dexketoprofen (ORpooled 1.01; 95%CI: 0.50-2.04), sulindac (ORpooled 1.01; 95%CI: 
0.48-2.15) proglumetacin (ORpooled 1.00; 95%CI: 0.41-2.47) and tiaprofenic acid (ORpooled 
1.01; 95%CI: 0.49-2.10) had upper 95% limits that exceeded 2. Higher doses showed higher 
risk estimates than lower doses. 
 
CONCLUSION 
The risk of AMI differed between 28 individual NSAIDs. The risk was highest for ketorolac, but 
was increased also for several other selective COX-2 and nonselective NSAIDs and was higher 
when using higher daily doses. The increased risk of AMI should not be considered an effect of 
some selective COX-2 inhibitors only. 
  
 
 
INTRODUCTION 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to reduce inflammation and 
provide pain relief. They act via reversible, competitive inhibition of cyclo-oxygenase (COX) 
enzymes. As inhibition of the COX-1 enzyme decreases the production of prostaglandins, 
gastrointestinal adverse events including ulcerations and bleeding occur often during NSAID 
use. This led to development of selective COX-2 inhibitors, which were marketed as coxibs. 
However, after successful market introduction of selective COX-2 inhibitors 10, 75 concerns were 
raised about their cardiovascular (CV) safety resulting in the voluntary withdrawal of rofecoxib 
in 2004.11 Reviews by the United States Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) concluded that coxibs increase the risk of CV events.93 It was 
recommended in 2005 to avoid the use of selective COX-2 inhibitors in patients with ischemic 
heart disease, stroke or peripheral arterial disease.89, 94, 95 At that point in time little 
information was available about the CV risk of NSAIDs, but further studies showed signals of 
increased arterial thrombosis risk for the nonselective (ns) NSAIDs, particularly when used in 
high doses and for long-term.96, 97 Based on the uncertainty, EMA requested a review of the CV 
safety of nsNSAIDs as well. The Safety of Non-Steroidal Anti-inflammatory Drugs (SOS) project 
was developed as a research and development project funded by the Directorate General of 
Research and Innovation of the European Commission under the Seventh Framework 
Programme to support EMA in their regulatory decision making.434 This SOS study aimed to 
assess and summarize the risk of AMI associated with the use of individual NSAIDs in Europe. 
 
METHODS 
 
Study design and data sources 
 
A nested case-control study was conducted within a cohort of new NSAID users during the 
study period.  
Data for this study was obtained from six different longitudinal population-based 
health care databases from four European countries [GePaRD from Germany (GE), OSSIFF and 
SISR from Italy (IT), IPCI and PHARMO from the Netherlands (NL) and THIN from the United 
Kingdom (UK)] covering a source population of around 32 million subjects. All databases have 
been used for pharmacoepidemiological research (Supplementary Table 1)237, 238, 435, 436 and are 
described more detailed elsewhere.437 
In short, the German Pharmacoepidemiological Research Database (GePaRD) is a 
database comprising data from five statutory health insurances throughout Germany that is 
created and maintained by BIPS. It currently covers around 14 million insurants and represents 
approximately 20% of the German population.436 The Health Improvement Network (THIN) 
database is a general practice database in the UK and currently captures medical records of 
11.1 million patients.237, 266 The Integrated Primary Care Information (IPCI) database is also a 
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general practice database but from the Netherlands and currently covers over 1.5 million 
people,238 PHARMO database is a medical record linkage system of 2.2 million community-
dwelling inhabitants in the Netherlands.435 OSSIFF (Osservatorio Interaziendale per la 
Farmacoepidemiologia e la Farmacoeconomia) is a database capturing national health service 
data and clinical registries from several local health agencies  in Lombardy) for a population of 
about 2.9 million people. The second Italian database SISR (Sistema Informativo Sanitario 
Regionale) obtains national health service data from the Lombardy region, with about nine 
million inhabitants (approximately 16% of the national population). OSSIFF was included in 
addition to the Lombardy SISR as it allows for validation of outcomes, overlapping patients 
were excluded from the Lombardy SISR. 
All general practice and claims databases contain information on demographics of 
the population, diagnoses (in- and/or outpatient), and drug prescriptions/dispensings. The 
diagnoses captured by the databases are coded with four different disease coding systems 
including the International Classification of Diseases (ICD) 9th or 10th revision,323 International 
Classification for Primary Care (ICPC),240 or READ.438 Mapping of concepts and codes was 
performed using the Unified Medical Language System (UMLS), a biomedical terminology 
integration system handling more than 150 medical dictionaries, according to a previously 
described workflow.439, 440 All drugs were mapped to the World Health Organization’s (WHO) 
classification of Anatomical Therapeutic Chemical (ATC).242 A distributed approach was used 
for collaboration: all database custodians extracted data locally; original data were 
transformed into a simple common data model (Jerboa© input files); mapping of codes for 
outcome and covariates was verified using an extensive harmonization strategy; and a 
common standardized script (Jerboa©, Java based)346 was supplied to create the aggregated 
tables that were subsequently encrypted and shared on a central data warehouse for further 
analysis and pooling. Details have been described previously. 346, 437 
 
Study cohort 
 
In each database, we identified a cohort of patients aged ≥18 years who received at least one 
new NSAID prescription (Supplementary Table 2) during the database-specific study period 
within the general study period which started 1 January 1999 and ended December 31st 2011 
(Supplementary Table 1). Before inclusion in the cohort subjects were deemed to have at least 
one year of continuous data enrollment in the database. 
The date of first NSAID prescription/dispensation during the study period was 
defined as cohort entry date. Patients were excluded if they received any NSAID prescription 
in the year before in order to construct a new user cohort and avoid prevalent user bias.168 
Patients needed to have at least one year of continuous database history, to allow uniform 
assessment of potential confounding factors and exclusion criteria. All subjects with a cancer 
diagnosis (except non-melanoma skin cancer) during the one year preceding cohort entry were 
excluded from the cohort. All NSAID cohort members were followed from the date of cohort 
 
 
entry until the date of acute myocardial infarction diagnosis, cancer, death, last data supply, 
transferring out of the database, or end of the study period, whichever was earliest.  
 
Cases and controls 
 
The outcome was a first hospitalization with a discharge diagnosis code of acute myocardial 
infarction (AMI) (GePaRD, PHARMO, OSSIFF, and SISR) or a first diagnosis of an AMI (THIN and 
IPCI) during follow-up (Supplementary Table 3 for ICD-9, ICD-10, READ and ICPC codes 
included). The date of recorded diagnosis or admission date of AMI was used as index date. 
Controls were members of the incident NSAID cohort who did not develop AMI during follow-
up until the cases’ index date. Within each database, up to 100 controls were matched to each 
case by risk set sampling on age (± 1 year), sex and cohort entry (± 28 days). Controls were 
assigned the same index date as the case. 
 
NSAID-exposure 
 
Exposure to individual NSAIDs was obtained from either prescriptions (THIN and IPCI) or from 
outpatient drug dispensings claims (GePaRD, PHARMO, OSSIFF, and SISR). Duration of a single 
NSAID dispensing/prescription was obtained by dividing the total units by the daily number of 
units prescribed (THIN, IPCI, and PHARMO: prescribed duration), for other databases standard 
durations were used based on the country specific defined daily dose (DDD) values.242  
 Classification of the recency of exposure to individual NSAIDs was based on the 
interval between index date and the end of the most recent NSAID use before the index date. 
If the exposure period 1) overlapped or ended within 14 days before index date NSAID use was 
classified as ‘current’ use; 2) ended between 15 and 183 days before the index date as ‘recent’ 
use and; 3) ended 184 days or more before the index date as ‘past’ use. Exposure periods were 
considered mutually exclusive. Duration of current use was then classified into very short (1-6 
days), short (7-29), medium (30-89) and long (≥ 90). If multiple NSAIDs were used in the 
current period, NSAID use was distributed to current use of all NSAIDs. Current use of an 
NSAID always overruled past use of other NSAIDs if patients switched between NSAIDs. Past 
use of any NSAID was considered as common reference group in order to compare across 
NSAIDs. 
In IPCI, THIN and PHARMO the daily dose of NSAID was estimated from the 
prescribing regimen and strength. Dose of current exposure to each individual NSAID was 
classified using the ratio of prescribed daily dose (PDD) compared to DDD in order to allow for 
aggregation and comparison across NSAIDs. For categorical analysis dose categories were 
defined as low dose (<0.8 PDD/DDD), normal dose (0.8-1.2 PDD/DDD) and high dose (≥1.3 
PDD/DDD) (see Supplementary Table 4 for DDD value for each individual NSAID evaluated). 
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Covariates 
 
Covariates were classified into based on recorded diagnoses or conditions (history of ischemic 
heart disease (excluding AMI); history of stroke; heart failure; diabetes mellitus type 2; 
hyperlipidemia; smoking) or their proxies based on used of medications for these diseases or 
conditions (use of ACE inhibitors, antithrombotic agents, low-dose aspirin, beta blockers, 
calcium channel blockers, diuretics, glucocorticoids, nitrates, oral contraceptives, platelet 
aggregation inhibitors, lipid lowering drugs and postmenopausal hormone therapy). They were 
measured during the 12 months prior to cohort entry (for all co-variates that could be 
intermediates between treatment and AMI, or in 30 or 90 days before index date (if not  
potential intermediates). In case there was no or missing information on the variable in the 
specific time window, the variable was considered as absence of the condition. 
 
Statistical analyses 
 
Baseline characteristics of cases and controls are described by database. To estimate the risk 
for AMI among current use of an individual NSAID in comparison to past use of any NSAID, 
matched odds ratios (ORmatched) and matched adjusted odds ratios (ORadj) with 95% 
Confidence Intervals (CIs) were calculated using conditional logistic regression analyses for 
each database separately if five or more exposed cases per database were available. Pooled 
NSAID-specific ORs (ORmeta) were calculated both using the inverse variance weighting 
method (fixed effect pooled estimates) and DerSimonian and Laird method to account for 
heterogeneity across databases (random effect pooled estimates).441 The degree of statistical 
heterogeneity across databases was measured by I2.442 Confidence limits of random effects 
estimates were calculated accounting for the uncertainty of tau, e.g. the value representing 
the variation in the true effect estimates across the databases.443  
Additionally, pooling of data across databases was performed by combining the 
matched case control sets without weighting and using a conditional logistic regression 
adjusted for covariates. This approach has most power and provides one overall risk measure 
(ORpooled) for all NSAIDs with at least five exposed cases across DBs. 
A stepwise approach was used for confounder selection in both approaches: 1) a-
priori selected confounders were always included; 2) univariate analyses for each potential 
confounder with a prevalence of 5% in controls, which were added to the model if Wald p-
value was <0.05; 3) backward selection of potential confounders (p-value>0.05). 
Categorical duration analyses were performed within current users of each individual 
NSAID, using short duration (7-29 days) as reference group. Dose analyses were done by 
categories comparing dose levels to past use of any NSAID and by continuous analyses through 
restricted cubic splines (3 knots) and through fractional polynomial regression (maximum of 2 
terms) which provides greater flexibility to dose-response curves.444 Since potency of NSAIDs is 
based on normal therapeutic doses, the relationship between COX-2 potency and the relative 
risk of AMI was plotted using normal daily doses (PDD/DDD between 0.8 and 1.2) and 
 
 
therefore could only be done in the databases that provided prescribed daily dose regimens. 
In line with the study by Garcia-Rodriguez,97 naproxen was removed from this plot, since it was 
used at very high doses. Correlation was estimated using the R2. 
Subsequent analyses evaluated the risk of AMI stratified by sex, age (≤60 or >60 
years), prior ischemic heart disease, and use of aspirin or lipid lowering drugs. Current use of 
any NSAID was also analyzed by stratifying factors to increase the power to detect effect 
modification. Multiplicative interaction was tested to identify effect modification by stratifying 
factors.  
For each database, the population attributable risk (PAR) was calculated to estimate 
the proportion of AMI in the target population that may be attributable to use of each NSAIDs 
using the following formula: PAR = (p*[OR-1])/(p*[OR-1]+1).347 where OR is the adjusted odds 
ratio from the nested case-control analysis and p is the exposure prevalence.445 For this 
calculation, we estimated p by the percentage of exposed cases.  
All analyses were performed using SAS (Cary, NC version 9.2). 
 
RESULTS 
 
The study cohort comprised 8,535,952 new NSAID users (Supplementary Figure 1), of whom 
101,227 patients developed an AMI after cohort entry. Of these, 79,553 (78.6%) cases could 
be matched to at least one control using the five matching criteria. Baseline characteristics of 
cases and matched controls are shown in Table 1. Cases had more often risk factors for AMI 
such as a prior history of ischemic heart disease, other cardiovascular diseases or use of 
cardiovascular drugs. 
The distribution of NSAID exposure in cases and controls is reported in Table 2. 
Whereas in the UK, NL and Germany similar NSAIDS were often used, Italy uses quite a 
different range of NSAIDs, for 11 individual NSAIDs data were not available from other 
countries but Italy (Supplementary Table 5). 
Meta-analytic estimates of the adjusted ORs across databases could be calculated for 
21 NSAIDs. The adjusted OR for current use ranged between 0.93 for oxaprozin to 2.06 for 
ketorolac (Figure 1, Table 2), but the width of the confidence intervals vary. Ten NSAIDs were 
associated with a significantly increased risk, for none of the 11 NSAIDs with non-significant 
associations in meta-analytic pooling the upper 95% limit was above 2. For most NSAIDs 
(except for celecoxib, diclofenac, ibuprofen and naproxen) no heterogeneity was seen 
according to the estimated I2 across databases (Table 2). 
In order to estimate the risk of AMI associated with infrequently used NSAIDs we also 
combined all matched case-control pairs across datasets without weighting (Figure 1, Table 2), 
this yielded estimates for 28 individual NSAIDs. For most NSAIDs, which had both estimates, 
the meta-analytic and pooled estimate were quite similar. The results of this combined 
analysis showed that the risk of AMI is significantly elevated for 12 NSAIDs. Compared to past 
use of any NSAID the odds ratio was highest for ketorolac, followed by indometacin, etoricoxib 
and rofecoxib (Figure 1), though the 95% confidence limits overlap between these NSAIDs. 
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Covariates 
 
Covariates were classified into based on recorded diagnoses or conditions (history of ischemic 
heart disease (excluding AMI); history of stroke; heart failure; diabetes mellitus type 2; 
hyperlipidemia; smoking) or their proxies based on used of medications for these diseases or 
conditions (use of ACE inhibitors, antithrombotic agents, low-dose aspirin, beta blockers, 
calcium channel blockers, diuretics, glucocorticoids, nitrates, oral contraceptives, platelet 
aggregation inhibitors, lipid lowering drugs and postmenopausal hormone therapy). They were 
measured during the 12 months prior to cohort entry (for all co-variates that could be 
intermediates between treatment and AMI, or in 30 or 90 days before index date (if not  
potential intermediates). In case there was no or missing information on the variable in the 
specific time window, the variable was considered as absence of the condition. 
 
Statistical analyses 
 
Baseline characteristics of cases and controls are described by database. To estimate the risk 
for AMI among current use of an individual NSAID in comparison to past use of any NSAID, 
matched odds ratios (ORmatched) and matched adjusted odds ratios (ORadj) with 95% 
Confidence Intervals (CIs) were calculated using conditional logistic regression analyses for 
each database separately if five or more exposed cases per database were available. Pooled 
NSAID-specific ORs (ORmeta) were calculated both using the inverse variance weighting 
method (fixed effect pooled estimates) and DerSimonian and Laird method to account for 
heterogeneity across databases (random effect pooled estimates).441 The degree of statistical 
heterogeneity across databases was measured by I2.442 Confidence limits of random effects 
estimates were calculated accounting for the uncertainty of tau, e.g. the value representing 
the variation in the true effect estimates across the databases.443  
Additionally, pooling of data across databases was performed by combining the 
matched case control sets without weighting and using a conditional logistic regression 
adjusted for covariates. This approach has most power and provides one overall risk measure 
(ORpooled) for all NSAIDs with at least five exposed cases across DBs. 
A stepwise approach was used for confounder selection in both approaches: 1) a-
priori selected confounders were always included; 2) univariate analyses for each potential 
confounder with a prevalence of 5% in controls, which were added to the model if Wald p-
value was <0.05; 3) backward selection of potential confounders (p-value>0.05). 
Categorical duration analyses were performed within current users of each individual 
NSAID, using short duration (7-29 days) as reference group. Dose analyses were done by 
categories comparing dose levels to past use of any NSAID and by continuous analyses through 
restricted cubic splines (3 knots) and through fractional polynomial regression (maximum of 2 
terms) which provides greater flexibility to dose-response curves.444 Since potency of NSAIDs is 
based on normal therapeutic doses, the relationship between COX-2 potency and the relative 
risk of AMI was plotted using normal daily doses (PDD/DDD between 0.8 and 1.2) and 
 
 
therefore could only be done in the databases that provided prescribed daily dose regimens. 
In line with the study by Garcia-Rodriguez,97 naproxen was removed from this plot, since it was 
used at very high doses. Correlation was estimated using the R2. 
Subsequent analyses evaluated the risk of AMI stratified by sex, age (≤60 or >60 
years), prior ischemic heart disease, and use of aspirin or lipid lowering drugs. Current use of 
any NSAID was also analyzed by stratifying factors to increase the power to detect effect 
modification. Multiplicative interaction was tested to identify effect modification by stratifying 
factors.  
For each database, the population attributable risk (PAR) was calculated to estimate 
the proportion of AMI in the target population that may be attributable to use of each NSAIDs 
using the following formula: PAR = (p*[OR-1])/(p*[OR-1]+1).347 where OR is the adjusted odds 
ratio from the nested case-control analysis and p is the exposure prevalence.445 For this 
calculation, we estimated p by the percentage of exposed cases.  
All analyses were performed using SAS (Cary, NC version 9.2). 
 
RESULTS 
 
The study cohort comprised 8,535,952 new NSAID users (Supplementary Figure 1), of whom 
101,227 patients developed an AMI after cohort entry. Of these, 79,553 (78.6%) cases could 
be matched to at least one control using the five matching criteria. Baseline characteristics of 
cases and matched controls are shown in Table 1. Cases had more often risk factors for AMI 
such as a prior history of ischemic heart disease, other cardiovascular diseases or use of 
cardiovascular drugs. 
The distribution of NSAID exposure in cases and controls is reported in Table 2. 
Whereas in the UK, NL and Germany similar NSAIDS were often used, Italy uses quite a 
different range of NSAIDs, for 11 individual NSAIDs data were not available from other 
countries but Italy (Supplementary Table 5). 
Meta-analytic estimates of the adjusted ORs across databases could be calculated for 
21 NSAIDs. The adjusted OR for current use ranged between 0.93 for oxaprozin to 2.06 for 
ketorolac (Figure 1, Table 2), but the width of the confidence intervals vary. Ten NSAIDs were 
associated with a significantly increased risk, for none of the 11 NSAIDs with non-significant 
associations in meta-analytic pooling the upper 95% limit was above 2. For most NSAIDs 
(except for celecoxib, diclofenac, ibuprofen and naproxen) no heterogeneity was seen 
according to the estimated I2 across databases (Table 2). 
In order to estimate the risk of AMI associated with infrequently used NSAIDs we also 
combined all matched case-control pairs across datasets without weighting (Figure 1, Table 2), 
this yielded estimates for 28 individual NSAIDs. For most NSAIDs, which had both estimates, 
the meta-analytic and pooled estimate were quite similar. The results of this combined 
analysis showed that the risk of AMI is significantly elevated for 12 NSAIDs. Compared to past 
use of any NSAID the odds ratio was highest for ketorolac, followed by indometacin, etoricoxib 
and rofecoxib (Figure 1), though the 95% confidence limits overlap between these NSAIDs. 
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Table 1. Characteristics of AMI cases and matched controls by database. 
 United Kingdom  The Netherlands 
 THIN  IPCI PHARMO 
 Cases Controls  Cases Controls Cases Controls 
Total Number 13,511 1,232,506  1,070 38,688 9,974 896,907 
 % %  % % % % 
Mean age (SD)*  64.3 (13.3) 63.1 (12.5)  63.3 (13.6) 58.7 (11.3) 61.0 (13.7) 59.3 (12.9) 
Sex*        
   Male 62.7 62.8  63.4 63.7 65.4 65.4 
   Female 37.3 37.2  36.6 36.3 34.6 34.6 
A-priori confounders        
Diseases**        
  Diabetes mellitus type 2      9.1 4.9  7.7 3.8 10.4 5.8 
  Heart Failure                 1.5 0.5  3.4 1.5 0.7 0.4 
  Hyperlipidemia                      18.5 12.3  12.6 8.9 17 11.7 
  Ischemic Heart Disease        5.1 2.3  4.6 2.2 1.8 0.9 
  Smoking                                  11.2 7.2  17.5 18.6 NA NA 
  Stroke                       0.5 0.3  2.4 1.8 0.1 0.1 
Use of Drugs***        
  ACE inh/AT II 
Antagonists  
19.2 13.4 
 
11.5 6.8 14.6 10.4 
  Low-dose Aspirin 33.4 20.4  15.7 5.6 28 16.7 
  Beta Blockers                   19.5 13.6  14.7 7.4 20.4 13.7 
  Calcium Channel 
Blockers             
18.8 12.1 
 
10.3 3.5 12.6 7.4 
  Diuretics  24.7 18.4  10.0 5.4 14.2 10.2 
   Glucocorticoids      7.1 4.1  3.9 1.6 6.4 3.7 
  Lipid lowering agents       32.9 22.5  14.2 8.8 24.3 18.0 
  Nitrates  20.3 5.5  6.1 1.0 15.6 4.4 
  Oral Contraceptives#           0.4 0.6  1.3 1.2 1.2 0.8 
  Hypertensive Drugs 1.2 0.9  2.5 2.7 4.2 3.5 
  Antiplatelets 6.8 2.4  2.9 0.7 4.9 2.3 
  Hormone Therapy# 6.5 6.7  2.8 1.9 5.8 8.0 
Potential Confounders        
Diseases**        
  Alcohol Abuse                        8.5 8.3  7.0 7.3 0.2 0.1 
  AF and AFl                  0.6 0.4  4.8 1.2 0.4 0.3 
  Chronic Liver Disease           0.1 0.1  2.1 1.6 0.1 0.1 
  Kidney Failure                        0.2 0.1  1.1 0.4 0.04 0.01 
  Obesity                         8.6 6.8  1.6 1.3 0.3 0.2 
  Osteoarthritis                        12.7 10.6  2.6 3.1 1.2 1.1 
  Other CV Disease         1.9 1.2  6.8 3.7 1.2 1.1 
  PAD                     0.02 0.01  1.3 0.8 0.3 0.1 
  RA and Infl Polyarthritis       8.7 6.7  11.1 9.4 1.2 0.9 
Use of Drugs***        
  Anticoagulants 3.0 2.4  2.5 1.3 6.1 4.6 
  Cardiac Glycosides    1.0 0.3 1.9 1.4 
  CYP2C9 Inducer drugs† 0.01 0.02    0.01 0.01 
  CYP2C9 Inhibitor drugs‡ 1.1 0.6  0.9 0.2 8.7 6.7 
 
*Age and sex are matching criteria. # Percentage only in females. † Includes Carbamazepine, Norethisterone (and estrogen 
combination) and Prednisone. ‡ Includes Cimetidine, Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Ticlopidine, 
Indometacin, Probenecid, Oxcarbazepine, Felbamate, Topiramate, Fluoxetine, Fluvoxamine, Modafinil and Ketoconazole. ** 
Assessed at 12 months prior to cohort entry. *** Assessed at 30 or 90 days before indexdate. AF and AFl, atrial fibrillation and 
flutter; RA and Infl Polyarthritis, rheumatoid arthritis and inflammatory polyarthritis; PAD, peripheral arterial disease. 
 
 
Table 1. Characteristics of AMI cases and matched controls by database (continued). 
 Germany  Italy 
 GePaRD  SISR OSSIFF 
 Cases Controls  Cases Controls Cases Controls 
Total Number 9,930 957,016  25,719 2,523,118 19,349 1,840,368 
 % %  % % % % 
Mean age (SD)*  62.4 (12.4) 62.0 (11.8)  69.8 (12.2) 69.5 (12.1) 67.7 (12.2) 67.0 (11.8) 
Sex*        
   Male 77.5 78.1  54.7 54.6 56.5 56.3 
   Female 22.5 21.9  45.3 45.4 43.5 43.7 
A-priori confounders        
Diseases**        
  Diabetes mellitus type 2 16.2 8.5  21.3 10.4 15.1 6.8 
  Heart Failure                 12.5 7.2  5.9 3.1 4.3 2.1 
  Hyperlipidemia                      26.1 17.7  22.7 16 14.6 9.4 
  Ischemic Heart Disease        29.0 15.9  5.5 1.9 4.6 1.6 
  Smoking                                  NA NA   NA NA NA NA 
  Stroke                       6.9 4.0  1.0 0.5 1.1 0.6 
Use of Drugs***        
  ACE Inh/AT II 
Antagonists  
30.2 22.2 
 
33.8 26.1 25.2 18.4 
  Low-dose Aspirin 11.5 5.4  29.1 19.2 24.1 15.2 
  Beta Blockers                   33.6 23.7  20.1 13.0 14.2 8.7 
  Calcium Channel 
Blockers             
18.0 12.3 
 
32.4 21.9 26.9 17.2 
  Diuretics  17.8 11.7  22.9 16.7 15.5 10.7 
   Glucocorticoids      5.9 4.1  5.7 3.7 5.0 3.3 
  Lipid lowering agents       24.3 17.1  21.2 14.5 19.3 12.6 
  Nitrates  10.6 3.0  21.4 7.8 20.7 7.0 
  Oral Contraceptives#           0.1 0.0  0.2 0.2 2.6 1.8 
  Hypertensive Drugs 21.0 16.6  22.5 20.4 16.7 14.8 
  Antiplatelets 5.6 1.9  9.8 4.7 7.6 3.5 
  Hormone Therapy# 10.1 13.6  1.3 1.7 1.9 1.9 
Potential Confounders        
Diseases**        
  Alcohol Abuse                        2.1 1.4  0.1 0.1 0.2 0.2 
  AF and AFl                  5.7 4.6  1.6 1.1 1.3 0.9 
  Chronic Liver Disease           11.3 10.6  0.7 0.5 0.5 0.5 
  Kidney Failure                        6.9 3.5  0.2 0.1 0.1 0.04 
  Obesity                         14.5 10.8  0.6 0.3 0.2 0.1 
  Osteoarthritis                        22.1 21.8  1.3 1.2 1.3 1.1 
  Other CV Disease         20.0 16.2  6.3 4.8 4.8 3.5 
  PAD                     8.9 4.9  1.6 0.5 1.4 0.5 
  RA and Infl Polyarthritis       7.2 5.9  0.6 0.3 0.7 0.5 
Use of Drugs***        
  Anticoagulants 5.9 5.1  7.0 5.2 7.0 5.1 
  Cardiac Glycosides 4.0 2.4  5.2 3.9 4.6 3.3 
  CYP2C9 Inducer drugs† 0.02 0.01      
  CYP2C9 Inhibitor drugs‡ 1.1 0.8  2.5 1.7 0.7 0.4 
 
*Age and sex are matching criteria. # Percentage only in females. † Includes Carbamazepine, Norethisterone (and estrogen 
combination) and Prednisone. ‡ Includes Cimetidine, Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Ticlopidine, 
Indometacin, Probenecid, Oxcarbazepine, Felbamate, Topiramate, Fluoxetine, Fluvoxamine, Modafinil and Ketoconazole. ** 
Assessed at 12 months prior to cohort entry. *** Assessed at 30 or 90 days before indexdate. AF and AFl, atrial fibrillation and 
flutter; RA and Infl Polyarthritis, rheumatoid arthritis and inflammatory polyarthritis; PAD, peripheral arterial disease. 
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Table 1. Characteristics of AMI cases and matched controls by database. 
 United Kingdom  The Netherlands 
 THIN  IPCI PHARMO 
 Cases Controls  Cases Controls Cases Controls 
Total Number 13,511 1,232,506  1,070 38,688 9,974 896,907 
 % %  % % % % 
Mean age (SD)*  64.3 (13.3) 63.1 (12.5)  63.3 (13.6) 58.7 (11.3) 61.0 (13.7) 59.3 (12.9) 
Sex*        
   Male 62.7 62.8  63.4 63.7 65.4 65.4 
   Female 37.3 37.2  36.6 36.3 34.6 34.6 
A-priori confounders        
Diseases**        
  Diabetes mellitus type 2      9.1 4.9  7.7 3.8 10.4 5.8 
  Heart Failure                 1.5 0.5  3.4 1.5 0.7 0.4 
  Hyperlipidemia                      18.5 12.3  12.6 8.9 17 11.7 
  Ischemic Heart Disease        5.1 2.3  4.6 2.2 1.8 0.9 
  Smoking                                  11.2 7.2  17.5 18.6 NA NA 
  Stroke                       0.5 0.3  2.4 1.8 0.1 0.1 
Use of Drugs***        
  ACE inh/AT II 
Antagonists  
19.2 13.4 
 
11.5 6.8 14.6 10.4 
  Low-dose Aspirin 33.4 20.4  15.7 5.6 28 16.7 
  Beta Blockers                   19.5 13.6  14.7 7.4 20.4 13.7 
  Calcium Channel 
Blockers             
18.8 12.1 
 
10.3 3.5 12.6 7.4 
  Diuretics  24.7 18.4  10.0 5.4 14.2 10.2 
   Glucocorticoids      7.1 4.1  3.9 1.6 6.4 3.7 
  Lipid lowering agents       32.9 22.5  14.2 8.8 24.3 18.0 
  Nitrates  20.3 5.5  6.1 1.0 15.6 4.4 
  Oral Contraceptives#           0.4 0.6  1.3 1.2 1.2 0.8 
  Hypertensive Drugs 1.2 0.9  2.5 2.7 4.2 3.5 
  Antiplatelets 6.8 2.4  2.9 0.7 4.9 2.3 
  Hormone Therapy# 6.5 6.7  2.8 1.9 5.8 8.0 
Potential Confounders        
Diseases**        
  Alcohol Abuse                        8.5 8.3  7.0 7.3 0.2 0.1 
  AF and AFl                  0.6 0.4  4.8 1.2 0.4 0.3 
  Chronic Liver Disease           0.1 0.1  2.1 1.6 0.1 0.1 
  Kidney Failure                        0.2 0.1  1.1 0.4 0.04 0.01 
  Obesity                         8.6 6.8  1.6 1.3 0.3 0.2 
  Osteoarthritis                        12.7 10.6  2.6 3.1 1.2 1.1 
  Other CV Disease         1.9 1.2  6.8 3.7 1.2 1.1 
  PAD                     0.02 0.01  1.3 0.8 0.3 0.1 
  RA and Infl Polyarthritis       8.7 6.7  11.1 9.4 1.2 0.9 
Use of Drugs***        
  Anticoagulants 3.0 2.4  2.5 1.3 6.1 4.6 
  Cardiac Glycosides    1.0 0.3 1.9 1.4 
  CYP2C9 Inducer drugs† 0.01 0.02    0.01 0.01 
  CYP2C9 Inhibitor drugs‡ 1.1 0.6  0.9 0.2 8.7 6.7 
 
*Age and sex are matching criteria. # Percentage only in females. † Includes Carbamazepine, Norethisterone (and estrogen 
combination) and Prednisone. ‡ Includes Cimetidine, Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Ticlopidine, 
Indometacin, Probenecid, Oxcarbazepine, Felbamate, Topiramate, Fluoxetine, Fluvoxamine, Modafinil and Ketoconazole. ** 
Assessed at 12 months prior to cohort entry. *** Assessed at 30 or 90 days before indexdate. AF and AFl, atrial fibrillation and 
flutter; RA and Infl Polyarthritis, rheumatoid arthritis and inflammatory polyarthritis; PAD, peripheral arterial disease. 
 
 
Table 1. Characteristics of AMI cases and matched controls by database (continued). 
 Germany  Italy 
 GePaRD  SISR OSSIFF 
 Cases Controls  Cases Controls Cases Controls 
Total Number 9,930 957,016  25,719 2,523,118 19,349 1,840,368 
 % %  % % % % 
Mean age (SD)*  62.4 (12.4) 62.0 (11.8)  69.8 (12.2) 69.5 (12.1) 67.7 (12.2) 67.0 (11.8) 
Sex*        
   Male 77.5 78.1  54.7 54.6 56.5 56.3 
   Female 22.5 21.9  45.3 45.4 43.5 43.7 
A-priori confounders        
Diseases**        
  Diabetes mellitus type 2 16.2 8.5  21.3 10.4 15.1 6.8 
  Heart Failure                 12.5 7.2  5.9 3.1 4.3 2.1 
  Hyperlipidemia                      26.1 17.7  22.7 16 14.6 9.4 
  Ischemic Heart Disease        29.0 15.9  5.5 1.9 4.6 1.6 
  Smoking                                  NA NA   NA NA NA NA 
  Stroke                       6.9 4.0  1.0 0.5 1.1 0.6 
Use of Drugs***        
  ACE Inh/AT II 
Antagonists  
30.2 22.2 
 
33.8 26.1 25.2 18.4 
  Low-dose Aspirin 11.5 5.4  29.1 19.2 24.1 15.2 
  Beta Blockers                   33.6 23.7  20.1 13.0 14.2 8.7 
  Calcium Channel 
Blockers             
18.0 12.3 
 
32.4 21.9 26.9 17.2 
  Diuretics  17.8 11.7  22.9 16.7 15.5 10.7 
   Glucocorticoids      5.9 4.1  5.7 3.7 5.0 3.3 
  Lipid lowering agents       24.3 17.1  21.2 14.5 19.3 12.6 
  Nitrates  10.6 3.0  21.4 7.8 20.7 7.0 
  Oral Contraceptives#           0.1 0.0  0.2 0.2 2.6 1.8 
  Hypertensive Drugs 21.0 16.6  22.5 20.4 16.7 14.8 
  Antiplatelets 5.6 1.9  9.8 4.7 7.6 3.5 
  Hormone Therapy# 10.1 13.6  1.3 1.7 1.9 1.9 
Potential Confounders        
Diseases**        
  Alcohol Abuse                        2.1 1.4  0.1 0.1 0.2 0.2 
  AF and AFl                  5.7 4.6  1.6 1.1 1.3 0.9 
  Chronic Liver Disease           11.3 10.6  0.7 0.5 0.5 0.5 
  Kidney Failure                        6.9 3.5  0.2 0.1 0.1 0.04 
  Obesity                         14.5 10.8  0.6 0.3 0.2 0.1 
  Osteoarthritis                        22.1 21.8  1.3 1.2 1.3 1.1 
  Other CV Disease         20.0 16.2  6.3 4.8 4.8 3.5 
  PAD                     8.9 4.9  1.6 0.5 1.4 0.5 
  RA and Infl Polyarthritis       7.2 5.9  0.6 0.3 0.7 0.5 
Use of Drugs***        
  Anticoagulants 5.9 5.1  7.0 5.2 7.0 5.1 
  Cardiac Glycosides 4.0 2.4  5.2 3.9 4.6 3.3 
  CYP2C9 Inducer drugs† 0.02 0.01      
  CYP2C9 Inhibitor drugs‡ 1.1 0.8  2.5 1.7 0.7 0.4 
 
*Age and sex are matching criteria. # Percentage only in females. † Includes Carbamazepine, Norethisterone (and estrogen 
combination) and Prednisone. ‡ Includes Cimetidine, Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Ticlopidine, 
Indometacin, Probenecid, Oxcarbazepine, Felbamate, Topiramate, Fluoxetine, Fluvoxamine, Modafinil and Ketoconazole. ** 
Assessed at 12 months prior to cohort entry. *** Assessed at 30 or 90 days before indexdate. AF and AFl, atrial fibrillation and 
flutter; RA and Infl Polyarthritis, rheumatoid arthritis and inflammatory polyarthritis; PAD, peripheral arterial disease. 
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Table 2. Association between current use of individual NSAIDs and AMI by meta-analysis (random and fixed 
effects) and by unweighted (matched set) pooled dataset.  
      Meta-analysis approach 
(random effects) 
 Fixed effects  Pooled dataset 
 Cases  
N 
Controls  
N 
Number 
of DBs 
ORmeta 
(95% CI) 
I2 * 
(%) 
ORfixed  
(95% CI) 
ORpooled 
(95% CI) 
Past Use 55,657 5,307,077 6 1 (ref) 1 (ref) 1 (ref) 
Recent Use# 23,896 2,181,526 6 1.08 (1.04-1.11) 65 1.08 (1.06-1.09) 1.08 (1.06-1.11) 
Current use of:      
  Aceclofenac 214 20,370 4 1.04 (0.90-1.19) 0 1.04 (0.9-1.19) 1.08 (0.85-1.36) 
  Acemetacin 14 1,178 1      1.00 (0.58-1.71) 
  Celecoxib 886 76,132 5 1.15 (1.00-1.32) 67 1.12 (1.05-1.20) 1.15 (1.05-1.25) 
  Dexibuprofen 41 2,651 2 1.15 (0.79-1.68) 0 1.15 (0.79-1.68) 1.06 (0.61-1.82) 
  Dexketoprofen 9 723 1      1.01 (0.50-2.04) 
  Diclofenac 3,064 230,213 6 1.31 (1.23-1.40) 60 1.32 (1.27-1.37) 1.28 (1.22-1.34) 
  Diclofenac comb 399 27,923 6 1.27 (1.12-1.43) 19 1.27 (1.15-1.40) 1.30 (1.17-1.45) 
  Etodolac 37 2,761 1 1.17 (0.85-1.63)    1.07 (0.76-1.50) 
  Etoricoxib 497 37,478 6 1.28 (1.16-1.42) 12 1.27 (1.16-1.39) 1.39 (1.24-1.57) 
  Flurbiprofen 27 1,972 2 1.05 (0.66-1.67) 0 1.05 (0.66-1.67) 1.00 (0.56-1.78) 
  Ibuprofen 1,564 119,219 6 1.24 (1.13-1.37) 61 1.25 (1.19-1.32) 1.25 (1.18-1.33) 
  Indometacin 196 11,789 5 1.47 (1.27-1.70) 0 1.47 (1.27-1.70) 1.51 (1.28-1.80) 
  Ketoprofen 559 47,969 3 1.12 (1.03-1.22) 0 1.12 (1.03-1.22) 1.00 (0.86-1.16) 
  Ketorolac 272 11,732 2 2.06 (1.83-2.32) 0 2.06 (1.83-2.32) 1.80 (1.49-2.18) 
  Lornoxicam 40 3,095 2 1.08 (0.77-1.52) 0 1.08 (0.77-1.51) 1.08 (0.62-1.87) 
  Mefenamic acid 12 981 1      1.02 (0.55-1.90) 
  Meloxicam 492 38,806 6 1.18 (1.08-1.29) 0 1.18 (1.08-1.29) 1.13 (1.02-1.27) 
  Nabumetone 46 3,795 4 1.03 (0.76-1.40) 0 1.03 (0.76-1.40) 1.03 (0.72-1.47) 
  Naproxen 486 38,659 6 1.19 (1.04-1.37) 47 1.18 (1.08-1.29) 1.22 (1.10-1.35) 
  Nimesulide 1,652 133,462 2 1.16 (1.10-1.22) 0 1.16 (1.10-1.22) 1.12 (1.03-1.22) 
  Oxaprozin 22 2,709 2 0.93 (0.63-1.38) 0 0.93 (0.63-1.38) 0.97 (0.52-1.79) 
  Piroxicam 636 51,898 5 1.17 (1.03-1.33) 34 1.20 (1.10-1.30) 1.27 (1.13-1.42) 
  Proglumetacin 11 930 1      1.00 (0.41-2.47) 
  Rofecoxib 690 51,674 4 1.26 (1.17-1.37) 0 1.26 (1.17-1.36) 1.30 (1.19-1.43) 
  Sulindac 11 494 1      1.01 (0.48-2.15) 
  Tenoxicam 32 3,104 2 1.02 (0.72-1.46) 0 1.02 (0.71-1.46) 0.99 (0.56-1.74) 
  Tiaprofenic acid 8 710      1.01 (0.49-2.10) 
  Valdecoxib 25 2,159 3 1.00 (0.66-1.52) 0 1.00 (0.66-1.52) 1.07 (0.58-1.99) 
 
* A high level of heterogeneity is present with an I2 value above 75%. 
 
For 16 NSAIDs the association with AMI was not significantly elevated, but there might be a 
risk present. However only for four of these 95%CI limits were wide with an upper limit above 
2, due to small numbers. When plotting the relative risk of AMI associated to  current use of 
normal dose as 0.8 to 1.2 defined daily doses of the most frequently used NSAIDs (obtained 
from  databases where we could investigate daily dose relationships) with the potency of 
inhibition of COX-2 there appears to be a small correlation (R2=0.45) (Supplementary Figure 
2). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Adjusted risk estimates of AMI for current use of individual NSAIDs versus past use of any NSAID in the 
pooled dataset ranked on magnitude of risk in the analyses 1) meta-analytic pooling by random effects model 
and 2) on individual datasets. 
 
 
In the THIN, IPCI and PHARMO databases NSAID dose and duration analyses could be 
conducted as prescription regimens were available. Categorical dose response analyses versus 
past use of any NSAID in this subset showed that higher doses of celecoxib, the fixed 
combination of diclofenac and misoprostol, etoricoxib and naproxen increased the risk of AMI 
(Figure 2). Continuous dose-response curves with cubic splines showed a significant dose 
response for diclofenac only (Supplementary Figure 3). For duration, no clear patterns were 
seen (Supplementary Figure 4). The risk of AMI seemed highest with shortest duration for 
diclofenac, which was also seen for ibuprofen and rofecoxib although confidence limits 
between categories overlapped.  
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Table 2. Association between current use of individual NSAIDs and AMI by meta-analysis (random and fixed 
effects) and by unweighted (matched set) pooled dataset.  
      Meta-analysis approach 
(random effects) 
 Fixed effects  Pooled dataset 
 Cases  
N 
Controls  
N 
Number 
of DBs 
ORmeta 
(95% CI) 
I2 * 
(%) 
ORfixed  
(95% CI) 
ORpooled 
(95% CI) 
Past Use 55,657 5,307,077 6 1 (ref) 1 (ref) 1 (ref) 
Recent Use# 23,896 2,181,526 6 1.08 (1.04-1.11) 65 1.08 (1.06-1.09) 1.08 (1.06-1.11) 
Current use of:      
  Aceclofenac 214 20,370 4 1.04 (0.90-1.19) 0 1.04 (0.9-1.19) 1.08 (0.85-1.36) 
  Acemetacin 14 1,178 1      1.00 (0.58-1.71) 
  Celecoxib 886 76,132 5 1.15 (1.00-1.32) 67 1.12 (1.05-1.20) 1.15 (1.05-1.25) 
  Dexibuprofen 41 2,651 2 1.15 (0.79-1.68) 0 1.15 (0.79-1.68) 1.06 (0.61-1.82) 
  Dexketoprofen 9 723 1      1.01 (0.50-2.04) 
  Diclofenac 3,064 230,213 6 1.31 (1.23-1.40) 60 1.32 (1.27-1.37) 1.28 (1.22-1.34) 
  Diclofenac comb 399 27,923 6 1.27 (1.12-1.43) 19 1.27 (1.15-1.40) 1.30 (1.17-1.45) 
  Etodolac 37 2,761 1 1.17 (0.85-1.63)    1.07 (0.76-1.50) 
  Etoricoxib 497 37,478 6 1.28 (1.16-1.42) 12 1.27 (1.16-1.39) 1.39 (1.24-1.57) 
  Flurbiprofen 27 1,972 2 1.05 (0.66-1.67) 0 1.05 (0.66-1.67) 1.00 (0.56-1.78) 
  Ibuprofen 1,564 119,219 6 1.24 (1.13-1.37) 61 1.25 (1.19-1.32) 1.25 (1.18-1.33) 
  Indometacin 196 11,789 5 1.47 (1.27-1.70) 0 1.47 (1.27-1.70) 1.51 (1.28-1.80) 
  Ketoprofen 559 47,969 3 1.12 (1.03-1.22) 0 1.12 (1.03-1.22) 1.00 (0.86-1.16) 
  Ketorolac 272 11,732 2 2.06 (1.83-2.32) 0 2.06 (1.83-2.32) 1.80 (1.49-2.18) 
  Lornoxicam 40 3,095 2 1.08 (0.77-1.52) 0 1.08 (0.77-1.51) 1.08 (0.62-1.87) 
  Mefenamic acid 12 981 1      1.02 (0.55-1.90) 
  Meloxicam 492 38,806 6 1.18 (1.08-1.29) 0 1.18 (1.08-1.29) 1.13 (1.02-1.27) 
  Nabumetone 46 3,795 4 1.03 (0.76-1.40) 0 1.03 (0.76-1.40) 1.03 (0.72-1.47) 
  Naproxen 486 38,659 6 1.19 (1.04-1.37) 47 1.18 (1.08-1.29) 1.22 (1.10-1.35) 
  Nimesulide 1,652 133,462 2 1.16 (1.10-1.22) 0 1.16 (1.10-1.22) 1.12 (1.03-1.22) 
  Oxaprozin 22 2,709 2 0.93 (0.63-1.38) 0 0.93 (0.63-1.38) 0.97 (0.52-1.79) 
  Piroxicam 636 51,898 5 1.17 (1.03-1.33) 34 1.20 (1.10-1.30) 1.27 (1.13-1.42) 
  Proglumetacin 11 930 1      1.00 (0.41-2.47) 
  Rofecoxib 690 51,674 4 1.26 (1.17-1.37) 0 1.26 (1.17-1.36) 1.30 (1.19-1.43) 
  Sulindac 11 494 1      1.01 (0.48-2.15) 
  Tenoxicam 32 3,104 2 1.02 (0.72-1.46) 0 1.02 (0.71-1.46) 0.99 (0.56-1.74) 
  Tiaprofenic acid 8 710      1.01 (0.49-2.10) 
  Valdecoxib 25 2,159 3 1.00 (0.66-1.52) 0 1.00 (0.66-1.52) 1.07 (0.58-1.99) 
 
* A high level of heterogeneity is present with an I2 value above 75%. 
 
For 16 NSAIDs the association with AMI was not significantly elevated, but there might be a 
risk present. However only for four of these 95%CI limits were wide with an upper limit above 
2, due to small numbers. When plotting the relative risk of AMI associated to  current use of 
normal dose as 0.8 to 1.2 defined daily doses of the most frequently used NSAIDs (obtained 
from  databases where we could investigate daily dose relationships) with the potency of 
inhibition of COX-2 there appears to be a small correlation (R2=0.45) (Supplementary Figure 
2). 
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Figure 2. Adjusted risk estimates for AMI in current users for dose of use of individual NSAIDs in three 
databases pooled (THIN, IPCI, PHARMO) using past use of any NSAID as common reference group. 
 
DDD, defined daily dose. Number of exposed cases do not add up to all current users of that particular NSAID in all three 
databases pooled as dose information could have been missing. 
 
Stratification by AMI risk factors did not reveal clear consistent patterns for potential effect 
modifiers across individual NSAIDs (Supplementary Table 6). Current use of any NSAID 
(grouping all individual NSAIDs together) showed significant effect modification for concurrent 
use of aspirin, lipid lowering drugs and by age, pointing to higher risk in non-users of aspirin 
and lipid lowering drugs and younger age. 
The population attributable risk (PAR) percentages varied between 0% and 2% for 
different NSAIDs and were slightly higher when the upper limit of the confidence interval was 
considered (Supplementary Table 7). In most of the databases the PAR was highest for 
diclofenac and ibuprofen, except in Italy where ibuprofen use is low and the PAR was highest 
for nimesulide and diclofenac. 
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DISCUSSION 
 
In this multinational case-control study nested in a new user NSAID cohort of more than 8.5 
million persons, we assessed the association with acute myocardial infarction for 28 individual 
NSAIDs. The study is unique in its kind. It capitalizes on the heterogeneity of prescribing 
patterns across countries, which allowed for analyses on more drugs than otherwise would be 
possible in a single database, while using a common data model, protocol, definitions, data 
transformation and analysis, which is a clear improvement from meta-analyses of 
heterogeneous observational studies, which has been practice for many years. 
 
Principal findings 
 
The highest point estimate for the risk of AMI was observed for current use of ketorolac in 
Italian databases. Various other widely used nonselective NSAIDs, such as indometacin, 
diclofenac, piroxicam, ibuprofen, naproxen, meloxicam and nimesulide; and selective COX-2 
inhibitors, as etoricoxib, rofecoxib and celecoxib, were associated with a small increase in risk 
of AMI. The percentage of AMI cases that can be avoided by taking away the exposure (PAR) 
was between 0% and 2% and highest for the most frequently used NSAIDS across all 
databases: ibuprofen and diclofenac in UK, NL and Germany and nimesulide and diclofenac in 
Italy. 
Following the withdrawal of rofecoxib and subsequent referral procedures for 
nonselective NSAIDs, many single studies have been conducted using different protocols and 
definitions.96, 97, 446-448 Meta-analyses of these observational studies identified large variability 
between studies and several methodological issues (e.g. including prevalent users, immortal 
time and recall bias) plus gaps in knowledge about dose effects, and effect estimates on 
individual NSAIDs, particularly for less commonly studied NSAID.434, 449 With this SOS study we 
tried to address most of these gaps and limitations. 
 
Comparison with other studies 
 
Our risk estimates are slightly lower (except for naproxen and etoricoxib) than the estimates 
from meta-analyses of clinical trials293 for the six NSAIDs (celecoxib, diclofenac, etoricoxib, 
ibuprofen, naproxen, rofecoxib) that have been studied in RCT meta-analyses (Table 3). 
Explanation might be that some of the large efficacy trials were done for comparison of gastro-
intestinal effects and used higher dosages than what is used in the majority of everyday 
practice.450 For the nine NSAIDs for which we have evidence from meta-analyses of published 
observational studies the SOS estimates were within the width of the confidence intervals 
(except for naproxen and etodolac). This consistency for the nine NSAIDs where we had 
external benchmarks gives us reassurance to the interpretation of results of the nineteen 
additional NSAIDs that were studied.293, 434  
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Figure 2. Adjusted risk estimates for AMI in current users for dose of use of individual NSAIDs in three 
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DISCUSSION 
 
In this multinational case-control study nested in a new user NSAID cohort of more than 8.5 
million persons, we assessed the association with acute myocardial infarction for 28 individual 
NSAIDs. The study is unique in its kind. It capitalizes on the heterogeneity of prescribing 
patterns across countries, which allowed for analyses on more drugs than otherwise would be 
possible in a single database, while using a common data model, protocol, definitions, data 
transformation and analysis, which is a clear improvement from meta-analyses of 
heterogeneous observational studies, which has been practice for many years. 
 
Principal findings 
 
The highest point estimate for the risk of AMI was observed for current use of ketorolac in 
Italian databases. Various other widely used nonselective NSAIDs, such as indometacin, 
diclofenac, piroxicam, ibuprofen, naproxen, meloxicam and nimesulide; and selective COX-2 
inhibitors, as etoricoxib, rofecoxib and celecoxib, were associated with a small increase in risk 
of AMI. The percentage of AMI cases that can be avoided by taking away the exposure (PAR) 
was between 0% and 2% and highest for the most frequently used NSAIDS across all 
databases: ibuprofen and diclofenac in UK, NL and Germany and nimesulide and diclofenac in 
Italy. 
Following the withdrawal of rofecoxib and subsequent referral procedures for 
nonselective NSAIDs, many single studies have been conducted using different protocols and 
definitions.96, 97, 446-448 Meta-analyses of these observational studies identified large variability 
between studies and several methodological issues (e.g. including prevalent users, immortal 
time and recall bias) plus gaps in knowledge about dose effects, and effect estimates on 
individual NSAIDs, particularly for less commonly studied NSAID.434, 449 With this SOS study we 
tried to address most of these gaps and limitations. 
 
Comparison with other studies 
 
Our risk estimates are slightly lower (except for naproxen and etoricoxib) than the estimates 
from meta-analyses of clinical trials293 for the six NSAIDs (celecoxib, diclofenac, etoricoxib, 
ibuprofen, naproxen, rofecoxib) that have been studied in RCT meta-analyses (Table 3). 
Explanation might be that some of the large efficacy trials were done for comparison of gastro-
intestinal effects and used higher dosages than what is used in the majority of everyday 
practice.450 For the nine NSAIDs for which we have evidence from meta-analyses of published 
observational studies the SOS estimates were within the width of the confidence intervals 
(except for naproxen and etodolac). This consistency for the nine NSAIDs where we had 
external benchmarks gives us reassurance to the interpretation of results of the nineteen 
additional NSAIDs that were studied.293, 434  
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Table 3. Risk estimates of AMI for individual NSAIDs from current SOS study, meta-analysis from observational 
studies434 and randomized clinical trials,293 using major vascular events as outcome. 
 
  
SOS study  
(pooled dataset) 
Meta-analysis 
published 
observational studies 
Composite Endpoint 
from meta-analysis of 
randomized clinical 
trials# 
 
Adjusted  
ORpooled (95% CI) 
Relative Risk  
(random effects) 
Adjusted  
Rate Ratio 
Reference group Past Use of any NSAID No / remote NSAID use Placebo 
Current use of:   
  Aceclofenac 1.08 (0.85-1.36)   
  Acemetacin 1.00 (0.58-1.71)   
  Celecoxib 1.15 (1.05-1.25) 1.23 (1.00-1.52)* 1.36 (0.91−2.02) 
  Dexibuprofen 1.06 (0.61-1.82)   
  Dexketoprofen 1.01 (0.50-2.04)   
  Diclofenac 1.28 (1.22-1.34) 1.41 (1.08-1.86)* 1.41 (1.12-1.78) 
  Diclofenac, comb 1.30 (1.17-1.45)   
  Etodolac 1.07 (0.76-1.50) 1.55 (1.16-2.06)  
  Etoricoxib 1.39 (1.24-1.57) 1.97 (1.35-2.89) 0.83 (0.18−3.77) 
  Flurbiprofen 1.00 (0.56-1.78)   
  Ibuprofen 1.25 (1.18-1.33) 1.20 (0.97-1.48)* 1.44 (0.89−2.33) 
  Indometacin 1.51 (1.28-1.80) 1.40 (1.21-1.62)  
  Ketoprofen 1.00 (0.86-1.16)   
  Ketorolac 1.80 (1.49-2.18)   
  Lornoxicam 1.08 (0.62-1.87)   
  Mefenamic acid 1.02 (0.55-1.90)   
  Meloxicam 1.13 (1.02-1.27) 1.25 (1.04-1.49)  
  Nabumetone 1.03 (0.72-1.47)   
  Naproxen 1.22 (1.10-1.35) 0.85 (0.73-1.00)* 0.93 (0.69−1.27) 
  Nimesulide 1.12 (1.03-1.22)   
  Oxaprozin 0.97 (0.52-1.79)   
  Piroxicam 1.27 (1.13-1.42)   
  Proglumetacin 1.00 (0.41-2.47)   
  Rofecoxib 1.30 (1.19-1.43) 1.43 (1.21-1.66)* 1.38 (0.99−1.94) 
  Sulindac 1.01 (0.48-2.15)   
  Tenoxicam 0.99 (0.56-1.74)   
  Tiaprofenic acid 1.01 (0.49-2.10)   
  Valdecoxib 1.07 (0.58-1.99)   
 
* in new users exposed to NSAIDs. 
# The outcome major vascular events included non-fatal MI, coronary death, MI or CHD death, non-fatal stroke, stroke death, 
any stroke and other vascular death). Daily dose studied in Clinical Trials: Diclofenac (150 mg); Ibuprofen (2400 mg); Naproxen 
(1000 mg); Celecoxib (100-800 mg, typical doses contributing the majority of information on major vascular events 400 mg); 
Rofecoxib (12.5-125 mg; typical dose 25 mg); Lumiracoxib (100-800 mg; typical dose 200 mg); Etoricoxib (5-120 mg; typical dose 
60/90 mg); Valdecoxib (1-80 mg; typical dose 20 mg). 
  
 
 
What are the key findings for individual nsNSAIDs in this study? The first is that diclofenac 
(median dose 150 mg, 1.5 DDD), a very frequently used NSAID in Europe, is associated with an 
increased risk of AMI of a similar magnitude as rofecoxib (median dose 25 mg, 1 DDD). Some 
recent meta-analyses have shown this as well.293, 434 With support of SOS data, regulatory 
action was therefore taken by EMA in 2013 to restrict the use of diclofenac.451 The second key 
finding is that there was one nonselective NSAID that was even more strongly associated with 
AMI than diclofenac: ketorolac, a finding supporting the negative overall safety profile of 
ketorolac in Italy, which among other NSAIDs also has showed the highest risk of acute liver 
failure needing transplantation.452 The third finding is that we observed a 22% increase in risk 
of AMI with naproxen use, which is in contrast with some previous studies96, 293, 434, 446, 453, 454 
but in line with others.96, 453, 455-457 In previous observational studies, naproxen increased the 
risk of AMI between 14% 456 and 19% 457 as compared to remote NSAID use, a similar 
comparator group we have chosen. Although trials provide higher level evidence for the 
specific study population, our finding on naproxen is in fact in line with the ones observed in 
clinical trials. In the TARGET trial, which was specifically designed to assess the gastrointestinal 
and cardiovascular safety of lumiracoxib, naproxen and ibuprofen, it appeared that there were 
no significant differences between the three drugs and the incidence of AMI, regardless of 
low-dose aspirin use.458 Our findings may as well be explained by different prescribing patterns 
in Germany since the increased risk was largely driven by the estimate from the German 
database which did not provide information on prescribed dose. In the dose response analyses 
that included UK and Dutch databases only, the OR was only significantly increased for the 
highest dose of naproxen as compared to past use of any NSAID and  the median dose for 
naproxen was 2 times the daily recommended dose (1000 mg). However, in the Dutch 
PHARMO databases the risk for naproxen was increased, whereas in the other Dutch database 
(IPCI) and the Italian and UK databases, the confidence levels of the estimate of naproxen 
included 1 and thus did not provide a significant increased risk. In the stratified analyses 
presence of ischemic heart disease yielded an higher risk for naproxen (ORadj 1.95) than in 
subjects without prior ischemic heart disease (ORadj 1.18) whereas for celecoxib, etoricoxib 
and rofecoxib the opposite effects were seen, suggesting that selective prescribing may have 
occurred. Other potential explanations could be potential protopathic bias, which was 
reported before.459  
The key findings related to selective COX-2 inhibitors are that the risk of AMI for 
etoricoxib compared to past use of any NSAID was higher than for diclofenac compared to past 
use of any NSAID and almost equal to that for rofecoxib, though the confidence limits of these 
risks were overlapping. An increased risk for etoricoxib was also found in the meta-analysis of 
observational studies.434 Although etoricoxib has not been studied extensively in placebo-
controlled trials, effects of etoricoxib, rofecoxib and celecoxib seemed similar in trials 
comparing COX-2 selective inhibitors to diclofenac.293 However, in the MEDAL trial the rate of 
thrombotic cardiovascular events (including a range of endpoints) was similar in the diclofenac 
and the etoricoxib treated group (hazard ratio 0.95; 95%CI: 0.81-1.11).460 This is very similar to 
our results if we would compare to observed association of diclofenac indirectly with the odds 
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Table 3. Risk estimates of AMI for individual NSAIDs from current SOS study, meta-analysis from observational 
studies434 and randomized clinical trials,293 using major vascular events as outcome. 
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highest dose of naproxen as compared to past use of any NSAID and  the median dose for 
naproxen was 2 times the daily recommended dose (1000 mg). However, in the Dutch 
PHARMO databases the risk for naproxen was increased, whereas in the other Dutch database 
(IPCI) and the Italian and UK databases, the confidence levels of the estimate of naproxen 
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use of any NSAID and almost equal to that for rofecoxib, though the confidence limits of these 
risks were overlapping. An increased risk for etoricoxib was also found in the meta-analysis of 
observational studies.434 Although etoricoxib has not been studied extensively in placebo-
controlled trials, effects of etoricoxib, rofecoxib and celecoxib seemed similar in trials 
comparing COX-2 selective inhibitors to diclofenac.293 However, in the MEDAL trial the rate of 
thrombotic cardiovascular events (including a range of endpoints) was similar in the diclofenac 
and the etoricoxib treated group (hazard ratio 0.95; 95%CI: 0.81-1.11).460 This is very similar to 
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ratio of etoricoxib. Our results regarding celecoxib are consistent with the meta-analysis of 
observational studies and show only a small (15%) increase in risk.434  
Dose response analyses showed that AMI risk varied by dose, which means that the 
overall estimates are largely driven by the dose that will be used in a country or given setting. 
Lower doses in general, but not for all drugs, have a lower risk in the databases we could use 
to study this. When comparing the potency of individual NSAIDs in the degree of COX-2 
inhibition by normal therapeutic doses, our results show a small correlation in line with a 
previous study but we could only look at 6 different NSAIDs whereas Garcia Rodriguez 
studied.97 This supports the previously suggested hypothesis that the extent of inhibition of 
COX-2–dependent prostacyclin may represent an independent determinant of the increased 
risk of AMI among NSAIDs with nonfunctional suppression of platelet COX-1, a property shared 
by most NSAIDs.461, 462 
Upon stratification for concurrent use of aspirin, lipid lowering drugs, presence of 
ischemic heart disease, sex, and age several significant interactions were observed, however 
some were incidental findings for single NSAIDs. E.g. the risk for AMI associated with 
diclofenac was higher in females than males. The risk was significantly higher in younger 
persons (<60 years) than older for naproxen, but when current use of all NSAIDs was 
aggregated, this effect modification was significant for the class. The risk of AMI was higher in 
non-users of aspirin than in users of aspirin during current use of any NSAID, however not all 
the databases had adequate information on low dose aspirin. The NSAID associated AMI risk 
was higher in non-users of lipid lowering drugs than in users, in particular for diclofenac.434 We 
did not observe a consistent pattern for the interaction between current use of any NSAID and 
risk of AMI by presence of co-morbid ischemic heart disease, although for most NSAIDs the 
risk of AMI was higher in patients with a history of ischemic heart disease. These findings are 
consistent with previous findings that show that the relative risk of AMI in current users of 
NSAIDs is higher in low-CV risk subjects, than in high-risk subjects, although the absolute risk 
may be higher in high-CV risk patients due to higher background rates. 96, 453 293  
 
Strengths and limitations of study 
 
We acknowledge the following limitations. Since NSAID use was assessed through 
computerized prescriptions/dispensing, we could not capture over-the-counter NSAID use, this 
may lead to non-differential misclassification. Channeling of COX-2 inhibitors to high GI-risk 
patients in the initial marketing phase and the cardiovascular contra-indications after 2004 
may have led to time-varying confounding by indication. However, firstly, we matched on 
calendar time both for the index date as well as cohort entry. Secondly past use of any NSAID 
was used as comparator (so past users had an indication to receive an NSAID), third we 
matched on database. In addition we adjusted for a large range of known risk factors for AMI. 
The matched and adjusted estimates were very similar, indicating that most of the potential 
confounding variables were time, sex and age-related and taken care of by the matching. 
Some residual confounding may remain due to inability to measure these confounders 
 
 
accurately (e.g. smoking), however because of the matching on database this is not likely to 
differ for cases and controls. However, any residual confounding should be really strong to 
explain the observed associations.442, 463 Our primary aim was to compare the risk of AMI 
across individual NSAIDs, taking the different doses across NSAIDs into account and therefore 
used ‘past’ use of any NSAID as common reference group. Though past users may differ from 
current users, using a different reference group, such as a single NSAID as comparator, is less 
appropriate as that particular NSAID may be used in different doses than the compared drugs 
and prescribing differences across countries could result in biased and less stable estimates. 
On the other hand, the use of a common reference group across all countries and DBs does 
allow interpretation of risks across different NSAIDs. Finally, although we applied a random 
effects model thereby providing conservative estimates, we observed heterogeneity for some 
NSAIDs when pooling results across databases. Multiple factors can explain the differences in 
risk estimates for the same individual NSAID across databases, such as regional susceptibility 
to AMI, also in relation to local eating behavior or lifestyle; differential drug utilization and 
differences in health care systems. We used a stepwise approach for inclusion of confounders 
in the model in order to derive a model with robust estimates. Although a model with 
inclusion of all confounders may have been an option, given that some conditions were very 
rare and not including these in the model will only lead to confounding when associations are 
large. Furthermore most confounders were forced into the model based on a priori 
knowledge. 
 
Conclusion and policy implications 
 
In conclusion, this study provides risk estimates for the association between the use of 28 
different NSAIDs and the risk of AMI. This allows for evaluating the variability of AMI risk 
across these NSAIDs in real life practice circumstances. The risk of AMI seems to correlate with 
COX-2 inhibition potency. The extent of the inhibition of COX-2–dependent prostacyclin 
among NSAIDs with nonfunctional suppression of platelet COX-1 is a property shared by most 
NSAIDs. Because the relative risks for AMI are only slightly elevated for most of the individual 
NSAIDs, the population attributable risks percentages are highest for the products with the 
highest prevalence of use across all the studied populations, which are diclofenac and 
ibuprofen in Germany, the Netherlands and the United Kingdom and nimesulide and 
diclofenac in Italy.  
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Supplementary Table 2. NSAIDs included in the SOS project with prevalence of use per 100,000 person-years. 
ATC Substance GePaRD IPCI PHARMO SISR OSSIFF THIN 
M01AA Butylpyrazolidines 
M01AA01 Phenylbutazone 39.9 2.8 3.0 0.04 
M01AA02 Mofebutazone 1.5 
M01AA03  Oxyphenbutazone 
M01AA05  Clofezone 
M01AA06  Kebuzone 
M01AB Acetic acid derivatives and related substances 
M01AB01 Indometacin 218.5 97.2 154.2 134.6 215.0 138.3 
M01AB02 Sulindac 9.1 23.4 1.0 1.3 3.5 
M01AB03 Tolmetin 0.2 1.3 
M01AB04 Zomepirac 
M01AB05 Diclofenac 8,092.4 5,482.9 4,373.6 1,666.9 2,342.2 3,379.8 
M01AB06 Alclofenac 
M01AB07 Bumadizone 
M01AB08 Etodolac 87.0 
M01AB09 Lonazolac 4.9 
M01AB10 Fentiazac 0.3 0.6 
M01AB11 Acemetacin 177.9 0.1 0.5 5.4 
M01AB12 Difenpiramide 
M01AB13 Oxametacin 
M01AB14 Proglumetacin 26.4 5.8 11.0 
M01AB15 Ketorolac 430.9 887.7 0.6 
M01AB16 Aceclofenac 77.7 17.5 43.1 411.9 411.9 12.2 
M01AB17 Bufexamac 
M01AB51 Indometacin, combinations 8.9 
M01AB55 Diclofenac, combinations 194.5 1,085.1 1,094.7 72.3 126.9 359.6 
M01AC  Oxicams 
M01AC01 Piroxicam 300.9 142.8 201.9 853.2 1535.2 78.0 
M01AC02 Tenoxicam 0.5 1.1 54.3 82.6 3.3 
M01AC04 Droxicam 
M01AC05 Lornoxicam 28.3 76.7 84.8 0.004 
M01AC06 Meloxicam 215.3 411.4 570.3 272.2 450.6 285.9 
M01AE Propionic acid derivatives 
M01AE01 Ibuprofen 8,478.5 1,889.1 3,692.5 555.3 575.1 2,957.7 
M01AE02 Naproxen 192.4 1,649.9 2,384.1 184.8 298.5 692.3 
M01AE03 Ketoprofen 42.1 23.9 45.5 1,193.1 1,519.7 23.9 
M01AE04 Fenoprofen 0.9 
M01AE05 Fenbufen 4.4 
M01AE06 Benoxaprofen 
M01AE07 Suprofen 
M01AE08 Pirprofen 
M01AE09 Flurbiprofen 0.042 3.2 7.9 33.9 62.8 22.8 
M01AE10 Indoprofen 
M01AE11 Tiaprofenic acid 12.9 58.1 34.7 2.2 7.1 7.1 
M01AE12 Oxaprozin 0.7 62.7 91.5 
M01AE13 Ibuproxam 
M01AE14 Dexibuprofen 93.5 7.6 29.6 71.1 74.4 4.9 
M01AE15 Flunoxaprofen 
M01AE16 Alminoprofen 
M01AE17 Dexketoprofen 269.8 0.9 2.7 0.019 0.028 14.2 
M01AE18 Naproxcinod 
M01AE51 Ibuprofen, combinations 0.009 10.2 
 
 
Supplementary Table 2. NSAIDs included in the SOS project with prevalence of use per 100,000 person-years 
(continued). 
ATC Substance GePaRD IPCI PHARMO SISR OSSIFF THIN 
M01AE52 Naproxen and esomeprazole 0.1 
M01AE53 Ketoprofen, combinations 0.005 0.009 
M01AG Fenamates 
M01AG01 Mefenamic acid 0.003 1.2 1.0 397.0 
M01AG02 Tolfenamic acid 1.2 1.1 7.0 
M01AG03 Flufenamic acid 
M01AG04 Meclofenamic acid 0.005 
M01AH Selective COX-2 inhibitors 
M01AH01 Celecoxib 241.6 217.8 303.1 501.2 897.4 386.4 
M01AH02 Rofecoxib 0.3 186.0 576.5 311.3 738.3 301.1 
M01AH03 Valdecoxib 83.5 2.8 11.7 27.1 30.1 17.8 
M01AH04 Parecoxib 7.1 0.039 
M01AH05 Etoricoxib 412.9 406.1 284.5 382.6 434.8 155.6 
M01AH06 Lumiracoxib 14.6 3.2 
M01AX Other anti-inflammatory and antirheumatic agents, non-steroids 
M01AX01 Nabumetone 7.1 51.4 148.7 22.8 42.8 31.0 
M01AX02 Niflumic acid 0.01 5.4 
M01AX04 Azapropazone 10.5 15.8 7.6 
M01AX07 Benzydamine 
M01AX13 Proquazone 
M01AX17 Nimesulide 1,540.3 2,042.7 
M01AX18 Feprazone  
M01AX22 Morniflumate 0.1 2.5 
M01AX23 Tenidap 
M01AX68 Feprazone, combinations 
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Supplementary Table 4. Doses considered in the current study in the three databases that captured prescribed 
doses (THIN, IPCI, PHARMO). 
  DDD value PDD/DDD* 
 Current use of: Cases   
 
Controls   
    Median (Q1-Q3) Mean (SD) 
 
Median (Q1-Q3) Mean (SD) 
Diclofenac 100 mg 1.5 (1.0-1.5) 1.3 (0.4) 
 
1.5 (1.0-1.5) 1.3 (0.5) 
Fixed Combination of 
Diclofenac with misoprostol 100 mg 1.5 (1.0-1.5) 1.3 (0.3) 
 
1.2 (1.0-1.5) 1.2 (0.3) 
Ibuprofen 1200 mg 1.0 (1.0-1.0) 1.0 (0.4) 
 
1.0 (1.0-1.0) 1.0 (0.3) 
Naproxen 500 mg 2.0 (1.5-2.0) 1.7 (0.5) 
 
2.0 (1.5-2.0) 1.7 (0.6) 
Meloxicam 15 mg 1.0 (0.5-1.0) 0.8 (0.3) 
 
1.0 (0.5-1.0) 0.8 (0.3) 
Celecoxib 200 mg 1.0 (1.0-1.0) 1.1 (0.5) 
 
1.0 (1.0-1.0) 1.1 (0.4) 
Rofecoxib 25 mg 1.0 (0.5-1.0) 0.9 (0.3) 
 
1.0 (0.5-1.0) 0.9 (0.3) 
Etoricoxib 60 mg 1.5 (1.0-1.5) 1.3 (0.5) 
 
1.5 (1.0-1.5) 1.3 (0.5) 
 
PDD, prescribed daily dose; DDD, defined daily dose.  
* PDD/DDD: the ratio of the prescribed daily dose with the defined daily dose as defined by the WHO.   
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Supplementary Table 4. Doses considered in the current study in the three databases that captured prescribed 
doses (THIN, IPCI, PHARMO). 
  DDD value PDD/DDD* 
 Current use of: Cases   
 
Controls   
    Median (Q1-Q3) Mean (SD) 
 
Median (Q1-Q3) Mean (SD) 
Diclofenac 100 mg 1.5 (1.0-1.5) 1.3 (0.4) 
 
1.5 (1.0-1.5) 1.3 (0.5) 
Fixed Combination of 
Diclofenac with misoprostol 100 mg 1.5 (1.0-1.5) 1.3 (0.3) 
 
1.2 (1.0-1.5) 1.2 (0.3) 
Ibuprofen 1200 mg 1.0 (1.0-1.0) 1.0 (0.4) 
 
1.0 (1.0-1.0) 1.0 (0.3) 
Naproxen 500 mg 2.0 (1.5-2.0) 1.7 (0.5) 
 
2.0 (1.5-2.0) 1.7 (0.6) 
Meloxicam 15 mg 1.0 (0.5-1.0) 0.8 (0.3) 
 
1.0 (0.5-1.0) 0.8 (0.3) 
Celecoxib 200 mg 1.0 (1.0-1.0) 1.1 (0.5) 
 
1.0 (1.0-1.0) 1.1 (0.4) 
Rofecoxib 25 mg 1.0 (0.5-1.0) 0.9 (0.3) 
 
1.0 (0.5-1.0) 0.9 (0.3) 
Etoricoxib 60 mg 1.5 (1.0-1.5) 1.3 (0.5) 
 
1.5 (1.0-1.5) 1.3 (0.5) 
 
PDD, prescribed daily dose; DDD, defined daily dose.  
* PDD/DDD: the ratio of the prescribed daily dose with the defined daily dose as defined by the WHO.   
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Supplementary Figure 1. Flowchart of source population and study population per database 
 
* In IPCI cancer subjects have been excluded from the incident NSAID users cohort in order to do case validation of outcomes, 
therefore numbers in the flowchart at the level of ‘Incident NSAID users’ and ‘Cancer free at NSAID cohort entry’ for IPCI are 
similar. 
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Supplementary Figure 2. Relation between degree of inhibition of whole blood COX-2 461 and risk of AMI for 
individual NSAIDs in the three databases that included doses (THIN, IPCI, PHARMO). 
 
* the OR for dose 0.8-1.2 pdd/ddd was chosen for plotting in this figure.  
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Supplementary Figure 3. Dose response estimated by fractional polynomial regression for diclofenac 
Supplementary Figure 3A shows the estimated dose-response curves for current use of diclofenac.  
The dose-response relationship is modeled through restricted cubic splines, implemented in a conditional logistic regression 
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ranges of the dose, restricted cubic splines were considered. Restricted cubic splines have a linear trend outside the most extreme 
knots. In the present analysis three knots were considered corresponding to 0 DDD, 0.8 DDDs and 1.2 DDDs. This choice of knots 
allows to represent a dose-response relationship potentially non-linear in the dose range from 0 DDD to 1.2 DDD, and assumed to 
be linear for doses over 1.2 DDDs  
The bold blue line represents the polynomial curve with 1st degree term with corresponding 95% confidence intervals, the bold 
red line represents polynomial curve with 2nd degree term with corresponding 95% confidence intervals. 
Dose on the x-asis represents the dose as was estimated from the prescribing regimen and strength. The dose is calculated by 
dividing the prescribed dose by the recommended daily dose (DDD).  
 
 
 
 
Supplementary Figure 4. Adjusted risk estimates of AMI in current users of individual NSAIDs for duration of use 
in three databases pooled (THIN, IPCI, PHARMO) using short duration (7-29 days) as reference group. 
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ABSTRACT 
 
BACKGROUND 
Use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of upper 
gastrointestinal (GI) complications and cardiovascular (CV) events. However, the risk may 
differ between individual NSAIDs and subjects. Decision models for selecting the safest NSAID 
to treat individual patients are not available. 
 
AIM 
To develop a decision model integrating GI and CV risks. 
 
METHODS 
The decision model integrated information from 1) case-control studies risks of individual 
NSAIDs on GI and CV events [acute myocardial infarction (AMI), ischemic stroke (IS), heart 
failure (HF)]; 2) a risk function for patient characteristics associated with GI and CV events; 3) 
disutility weights for each outcome. Data were retrieved from six European healthcare data 
sources: IPCI, PHARMO (NL); SISR, OSSIFF (Italy); GePaRD (Germany) and THIN (UK) during 
1999-2011. For thirteen individual NSAID we provided an overall risk from the decision model. 
 
RESULTS 
In the case-control studies 15,046 upper GI complication; 95,163 HF; 79,553 AMI and 35,691 IS 
cases were identified among 8.9 million new NSAID users. The lowest risks were seen for use 
of celecoxib for upper GI complication (OR=1.1) and for HF (OR=1.0), for IS for ketoprofen 
(OR=0.9) and for AMI for tenoxicam and aceclofenac (OR=1.0). For all outcomes ketorolac 
yielded the highest risks. In the risk function and for each outcome, age was the most 
important predictor, followed by history of the outcome and sex. In the final decision model, 
over different scenarios, most preferable NSAIDs were aceclofenac and celecoxib, thereafter 
nimesulide and ibuprofen. Piroxicam and ketorolac were the least preferable NSAIDs. 
 
CONCLUSION 
We provided an integrated GI and CV safety decision model for new NSAID users, which may 
guide physicians in clinical decision making. 
  
 
 
INTRODUCTION 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used painkillers with 
antipyretic, anti-inflammatory and pain relieving properties and are considered relatively 
harmless drugs. However, since long time it is known that their use is restricted by the 
occurrence of upper gastrointestinal (GI) complications such as peptic ulcer perforations, 
obstructions, and bleeding.325 In order to reduce the upper GI complication risk associated 
with NSAID use, selective cyclo-oxygenase (COX)-2 inhibitors were developed. By preferentially 
inhibiting COX-2, and to a lesser extent the house-keeper isoform COX-1, selective COX-2 
inhibitors are effective pain relievers while having a lower risk of upper GI complication 
compared with the traditional, nonselective (ns)NSAIDs.10, 11, 464 Yet, this preferable benefit of 
COX-2 inhibitors over the traditional NSAIDs was abolished by the risk increase of serious 
cardiovascular (CV) events following clinical trials.11, 89, 95 This led to the recommendation from 
the United States (US) Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) to avoid selective COX-2 inhibitors in patients with ischemic heart disease, 
stroke or peripheral arterial disease.89, 94, 95, 465 However, subsequent signals regarding the 
increased arterial thrombosis risk for use of the traditional nsNSAIDs arose,293 particularly 
when they were used at high doses and for long-term therapy leading to restriction of 
diclofenac use in 2013.451 
The integration of this information for clinicians is difficult as the risk of an NSAID-
related adverse event may be different between individuals and dependent on underlying co-
morbid conditions and indications of use. For instance, the GI and CV risk profile of subjects 
influence the risk of NSAID-related adverse events which in turn may influence the choice for 
NSAID prescription to either a nsNSAID or a selective COX-2 inhibitor. Besides, we currently 
know that the risk of GI and CV events differs for each individual NSAID and should not be 
considered class-specific (eg. nsNSAIDs and selective COX-2 inhibitors). A decision model is an 
intuitive tool to visualize the sequences of events that can occur following decisions, taking the 
negative impact of health outcomes into account. Previous decision analytic studies have 
reported on a difference in risk for single outcomes,466 provided cost-effectiveness analyses,467 
reported population risk estimates rather than the risk for an individual patient, or did not 
differentiate between individual types of NSAIDs.468, 469 However, in clinical practice it is more 
informative to know which individual NSAID yields the lowest upper GI and CV risk for an 
individual patient. The SOS (Safety of Non-steroidal Anti-inflammatory Drugs) project was 
initiated as a project funded by the European Commission to address issues on CV and UGI 
risks for the EMA. The aim of the current study was to provide a decision analytic model for 
each individual NSAID compound balancing the upper GI and CV safety for individual patients.  
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NSAID Cohort 
 
In each database, we identified a cohort of patients aged 18 years or older who received at 
least one NSAID prescription (see Supplementary Table 2 Chapter 6.1) during the database-
specific study period which started at the first of January 1999 or later, depending on data 
availability (see Supplementary Table 1 Chapter 6.1).  
Cohort entry was defined as the date of first NSAID prescription/dispensing during 
the study period. Subjects receiving any NSAID prescription in the year prior to cohort entry 
were excluded in order to construct a new user cohort to avoid potential biases derived from 
the inclusion of prevalent users.470 Patients were required to have at least one year of 
continuous database history. All subjects with a cancer diagnosis (except non-melanoma skin 
cancer) in the year preceding cohort entry were excluded from the cohort. All NSAID cohort 
members were followed from the date of cohort entry until the date of outcome (see below), 
exclusion criteria, death, last data supply, transferring out of the database, or end of the 
database-specific study period, whichever was earliest. 
 
Definition of Outcomes and related risk factors 
 
Events of interest included upper GI complication, acute myocardial infarction (AMI), ischemic 
stroke (IS) and heart failure (HF). More detailed information is given in Supplementary Table 3. 
The choice of risk factors was made based on literature review, consortium agreement and on 
importance of the risk factors and ease and availability in clinical practice. In order to keep the 
model as simple as possible but still including the most relevant risk factors, age, sex and a 
prior history of the outcome were included. 
 
Decision model development 
 
The decision model was developed following the process depicted in Figure 1. The model was 
derived from 1) risk estimates for individual NSAIDs for each of the four outcomes; 2) absolute 
risk of outcomes based on risk factors; and 3) impact of the event on the health of the 
individual, presented as disutility. The decision model integrated all these results to provide 
one overall absolute risk yielding the relative safety for each individual NSAID for a specific 
patient with certain characteristics. 
 
1. Risk estimates from case-control studies 
 
Four matched case-control studies nested within a new NSAID user cohort were conducted 
within each database. For each outcome (upper GI complication, AMI, IS and HF) the odds 
ratios and corresponding 95% confidence intervals (CI) during individual NSAID exposure were 
obtained by conditional logistic regression models, adjusting for selected confounders. These 
confounders were classified into two sets: 1) a priori confounders that were always considered 
METHODS 
 
Data sources 
 
Data for this study was obtained from six different longitudinal population-based health care 
databases from four European countries [Germany (GE), Italy (IT), Netherlands (NL) and United 
Kingdom (UK)] covering a source population of around 32 million subjects. All databases have 
been used for pharmacoepidemiological research (see Supplementary Table 1 Chapter 6.1).237, 
238, 435, 436  
In short, the German Pharmacoepidemiological Research Database (GePaRD) is a 
database comprising data from five statutory health insurances throughout Germany that is 
created and maintained by BIPS. It currently covers around 14 million insurants and represents 
approximately 20% of the German population.436 The Health Improvement Network (THIN) 
database is a general practice database in the UK and currently captures medical records of 
11.1 million patients.237 The Integrated Primary Care Information (IPCI) database is also a 
general practice database but from the Netherlands and currently covers over 1.5 million 
people,238 PHARMO database is a medical record linkage system of 2.2 million community-
dwelling inhabitants in the Netherlands.435 OSSIFF (Osservatorio Interaziendale per la 
Farmacoepidemiologia e la Farmacoeconomia) is a database capturing national health service 
data and clinical registries from several local health agencies in Lombardy) for a population of 
about 2.9 million people. The second Italian database SISR (Sistema Informativo Sanitario 
Regionale) obtains national health service data from the Lombardy region, with about nine 
million inhabitants (approximately 16% of the national population). OSSIFF was included in 
addition to the Lombardy SISR as it allows for validation of outcomes; overlapping patients 
were excluded from the Lombardy SISR. 
All general practice and claims databases contain information on demographics of 
the population, diagnoses (in- and/or outpatient), and drug prescriptions/dispensings. The 
diagnoses captured by the databases are coded with four different disease coding systems 
including the International Classification of Diseases (ICD) 9th or 10th revision,323 International 
Classification for Primary Care (ICPC),240 or READ.438 Mapping of concepts and codes was 
performed using the Unified Medical Language System (UMLS), a biomedical terminology 
integration system handling more than 150 medical dictionaries, according to a previously 
described workflow.439, 440 All drugs were mapped to the World Health Organization’s (WHO) 
classification of Anatomical Therapeutic Chemical (ATC).242 A distributed approach was used 
for collaboration: all database custodians extracted data locally; original data were 
transformed into a simple common data model (Jerboa© input files); mapping of codes for 
outcome and covariates was verified using an extensive harmonization strategy; and a 
common standardized script (Jerboa©, Java-based)346 was supplied to create the aggregated 
tables that were subsequently encrypted and shared on a central data warehouse for further 
analysis and pooling. Details have been described previously.346, 380 
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tables that were subsequently encrypted and shared on a central data warehouse for further 
analysis and pooling. Details have been described previously.346, 380 
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in the model; and 2) a set of confounders that underwent a backward selection. A random 
effects meta-analytic approach was applied to obtain an overall pooled estimate for each 
individual NSAID per outcome. The risk estimates for each NSAID are shown in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Work flow for development of the decision model. 
 
Table 1. Odds Ratio estimates from random effects meta-analysis model on individual NSAIDs from the SOS case 
control studies (current use vs. past use of any NSAID). 
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Available in 
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model 
Past use of any NSAID 1 (ref) 1 (ref) 1 (ref) 1 (ref)  
Current use of:           
Aceclofenac 1.20 0.97 1.04 1.24 Yes 
Celecoxib 1.16 0.96 1.15 1.02 Yes 
Diclofenac 3.26 1.21 1.31 1.30 Yes 
Diclofenac, combi 2.15 1.02 1.27   No 
Etoricoxib 3.26 1.67 1.28 1.11 Yes 
Flurbiprofen 3.69   1.05   
Ibuprofen 1.53 1.24 1.24 1.16 Yes 
Indometacin 3.00 1.55 1.47 1.18 Yes 
Ketoprofen 2.83 1.04 1.12 0.93 Yes 
Ketorolac 6.53 1.85 2.06 1.46 Yes 
Lornoxicam 4.06   1.08   No 
Meloxicam 3.17 1.04 1.18 0.99 Yes 
Nabumetone   1.48 1.03   No 
Naproxen 2.96 1.18 1.19 1.06 Yes 
Nimesulide 1.21 1.19 1.16 1.14 Yes 
Oxaprozin 6.07   0.93   No 
Piroxicam 4.16 1.28 1.17 1.13 Yes 
Rofecoxib 2.12 1.36 1.26 1.18 Yes 
Tenoxicam 2.88   1.02   No 
Valdecoxib     1.00   No 
Nr of studied NSAIDs 18 15 20 13 13 
 
 
2. Risk estimates from prediction models 
 
A risk function was built to investigate the effect of patient characteristics such as age, sex, 
medical history of an outcome, country of origin and follow-up period on the risk of each 
outcomes using a Poisson regression model. Age was categorized in 10 year groups (18-29; 30-
39; 40-49; 50-59; 60-69; 70-79 and ≥80 years) using age group 40-49 years as reference group. 
We fitted models in each of the six databases and pooled the regression coefficients by a 
random effects model in order to account for clustering of patients within databases and to 
obtain an overall estimate for each characteristic. The model intercepts were adjusted per 
database for the pooled regression coefficients.  
 
3. Utilities of health states 
 
Utilities are cardinal values between 0 (death) and 1 (perfect health). A value representing the 
impact of the outcome on the quality of life (utility) was derived from literature.471 The 
disutility (i.e., 1-utility) is the negative impact of the occurrence of the event on the patient’s 
quality of life. By using disutilities, the probabilities (i.e., the risk based on risk functions) of 
developing an outcome can be compared between individual NSAIDs. We considered utilities 
of outcomes in two periods: at 4 weeks (for an acute effect) and at 1 year (for a chronic effect) 
(Table 2). It shows that experiencing IS provides the largest disutility both on the short term 
and long term. This means that NSAIDs associated with a higher risk of IS (given all other risks 
remain the same) will be preferred less. 
 
Table 2. Disutilities used to assess the impact of the occurrence of the outcome on the quality of life*. 
 
 Outcome 
Time Horizon Upper 
Gastrointestinal 
Complication 
 Heart Failure  Acute 
Myocardial 
Infarction 
 Ischemic 
Stroke 
Acute effect  0.54  0.29  0.63  0.65 
Chronic effect  0.02  0.00  0.12  0.29 
 
* Derived from Latimer et al.471. Acute effect at 4 weeks, chronic effect at 1 year. 
 
Integration of results 
 
To arrive from the cumulative risk estimates to NSAID associated absolute risk, the risk needs 
to be integrated with the relative risk associated with the NSAID. The risk functions provided 
the absolute risk of an outcome given a certain follow-up period. In order to calculate the 
NSAID related absolute risk the relative risk estimates from the case-control studies should be 
included as well. Thus the final decision model required information from the risk function, 
utilities and the estimates from the case-control studies. In order to combine this information 
for the calculation of the absolute risks, the baseline risk in each database was adjusted for the 
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proportion of follow-up time that consisted of the duration of NSAID exposure. In this way, the 
original database specific intercepts were independent of the overall effect of NSAIDs. Finally 
the estimates from the case-control analyses for each individual NSAID were incorporated to 
the model. By applying the disutilities the final cumulative risks were obtained. 
 
Model performance 
 
Model performance of the prediction models was assessed through calibration and 
discrimination. Calibration provides information on whether the predictions agree with the 
actual observations. It was evaluated by the slope of the linear predictor of the regression 
model used to compare the observed and predicted outcomes. Ideally the calibration slope is 
equal to 1. The calibration slope was calculated through a Poisson regression model for the 
outcome and the linear predictors as only covariable.472 The linear predictor was calculated as 
summing up the products of the regression coefficients of the model and the predictor values. 
Discrimination is the ability to distinguish between patient with and without the event. 
Discrimination was assessed by concordance (c) statistic. The c-statistic ranges from 0.5 (no 
discriminative ability; no better than flipping a coin) to 1.0 (model perfectly discriminates 
between those patients who will develop an event and who not).  
 
Validation 
 
The performance of prediction models in new patients is often worse than expected based on 
performance estimated from the development data. This optimism and overfitting was 
diminished by applying an internal validation technique as cross-validation. Six-fold cross 
validation was done by creating a model and quantifying the model performance (calibration 
and discrimination) six times while omitting one database each time from the development 
process and using as validation cohort.  
 
Subgroup analyses 
We performed subgroup analyses by considering the use of PPIs and low-dose aspirin as an 
effect modifier for the NSAID effect on the outcomes (for PPI on upper GI complication and for 
low-dose aspirin on upper GI complication and AMI). 
 
RESULTS 
 
Study Population 
 
The study population included 8.9 million new NSAID users, of which the majority was female 
(55%-57%) in the Netherlands, Italy and the United Kingdom, except for Germany in which 
49% was female (Table 3). Mean age in the cohort of incident NSAID users was between 46 
and 49 years in the Netherlands, Germany and the United Kingdom, but was higher in Italy (55 
to 57 years). The mean time spent in the NSAID cohort was shortest in IPCI with 2 years and 
longest in the Italian database OSSIFF with 4.1 years. 
Upper GI complications had the lowest incidence (between 3.4-9.7) per 10,000 
person-years (PYs), with a total of 23,411 events occurring after a median of 1.1 years (IPCI) up 
to 2 years (OSSIFF and TIN) after start of NSAID therapy (Table 3). There were 79,876 events of 
heart failure resulting in incidence rates between 14 and 40 events per 10,000 PYs with the 
highest incidence in Italy. We observed 68,757 AMI events, yielding incidence rates between 
16 and 30 events per 10,000 PYs and we captured 35,691 IS with incidences ranging between 
6.5 (THIN) and 18.5 (GePaRD) per 10,000 PYs. 
 
Risk estimates from case-control studies 
 
Over all databases, 15,046 upper GI complication; 95,163 HF; 79,553 AMI and 35,691 IS cases 
were included in the case-control studies. For thirteen individual NSAIDs a risk estimate was 
available for all four outcomes. Ketorolac had the highest risk estimate for all outcomes (Table 
1). For other NSAIDs, ranking differed across the outcomes. Risk estimates were highest for 
the outcome upper GI complications. 
 
Risk estimates from prediction models 
 
The incidence rate ratios derived from the prediction models are shown in Table 4. For all 
outcomes increasing age, male sex, a history of the event were predictors of the outcome. A 
longer follow-up was inversely associated with the outcome. Cumulative risk could be 
calculated for each of the outcomes based on the integration of the prediction models and 
NSAID specific risk estimates. The cumulative risk varied by age, sex, a prior history of the 
event and time horizon. In Figure 2 the cumulative risks of each of the outcomes at 1 year for a 
male subject with and without a prior history of the event are shown. 
 
Figure 2. Cumulative 1 year risk of outcomes in male patients with and without a prior history of the outcome by 
age and by database. 
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Figure 2. Cumulative 1 year risk of outcomes in male patients with and without a prior history of the outcome by 
age and by database. 
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Figure 2. Cumulative 1 year risk of outcomes in male patients with and without a prior history of the outcome by 
age and by database. 
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Table 4. Multivariable rate ratios of risk factors for the outcome after pooling the estimates across databases by 
a random effects meta-analysis. 
 
Upper GI Compl Heart Failure AMI Ischemic Stroke 
IRR (95%CI) IRR (95%CI) IRR (95%CI) IRR (95%CI) 
Age (years):    
 40-49  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 18-29  0.38 (0.3-0.5) 0.10 (0.08-0.13) 0.04 (0.03-0.05) 0.18 (0.14-0.23) 
 30-39  0.60 (0.5-0.7) 0.32 (0.29-0.36) 0.24 (0.23-0.26) 0.39 (0.33-0.45) 
 50-59  1.80 (1.6-2.0) 3.33 (2.97-3.72) 2.04 (1.94-2.15) 2.60 (2.45-2.76) 
 60-69  3.13 (2.6-3.8) 9.94 (9.42-10.49) 3.24 (3.09-3.41) 6.14 (5.81-6.49) 
 70-79  5.71 (4.2-7.8) 30.65 (28.10-33.46) 5.46 (5.04-5.91) 14.07 (12.58-15.73) 
 > 80  10.9 0(6.9-17) 74.13 (70.27-78.21) 8.91 (7.35-10.81) 25.25 (20.49-31.11) 
Sex:    
 Male  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 Female  0.63 (0.5-0.8) 0.65 (0.64-0.66) 0.42 (0.39-0.44) 0.64 (0.59-0.70) 
History of 
Outcome*:     
 No  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 Yes 2.43 (1.9-3.1) 2.59 (1.84-3.64) 1.74 (1.11-2.73) 2.23 (1.70-2.92) 
Follow-up 
time:      
 0-2 weeks  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 2-4 weeks  0.69 (0.6-0.8) 0.79 (0.69-0.90) 0.78 (0.65-0.94) 0.83 (0.73-0.93) 
 4 weeks-1 year  0.32 (0.2-0.5) 0.57 (0.50-0.65) 0.64 (0.56-0.72) 0.72 (0.64-0.81) 
 1-2 years  0.29 (0.2-0.4) 0.59 (0.53-0.66) 0.66 (0.58-0.75) 0.74 (0.68-0.82) 
 2-5 years  0.30 (0.2-0.4) 0.67 (0.64-0.71) 0.71 (0.63-0.81) 0.85 (0.78-0.92) 
Databases:    
 SISR  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 GePaRD  1.98 (1.9-2.1) 1.08 (1.05-1.10) 0.90 (0.88-0.92) 2.14 (2.08-2.19) 
 THIN  1.86 (1.8-1.9) 0.83 (0.81-0.85) 0.74 (0.72-0.76) 0.70 (0.67-0.72) 
 IPCI  1.08 (1.0-1.2) 0.04 (0.03-0.06) 1.22 (1.14-1.30) 0.10 (0.07-0.14) 
 PHARMO  0.78 (0.7-0.8) 0.73 (0.72-0.76) 1.05 (1.02-1.07) 0.03 (0.02-0.04) 
 OSSIFF  1.19 (1.1-1.2) 1.03 (1.01-1.05) 1.10 (1.08-1.12) 1.14 (1.11-1.18) 
 
Cross validation 
 
The performance of the prediction models showed a fairly good c-statistic for each of the 
outcomes in each database by means of cross validation (Supplementary Table 4). Only for 
upper GI complication when the model was created in SISR, OSSIFF, PHARMO, THIN and 
GePaRD and subsequently tested in IPCI, the predictive ability for upper GI complication was 
lower than in the other databases. 
The calibration slopes were in general close to 1, except for upper GI complication 
(IPCI and THIN <1 representing optimism), AMI (IPCI) and IS (PHARMO). 
 
Decision Model  
 
By integration of the cumulative risks with the disutilities we could compare the different 
NSAIDs over a number of scenarios (Table 5). For thirteen NSAIDs we had a risk estimate for all 
four outcomes and these NSAIDs were included in the decision model. In general, celecoxib 
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 4 weeks-1 year  0.32 (0.2-0.5) 0.57 (0.50-0.65) 0.64 (0.56-0.72) 0.72 (0.64-0.81) 
 1-2 years  0.29 (0.2-0.4) 0.59 (0.53-0.66) 0.66 (0.58-0.75) 0.74 (0.68-0.82) 
 2-5 years  0.30 (0.2-0.4) 0.67 (0.64-0.71) 0.71 (0.63-0.81) 0.85 (0.78-0.92) 
Databases:    
 SISR  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 GePaRD  1.98 (1.9-2.1) 1.08 (1.05-1.10) 0.90 (0.88-0.92) 2.14 (2.08-2.19) 
 THIN  1.86 (1.8-1.9) 0.83 (0.81-0.85) 0.74 (0.72-0.76) 0.70 (0.67-0.72) 
 IPCI  1.08 (1.0-1.2) 0.04 (0.03-0.06) 1.22 (1.14-1.30) 0.10 (0.07-0.14) 
 PHARMO  0.78 (0.7-0.8) 0.73 (0.72-0.76) 1.05 (1.02-1.07) 0.03 (0.02-0.04) 
 OSSIFF  1.19 (1.1-1.2) 1.03 (1.01-1.05) 1.10 (1.08-1.12) 1.14 (1.11-1.18) 
 
Cross validation 
 
The performance of the prediction models showed a fairly good c-statistic for each of the 
outcomes in each database by means of cross validation (Supplementary Table 4). Only for 
upper GI complication when the model was created in SISR, OSSIFF, PHARMO, THIN and 
GePaRD and subsequently tested in IPCI, the predictive ability for upper GI complication was 
lower than in the other databases. 
The calibration slopes were in general close to 1, except for upper GI complication 
(IPCI and THIN <1 representing optimism), AMI (IPCI) and IS (PHARMO). 
 
Decision Model  
 
By integration of the cumulative risks with the disutilities we could compare the different 
NSAIDs over a number of scenarios (Table 5). For thirteen NSAIDs we had a risk estimate for all 
four outcomes and these NSAIDs were included in the decision model. In general, celecoxib 
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was first or second preferred NSAID over all different scenarios. Thereafter, ketoprofen and 
aceclofenac were often first or second preferred choices, particularly when a prior history of 
events was present, though they also ranked up to 6th option. Naproxen was between 5th to 7th 
option, rofecoxib between 5th and 9th option, while diclofenac ranked from 9th option to 11th 
option. Ketorolac and etoricoxib ranked lowest and were least preferable NSAIDs. However 
based on the absolute risks, for some scenarios all NSAIDs may provide a similar absolute risk 
and thus more NSAIDs may be considered appropriate than the first or second highest ranked 
NSAID (Supplementary Table 5). For instance, in scenario 7; a male aged between 18 and 29 in 
the UK without any history of the outcomes, the absolute risks ranged between 0.000016% for 
celecoxib (safest) and 0.000038% for etoricoxib (most harmful) which is a doubling in risk, but 
the absolute difference is still small. 
 
Subgroup analyses 
 
When considering the use of PPIs as effect modifier for upper GI complications (e.g. those 
using an NSAID concurrently with a PPI have a lower risk of upper GI complications than those 
only using an NSAID) still celecoxib, ketoprofen and aceclofenac were most preferred NSAIDs 
and ketorolac and etoricoxib least preferred NSAIDs (data not shown). Low-dose aspirin affects 
the risk of cardiovascular events and upper GI complications, therefore when LDA is used 
concomitantly with an NSAID again ketoprofen and celecoxib were considered relatively 
safest. Meloxicam also was relatively safe. Ketorolac, indometacin and diclofenac were 
considered most harmful (data not shown). 
 
Table 5. Decision model outcome: example of the result of the decision model; the NSAID which is considered 
the safest with respect to upper gastrointestinal complication, heart failure, acute myocardial infarction, and 
ischemic stroke is ranked highest. Effectiveness in pain relief is assumed similar between NSAIDs. 
 
 Scenario 1 2 3 4 5 
 DB United Kingdom United Kingdom United Kingdom United Kingdom United Kingdom 
 Sex Female Male Female Male Female 
 Age 50-60 50-60 60-70 60-70 18-30 
 UGIC No No No No No 
 AMI No No No No No 
 HF No No No No No 
 IS No No No No No 
 Time period 4 weeks 4 weeks 4 weeks 4 weeks 4 weeks 
Safest 1 Celecoxib Ketoprofen Ketoprofen Aceclofenac Celecoxib 
 2 Ketoprofen Celecoxib Celecoxib Celecoxib Aceclofenac 
 3 Aceclofenac Aceclofenac Meloxicam Nimesulide Nimesulide 
 4 Nimesulide Nimesulide Nimesulide Ibuprofen Ibuprofen 
 5 Meloxicam Meloxicam Aceclofenac Rofecoxib Rofecoxib 
 6 Naproxen Naproxen Naproxen Ketoprofen Ketoprofen 
 7 Ibuprofen Ibuprofen Ibuprofen Naproxen Naproxen 
 8 Rofecoxib Piroxicam Rofecoxib Meloxicam Indometacin 
 9 Piroxicam Rofecoxib Piroxicam Indometacin Meloxicam 
 10 Diclofenac Diclofenac Indometacin Diclofenac Diclofenac 
 11 Indometacin Indometacin Diclofenac Piroxicam Etoricoxib 
Most 12 Ketorolac Etoricoxib Ketorolac Etoricoxib Piroxicam 
harmful 13 Etoricoxib Ketorolac Etoricoxib Ketorolac Ketorolac 
 
 
 
Table 5. Decision model outcome: example of the result of the decision model; the NSAID which is considered 
the safest with respect to upper gastrointestinal complication, heart failure, acute myocardial infarction, and 
ischemic stroke is ranked highest. Effectiveness in pain relief is assumed similar between NSAIDs (continued). 
 
 Scenario 6 7 8 9 10 
 DB United Kingdom United Kingdom United Kingdom Italy (SISR) Italy (SISR) 
 Sex Female Male Male Female Male 
 Age 80+ 18-30 80+ 50-60 50-60 
 UGIC No No No No No 
 AMI No No No No No 
 HF No No No No No 
 IS No No No No No 
 Time period 4 weeks 4 weeks 4 weeks 4 weeks 4 weeks 
Safest 1 Ketoprofen Celecoxib Ketoprofen Ketoprofen Ketoprofen 
 2 Celecoxib Nimesulide Celecoxib Celecoxib Celecoxib 
 3 Meloxicam Aceclofenac Meloxicam Meloxicam Aceclofenac 
 4 Nimesulide Ibuprofen Nimesulide Aceclofenac Meloxicam 
 5 Naproxen Ketoprofen Aceclofenac Nimesulide Nimesulide 
 6 Aceclofenac Rofecoxib Naproxen Naproxen Naproxen 
 7 Ibuprofen Meloxicam Ibuprofen Piroxicam Piroxicam 
 8 Rofecoxib Naproxen Piroxicam Ibuprofen Ibuprofen 
 9 Piroxicam Indometacin Rofecoxib Rofecoxib Rofecoxib 
 10 Indometacin Piroxicam Indometacin Diclofenac Diclofenac 
 11 Diclofenac Diclofenac Diclofenac Indometacin Indometacin 
Most 12 Ketorolac Ketorolac Ketorolac Ketorolac Ketorolac 
harmful 13 Etoricoxib Etoricoxib Etoricoxib Etoricoxib Etoricoxib 
 Scenario 11 12 13 14 15 
 DB United Kingdom United Kingdom United Kingdom United Kingdom NL (IPCI) 
 Sex Female Female Female Female Female 
 Age 50-60 50-60 50-60 50-60 50-60 
 UGIC No Yes Yes No No 
 AMI No Yes Yes No No 
 HF No Yes Yes No No 
 IS No Yes Yes No No 
 Time period 1 year 1 year 4 weeks 5 years 4 weeks 
Safest 1 Ketoprofen Celecoxib Celecoxib Aceclofenac Aceclofenac 
 2 Celecoxib Ketoprofen Ketoprofen Celecoxib Celecoxib 
 3 Aceclofenac Aceclofenac Aceclofenac Nimesulide Nimesulide 
 4 Nimesulide Nimesulide Nimesulide Ibuprofen Ibuprofen 
 5 Meloxicam Meloxicam Meloxicam Rofecoxib Rofecoxib 
 6 Naproxen Naproxen Naproxen Ketoprofen Ketoprofen 
 7 Ibuprofen Ibuprofen Ibuprofen Naproxen Naproxen 
 8 Piroxicam Rofecoxib Rofecoxib Meloxicam Meloxicam 
 9 Rofecoxib Piroxicam Piroxicam Indometacin Diclofenac 
 10 Diclofenac Diclofenac Indometacin Diclofenac Etoricoxib 
 11 Indometacin Indometacin Diclofenac Piroxicam Piroxicam 
Most 12 Ketorolac Ketorolac Ketorolac Etoricoxib Indometacin 
harmful 13 Etoricoxib Etoricoxib Etoricoxib Ketorolac Ketorolac 
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was first or second preferred NSAID over all different scenarios. Thereafter, ketoprofen and 
aceclofenac were often first or second preferred choices, particularly when a prior history of 
events was present, though they also ranked up to 6th option. Naproxen was between 5th to 7th 
option, rofecoxib between 5th and 9th option, while diclofenac ranked from 9th option to 11th 
option. Ketorolac and etoricoxib ranked lowest and were least preferable NSAIDs. However 
based on the absolute risks, for some scenarios all NSAIDs may provide a similar absolute risk 
and thus more NSAIDs may be considered appropriate than the first or second highest ranked 
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DISCUSSION 
 
In the current study we provided an integrated decision model for new NSAID users on upper 
gastrointestinal and cardiovascular outcomes as we took advantage of the heterogeneity of 
NSAID exposure across European countries and of the sample size. Individualized predictions 
of NSAID treatment effects did not differ largely on patient characteristics as age, sex, country 
or comorbid diseases. Over a range of scenarios least harmful NSAIDs included celecoxib and 
ketoprofen, while ketorolac and etoricoxib were preferred less. 
In recent years we have learned that the cardiovascular safety of NSAIDs was not a 
sole feature attributed to selective COX-2 inhibitors but as well to the nonselective NSAIDs.96, 
97, 293, 434, 446-449, 473, 474 Particularly for diclofenac evidence - for observational studies derived 
from the SOS-project - of an increased risk of AMI has accumulated in past years.293, 434 This 
resulted in the European regulatory agency EMA to restrict the use of diclofenac.475 However, 
the benefit-risk balance of NSAIDs includes besides cardiovascular outcomes also the upper 
gastrointestinal tract. Selective COX-2 inhibitors were developed as safer NSAIDs than the 
traditional ones and have been proven to be less harmful in clinical trials with respect to the 
upper gastrointestinal tract.10, 11 The dilemma about cardiovascular and gastrointestinal risks 
of different NSAIDs is however what a physician in routine clinical care needs to deal with. 
Individualized predictions of NSAID treatment effects therefore, provide an opportunity to 
determine what the implications of NSAID treatment decisions would be on an individual level. 
Making treatment decisions on the basis of a predicted treatment effect for individual patients 
may in some situations result in more net benefit on a group level than treating all patients.  
There are only a few studies available integrating CV and GI risks for NSAIDs. In line 
with a simulation study comparing the additional number of GI and CV events that would 
occur for use of diclofenac, ibuprofen and naproxen compared to use of celecoxib,476 also 
celecoxib appeared to have the least harmful profile. However, this study relied on a simulated 
population and information on relative risks of individual NSAIDs on coronary heart disease, 
congestive heart failure and peptic ulcer complications was retrieved from the literature.476 
Another simulation study showed that the harm-benefit ratio of selective COX-2 inhibitors on 
the incidence of upper GI events may be offset by an increase in AMI events, when assuming 
drug effects from trials or the CPRD population.468 In contrast to both studies, we were able to 
estimate both the individual NSAID effects in a new user NSAID cohort and the risk factors for 
the outcomes in the same underlying cohort. A decision analysis comparing only rofecoxib 
with naproxen, as a typical participant of the VIGOR trial that resulted in the rofecoxib scandal, 
incorporated AMI risk and upper GI toxicity on life expectancy.477 Apart from the result that 
naproxen may result in longer life expectancy in 58-year old women with rheumatoid arthritis, 
the generalizability of the study is limited as it included only 2 individual NSAID compounds.477 
The results of the decision model in the current study were mainly driven by the highest risk 
estimates that were seen for upper GI complication as outcome. Although the impact of 
having an AMI and IS at 4 weeks and 1 year was considered worse than an upper GI 
 
 
complication, NSAIDs risks on upper GI complication ranged between 1.2 and 6.5 whereas 
those for AMI and IS between 0.9 and 2.1 and 1.0 and 1.3, respectively. Even when considering 
that PPIs and low-dose aspirin affect the risk of upper GI243 and cardiovascular endpoints293, 
results of the decision model were pretty consistent. 
In this study we took the perspective of the physician and of the patient, rather than 
of the healthcare payer. We have not considered cost-effectiveness of treatments in the 
models, because since PPIs and NSAIDs have become available generically on the market, costs 
of adding a PPI to NSAID therapy, both nsNSAIDs and selective COX-2 inhibitors, has been 
shown cost-effective.478 
 The strengths of the current study include the setting and design of the study. We 
were able to estimate NSAID treatment effects in a new user cohort in all six databases using 
the same protocol and data transformations. By profiting the heterogeneity of NSAID exposure 
and the size of the SOS platform we were able to include thirteen different individual NSAID 
compounds and provide robust estimates from cross-validated prediction models. 
We acknowledge the following limitations. Firstly, we assumed that all NSAID 
compounds were equally effective in pain relief, though this is generally observed in clinical 
trials 11, 318, 458 and based on a review 479 it may not be necessarily applicable to our study 
population. Secondly, we assumed that prognostic risk factors for the outcomes, such as male 
sex, were similar for the different NSAIDs. Thirdly, the risk of upper GI complication and CV 
outcomes on short-term and long-term was based on baseline information and did not 
incorporate the duration of NSAID therapy. This was considered given common clinical 
practice where a physician needs to decide which NSAID to prescribe based on information at 
that current moment. Fourthly, the disutilities chosen may not be applicable to all patients. 
For instance, the impact of an outcome may differ between each individual patient and the 
disutility at 1 year may not be the same at 5 years, though we did consider it as such in the 
model. 
In conclusion, we assessed and compared the cardiovascular and gastrointestinal 
safety of individual NSAIDs and provided a decision analytic model to aid in the choice of 
treatment, taking into account both the cardiovascular (ischemic stroke, myocardial infarction, 
heart failure) and upper gastrointestinal complications risks. Over a range of scenarios 
celecoxib and ketoprofen were considered the relative safest of 13 individual NSAIDs studied. 
Our results may aid physicians in clinical decision making. 
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SUPPLEMENTARY MATERIAL 
 
 
 
Supplementary Table 3. Definition of Events of Interest. 
 
Event Definition 
Upper Gastrointestinal 
Complication 
Upper gastrointestinal complication (UGIC) events were defined as a patient 
with peptic ulcer disease or gastritis complicated by bleeding, perforation or 
obstruction. 
Uncomplicated peptic ulcer disease, lower GI disease, unspecified GI bleeding, 
or symptoms indicating UGI bleeding, such as melena or hematemesis without 
a diagnosis of peptic ulcer disease, were not considered as UGI event. 
Acute Myocardial Infarction Acute myocardial infarction was defined as an infarction of myocardial tissue 
including transmural, subendocardial, or unspecified acute myocardial 
infarction. 
Heart Failure Heart failure was defined as a patient with congestive heart failure, left sided 
heart failure and unspecified heart failure being the main reason for 
hospitalization or diagnosis. Heart failure incidental to hospitalization for other 
causes were not considered. 
Ischemic stroke Ischemic stroke was defined as an occlusion of cerebral arteries resulting in 
signs and disturbances of cerebral function lasting > 24 hours.  
Transient cerebral ischemia (TIA) was not considered as ischemic stroke. Stroke 
secondary to a trauma was also not included. 
 
Events of interest included a first encountered hospitalization of the event in hospital discharge or administrative databases 
(GePaRD, PHARMO, OSSIFF and SISR) or a first diagnosis of the event in primary care databases (THIN, IPCI). 
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Supplementary Table 4. Performance of prediction models at cross validation by outcomes. 
 
Dataset SISR OSSIFF PHARMO IPCI THIN GePaRD 
 Upper gastrointestinal complications 
c-statistic 0.75 0.75 0.75 0.75 0.75 0.75 
calibration slope (SE) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 
 Heart Failure 
c-statistic 0.84 0.84 0.89 0.87 0.87 0.87 
calibration slope (SE) 1.05 (0.006) 1.01 (0.007) 1.01 (0.007) 0.96 (0.172) 0.95 (0.009) 1.06 (0.007) 
 Acute myocardial infarction 
c-statistic 0.75 0.75 0.75 0.75 0.75 0.75 
calibration slope (SE) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 
 Ischemic stroke (IS) 
c-statistic 0.79 0.79 0.79 0.79 0.79 0.79 
calibration slope (SE) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 
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Supplementary Table 4. Performance of prediction models at cross validation by outcomes. 
 
Dataset SISR OSSIFF PHARMO IPCI THIN GePaRD 
 Upper gastrointestinal complications 
c-statistic 0.75 0.75 0.75 0.75 0.75 0.75 
calibration slope (SE) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 1.15 (0.016) 
 Heart Failure 
c-statistic 0.84 0.84 0.89 0.87 0.87 0.87 
calibration slope (SE) 1.05 (0.006) 1.01 (0.007) 1.01 (0.007) 0.96 (0.172) 0.95 (0.009) 1.06 (0.007) 
 Acute myocardial infarction 
c-statistic 0.75 0.75 0.75 0.75 0.75 0.75 
calibration slope (SE) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 1.06 (0.009) 
 Ischemic stroke (IS) 
c-statistic 0.79 0.79 0.79 0.79 0.79 0.79 
calibration slope (SE) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 1.10 (0.011) 
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ABSTRACT 
 
BACKGROUND 
Combining data from several databases is increasingly gaining popularity. There is uncertainty 
whether analysis of pooled individual-patient level data (one-stage) or meta-analysis of 
database-specific estimates (two-stage) should be preferred. 
 
AIM 
To compare one- and two-stage analyses in the context of a matched nested case-control 
design. 
 
METHODS 
Within the SAFEGUARD project 8 European and 1 US database collected data on incident 
T2DM subjects (1999-2013). Within each database a common work-up of definitions and data 
model was used. Cases  with acute myocardial infarction (AMI) were matched to maximum 10 
controls on age (±1 year), sex, database and follow-up time (±3 months). Effects of metformin 
and glimepiride monotherapy were estimated relative to a common reference exposure. One- 
and two-stage analyses were conducted including common confounders. In the one-stage 
model, we evaluated whether database acted as an effect modifier for confounders and 
exposure estimates. Heterogeneity in meta-analytic pooling was assessed by I2 values. 
 
RESULTS 
In total 25,979 AMI cases were matched to 127,570 controls. Metformin monotherapy was 
used by 24% of cases; glimepiride monotherapy by 6.9%. Unadjusted one-stage and two-stage 
analyses provided  similar estimates (metformin: ORone-stage=0.82, 95% CI: 0.78-0.86; 
ORfixed=0.83, 95% CI: 0.79-0.88; I
2=49%; glimepiride: ORone-stage=0.99, 95% CI: 0.93-1.05 versus 
ORrandom=1.04, 95% CI: 0.90-1.20; I
2=68.1%;). Adjusting for confounders did not provide larger 
differences between the models. In one-stage analysis, the database does however seem to 
act as an effect modifier when including interactions with exposure and covariates (P<0.05). 
 
CONCLUSION 
One- and two-stage analyses yielded similar estimates including a range of confounders in the 
setting of the SAFEGUARD project with a common work up and common data model. In the 
one-stage analysis the database seemed to act as an effect modifier for confounder and 
exposure effects despite homogeneity in the exposure estimates according to meta-analytic 
pooling. 
 
 
 
INTRODUCTION 
 
One of the most important reasons to conduct observational studies is the allowance of 
addressing research questions of drug safety in the “real world” that cannot be addressed in 
randomized clinical trials.133, 480 Observational studies utilizing electronic healthcare data from 
primary or secondary care are therefore particularly valuable when adverse events are 
unknown or considered rare.133 Initially, these studies were conducted independently of each 
other. This resulted in studies addressing the same research question by different study 
designs and different definitions of outcomes, covariables and exposure. In order to derive 
more robust evidence from these single studies, study-specific results were combined in meta-
analyses. In recent years, collaboration between data sources to collectively study the same 
research question has gained popularity.243, 346, 440, 481, 482 This resulted in several multi-database 
studies using multiple data sources from different sites and countries with a high potential of 
heterogeneity between the data sources. Combining data from several sources is possible in 
mainly two ways: 1) one-stage analysis; which consists of performing the analysis on one large 
database where individual patient-level data from different databases is pooled; or 2) two-
stage meta-analysis; in which the analyses are performed on each single database and the 
summary statistics are combined using standard meta-analysis techniques.483 There is an 
ongoing debate whether one of the two techniques should be preferred over the other.484 
Despite clear practical and flexibility reasons for analyzing individual patient-level data, the 
main disadvantage of these analyses remains data sharing and privacy issues.484 Another 
proposed method of pooling data from different study sites is pooling on propensity scores.485 
Cohort studies using this propensity score-based pooling  yielded  similar estimates as derived 
from meta-analyzing the estimates when adjusting for universal (common) or local (data site 
specific) confounders.485-487 How these methods perform in the context of multi-database 
studies with a matched case-control design is unknown, particularly when a common data 
model is used. The aim of the current study is to compare one-stage and two-stage meta-
analyses using data from the SAFEGUARD project. 
 
METHODS 
 
Data sources 
 
Data for this study was obtained from nine longitudinal population-based health care 
databases participating in the SAFEGUARD project (Safety Evaluation of Adverse Reactions in 
Diabetes: http://www.safeguard-diabetes.org/ ) from five European countries [Germany (GE), 
Italy (IT), the Netherlands (NL), Spain (ES), the United Kingdom (UK)] and the United States 
(US) covering a source population of around 50 million subjects. All databases have been 
extensively used for pharmacoepidemiological research. Characteristics of the databases are 
summarized in Table 1. In short, the Clinical Practice Research Datalink (CPRD) database is a 
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general practice (GP) database in the UK and currently captures medical records of 13.2 million 
patients. BIFAP (Base de Datos para la Investigación Farmacoepidemiologica en Atención 
Primaria) is a Spanish GP database in which GPs from different communities in Spain are 
captured.488 The Integrated Primary Care Information (IPCI) database is a GP database from 
the Netherlands and covers over 1 million people.238 PHARMO database is a medical record 
linkage system of 2.2 million community-dwelling inhabitants in the Netherlands.435 Three 
Italian databases were included: the Health Search Database/CSD Longitudinal Patient (HSD), 
Regional Database Puglia (CMNS), and Regional Database Lombardy (UNIMIB). HSD is a GP 
database which covers 1.5 million patients (aged 15 years and older). CMNS and UNIMIB are 
administrative databases with regional coverage of the Italian citizens. UNIMIB has full 
population coverage of the Lombardia region, resulting in electronic medical records from 16% 
of the Italian population. The German Pharmacoepidemiological Research Database (GePaRD) 
is a database comprising data from five statutory health insurances throughout Germany. It 
currently covers around 14 million insurants and represents approximately 20% of the German 
population.436 The Caremark-Medicare linked database provides healthcare transaction data 
on US community-dwelling patients 65 years and older who receive their health insurance 
through Medicare. Medicare retrieves information on drug prescriptions and claims through 
Caremark. 
All GP and administrative databases contain information on demographics of the 
population, diagnoses (in- and/or outpatient), and drug prescriptions/dispensings. The 
diagnoses captured by the databases are coded with four different disease coding systems 
including the International Classification of Diseases (ICD) 9th or 10th revision,323 International 
Classification for Primary Care (ICPC),240 or READ system.438 Details on the databases regarding 
coding systems, study period and drug exposure are listed in Table 1. 
Mapping of concept and codes was performed using the Unified Medical Language 
System (UMLS). The UMLS is a biomedical terminology integration system handling more than 
150 medical dictionaries, according to a previously described workflow.380, 440 All drugs were 
mapped to the World Health Organization’s (WHO) classification of Anatomical Therapeutic 
Chemical (ATC).242  A distributed approach was used for collaboration: all database custodians 
processed data locally; original data were transformed into a simple common data model 
(Jerboa ©);346 mapping of codes for outcome and covariates was verified using an extensive 
harmonization strategy; and a common standardized script was used to create an aggregated 
data output for all databases that were subsequently encrypted and shared on a central 
remote research environment for further analysis and pooling. Details on such a collaborative 
approach have been described previously.346, 380  
 Approval by the institutional review boards was obtained.
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general practice (GP) database in the UK and currently captures medical records of 13.2 million 
patients. BIFAP (Base de Datos para la Investigación Farmacoepidemiologica en Atención 
Primaria) is a Spanish GP database in which GPs from different communities in Spain are 
captured.488 The Integrated Primary Care Information (IPCI) database is a GP database from 
the Netherlands and covers over 1 million people.238 PHARMO database is a medical record 
linkage system of 2.2 million community-dwelling inhabitants in the Netherlands.435 Three 
Italian databases were included: the Health Search Database/CSD Longitudinal Patient (HSD), 
Regional Database Puglia (CMNS), and Regional Database Lombardy (UNIMIB). HSD is a GP 
database which covers 1.5 million patients (aged 15 years and older). CMNS and UNIMIB are 
administrative databases with regional coverage of the Italian citizens. UNIMIB has full 
population coverage of the Lombardia region, resulting in electronic medical records from 16% 
of the Italian population. The German Pharmacoepidemiological Research Database (GePaRD) 
is a database comprising data from five statutory health insurances throughout Germany. It 
currently covers around 14 million insurants and represents approximately 20% of the German 
population.436 The Caremark-Medicare linked database provides healthcare transaction data 
on US community-dwelling patients 65 years and older who receive their health insurance 
through Medicare. Medicare retrieves information on drug prescriptions and claims through 
Caremark. 
All GP and administrative databases contain information on demographics of the 
population, diagnoses (in- and/or outpatient), and drug prescriptions/dispensings. The 
diagnoses captured by the databases are coded with four different disease coding systems 
including the International Classification of Diseases (ICD) 9th or 10th revision,323 International 
Classification for Primary Care (ICPC),240 or READ system.438 Details on the databases regarding 
coding systems, study period and drug exposure are listed in Table 1. 
Mapping of concept and codes was performed using the Unified Medical Language 
System (UMLS). The UMLS is a biomedical terminology integration system handling more than 
150 medical dictionaries, according to a previously described workflow.380, 440 All drugs were 
mapped to the World Health Organization’s (WHO) classification of Anatomical Therapeutic 
Chemical (ATC).242  A distributed approach was used for collaboration: all database custodians 
processed data locally; original data were transformed into a simple common data model 
(Jerboa ©);346 mapping of codes for outcome and covariates was verified using an extensive 
harmonization strategy; and a common standardized script was used to create an aggregated 
data output for all databases that were subsequently encrypted and shared on a central 
remote research environment for further analysis and pooling. Details on such a collaborative 
approach have been described previously.346, 380  
 Approval by the institutional review boards was obtained.
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Study Cohorts 
 
A cohort of patients with type 2 diabetes mellitus (T2DM) was identified using a harmonized 
definition of T2DM across the databases. The cohort included all patients who an incident 
prescription of non-insulin blood glucose lowering drug (NIBGLD). At least one year of 
available healthcare data prior to study entry was required in order to assess the patient’s 
medical history and to discriminate between prevalent and incident T2DM. 
Follow-up started at the date of first NIBLGD prescription recording and ended at 
date of study outcome (see below), death, end of study period (Table 1) or moving out of 
region, whichever was earliest. Gestational diabetes was not considered as inclusion criterion. 
Subjects with any type of malignancy (except for non-melanoma skin cancer) before cohort 
entry were excluded. Cancers occurring during cohort time were censored at date of cancer 
diagnosis. 
 
Cases and controls 
 
In the SAFEGUARD project several outcomes were analyzed. For this study, we used acute 
myocardial infarction (AMI) as outcome as this is a clearly defined outcome and has been 
validly used in previous studies. Codes used to identify AMI are given in Supplementary Table 
1. Cases experiencing their first AMI during cohort time were matched to a maximum of 10 
controls by incidence density sampling on age (±1 year), sex, database and time in the cohort 
(±3 months). 
 
Exposure 
 
Exposure to NIBGLDs was obtained from either prescriptions (BIFAP, CPRD, HSD, IPCI, 
PHARMO) or from outpatient drug dispensings claims (CMNS, GePaRD, MEDICARE, PHARMO 
and UNIMIB). Duration of a single NIBGLD dispensing/prescription was obtained by dividing 
the total units by the daily number of units prescribed (BIFAP, CPRD, HSD, IPCI, PHARMO), for 
other databases standard durations were used based on the country specific defined daily 
dose (DDD) values.242 
Classification of the recency of exposure to NIBGLDs was based on the interval 
between index date and the end of the most recent NIBGLD use before the index date. If the 
exposure period 1) overlapped or ended within 30 days before index date  use was classified 
as ‘current’ use; 2) ended between 31 and 62 days before the index date as ‘recent’ use and; 
3) ended more than 63 days before the index date as ‘past’ use.  
Exposure of interest included two medications that are likely to be commonly used, 
namely metformin and glimepiride as monotherapy. We considered current use of metformin 
with a sulfonylurea (either in fixed or loose combination) as reference category to compare 
our exposures of interest to. Current use of any other NIBGLD as monotherapy or combination 
of drugs was considered as separate category. Exposure groups were therefore mutually 
 
 
exclusive. It should be noted that monotherapy of metformin and glimepiride are primarily 
used in the first stage of T2DM treatment, whereas the common reference group to which we 
compared our exposures of interest to is considered at a second stage of T2DM therapy. For 
the purpose of comparing the one- and two-stage analyses we assumed the stage at which the 
drug is considered would not affect the comparison between one-stage and two-stage 
analyses.  
 
Covariate selection 
 
For the SAGFEGUARD study, a list of covariates was defined based on scientific and clinical 
knowledge. Time window of covariate assessment was 1 year prior to cohort entry date or 
index date for comorbid diseases and 30 days prior to cohort entry or index date for use of 
drugs. Covariates that were assessed at 1) cohort entry included use of ACE-inhibitors, 
anticoagulants, anti-hypertensive drugs, angiotensin II agonists, beta-blockers, calcium 
antagonists, hormone replacement therapy, diuretics, lipid lowering drugs, oestrogens, 
systemic contraceptives, vasodilators; 2) at index date use of anti-arrythmic drugs, 
anticoagulants, antiplatelets, high-dose aspirin (>325 mg/day), low-dose aspirin (≤325 
mg/day), hormone replacement therapy, estrogens, systemic contraceptives, vasodilators; 
hyperlipidemia, heart failure, obesity, smoking and hypoglycemic events; 3) or both at cohort 
entry and index date: atrial fibrillation, cerebrovascular diseases, chronic kidney disease, 
ischemic heart disease, myocardial infarction, peripheral arterial disease, renal failure, alcohol 
abuse, cardiomyopathy, chronic liver disease, coagulopathies, congenital heart disease, 
chronic obstructive pulmonary disease, drug abuse, deep vein thrombosis and pulmonary 
embolism, endocarditis, cardiac valve disorders, ventricular arrhythmia. In case there was no 
or missing information on the variable in the specific time window, the variable was 
considered as absence of the condition. 
We considered different ways to include confounders, based on: 1) the prevalence of 
the confounder; 2) their association with the outcome, e.g. the difference between the crude 
beta and beta adjusted for the confounder; 3) the strength of confounding as defined by the 
Bross formula,442 which is a function of the first two steps as described above. Covariates were 
selected for adjustment in the three abovementioned ways in each database separately and in 
the pooled data. Furthermore we selected single confounders and confounders that were 
present in all databases (‘common confounders’) and showed the strongest potential for 
confounding across the databases (point 3 as described above). 
 
Statistical analyses 
 
The study populations were described by database. Conditional logistic regression was 
conducted both within each database and within the pooled data (one-stage analysis). In case 
a confounder was not available or present in a database this database was left out of the one- 
and two-stage analyses. 
	 Pooling	of	data	from	multiple	data	sources	|	281 
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analyses.  
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considered as absence of the condition. 
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the confounder; 2) their association with the outcome, e.g. the difference between the crude 
beta and beta adjusted for the confounder; 3) the strength of confounding as defined by the 
Bross formula,442 which is a function of the first two steps as described above. Covariates were 
selected for adjustment in the three abovementioned ways in each database separately and in 
the pooled data. Furthermore we selected single confounders and confounders that were 
present in all databases (‘common confounders’) and showed the strongest potential for 
confounding across the databases (point 3 as described above). 
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We investigated whether database acted as effect modifier for confounder and exposure 
associations by adding interactions of database with confounders to allow for varying 
strengths of confounding effects across the databases and the one-stage analysis is ‘allowed’ 
and one overall estimate for exposure and confounders can be considered in the individual 
patient-level pooled dataset. 
The two-stage analysis was conducted by meta-analyzing the estimates obtained in 
each single database and weighing each database using the inverse of the variance.491 As a 
measure of heterogeneity in the estimates across the databases the I2 was calculated.492  
 
RESULTS 
 
Out of the source population of over 52 million subjects we identified 1.8 million incident 
T2DM subjects. In this cohort, we could match 25,979 AMI cases to 127,570 controls (Table 2). 
Basic demographics and prevalence of confounders in cases and controls per database are 
shown in Table 3. Mean age at index date was lowest for IPCI (64.2 and 63.2 years, for cases 
and controls respectively) and highest for Medicare (77.9 years both). Most study subjects 
were male (51% to 69%). Median time in the cohort for cases varied between 0.8 year (IPCI) 
and 3.5 years (UNIMIB); and varied for controls between 0.7 year (IPCI) and 3.6 years 
(UNIMIB). 
 
Table 2. Exposure of metformin and glimepiride per database. 
 
 Total 
Number 
Total 
Number 
 Metformin monotherapy  Glimepiride monotherapy 
 Cases Controls Cases Controls 
of Cases 
of 
Controls 
 
N (%) N (%) N (%) N (%) 
GePaRD 3,511 16,153  1,174 (33.4) 6,027 (37.3)  405 (11.5) 1,451 (9.0) 
CMNS 2,062 10,375  346 (16.8) 2,037 (19.6)  131 (6.4) 639 (6.2) 
UNIMIB 9,794 48,154  1,508 (15.4) 7,945 (16.5) 807 (8.2) 3,586 (7.4) 
HSD 748 3,678  165 (22.1) 880 (23.9)  53 (7.1) 285 (7.7) 
BIFAP 802 3,848  252 (31.4) 1,360 (35.3)  22 (2.7) 96 (2.5) 
CPRD 4,598 22,429  1,764 (38.4) 9,247 (41.2)  66 (1.4) 260 (1.2) 
IPCI 76 303  48 (63.2) 206 (68.0)  0 (0) 0 (0) 
PHARMO 1,483 7,359  510 (34.4) 2,595 (35.3)  137 (9.2) 705 (9.6) 
MEDICARE 2,905 15,271  486 (16.7) 3,456 (22.6)  181 (6.2) 756 (5.0) 
Pooled dataset 25,979 127,570  6,253 (24.1) 33,753 (26.5)  1,802 (6.9) 7,778 (6.1) 
 
Prevalence of Confounders 
 
Prevalences of confounders in cases and controls varied between databases (Table 3). In 
general, use of antiplatelets, low-dose aspirin beta-blockers, vasodilators and respiratory drugs 
close to index date and presence of cerebrovascular diseases, chronic kidney disease, ischemic 
heart disease, hyperlipidemia, peripheral arterial disease, renal failure and smoking were more 
frequent among cases than controls. Presence of obesity and chronic liver disease was more 
 
 
common among controls than among cases. The prevalence of some confounders among 
cases and controls was different between databases, for instance use of diuretics was more 
common among cases in Medicare and BIFAP, whereas the opposite was seen in the other 
databases. Use of ACE-inhibitors was almost as frequent as in controls in all databases except 
for CPRD and Medicare. 
 
Exposure 
 
Current metformin use was common at index date, with between 15% and 63% of cases and 
between 16% and 68% of controls exposed. Glimepiride was less often used, by 1.4% to 11.5% 
of cases and 1.2% to 9.6% of controls. None of the study subjects in IPCI was exposed to 
glimepiride, thus IPCI was not included in the analyses on glimepiride. 
 
Unadjusted analysis 
 
Estimates per database and from one-stage and two-stage analyses are shown in Figure 1. For 
metformin heterogeneity between databases was observed (I2=49%) with one-stage and two-
stage analyses providing very similar estimates (ORone-stage=0.82, 95% CI: 0.78-0.86; 
ORfixed=0.83, 95% CI: 0.79-0.88). For glimepiride the level of heterogeneity was larger (I
2=68%). 
The estimates from one-stage and two-stage analyses were still close to each other               
(ORone-stage=0.99, 95% CI: 0.93-1.05 versus ORrandom=1.04, 95% CI: 0.90-1.20), with the estimate 
from the random effects model was included in the 95% confidence limit of the one-stage 
analysis. 
 
 
Figure 1. Unadjusted odds ratios by one- and two-stage analyses for current use of metformin as monotherapy 
and glimepiride as monotherapy versus current use of metformin plus a sulfonylurea. 
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Table 3. Prevalence of Confounders in cases and controls per database. 
 GePaRD CMNS UNIMIB 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 3,511 16,153 2,062 10,375 9,794 48,154 
Age       
Mean (SD) 67.6 (11.2) 67.4 (11.1) 67.5 (11.6) 67.5 (11.5) 69.5 (11.9) 69.3 (12) 
Median (IQR) 68 (60-75) 68 (60-75) 67 (59-77) 67 (59-76) 70 (61-79) 70 (61-78) 
Sex       
Female 1,079 (30.7) 4,931 (30.5) 646 (31.3) 3,236 (31.2) 3,139 
(32.05) 
15,514 
(32.2) 
Male 2,432 (69.3) 11,222 
(69.5) 
1,416 (68.7) 7,139 (68.8) 6,655 (67.9) 32,640 
(67.8) 
A priori defined 
confounders 
      
Use of:       
ACE-inhibitors* 1,056 (30.1) 4,572 (28.3) 412 (20.0) 2,018 (19.5) 2,346 
(23.95) 
10,750 
(22.3) 
Anticoagulants* 114 (3.2) 522 (3.2) 39 (1.9) 175 (1.7) 233 (2.38) 1,045 (2.17) 
Anti-hypertensive drugs* 112 (3.2) 433 (2.7) 49 (2.4) 296 (2.85) 311 (3.18) 1,296 (2.7) 
Angiotensin II 
antagonists* 
431 (12.3) 1974 (12.2) 212 (10.3) 1,071 (10.2) 1,064 (10.9) 4,722 (9.8) 
Beta-blockers* 1064 (30.3) 4495 (27.8) 216 (10.5) 796 (7.7) 1,498 (15.3) 5,527 (11.5) 
Calcium antagonists* 260 (7.4) 1,011 (6.3) 121 (5.9) 463 (4.5) 769 (7.9) 2,853 (5.9) 
Hormone replacement 
therapy* 
64 (1.8) 338 (2.1)   53 (0.5) 329 (0.7) 
Diuretics* 1,141 (32.5) 5,135 (31.8) 445 (21.6) 2,380 (22.9) 2,311 (23.6) 10,628 
(22.1) 
Lipid lowering drugs* 682 (19.4) 2,738 (17.0) 287 (13.9) 1,215 (11.7) 1,498 (15.3) 6,084 (12.6) 
Oestrogens* 61 (1.7) 323 (2.0) 6 (0.3) 22 (0.2) 71 (0.72) 432 (0.9) 
Systemic contraceptives*     13 (0.13) 64 (0.1) 
Vasodilators* 263 (7.5) 665 (4.1) 174 (8.4) 443 (4.3) 958 (9.78) 2,402 (5.0) 
Hyperlipidemia‡ 1,999 (56.9) 8294 (51.3) 487 (23.6) 2,110 (20.3) 2,299 
(23.47) 
9,135 (19.0) 
Anti-arrythmic drugs# 20 (0.6) 114 (0.7) 45 (2.28) 234 (2.3) 273 (2.79) 1,358 (2.8) 
Anticoagulants# 197 (5.6) 791 (4.9) 72 (3.5) 336 (3.2) 373 (3.81) 1,403 (2.9) 
Antiplatelets# 232 (6.6) 531 (3.3) 142 (6.9) 384 (3.7) 508 (5.19) 1,541 (3.2) 
Aspirin in high dose# 30 (0.9) 106 (0.7)     
Low-dose aspirin# 452 (12.9) 1,295 (8.0) 470 (22.8) 2,126 (20.5) 2,073 
(21.17) 
7,727 (16.0) 
Hormone replacement 
therapy# 
51 (1.5) 315 (2.0)   20 (0.2) 139 (0.3) 
Oestrogens# 50 (1.4) 297 (1.8) 7 (0.3) 22 (0.2) 30 (0.31) 186 (0.39) 
Systemic contraceptives#     7 (0.1) 22 (0.05) 
Vasodilators# 398 (11.3) 667 (4.1) 256 (12.4) 575 (5.5) 1558 (15.9) 3,221 (6.7) 
Comorbid diseases:       
Atrial Fibrillation† 424 (12.1) 1,485 (9.2) 84 (4.1) 331 (3.2) 525 (5.4) 2,054 (4.3) 
Any cerebrovascular 
disease† 
856 (24.4) 3,244 (20.1) 199 (9.7) 615 (5.9) 1,104 (11.3) 3,510 (7.3) 
Chronic Kidney disease† 853 (24.3) 3,256 (20.2) 119 (5.7) 298 (2.9) 499 (5.1) 1,317 (2.7) 
Ischemic Heart Disease† 1,916 (54.6) 4,819 (29.8) 372 (18.0) 811 (7.8) 1,755 (17.9) 4,627 (9.6) 
Myocardial Infarction† 1,088 (31.0) 1334 (8.3) 172 (8.3) 391 (3.8) 1,051 (10.7) 2,864 (5.9) 
Peripheral Arterial 
Disease† 
794 (22.6) 2,694 (16.7) 115 (5.6) 275 (2.7) 584 (5.96) 1,323 (2.7) 
Renal Failure† 39 (1.1) 66 (0.4) 12 (0.6) 10 (0.10) 61 (0.62) 104 (0.22) 
Heart Failure‡ 586 (16.7) 1,856 (11.5) 98 (4.8) 358 (3.5) 530 (5.4) 1,586 (3.3) 
Obesity‡ 943 (26.9) 4,518 (28.0) 33 (1.6) 162 (1.6) 125 (1.3) 536 (1.1) 
Smoking‡       
Cancer 240 (6.8) 1,235 (7.6) 72 (3.5) 330 (3.2) 506 (5.2) 2,382 (4.9) 
 
 
Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
* assessed in 30 days before cohort entry; # assessed 30 days before index date; † assessed at cohort entry and index date; ‡ 
assessed 1 year before cohort entry. 
  
 GePaRD CMNS UNIMIB 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 3,511 16,153 2,062 10,375 9,794 48,154 
Potential Confounders       
Use of:       
PDE5 inhibitors*        
Respiratory drugs* 173 (4.9) 594 (3.7) 96 (4.7) 382 (3.7) 354 (3.6) 1,516 (3.1) 
Cardiac glycosides# 101 (2.9) 288 (1.8) 58 (2.8) 247 (2.4) 195 (2.0) 718 (1.5) 
PDE5 inhibitors#        
Respiratory drugs# 226 (6.4) 697 (4.3) 120 (5.8) 441 (4.3) 522 (5.3) 1,818 (3.8) 
Glucocorticoids# 205 (5.8) 535 (3.3) 109 (5.3) 318 (3.1) 288 (2.9) 822 (1.7) 
Comorbid diseases:       
Alcohol Abuse† 186 (5.3) 828 (5.1) 14 (0.7) 68 (0.7) 105 (1.1) 495 (1.0) 
Cardiomyopathy† 103 (2.9) 292 (1.8) 27 (1.3) 96 (0.9) 194 (2.0) 636 (1.3) 
Chronic Liver disease† 918 (26.1) 4,493 (27.8) 144 (7.0) 619 (6.0) 389 (4.0) 1942 (4.0) 
Coagulopathies† 214 (6.1) 935 (5.8) 9 (0.4) 33 (0.3) 49 (0.5) 198 (0.4) 
Congenital heart disease† 22 (0.6) 87 (0.5)   17 (0.2) 58 (0.1) 
Chronic Obstructive 
Pulmonary Disease† 
591 (16.8) 2162 (13.4) 226 (11.0) 771 (7.4) 565 (5.8) 2008 (4.2) 
Drug abuse† 52 (1.5) 207 (1.3)   9 (0.1) 40 (0.1) 
Deep Vein Thrombosis/ 
Pulmonary Embolism† 
93 (2.6) 355 (2.2) 6 (0.3) 22 (0.2) 85 (0.9) 346 (0.7) 
Endocarditis† 21 (0.6) 126 (0.8)     
Cardiac valve disorders† 512 (14.6) 1581 (9.8) 68 (3.3) 193 (1.9) 238 (2.4) 853 (1.8) 
Ventricular arrythmia† 69 (2.0) 165 (1.0) 12 (0.6) 31 (0.3) 53 (0.5) 222 (0.5) 
Hypoglycemic events# 21 (0.6) 67 (0.4)   9 (0.1) 18 (0.04) 
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Table 3. Prevalence of Confounders in cases and controls per database. 
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(23.95) 
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Anticoagulants* 114 (3.2) 522 (3.2) 39 (1.9) 175 (1.7) 233 (2.38) 1,045 (2.17) 
Anti-hypertensive drugs* 112 (3.2) 433 (2.7) 49 (2.4) 296 (2.85) 311 (3.18) 1,296 (2.7) 
Angiotensin II 
antagonists* 
431 (12.3) 1974 (12.2) 212 (10.3) 1,071 (10.2) 1,064 (10.9) 4,722 (9.8) 
Beta-blockers* 1064 (30.3) 4495 (27.8) 216 (10.5) 796 (7.7) 1,498 (15.3) 5,527 (11.5) 
Calcium antagonists* 260 (7.4) 1,011 (6.3) 121 (5.9) 463 (4.5) 769 (7.9) 2,853 (5.9) 
Hormone replacement 
therapy* 
64 (1.8) 338 (2.1)   53 (0.5) 329 (0.7) 
Diuretics* 1,141 (32.5) 5,135 (31.8) 445 (21.6) 2,380 (22.9) 2,311 (23.6) 10,628 
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Aspirin in high dose# 30 (0.9) 106 (0.7)     
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(21.17) 
7,727 (16.0) 
Hormone replacement 
therapy# 
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Obesity‡ 943 (26.9) 4,518 (28.0) 33 (1.6) 162 (1.6) 125 (1.3) 536 (1.1) 
Smoking‡       
Cancer 240 (6.8) 1,235 (7.6) 72 (3.5) 330 (3.2) 506 (5.2) 2,382 (4.9) 
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* assessed in 30 days before cohort entry; # assessed 30 days before index date; † assessed at cohort entry and index date; ‡ 
assessed 1 year before cohort entry. 
  
 GePaRD CMNS UNIMIB 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 3,511 16,153 2,062 10,375 9,794 48,154 
Potential Confounders       
Use of:       
PDE5 inhibitors*        
Respiratory drugs* 173 (4.9) 594 (3.7) 96 (4.7) 382 (3.7) 354 (3.6) 1,516 (3.1) 
Cardiac glycosides# 101 (2.9) 288 (1.8) 58 (2.8) 247 (2.4) 195 (2.0) 718 (1.5) 
PDE5 inhibitors#        
Respiratory drugs# 226 (6.4) 697 (4.3) 120 (5.8) 441 (4.3) 522 (5.3) 1,818 (3.8) 
Glucocorticoids# 205 (5.8) 535 (3.3) 109 (5.3) 318 (3.1) 288 (2.9) 822 (1.7) 
Comorbid diseases:       
Alcohol Abuse† 186 (5.3) 828 (5.1) 14 (0.7) 68 (0.7) 105 (1.1) 495 (1.0) 
Cardiomyopathy† 103 (2.9) 292 (1.8) 27 (1.3) 96 (0.9) 194 (2.0) 636 (1.3) 
Chronic Liver disease† 918 (26.1) 4,493 (27.8) 144 (7.0) 619 (6.0) 389 (4.0) 1942 (4.0) 
Coagulopathies† 214 (6.1) 935 (5.8) 9 (0.4) 33 (0.3) 49 (0.5) 198 (0.4) 
Congenital heart disease† 22 (0.6) 87 (0.5)   17 (0.2) 58 (0.1) 
Chronic Obstructive 
Pulmonary Disease† 
591 (16.8) 2162 (13.4) 226 (11.0) 771 (7.4) 565 (5.8) 2008 (4.2) 
Drug abuse† 52 (1.5) 207 (1.3)   9 (0.1) 40 (0.1) 
Deep Vein Thrombosis/ 
Pulmonary Embolism† 
93 (2.6) 355 (2.2) 6 (0.3) 22 (0.2) 85 (0.9) 346 (0.7) 
Endocarditis† 21 (0.6) 126 (0.8)     
Cardiac valve disorders† 512 (14.6) 1581 (9.8) 68 (3.3) 193 (1.9) 238 (2.4) 853 (1.8) 
Ventricular arrythmia† 69 (2.0) 165 (1.0) 12 (0.6) 31 (0.3) 53 (0.5) 222 (0.5) 
Hypoglycemic events# 21 (0.6) 67 (0.4)   9 (0.1) 18 (0.04) 
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Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
  
 HSD CPRD BIFAP 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 748 3,678 4,598 22,429 802 3,848 
Age       
Mean (SD) 68.5 (10.9) 68.6 (10.6) 67.5 (12.8) 67.5 (12.5) 67.8 (12.5) 67.4 (12) 
Median (IQR) 69 (61-77) 69 (61-77) 68 (58-77) 69 (59-77) 68 (58-78) 68 (58-77) 
Sex       
Female 247 (33.0) 1,223 (33.3) 1,708 (37.1) 8,365 (37.3) 235 (29.3) 1,094 (28.4) 
Male 501 (67.0) 2,455 (66.7) 2,890 (62.9) 14,064 
(62.7) 
567 (70.7) 2,754 (71.6) 
A priori defined 
confounders 
      
Use of:       
ACE-inhibitors* 144 (19.3) 747 (20.3) 1,175 (25.6) 5,084 (22.7) 128 (16.0) 659 (17.1) 
Anticoagulants* 13 (1.7) 89 (2.4) 128 (2.8) 443 (2.0) 28 (3.5) 102 (2.7) 
Anti-hypertensive drugs* 15 (2.0) 89 (2.4) 164 (3.6) 843 (3.8) 18 (2.2) 74 (1.9) 
Angiotensin II 
antagonists* 
73 (9.8) 342 (9.3) 294 (6.4) 1,302 (5.8) 75 (9.4) 339 (8.8) 
Beta-blockers* 27 (3.6) 148 (4.0) 1,113 (24.2) 4,451 (19.8) 70 (8.7) 290 (7.5) 
Calcium antagonists* 62 (8.3) 325 (8.8) 638 (13.9) 2,659 (11.9) 43 (5.4) 210 (5.5) 
Hormone replacement 
therapy* 
  92 (2.0) 410 (1.8)   
Diuretics* 141 (18.9) 758 (20.6) 1,272 (27.7) 5,612 (25.0) 191 (23.8) 803 (20.9) 
Lipid lowering drugs* 89 (11.9) 431 (11.7) 1,646 (35.8) 6,815 (30.4) 154 (19.2) 761 (19.8) 
Oestrogens*   118 (2.6) 501 (2.2)   
Systemic contraceptives*       
Vasodilators* 38 (5.1) 140 (3.8) 539 (11.7) 1,045 (4.7) 28 (3.5) 99 (2.6) 
Hyperlipidemia‡ 140 (18.7) 639 (17.4) 1,875 (40.8) 7,677 (34.2) 217 (27.1) 1087 (28.2) 
Anti-arrythmic drugs# 15 (2.0) 72 (2.0) 62 (1.3) 216 (1.0) 9 (1.1) 33 (0.9) 
Anticoagulants# 47 (6.3) 140 (3.8) 246 (5.4) 860 (3.8) 47 (5.9) 178 (4.6) 
Antiplatelets# 56 (7.5) 192 (5.2) 405 (8.8) 1,015 (4.5) 71 (8.9) 199 (5.2) 
Aspirin in high dose#   61 (1.3) 159 (0.7)   
Low-dose aspirin# 235 (31.4) 1,023 (27.8) 2,015 (43.8) 8,532 (38.0) 218 (27.2) 809 (21.0) 
Hormone replacement 
therapy# 
  56 (1.2) 284 (1.3)   
Oestrogens#   80 (1.7) 353 (1.6)   
Systemic contraceptives#       
Vasodilators# 110 (14.7) 254 (6.9) 869 (18.9) 1,347 (6.0) 83 (10.3) 153 (4.0) 
Comorbid diseases:       
Atrial Fibrillation† 30 (4.0) 120 (3.3) 292 (6.4) 827 (3.7) 33 (4.1) 126 (3.3) 
Any cerebrovascular 
disease† 
81 (10.8) 306 (8.3) 321 (7.0) 1,017 (4.5) 49 (6.1) 151 (3.9) 
Chronic Kidney disease† 64 (8.6) 147 (4.0) 760 (16.5) 3,019 (13.5) 27 (3.4) 87 (2.3) 
Ischemic Heart Disease† 108 (14.4) 268 (7.3) 1,150 (25.0) 2,563 (11.4) 79 (9.9) 116 (3.0) 
Myocardial Infarction† 5 (0.7) 81 (2.2) 180 (3.9) 603 (2.7) 7 (0.9) 74 (1.9) 
Peripheral Arterial 
Disease† 
31 (4.1) 83 (2.3) 627 (13.6) 2,131 (9.5) 35 (4.4) 85 (2.2) 
Renal Failure†   56 (1.2) 192 (0.9)   
Heart Failure‡ 21 (2.8) 108 (2.9) 98 (2.1) 210 (0.9) 27 (3.5) 92 (2.4) 
Obesity‡ 45 (6.0) 204 (5.5) 1,660 (36.1) 7,629 (34.0) 169 (21.1) 919 (23.9) 
Smoking‡ 36 (4.8) 96 (2.6) 259 (5.6) 1,121 (5.0) 105 (13.1) 393 (10.2) 
Cancer 38 (5.1) 190 (5.2) 177 (3.8) 549 (2.4) 15 (1.9) 111 (2.9) 
 
 
Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
* assessed in 30 days before cohort entry; # assessed 30 days before index date; † assessed at cohort entry and index date; ‡ 
assessed 1 year before cohort entry.  
 HSD CPRD BIFAP 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 748 3,678 4,598 22,429 802 3,848 
Potential Confounders       
Use of:       
PDE5 inhibitors*    83 (1.8) 378 (1.7)   
Respiratory drugs* 32 (4.3) 100 (2.7) 480 (10.4) 1474 (6.7) 33 (4.1) 207 (5.4) 
Cardiac glycosides# 22 (2.9) 105 (2.9) 197 (4.3) 585 (2.6) 25 (3.1) 77 (2.0) 
PDE5 inhibitors#    192 (4.2) 1118 (5.0)   
Respiratory drugs# 43 (5.7) 135 (3.7) 624 (13.6) 1702 (7.6) 56 (7.0) 248 (6.4) 
Glucocorticoids# 23 (3.1) 89 (2.4) 480 (10.4) 1238 (5.5) 26 (3.2) 75 (1.9) 
Comorbid diseases:       
Alcohol Abuse† 5 (0.7) 49 (1.3) 121 (2.6) 541 (2.4) 37 (4.6) 217 (5.6) 
Cardiomyopathy†   18 (0.4) 38 (0.2) 9 (1.1) 31 (0.8) 
Chronic Liver disease† 28 (3.7) 217 (5.9) 70 (1.5) 255 (1.1)   
Coagulopathies† 6 (0.8) 22 (0.6) 21 (0.5) 63 (0.3) 10 (1.2) 44 (1.14) 
Congenital heart 
disease† 
  5 (0.1) 15 (0.1)   
Chronic Obstructive 
Pulmonary Disease† 
50 (6.7) 167 (4.5) 409 (8.9) 1,056 (4.7) 38 (4.7) 148 (3.85) 
Drug abuse† 41 (5.5) 182 (4.9) 18 (0.4) 25 (0.1)   
Deep Vein Thrombosis/ 
Pulmonary Embolism† 
  85 (1.8) 239 (1.1) 14 (1.7) 36 (0.9) 
Endocarditis†       
Cardiac valve disorders† 19 (2.5) 59 (1.6) 118 (2.6) 320 (1.4) 19 (2.4) 44 (1.1) 
Ventricular arrythmia† 9 (1.2) 12 (0.3)     
Hypoglycemic events#       
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Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
  
 HSD CPRD BIFAP 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 748 3,678 4,598 22,429 802 3,848 
Age       
Mean (SD) 68.5 (10.9) 68.6 (10.6) 67.5 (12.8) 67.5 (12.5) 67.8 (12.5) 67.4 (12) 
Median (IQR) 69 (61-77) 69 (61-77) 68 (58-77) 69 (59-77) 68 (58-78) 68 (58-77) 
Sex       
Female 247 (33.0) 1,223 (33.3) 1,708 (37.1) 8,365 (37.3) 235 (29.3) 1,094 (28.4) 
Male 501 (67.0) 2,455 (66.7) 2,890 (62.9) 14,064 
(62.7) 
567 (70.7) 2,754 (71.6) 
A priori defined 
confounders 
      
Use of:       
ACE-inhibitors* 144 (19.3) 747 (20.3) 1,175 (25.6) 5,084 (22.7) 128 (16.0) 659 (17.1) 
Anticoagulants* 13 (1.7) 89 (2.4) 128 (2.8) 443 (2.0) 28 (3.5) 102 (2.7) 
Anti-hypertensive drugs* 15 (2.0) 89 (2.4) 164 (3.6) 843 (3.8) 18 (2.2) 74 (1.9) 
Angiotensin II 
antagonists* 
73 (9.8) 342 (9.3) 294 (6.4) 1,302 (5.8) 75 (9.4) 339 (8.8) 
Beta-blockers* 27 (3.6) 148 (4.0) 1,113 (24.2) 4,451 (19.8) 70 (8.7) 290 (7.5) 
Calcium antagonists* 62 (8.3) 325 (8.8) 638 (13.9) 2,659 (11.9) 43 (5.4) 210 (5.5) 
Hormone replacement 
therapy* 
  92 (2.0) 410 (1.8)   
Diuretics* 141 (18.9) 758 (20.6) 1,272 (27.7) 5,612 (25.0) 191 (23.8) 803 (20.9) 
Lipid lowering drugs* 89 (11.9) 431 (11.7) 1,646 (35.8) 6,815 (30.4) 154 (19.2) 761 (19.8) 
Oestrogens*   118 (2.6) 501 (2.2)   
Systemic contraceptives*       
Vasodilators* 38 (5.1) 140 (3.8) 539 (11.7) 1,045 (4.7) 28 (3.5) 99 (2.6) 
Hyperlipidemia‡ 140 (18.7) 639 (17.4) 1,875 (40.8) 7,677 (34.2) 217 (27.1) 1087 (28.2) 
Anti-arrythmic drugs# 15 (2.0) 72 (2.0) 62 (1.3) 216 (1.0) 9 (1.1) 33 (0.9) 
Anticoagulants# 47 (6.3) 140 (3.8) 246 (5.4) 860 (3.8) 47 (5.9) 178 (4.6) 
Antiplatelets# 56 (7.5) 192 (5.2) 405 (8.8) 1,015 (4.5) 71 (8.9) 199 (5.2) 
Aspirin in high dose#   61 (1.3) 159 (0.7)   
Low-dose aspirin# 235 (31.4) 1,023 (27.8) 2,015 (43.8) 8,532 (38.0) 218 (27.2) 809 (21.0) 
Hormone replacement 
therapy# 
  56 (1.2) 284 (1.3)   
Oestrogens#   80 (1.7) 353 (1.6)   
Systemic contraceptives#       
Vasodilators# 110 (14.7) 254 (6.9) 869 (18.9) 1,347 (6.0) 83 (10.3) 153 (4.0) 
Comorbid diseases:       
Atrial Fibrillation† 30 (4.0) 120 (3.3) 292 (6.4) 827 (3.7) 33 (4.1) 126 (3.3) 
Any cerebrovascular 
disease† 
81 (10.8) 306 (8.3) 321 (7.0) 1,017 (4.5) 49 (6.1) 151 (3.9) 
Chronic Kidney disease† 64 (8.6) 147 (4.0) 760 (16.5) 3,019 (13.5) 27 (3.4) 87 (2.3) 
Ischemic Heart Disease† 108 (14.4) 268 (7.3) 1,150 (25.0) 2,563 (11.4) 79 (9.9) 116 (3.0) 
Myocardial Infarction† 5 (0.7) 81 (2.2) 180 (3.9) 603 (2.7) 7 (0.9) 74 (1.9) 
Peripheral Arterial 
Disease† 
31 (4.1) 83 (2.3) 627 (13.6) 2,131 (9.5) 35 (4.4) 85 (2.2) 
Renal Failure†   56 (1.2) 192 (0.9)   
Heart Failure‡ 21 (2.8) 108 (2.9) 98 (2.1) 210 (0.9) 27 (3.5) 92 (2.4) 
Obesity‡ 45 (6.0) 204 (5.5) 1,660 (36.1) 7,629 (34.0) 169 (21.1) 919 (23.9) 
Smoking‡ 36 (4.8) 96 (2.6) 259 (5.6) 1,121 (5.0) 105 (13.1) 393 (10.2) 
Cancer 38 (5.1) 190 (5.2) 177 (3.8) 549 (2.4) 15 (1.9) 111 (2.9) 
 
 
Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
* assessed in 30 days before cohort entry; # assessed 30 days before index date; † assessed at cohort entry and index date; ‡ 
assessed 1 year before cohort entry.  
 HSD CPRD BIFAP 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 748 3,678 4,598 22,429 802 3,848 
Potential Confounders       
Use of:       
PDE5 inhibitors*    83 (1.8) 378 (1.7)   
Respiratory drugs* 32 (4.3) 100 (2.7) 480 (10.4) 1474 (6.7) 33 (4.1) 207 (5.4) 
Cardiac glycosides# 22 (2.9) 105 (2.9) 197 (4.3) 585 (2.6) 25 (3.1) 77 (2.0) 
PDE5 inhibitors#    192 (4.2) 1118 (5.0)   
Respiratory drugs# 43 (5.7) 135 (3.7) 624 (13.6) 1702 (7.6) 56 (7.0) 248 (6.4) 
Glucocorticoids# 23 (3.1) 89 (2.4) 480 (10.4) 1238 (5.5) 26 (3.2) 75 (1.9) 
Comorbid diseases:       
Alcohol Abuse† 5 (0.7) 49 (1.3) 121 (2.6) 541 (2.4) 37 (4.6) 217 (5.6) 
Cardiomyopathy†   18 (0.4) 38 (0.2) 9 (1.1) 31 (0.8) 
Chronic Liver disease† 28 (3.7) 217 (5.9) 70 (1.5) 255 (1.1)   
Coagulopathies† 6 (0.8) 22 (0.6) 21 (0.5) 63 (0.3) 10 (1.2) 44 (1.14) 
Congenital heart 
disease† 
  5 (0.1) 15 (0.1)   
Chronic Obstructive 
Pulmonary Disease† 
50 (6.7) 167 (4.5) 409 (8.9) 1,056 (4.7) 38 (4.7) 148 (3.85) 
Drug abuse† 41 (5.5) 182 (4.9) 18 (0.4) 25 (0.1)   
Deep Vein Thrombosis/ 
Pulmonary Embolism† 
  85 (1.8) 239 (1.1) 14 (1.7) 36 (0.9) 
Endocarditis†       
Cardiac valve disorders† 19 (2.5) 59 (1.6) 118 (2.6) 320 (1.4) 19 (2.4) 44 (1.1) 
Ventricular arrythmia† 9 (1.2) 12 (0.3)     
Hypoglycemic events#       
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Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
  
 IPCI PHARMO MEDICARE 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 76 303 1,483 7,359 2,905 15,271 
Age       
Mean (SD) 64.2 (11.2) 63.2 (10.4) 67.7 (12) 67.6 (11.8) 77.9 (6.7) 77.9 (6.7) 
Median (IQR) 65 (55.5-
71.5) 
65 (55-70) 69 (59-77) 69 (59-77) 78 (72-83) 77 (72-83) 
Sex       
Female 28 (36.8) 117 (38.6) 507 (34.2) 2498 (33.9) 1,374 (47.3) 7,458 (48.8) 
Male 48 (63.2) 186 (61.4) 976 (65.8) 4861 (66.1) 1,531 (52.7) 7,813 (51.2) 
A priori defined 
confounders 
      
Use of:       
ACE-inhibitors* 10 (13.2) 38 (12.5) 225 (15.2) 1,065 (14.5) 283 (9.7) 1,212 (7.9) 
Anticoagulants*  3 (1.0) 74 (5.0) 310 (4.2) 118 (4.1) 451 (3.0) 
Anti-hypertensive drugs* 2 (2.6) 11 (3.6) 12 (0.8) 66 (0.9) 71 (2.4) 199 (1.3) 
Angiotensin II 
antagonists* 
9 (11.8) 34 (11.2) 158 (10.7) 661 (9.0) 245 (8.4) 896 (5.9) 
Beta-blockers* 6 (7.9) 29 (9.6) 444 (29.9) 1,835 (24.9) 478 (16.5) 1682 (11.0) 
Calcium antagonists* 15 (19.7) 59 (19.5) 117 (7.9) 426 (5.8) 307 (10.6) 992 (6.5) 
Hormone replacement 
therapy* 
2 (2.6) 12 (4.0) 10 (0.7) 62 (0.8) 27 (0.9) 127 (0.8) 
Diuretics* 0 (0.0) 1 (0.3) 391 (26.4) 1,854 (25.2) 537 (18.5) 1,948 (12.8) 
Lipid lowering drugs* 17 (22.4) 84 (27.7) 335 (22.6) 1,567 (21.3) 613 (21.1) 2,356 (15.4) 
Oestrogens* 2 (2.6) 4 (1.3) 28 (1.9) 124 (1.7) 11 (0.4) 70 (0.4) 
Systemic contraceptives* 2 (2.6) 2 (0.7) 17 (1.1) 62 (0.8)   
Vasodilators* 3 (3.9) 5 (1.65) 143 (9.6) 332 (4.5) 108 (3.7) 196 (1.3) 
Hyperlipidemia‡ 16 (21.1) 55 (18.2) 379 (25.6) 1,748 (23.8) 1272 (43.8) 4,954 (32.4) 
Anti-arrythmic drugs# 0 (0.0) 1 (0.3) 14 (0.9) 79 (1.1) 60 (2.1) 265 (1.7) 
Anticoagulants# 1 (1.3) 5 (1.7) 128 (8.6) 533 (7.2) 323 (11.1) 1,332 (8.7) 
Antiplatelets# 0 (0.0) 2 (0.7) 334 (22.5) 1,093 (14.9) 626 (21.5) 1,729 (11.3) 
Aspirin in high dose# 8 (10.5) 23 (7.6)     
Low-dose aspirin# 0 (0.0) 1 (0.3) 305 (20.6) 1,165 (15.8)   
Hormone replacement 
therapy# 
0 (0.0) 2 (0.7) 10 (0.7) 46 (0.6) 71 (2.4) 434 (2.8) 
Oestrogens# 1 (1.3) 3 (1.0) 28 (1.9) 97 (1.3) 35 (1.2) 246 (1.6) 
Systemic contraceptives# 1 (1.3) 2 (0.7) 18 (1.2) 51 (0.7)   
Vasodilators# 3 (3.9) 4 (1.3) 294 (19.8) 451 (6.1) 338 (11.6) 716 (4.7) 
Comorbid diseases:       
Atrial Fibrillation† 0 (0.0) 1 (0.3) 65 (4.4) 256 (3.5) 491 (16.9) 1,414 (9.3) 
Any cerebrovascular 
disease† 
0 (0.0) 2 (0.7) 77 (5.2) 212 (2.9) 535 (18.4) 1,373 (9.0) 
Chronic Kidney disease† 2 (2.6) 3 (1.0) 18 (1.2) 55 (0.7) 616 (21.2) 1,454 (9.5) 
Ischemic Heart Disease† 1 (1.3) 2 (0.7) 226 (15.2) 474 (6.4) 1,354 (46.6) 3,405 (22.3) 
Myocardial Infarction† 2 (2.63 0 (0.0) 104 (7.0) 256 (3.5) 375 (12.9) 942 (6.2) 
Peripheral Arterial 
Disease† 
0 (0.0) 1 (0.3) 45 (3.0) 116 (1.6) 449 (15.5) 989 (6.5) 
Renal Failure† 0 (0.0) 0 (0.0) 5 (0.3) 14 (0.2) 73 (2.5) 87 (0.6) 
Heart Failure‡ 25 (32.9) 101 (33.3) 27 (1.8) 94 (1.3) 446 (15.4) 1057 (6.9) 
Obesity‡ 2 (2.6) 1 (0.3) 6 (0.4) 27 (0.4) 81 (2.8) 288 (1.9) 
Smoking‡ 4 (5.3) 9 (3.0)   118 (4.1) 295 (1.9) 
Cancer 3 (3.9) 1 (0.3) 55 (3.7) 257 (3.5) 170 (5.9) 617 (4.0) 
 
 
Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
* assessed in 30 days before cohort entry; # assessed 30 days before index date; † assessed at cohort entry and index date; ‡ 
assessed 1 year before cohort entry. 
 
Adjusted analyses 
 
Figure 2 shows  the estimates for metformin obtained from one-stage and two-stage analyses 
when adjusting for a single confounder. Little effect on the estimate by adjusting for single 
variables was seen. Also adding 5 common confounders to the models did not affect the 
exposure estimate. The difference between the estimate from one- and two-stage analyses 
was small when adjusting for most confounders. However, when we adjusted for  1st year of 
type 2 diabetes mellitus or for use of PDE5 inhibitors and no interaction term of the covariate 
with database was included, the one-stage estimate was different from the two-stage 
estimate (T2DM: ORone-stage=0.82, 95% CI: 0.79-0.87 versus ORrandom=0.88, 95% CI: 0.82-0.95; 
PDE5 inhibitors: ORone-stage=0.82, 95% CI: 0.78-0.86 versus ORrandom=0.89, 95% CI: 0.81-0.98) 
(Figure 2 and Supplementary Table 2). When adding the interaction term, the exposure 
estimates were very similar for all adjusted estimates. However, based on the P-value of the 
interaction terms, one should consider to stratify in the one-stage analysis on database level (P 
interaction terms < 0.05) when adjusting for most confounders; which means database specific 
estimates should be considered. 
 
 IPCI PHARMO MEDICARE 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 76 303 1,483 7,359 2,905 15,271 
Potential Confounders       
Use of:       
PDE5 inhibitors*  0 (0) 1 (0.3)   12 (0.4) 57 (0.4) 
Respiratory drugs* 2 (2.6) 16 (5.3) 87 (5.9) 459 (6.2) 103 (3.5) 234 (1.5) 
Cardiac glycosides# 2 (2.6) 4 (1.3) 47 (3.2) 197 (2.7) 128 (4.4) 478 (3.1) 
PDE5 inhibitors#    19 (1.3) 59 (0.8) 28 (1.0) 138 (0.9) 
Respiratory drugs# 2 (2.6) 18 (5.9) 122 (8.2) 548 (7.4) 258 (8.9) 761 (5.0) 
Glucocorticoids# 2 (2.6) 7 (2.3) 86 (5.8) 278 (3.8) 182 (6.3) 450 (2.9) 
Comorbid diseases:       
Alcohol Abuse† 1 (1.3) 1 (0.3) 11 (0.7) 42 (0.6) 31 (1.1) 68 (0.4) 
Cardiomyopathy† 2 (2.6) 0 (0.0) 5 (0.3) 23 (0.3) 180 (6.2) 356 (2.3) 
Chronic Liver disease† 0 (0.0) 1 (0.3) 8 (0.5) 40 (0.5) 76 (2.6) 286 (1.9) 
Coagulopathies†     199 (6.9) 522 (3.4) 
Congenital heart 
disease† 
    21 (0.7) 56 (0.4) 
Chronic Obstructive 
Pulmonary Disease† 
  39 (2.6) 150 (2.0) 610 (21.0) 1,513 (9.9) 
Drug abuse†     29 (1.0) 58 (0.4) 
Deep Vein Thrombosis/ 
Pulmonary Embolism† 
    80 (2.8) 217 (1.4) 
Endocarditis† 0 (0.0) 1 (0.3)   21 (0.7) 57 (0.4) 
Cardiac valve disorders† 1 (1.3) 1 (0.3) 21 (1.4) 76 (1.0) 344 (11.8) 861 (5.6) 
Ventricular arrythmia†   5 (0.34) 31 (0.42) 7 (0.2) 18 (0.1) 
Hypoglycemic events#     53 (1.8) 58 (0.4) 
	 Pooling	of	data	from	multiple	data	sources	|	289 
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Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
  
 IPCI PHARMO MEDICARE 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 76 303 1,483 7,359 2,905 15,271 
Age       
Mean (SD) 64.2 (11.2) 63.2 (10.4) 67.7 (12) 67.6 (11.8) 77.9 (6.7) 77.9 (6.7) 
Median (IQR) 65 (55.5-
71.5) 
65 (55-70) 69 (59-77) 69 (59-77) 78 (72-83) 77 (72-83) 
Sex       
Female 28 (36.8) 117 (38.6) 507 (34.2) 2498 (33.9) 1,374 (47.3) 7,458 (48.8) 
Male 48 (63.2) 186 (61.4) 976 (65.8) 4861 (66.1) 1,531 (52.7) 7,813 (51.2) 
A priori defined 
confounders 
      
Use of:       
ACE-inhibitors* 10 (13.2) 38 (12.5) 225 (15.2) 1,065 (14.5) 283 (9.7) 1,212 (7.9) 
Anticoagulants*  3 (1.0) 74 (5.0) 310 (4.2) 118 (4.1) 451 (3.0) 
Anti-hypertensive drugs* 2 (2.6) 11 (3.6) 12 (0.8) 66 (0.9) 71 (2.4) 199 (1.3) 
Angiotensin II 
antagonists* 
9 (11.8) 34 (11.2) 158 (10.7) 661 (9.0) 245 (8.4) 896 (5.9) 
Beta-blockers* 6 (7.9) 29 (9.6) 444 (29.9) 1,835 (24.9) 478 (16.5) 1682 (11.0) 
Calcium antagonists* 15 (19.7) 59 (19.5) 117 (7.9) 426 (5.8) 307 (10.6) 992 (6.5) 
Hormone replacement 
therapy* 
2 (2.6) 12 (4.0) 10 (0.7) 62 (0.8) 27 (0.9) 127 (0.8) 
Diuretics* 0 (0.0) 1 (0.3) 391 (26.4) 1,854 (25.2) 537 (18.5) 1,948 (12.8) 
Lipid lowering drugs* 17 (22.4) 84 (27.7) 335 (22.6) 1,567 (21.3) 613 (21.1) 2,356 (15.4) 
Oestrogens* 2 (2.6) 4 (1.3) 28 (1.9) 124 (1.7) 11 (0.4) 70 (0.4) 
Systemic contraceptives* 2 (2.6) 2 (0.7) 17 (1.1) 62 (0.8)   
Vasodilators* 3 (3.9) 5 (1.65) 143 (9.6) 332 (4.5) 108 (3.7) 196 (1.3) 
Hyperlipidemia‡ 16 (21.1) 55 (18.2) 379 (25.6) 1,748 (23.8) 1272 (43.8) 4,954 (32.4) 
Anti-arrythmic drugs# 0 (0.0) 1 (0.3) 14 (0.9) 79 (1.1) 60 (2.1) 265 (1.7) 
Anticoagulants# 1 (1.3) 5 (1.7) 128 (8.6) 533 (7.2) 323 (11.1) 1,332 (8.7) 
Antiplatelets# 0 (0.0) 2 (0.7) 334 (22.5) 1,093 (14.9) 626 (21.5) 1,729 (11.3) 
Aspirin in high dose# 8 (10.5) 23 (7.6)     
Low-dose aspirin# 0 (0.0) 1 (0.3) 305 (20.6) 1,165 (15.8)   
Hormone replacement 
therapy# 
0 (0.0) 2 (0.7) 10 (0.7) 46 (0.6) 71 (2.4) 434 (2.8) 
Oestrogens# 1 (1.3) 3 (1.0) 28 (1.9) 97 (1.3) 35 (1.2) 246 (1.6) 
Systemic contraceptives# 1 (1.3) 2 (0.7) 18 (1.2) 51 (0.7)   
Vasodilators# 3 (3.9) 4 (1.3) 294 (19.8) 451 (6.1) 338 (11.6) 716 (4.7) 
Comorbid diseases:       
Atrial Fibrillation† 0 (0.0) 1 (0.3) 65 (4.4) 256 (3.5) 491 (16.9) 1,414 (9.3) 
Any cerebrovascular 
disease† 
0 (0.0) 2 (0.7) 77 (5.2) 212 (2.9) 535 (18.4) 1,373 (9.0) 
Chronic Kidney disease† 2 (2.6) 3 (1.0) 18 (1.2) 55 (0.7) 616 (21.2) 1,454 (9.5) 
Ischemic Heart Disease† 1 (1.3) 2 (0.7) 226 (15.2) 474 (6.4) 1,354 (46.6) 3,405 (22.3) 
Myocardial Infarction† 2 (2.63 0 (0.0) 104 (7.0) 256 (3.5) 375 (12.9) 942 (6.2) 
Peripheral Arterial 
Disease† 
0 (0.0) 1 (0.3) 45 (3.0) 116 (1.6) 449 (15.5) 989 (6.5) 
Renal Failure† 0 (0.0) 0 (0.0) 5 (0.3) 14 (0.2) 73 (2.5) 87 (0.6) 
Heart Failure‡ 25 (32.9) 101 (33.3) 27 (1.8) 94 (1.3) 446 (15.4) 1057 (6.9) 
Obesity‡ 2 (2.6) 1 (0.3) 6 (0.4) 27 (0.4) 81 (2.8) 288 (1.9) 
Smoking‡ 4 (5.3) 9 (3.0)   118 (4.1) 295 (1.9) 
Cancer 3 (3.9) 1 (0.3) 55 (3.7) 257 (3.5) 170 (5.9) 617 (4.0) 
 
 
Table 3. Prevalence of Confounders in cases and controls per database (continued). 
 
* assessed in 30 days before cohort entry; # assessed 30 days before index date; † assessed at cohort entry and index date; ‡ 
assessed 1 year before cohort entry. 
 
Adjusted analyses 
 
Figure 2 shows  the estimates for metformin obtained from one-stage and two-stage analyses 
when adjusting for a single confounder. Little effect on the estimate by adjusting for single 
variables was seen. Also adding 5 common confounders to the models did not affect the 
exposure estimate. The difference between the estimate from one- and two-stage analyses 
was small when adjusting for most confounders. However, when we adjusted for  1st year of 
type 2 diabetes mellitus or for use of PDE5 inhibitors and no interaction term of the covariate 
with database was included, the one-stage estimate was different from the two-stage 
estimate (T2DM: ORone-stage=0.82, 95% CI: 0.79-0.87 versus ORrandom=0.88, 95% CI: 0.82-0.95; 
PDE5 inhibitors: ORone-stage=0.82, 95% CI: 0.78-0.86 versus ORrandom=0.89, 95% CI: 0.81-0.98) 
(Figure 2 and Supplementary Table 2). When adding the interaction term, the exposure 
estimates were very similar for all adjusted estimates. However, based on the P-value of the 
interaction terms, one should consider to stratify in the one-stage analysis on database level (P 
interaction terms < 0.05) when adjusting for most confounders; which means database specific 
estimates should be considered. 
 
 IPCI PHARMO MEDICARE 
 Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Cases  
N (%) 
Controls  
N (%) 
Total number 76 303 1,483 7,359 2,905 15,271 
Potential Confounders       
Use of:       
PDE5 inhibitors*  0 (0) 1 (0.3)   12 (0.4) 57 (0.4) 
Respiratory drugs* 2 (2.6) 16 (5.3) 87 (5.9) 459 (6.2) 103 (3.5) 234 (1.5) 
Cardiac glycosides# 2 (2.6) 4 (1.3) 47 (3.2) 197 (2.7) 128 (4.4) 478 (3.1) 
PDE5 inhibitors#    19 (1.3) 59 (0.8) 28 (1.0) 138 (0.9) 
Respiratory drugs# 2 (2.6) 18 (5.9) 122 (8.2) 548 (7.4) 258 (8.9) 761 (5.0) 
Glucocorticoids# 2 (2.6) 7 (2.3) 86 (5.8) 278 (3.8) 182 (6.3) 450 (2.9) 
Comorbid diseases:       
Alcohol Abuse† 1 (1.3) 1 (0.3) 11 (0.7) 42 (0.6) 31 (1.1) 68 (0.4) 
Cardiomyopathy† 2 (2.6) 0 (0.0) 5 (0.3) 23 (0.3) 180 (6.2) 356 (2.3) 
Chronic Liver disease† 0 (0.0) 1 (0.3) 8 (0.5) 40 (0.5) 76 (2.6) 286 (1.9) 
Coagulopathies†     199 (6.9) 522 (3.4) 
Congenital heart 
disease† 
    21 (0.7) 56 (0.4) 
Chronic Obstructive 
Pulmonary Disease† 
  39 (2.6) 150 (2.0) 610 (21.0) 1,513 (9.9) 
Drug abuse†     29 (1.0) 58 (0.4) 
Deep Vein Thrombosis/ 
Pulmonary Embolism† 
    80 (2.8) 217 (1.4) 
Endocarditis† 0 (0.0) 1 (0.3)   21 (0.7) 57 (0.4) 
Cardiac valve disorders† 1 (1.3) 1 (0.3) 21 (1.4) 76 (1.0) 344 (11.8) 861 (5.6) 
Ventricular arrythmia†   5 (0.34) 31 (0.42) 7 (0.2) 18 (0.1) 
Hypoglycemic events#     53 (1.8) 58 (0.4) 
	 Pooling	of	data	from	multiple	data	sources	|	291  290	|	Chapter	7.1
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Figure 3. Unadjusted and adjusted odds ratios by one- and two-stage analyses for current use of glimepiride as 
monotherapy compared to current use of metformin with a sulfonylurea. 
 
For glimepiride the one-stage and two-stage analyses yielded similar estimates, also when 
adjusting for a single confounder of when adjusting for multiple common confounders. 
However, for most adjusted estimates a higher level of heterogeneity was seen than for 
metformin. Adding the interaction term of confounder with  database did not affect the 
exposure estimate, though the interaction terms were significant (Supplementary Table 3). 
 
DISCUSSION 
 
In this matched nested case-control study among nine databases in the SAFEGUARD project 
using a common data model we compared one-stage and two-stage analyses to obtain an 
overall meta-analytic estimate. Both analyses provided similar estimates even when including 
a variety of confounders and interactions of  database with the covariates. 
Nowadays there are many projects that are using a common data model or 
distributed network, such as Mini-Sentinel,490, 493 HMO Research Network,494 the Observational 
Medical Outcomes Partnership (OMOP),489 the EU-ADR project346 and IMI-PROTECT.237 One of 
the key reasons that such distributed networks have been developed is the need to conduct 
large-scale epidemiologic studies while preserving data privacy and legacy issues. Within these 
networks it is possible that data partners contribute summary data or results while keeping 
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Figure 3. Unadjusted and adjusted odds ratios by one- and two-stage analyses for current use of glimepiride as 
monotherapy compared to current use of metformin with a sulfonylurea. 
 
For glimepiride the one-stage and two-stage analyses yielded similar estimates, also when 
adjusting for a single confounder of when adjusting for multiple common confounders. 
However, for most adjusted estimates a higher level of heterogeneity was seen than for 
metformin. Adding the interaction term of confounder with  database did not affect the 
exposure estimate, though the interaction terms were significant (Supplementary Table 3). 
 
DISCUSSION 
 
In this matched nested case-control study among nine databases in the SAFEGUARD project 
using a common data model we compared one-stage and two-stage analyses to obtain an 
overall meta-analytic estimate. Both analyses provided similar estimates even when including 
a variety of confounders and interactions of  database with the covariates. 
Nowadays there are many projects that are using a common data model or 
distributed network, such as Mini-Sentinel,490, 493 HMO Research Network,494 the Observational 
Medical Outcomes Partnership (OMOP),489 the EU-ADR project346 and IMI-PROTECT.237 One of 
the key reasons that such distributed networks have been developed is the need to conduct 
large-scale epidemiologic studies while preserving data privacy and legacy issues. Within these 
networks it is possible that data partners contribute summary data or results while keeping 
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data on individual-level locally and thus accounting for security issues. In one-stage analyses 
information from individual study subjects is needed. A disadvantage of the one-stage 
analysis,  also known as individual patient-level pooled data analysis, is that only variables and 
exposures common to all databases can be used, whereas in two-stage meta-analysis 
estimates can be pooled when adjustment for varying confounders between the databases 
was performed or when not all separate databases provide a risk estimate. On the contrary, in 
two-stage meta-analyses statistical heterogeneity is often obtained rapidly due to the sizes of 
the single databases, but this may not be always clinically relevant.492 However, neglecting the 
fact that the confounder strength could vary between databases analyzing individual patient-
level pooled data as one large dataset may result in biased exposure estimates. The inclusion 
of the data source as a possible effect modifier in one-stage analyses may encounter these 
effects. 
Several studies from the US have used local or universal propensity score (PS) models 
to summarize individual-level data from a large number of covariates in such way that use of 
this non identifiable measure of the propensity score subsequently allows pooling of site 
specific data.485-487 These cohort studies showed that estimates from analyses with adjustment 
for local or universal PS provided results that are similar to results from  analyses using 
individual-patient level data.485-487 Despite that PS-based pooling allows for consistency of 
adjustment for common confounders across the data sites, it does not fully use additional 
confounder information that may be available at certain data sites. The final obtained 
exposure estimates in each of the data sites should still be summarized in a summary and 
overall statistic.485 A key advantage of the ability to pool individual patient-level data is to 
conduct more specific and flexible analyses, such as multivariable-adjusted and stratified 
analyses. Additionally, considering a rare exposure it may be possible to obtain enough 
exposed events when combining all data from partners, whereas this may not be possible 
when each individual data site provides a risk estimate. However, when considering that 
different data sources may contain heterogeneous populations and variations of the ability to 
capture covariates we evaluated whether individual-patient level pooling of data should be 
preferred over two-stage analysis that is usually considered in distributed networks.490 
We noticed that both methods provided similar results, not only when adjusting for 
single variables, but also when adjusting for covariates that were common across all the 
databases. It has been proven that, if there is no heterogeneity of the exposure effect among 
databases, the individual-patient level data analysis and meta-analysis provide similar results 
when a maximum likelihood estimation, such as in logistic regression, is used.495 What may be 
one of the main reasons that we observed very similar results between the one-stage and two-
stage analyses is the common work-up in a distributed network of electronic healthcare 
databases. The EU-ADR project has provided a platform that allowed data partners to locally 
extract and transform data to a standard format before running the common software 
(Jerboa©).346 By using a common model, uniform data-file structures, definitions of events and 
covariates are achieved. The subsequent statistical analysis on the obtained data is a fairly 
easy step which may be easily applied to each site-specific dataset. Besides this common data 
 
 
model, a huge effort within the SAFEGUARD project was done to harmonize definitions of 
events and covariates to identify disease codes from different coding systems, health care 
systems and different natures of the databases for the same clinical concept. As we have 
learned in the past years, interpretation of the same research question or even same protocol 
applied to the same database may lead to different programming specifications and diverse 
conclusions.496-499 The statistical combination of results from different databases may be more 
problematic and jeopardized when underlying populations, definitions and confounding 
aspects are more heterogeneous between the databases.500 It is therefore highly important to 
consider combining data or results only from populations and databases that in principle can 
be considered equal or comparable. Although the US population in the current study may be 
of older age, it appeared that the exposure effect and confounder-outcome associations 
showed the same pattern as in the other databases. For instance, we included two versions of 
adjustment for five common confounders with one version excluding the Medicare dataset as 
this did not contain information on low-dose aspirin use. Nevertheless, both versions of 
adjustment for common confounders provided similar results. 
Within the incident type 2 diabetes mellitus cohort we matched on the most 
important factors for outcomes in these patients. This may subsequently have resulted in 
removing most important confounding, although the matching itself may as well have 
introduced residual confounding. 
Strength of the current study is the availability of data on both stages of the models 
while having a common work-up, data transformation and statistical analyses in a large 
distributed network of data partners. By doing so, we removed any influence of different 
interpretations and programming specifications from each data site.  
 Our study also suffers from limitations. First, we used a nested case-control design 
matching up to 10 controls to each case thus we relied on conditional logistic regression 
whereas generalized linear mixed models may allow more flexible analyses. Also, we used a 
common data model and thus our results of comparison between one- and two-stage analyses 
may not necessarily be applicable to studies or distributed networks not using a common data 
model. As we have investigated acute myocardial infarction, assuming this is a commonly 
investigated outcome and likely captured accurately in all of the participating databases, our 
results are theoretically only applicable to this outcome and two exposures. Although caution 
should be considered, interpretation of our results in the context of other acute, common and 
easily defined outcomes and other types of drugs may be applicable. 
In conclusion, in this nested case-control study among nine databases in the 
SAFEGUARD project using a common data model estimates from one-stage and two-stage 
analyses were similar in unadjusted analyses and when including a variety of confounders. 
When sharing individual-level data is not possible, meta-analysis of estimates from different 
data sites obtained in a distributed network with a common data model may be considered an 
as good alternative to one-stage analysis. 
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Supplementary Table 2. Odds Ratios from one-stage and two-stage analyses for current use of metformin 
monotherapy compared to current use of metformin with a sulfonylurea. 
 
One-Stage  Two-Stage 
No interaction Interaction P-value   Fixed effects Random effects 
Model OR 95%CI OR 95%CI ‡  OR 95%CI OR 95%CI I² 
Matched 0.82 0.78-0.86 NA   0.83 0.79-0.88 0.84 0.78-0.91 49 
Adjusted:   
5 common 
confounders* 0.82 0.78-0.86 0.82 0.78-0.86 
  
0.82 0.78-0.87 0.83 0.77-0.90 42 
5 common 
confounders# 0.81 0.77-0.85 0.81 0.78-0.86 
  
0.82 0.78-0.86 0.83 0.77-0.90 49 
Use of:   
ACE-inhibitors 0.82 0.78-0.86 0.82 0.78-0.86 0.001  0.83 0.79-0.87 0.84 0.77-0.90 47 
Low-dose 
aspirin 0.82 0.78-0.86 0.82 0.78-0.87 <0.0001 
 
0.83 0.79-0.88 0.84 0.77-0.93 56 
Beta-blockers 0.81 0.78-0.86 0.81 0.78-0.85 <0.0001  0.83 0.79-0.87 0.83 0.77-0.90 48 
Calcium 
antagonists 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.83 0.79-0.87 0.83 0.77-0.90 49 
Diuretics 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001  0.83 0.79-0.87 0.83 0.77-0.90 47 
Lipid lowering 
drugs 0.81 0.77-0.85 0.81 0.77-0.85 <0.0001 
 
0.82 0.78-0.86 0.83 0.76-0.89 49 
PDE5 
inhibitors 0.82 0.78-0.86 0.90 0.83-0.96 0.341 
 
0.90 0.84-0.97 0.89 0.81-0.98 38 
Systemic 
contraceptives 0.82 0.78-0.86 0.83 0.78-0.88 0.657 
 
0.84 0.79-0.88 0.85 0.75-0.96 68 
Vasodilators 0.82 0.79-0.87 0.82 0.78-0.86 <0.0001  0.83 0.79-0.88 0.84 0.78-0.91 45 
Diseases:   
Atrial 
Fibrillation 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.79 0.76-0.83 0.80 0.74-0.86 51 
Chronic Kidney 
Disease 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.83 0.79-0.88 0.84 0.78-0.91 49 
Deep Vein 
Thrombosis/Pu
lmonary 
embolism 0.82 0.78-0.86 0.82 0.78-0.86 0.068 
 
0.83 0.79-0.87 0.84 0.77-0.91 53 
Endocarditis 0.82 0.78-0.86 0.81 0.77-0.85 0.916  0.82 0.78-0.86 0.82 0.76-0.89 47 
Hyperlipidemia 0.81 0.77-0.85 0.81 0.77-0.85 <0.0001  0.82 0.78-0.86 0.83 0.76-0.89 49 
Hypoglycemic 
events 0.82 0.78-0.86 0.83 0.79-0.87 0.004 
 
0.84 0.8-0.89 0.85 0.78-0.94 64 
Ischemic Heart 
Disease 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.83 0.79-0.87 0.84 0.78-0.9 40 
Myocardial 
Infarction 0.83 0.79-0.87 0.82 0.79-0.87 <0.0001 
 
0.83 0.79-0.87 0.84 0.77-0.91 54 
Obesity 0.82 0.78-0.86 0.82 0.78-0.86 0.008  0.83 0.79-0.87 0.84 0.78-0.91 47 
PAD† 0.83 0.79-0.87 0.83 0.79-0.87 <0.0001  0.84 0.8-0.88 0.85 0.78-0.91 48 
Renal Failure 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001  0.84 0.8-0.89 0.85 0.77-0.95 72 
1st year of 
T2DM 0.82 0.79-0.87 0.89 0.83-0.95 0.111 
 
0.89 0.83-0.95 0.88 0.82-0.95 14 
 
NA, not applicable. 
*adjusted for hyperlipidemia, ischemic heart disease, use of lipid lowering drugs, vasodilators and beta-blockers. 
# adjusted for hyperlipidemia, use of lipid lowering drugs, vasodilators, low-dose aspirin and beta-blockers. 
† PAD, peripheral arterial disease. ‡ P-value interaction. 
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Supplementary Table 2. Odds Ratios from one-stage and two-stage analyses for current use of metformin 
monotherapy compared to current use of metformin with a sulfonylurea. 
 
One-Stage  Two-Stage 
No interaction Interaction P-value   Fixed effects Random effects 
Model OR 95%CI OR 95%CI ‡  OR 95%CI OR 95%CI I² 
Matched 0.82 0.78-0.86 NA   0.83 0.79-0.88 0.84 0.78-0.91 49 
Adjusted:   
5 common 
confounders* 0.82 0.78-0.86 0.82 0.78-0.86 
  
0.82 0.78-0.87 0.83 0.77-0.90 42 
5 common 
confounders# 0.81 0.77-0.85 0.81 0.78-0.86 
  
0.82 0.78-0.86 0.83 0.77-0.90 49 
Use of:   
ACE-inhibitors 0.82 0.78-0.86 0.82 0.78-0.86 0.001  0.83 0.79-0.87 0.84 0.77-0.90 47 
Low-dose 
aspirin 0.82 0.78-0.86 0.82 0.78-0.87 <0.0001 
 
0.83 0.79-0.88 0.84 0.77-0.93 56 
Beta-blockers 0.81 0.78-0.86 0.81 0.78-0.85 <0.0001  0.83 0.79-0.87 0.83 0.77-0.90 48 
Calcium 
antagonists 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.83 0.79-0.87 0.83 0.77-0.90 49 
Diuretics 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001  0.83 0.79-0.87 0.83 0.77-0.90 47 
Lipid lowering 
drugs 0.81 0.77-0.85 0.81 0.77-0.85 <0.0001 
 
0.82 0.78-0.86 0.83 0.76-0.89 49 
PDE5 
inhibitors 0.82 0.78-0.86 0.90 0.83-0.96 0.341 
 
0.90 0.84-0.97 0.89 0.81-0.98 38 
Systemic 
contraceptives 0.82 0.78-0.86 0.83 0.78-0.88 0.657 
 
0.84 0.79-0.88 0.85 0.75-0.96 68 
Vasodilators 0.82 0.79-0.87 0.82 0.78-0.86 <0.0001  0.83 0.79-0.88 0.84 0.78-0.91 45 
Diseases:   
Atrial 
Fibrillation 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.79 0.76-0.83 0.80 0.74-0.86 51 
Chronic Kidney 
Disease 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.83 0.79-0.88 0.84 0.78-0.91 49 
Deep Vein 
Thrombosis/Pu
lmonary 
embolism 0.82 0.78-0.86 0.82 0.78-0.86 0.068 
 
0.83 0.79-0.87 0.84 0.77-0.91 53 
Endocarditis 0.82 0.78-0.86 0.81 0.77-0.85 0.916  0.82 0.78-0.86 0.82 0.76-0.89 47 
Hyperlipidemia 0.81 0.77-0.85 0.81 0.77-0.85 <0.0001  0.82 0.78-0.86 0.83 0.76-0.89 49 
Hypoglycemic 
events 0.82 0.78-0.86 0.83 0.79-0.87 0.004 
 
0.84 0.8-0.89 0.85 0.78-0.94 64 
Ischemic Heart 
Disease 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001 
 
0.83 0.79-0.87 0.84 0.78-0.9 40 
Myocardial 
Infarction 0.83 0.79-0.87 0.82 0.79-0.87 <0.0001 
 
0.83 0.79-0.87 0.84 0.77-0.91 54 
Obesity 0.82 0.78-0.86 0.82 0.78-0.86 0.008  0.83 0.79-0.87 0.84 0.78-0.91 47 
PAD† 0.83 0.79-0.87 0.83 0.79-0.87 <0.0001  0.84 0.8-0.88 0.85 0.78-0.91 48 
Renal Failure 0.82 0.78-0.86 0.82 0.78-0.86 <0.0001  0.84 0.8-0.89 0.85 0.77-0.95 72 
1st year of 
T2DM 0.82 0.79-0.87 0.89 0.83-0.95 0.111 
 
0.89 0.83-0.95 0.88 0.82-0.95 14 
 
NA, not applicable. 
*adjusted for hyperlipidemia, ischemic heart disease, use of lipid lowering drugs, vasodilators and beta-blockers. 
# adjusted for hyperlipidemia, use of lipid lowering drugs, vasodilators, low-dose aspirin and beta-blockers. 
† PAD, peripheral arterial disease. ‡ P-value interaction. 
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SUMMARY 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for pain relief and anti-
inflammatory purposes. They are often combined with proton pump inhibitors (PPIs), the most 
potent blockers of gastric acid secretion to reduce gastroduodenal complications of NSAID use. 
This thesis studied the use and safety of NSAIDs and PPIs. An overview of the main results of 
studies in this thesis is shown in Table 1. After an introduction to the topic in the first section 
we continue in the second section with a review of the use of PPIs in elderly. PPIs are often co-
prescribed with NSAIDs in order to mitigate the risk of NSAID-related upper gastrointestinal 
(GI) erosions and ulcers, including complicated ulcer disease. However, the use of PPIs is 
associated with increased risks of adverse events, as is discussed in Chapter 2.1. The evidence 
that has been accumulated for these associations so far is, nevertheless, scarce.  
 
In Section 3 we focus on the occurrence of two esophageal diseases [i.e., Barrett’s esophagus 
(BE) and esophageal adenocarcinoma (EAC)] that may be prevented or treated by use of 
NSAIDs or PPIs. The pathogenesis of Barrett’s esophagus (BE) include prolonged gastro-
esophageal reflux from the stomach into the lower esophagus. Subsequently, esophageal 
adenocarcinoma (EAC) could develop through stepwise progression from BE to low-grade and 
high-grade dysplasia until neoplasia. Current treatment regimens for patients diagnosed with 
BE include amongst others the use of proton pump inhibitors. We first showed that the 
incidence of BE increased in the Netherlands and the United Kingdom until 2003 and levelled 
off thereafter. In contrast, the incidence of EAC continued to increase until now. However, 
among BE patients incident EAC occurred in only 0.3% of BE patients (Chapter 3.1). The 
survival rate of EAC is still very poor, leaving substantial need for additional therapy or 
prevention of EAC. However, we could not demonstrate that NSAIDs and PPIs resulted in a 
decrease in risk of EAC among BE patients (Chapter 3.2). 
 
Section 4 is devoted to the risk of upper gastrointestinal (GI) events associated with NSAIDs. 
NSAIDs inhibit cyclo-oxygenase (COX)-1 and COX-2 enzyme to a varying extent. After the 
introduction of selective COX-2 inhibitors on the market, these were preferentially prescribed 
to high-risk patients. In Chapter 4.1 we demonstrate that use of a propensity score based on 
information in the electronic health care record allows to take channeling of NSAIDs to higher 
risk patients into account. Based on a similar propensity (or chance) to receive either 
nonselective (ns) NSAIDs or selective COX-2 inhibitors the use of a PPI with traditional 
nsNSAIDs yielded an equal risk of upper GI complications as selective COX-2 inhibitors (Chapter 
4.2). The risk of upper GI events may be influenced by other patient characteristics and by use 
of other drugs. Though guidelines suggest to avoid certain drug combinations it was unclear to 
which extent the risk of upper GI bleeding was increased and whether there could be a 
difference between nsNSAIDs and selective COX-2 inhibitors. In Chapter 4.3 we show that 
when multiple drugs are used concomitantly with nsNSAIDs, selective COX-2 inhibitors or low-
 
 
dose aspirin, the risk of upper GI bleeding differs and may be higher than expected on the 
basis of the individual risks.  
 
In section 5 we look at the effects of NSAIDs and PPIs on the lower GI tract. First we looked at 
the occurrence of microscopic colitis (MC) and demonstrated that the increase in incidence of 
MC in the Netherlands is not explained by an increase in the total number of colonoscopies in 
the last decade, which is a procedure that is required to detect microscopic colitis (Chapter 
5.1). We demonstrated that NSAIDs and PPIs were associated with an increase in the risk of 
MC (Chapter 5.2). In the last chapter of section 5 (Chapter 5.3) we looked at the prognosis of 
MC patients by using data from the national pathology registers in Denmark and the 
Netherlands. Patients with MC were more often diagnosed with colorectal polyps and 
adenomas during follow-up as compared to the general population. 
 
In section 6 we continued with NSAIDs but now focused on their cardiovascular effects. Based 
on a multi-national project we were able to estimate the risk of acute myocardial infarction 
(AMI) for twenty-eight individual NSAID compounds. The risk of AMI was increased for 
thirteen different NSAIDs (Chapter 6.1). When combining all evidence from different studies in 
the multi-national project we were able to provide a decision model to assess for an individual 
patient which NSAID is relatively the safest choice (Chapter 6.2). It appeared that celecoxib 
and ketoprofen were most favorable NSAIDs while ketorolac and etoricoxib were most 
harmful NSAIDs. 
 
Since all of the work in the previous sections is based on the use of electronic health care 
databases in one or more countries, the last section (section 7, Chapter 7.1) describes a 
methodological approach on how to integrate and how to combine results or data from these 
separate data sources. Individual patient-level data analysis appeared to provide very similar 
results as compared to the regular meta-analysis from data site specific results.  
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DISCUSSION 
 
USE AND EFFECTS OF PROTON PUMP INHIBITORS 
 
Health care is a rapidly evolving and developing area. Nowadays, many novel, experimental 
therapies are being studied, implemented and becoming available for a wide variety of 
patients. The field of medicine is shifting from patient care to cure and prevention of disease. 
This goes hand in hand with increasing use of medical diagnostic and therapeutic utilities, 
including medication. In this thesis, we focus on the gastro-intestinal (GI) tract. Proton pump 
inhibitors are drugs that are used for gastrointestinal diseases and have been on the market 
for decades. The use of proton pump inhibitors have made a major change in the frequency of 
hospitalizations for GI events in the past decades.  
As PPIs are the most potent acid-inhibiting drugs, they are often co-prescribed with 
NSAIDs to prevent the negative effect that NSAIDs may have on the GI tract. However, there 
are other indications for use of PPIs as described in this thesis The majority of PPI users are 
elderly people and use of these drugs in elderly has been reported to be associated with 
adverse events such as fractures, bacterial enteric infections and vitamin deficiencies. 
However based on the available literature, we could not find evidence that there would be 
strong associations between PPI use and outcomes including bone fractures, pneumonia, 
vitamin B12 and iron absorption, Clostridium difficile infection and other enteric infections, 
hypomagnesemia and acute interstitial nephritis. Also the inconsistency of evidence leaves it 
unclear whether drug-interaction between PPIs and clopidogrel or low-dose aspirin would be 
clinically relevant. The risks reported in the different studies are modest and many questions 
can be raised when interpreting the results. In addition the outcomes are rare resulting in low 
excess risks in the population even if the risk would be slightly elevated. Considering the 
benefits and the risks of PPIs the relevant question to ask nowadays is probably not so much 
whether we should treat or not with a PPI based on potential risks, but whether the elderly 
patient has the proper indication for continued use of the PPI. Properly balancing the 
indication, benefits and harms of PPI therapy on an individual level can substantially minimize 
avoidable risk, morbidity and reduce health care costs.  
We know that PPIs are very effective drugs to reduce the risk of upper GI events, 
such as bleeding and perforation. Furthermore in recent years, the costs of PPIs have dropped 
considerably. The widespread use of PPIs for a large variety of indications and often prolonged 
duration led to an enormous amount of costs in health care budgets.16 The minister of Health, 
Welfare and Sport decided in 2013 therefore that PPIs should no longer be reimbursed for all 
patients. Since this decision could have a negative effect on the prevention of GI bleedings 
when using NSAIDs or low-dose aspirin it was surprising that the number of upper GI bleedings 
was reported to decrease in 2014.16 Not only a decrease in the budget of PPI reimbursement 
was achieved, but as well in care of patients with upper GI bleeding or complications. However 
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DISCUSSION 
 
USE AND EFFECTS OF PROTON PUMP INHIBITORS 
 
Health care is a rapidly evolving and developing area. Nowadays, many novel, experimental 
therapies are being studied, implemented and becoming available for a wide variety of 
patients. The field of medicine is shifting from patient care to cure and prevention of disease. 
This goes hand in hand with increasing use of medical diagnostic and therapeutic utilities, 
including medication. In this thesis, we focus on the gastro-intestinal (GI) tract. Proton pump 
inhibitors are drugs that are used for gastrointestinal diseases and have been on the market 
for decades. The use of proton pump inhibitors have made a major change in the frequency of 
hospitalizations for GI events in the past decades.  
As PPIs are the most potent acid-inhibiting drugs, they are often co-prescribed with 
NSAIDs to prevent the negative effect that NSAIDs may have on the GI tract. However, there 
are other indications for use of PPIs as described in this thesis The majority of PPI users are 
elderly people and use of these drugs in elderly has been reported to be associated with 
adverse events such as fractures, bacterial enteric infections and vitamin deficiencies. 
However based on the available literature, we could not find evidence that there would be 
strong associations between PPI use and outcomes including bone fractures, pneumonia, 
vitamin B12 and iron absorption, Clostridium difficile infection and other enteric infections, 
hypomagnesemia and acute interstitial nephritis. Also the inconsistency of evidence leaves it 
unclear whether drug-interaction between PPIs and clopidogrel or low-dose aspirin would be 
clinically relevant. The risks reported in the different studies are modest and many questions 
can be raised when interpreting the results. In addition the outcomes are rare resulting in low 
excess risks in the population even if the risk would be slightly elevated. Considering the 
benefits and the risks of PPIs the relevant question to ask nowadays is probably not so much 
whether we should treat or not with a PPI based on potential risks, but whether the elderly 
patient has the proper indication for continued use of the PPI. Properly balancing the 
indication, benefits and harms of PPI therapy on an individual level can substantially minimize 
avoidable risk, morbidity and reduce health care costs.  
We know that PPIs are very effective drugs to reduce the risk of upper GI events, 
such as bleeding and perforation. Furthermore in recent years, the costs of PPIs have dropped 
considerably. The widespread use of PPIs for a large variety of indications and often prolonged 
duration led to an enormous amount of costs in health care budgets.16 The minister of Health, 
Welfare and Sport decided in 2013 therefore that PPIs should no longer be reimbursed for all 
patients. Since this decision could have a negative effect on the prevention of GI bleedings 
when using NSAIDs or low-dose aspirin it was surprising that the number of upper GI bleedings 
was reported to decrease in 2014.16 Not only a decrease in the budget of PPI reimbursement 
was achieved, but as well in care of patients with upper GI bleeding or complications. However 
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this was an ecological study (a study in which variables are correlated based on group level 
measurements). Typically ecological studies are used to describe patterns among the 
population, e.g. the incidence of cancer in different geographical areas in a country, but do not 
allow to make causal statements. This implies that the observed simultaneous occurrence of 
reduced reimbursement of PPIs and a decrease in incidence of upper GI bleedings can also be 
attributed to an ecological fallacy. It would be highly counterintuitive to assume that not 
reimbursing PPIs (thereby reducing the use in the population) reduces the risk of upper GI 
bleeding. It is likely that other factors may explain this finding, such as: those that need the 
PPIs the most, e.g. high risk patients actually are using the PPIs; whereas the ‘inappropriate’ 
users are not anymore. A more in to depth and detailed study on the actual intake of PPIs, the 
characteristics of patients using PPIs and the outcome of these patients (e.g. need of 
emergency department visits, hospitalization, endoscopy) should be performed before making 
such a strong statement on the ‘effective’ removal of PPI reimbursement. 
 
NSAIDS AND PPIS IN THE CONTEXT OF BARRETT’S ESOPHAGUS AND 
ESOPHAGEAL ADENOCARCINOMA 
 
Incidence of Barrett’s esophagus and esophageal adenocarcinoma 
 
Barrett’s esophagus (BE) is characterized by replacement of the squamous epithelium of the 
esophagus by metaplastic columnar epithelium. It is considered a consequence of prolonged 
gastro-esophageal reflux into the lower esophagus.219, 220 Apart from obesity and smoking, BE 
is an important risk factor for the development of esophageal adenocarcinoma (EAC) via a 
stepwise pathway of low-grade and high-grade dysplasia.219, 220 It is estimated that the risk of 
EAC is increased approximately 30 to 125 fold in persons with BE.221 Endoscopic surveillance 
for EAC among patients with BE is therefore recommended,222 though there is only modest 
evidence that endoscopic surveillance of BE improves EAC-related outcomes.501 Although 
several studies reported on incidences of BE based on selected patients in hospitals or 
specialty clinics,232, 234, 235 the epidemiology of BE and EAC among the general population, and 
particularly of EAC among patients with BE remained until some years ago largely unknown. 
We showed that the incidence of BE increased in the beginning of the millennium both in the 
United Kingdom with 35% and in the Netherlands with 41%, but the incidence levelled off 
after 2003. In contrast, the incidence of EAC in a cohort of BE patients continues to increase. 
The one-year risk of EAC among newly diagnosed BE patients was 0.09%.The levelling off of BE 
incidence was also observed by others,223 and may be explained by the following items: 1) 
restriction of gastroscopy referrals in dyspepsia guidelines; 2) birth cohort effect; 3) better and 
earlier treatment of GERD and dyspepsia. Since BE is a well acknowledged risk factor for EAC 
development, patterns in the incidence of BE are likely to impact the incidence of EAC as well, 
although any effect of this is likely to appear in the next 10 to 15 years due to the decade-long 
 
 
lag time between BE and EAC development. Given the fact that many BE patients are 
asymptomatic, identifying the ‘true’ incidence of BE among the general population is 
challenging. A population-based screening program to diagnose and detect all subjects with BE 
in the population may not be cost-effective as screening for EAC is not cost effective either.502 
Although we adhere to the stepwise development of neoplasia approach from BE to EAC, it 
was shown that 95% of subjects undergoing EAC resection had not been diagnosed with BE 
before.503 The current endoscopic surveillance regimen for patients with BE is therefore under 
debate.504 This debate is also fueled by the fact that 25% of EACs are diagnosed within 1 year 
after initial BE diagnosis.504 A better diagnostic approach may be to screen high-risk patients. 
Additional risk stratification methods such as molecular markers may be considered for this 
and are currently being studied.502 In order to identify the most promising markers for 
appropriate and optimal risk stratification with individual patient predictions requires close 
collaboration across different Barrett’s disease cohorts to capitalize on power and 
heterogeneity across populations. The benefit of screening for BE or EAC should not be limited 
to the effect of EAC development but also to the effect on EAC-specific and overall mortality. 
Recognizing a large variety of potential, yet imperfect, strategies and markers to control the 
overall burden of EAC, the optimal way at the moment to gain effective primary prevention of 
BE and EAC would be controlling for risk factors of BE such as obesity, smoking and gastro-
esophageal reflux.502 
 
Risk of esophageal adenocarcinoma in patients with Barrett’s esophagus 
 
Gastrointestinal cancers account for almost 25% of all cancers and approximately 4.9% of all 
deaths worldwide.225 Death rates of most cancers decreased in recent years, while the marked 
increase in death rate for esophageal adenocarcinoma between 1970 and 2005 is now also 
slowly tapering off and decreasing.505 Despite the evolving therapeutic options for esophageal 
cancer, the age-standardized mortality rate remains 5.1/100,000 person-years.254 As a result, 
there remains a substantial need for additional therapy or even effective prevention of 
esophageal cancer, particularly given the low 5-year survival rate of 13% to 17%.505 Some 
investigators have shown unexpectedly large risk reductions of EAC, up to 70% by use of 
NSAIDs, PPIs, low-dose aspirin and statins. These results were however seen in selected 
populations and immortal time bias was present.245, 261, 266 Whether such a chemopreventive 
effect of these drugs applies to an unselected population of newly diagnosed BE patients is 
unknown. We could not show a significant risk reduction of high-grade dysplasia (HGD) or EAC 
by use of these drugs as reported in this thesis. This indicates that for an unselected group of 
patients with BE, as is common in daily clinical practice in non-academic, non-specialized 
hospitals, chemoprevention of EAC by NSAIDs, PPIs, low-dose aspirin and statins should not be 
considered as routine care. There are several reasons why our study may have been unable to 
confirm results from previous studies. First we had less power than other studies, which 
impacts significance of effect sizes and demonstrates that previously observed effects are 
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this was an ecological study (a study in which variables are correlated based on group level 
measurements). Typically ecological studies are used to describe patterns among the 
population, e.g. the incidence of cancer in different geographical areas in a country, but do not 
allow to make causal statements. This implies that the observed simultaneous occurrence of 
reduced reimbursement of PPIs and a decrease in incidence of upper GI bleedings can also be 
attributed to an ecological fallacy. It would be highly counterintuitive to assume that not 
reimbursing PPIs (thereby reducing the use in the population) reduces the risk of upper GI 
bleeding. It is likely that other factors may explain this finding, such as: those that need the 
PPIs the most, e.g. high risk patients actually are using the PPIs; whereas the ‘inappropriate’ 
users are not anymore. A more in to depth and detailed study on the actual intake of PPIs, the 
characteristics of patients using PPIs and the outcome of these patients (e.g. need of 
emergency department visits, hospitalization, endoscopy) should be performed before making 
such a strong statement on the ‘effective’ removal of PPI reimbursement. 
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for EAC among patients with BE is therefore recommended,222 though there is only modest 
evidence that endoscopic surveillance of BE improves EAC-related outcomes.501 Although 
several studies reported on incidences of BE based on selected patients in hospitals or 
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particularly of EAC among patients with BE remained until some years ago largely unknown. 
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after initial BE diagnosis.504 A better diagnostic approach may be to screen high-risk patients. 
Additional risk stratification methods such as molecular markers may be considered for this 
and are currently being studied.502 In order to identify the most promising markers for 
appropriate and optimal risk stratification with individual patient predictions requires close 
collaboration across different Barrett’s disease cohorts to capitalize on power and 
heterogeneity across populations. The benefit of screening for BE or EAC should not be limited 
to the effect of EAC development but also to the effect on EAC-specific and overall mortality. 
Recognizing a large variety of potential, yet imperfect, strategies and markers to control the 
overall burden of EAC, the optimal way at the moment to gain effective primary prevention of 
BE and EAC would be controlling for risk factors of BE such as obesity, smoking and gastro-
esophageal reflux.502 
 
Risk of esophageal adenocarcinoma in patients with Barrett’s esophagus 
 
Gastrointestinal cancers account for almost 25% of all cancers and approximately 4.9% of all 
deaths worldwide.225 Death rates of most cancers decreased in recent years, while the marked 
increase in death rate for esophageal adenocarcinoma between 1970 and 2005 is now also 
slowly tapering off and decreasing.505 Despite the evolving therapeutic options for esophageal 
cancer, the age-standardized mortality rate remains 5.1/100,000 person-years.254 As a result, 
there remains a substantial need for additional therapy or even effective prevention of 
esophageal cancer, particularly given the low 5-year survival rate of 13% to 17%.505 Some 
investigators have shown unexpectedly large risk reductions of EAC, up to 70% by use of 
NSAIDs, PPIs, low-dose aspirin and statins. These results were however seen in selected 
populations and immortal time bias was present.245, 261, 266 Whether such a chemopreventive 
effect of these drugs applies to an unselected population of newly diagnosed BE patients is 
unknown. We could not show a significant risk reduction of high-grade dysplasia (HGD) or EAC 
by use of these drugs as reported in this thesis. This indicates that for an unselected group of 
patients with BE, as is common in daily clinical practice in non-academic, non-specialized 
hospitals, chemoprevention of EAC by NSAIDs, PPIs, low-dose aspirin and statins should not be 
considered as routine care. There are several reasons why our study may have been unable to 
confirm results from previous studies. First we had less power than other studies, which 
impacts significance of effect sizes and demonstrates that previously observed effects are 
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likely to be much smaller. Second we were rigorous in addressing biases that may have been 
part of previous studies such as selective survival bias,506 disease severity, time window bias or 
immortal time bias.276, 277 Third, drug exposure may be misclassified in some of the studies; it is 
not clear what the correct exposure window should be for prevention of cancer, and what the 
shape an exposure-effect relation would be. If there would be a chemopreventive effect it 
could be in the stage of BE to EAC, but also occur at an earlier stage, such as; prevention of BE 
or dysplasia development rather than of adenocarcinoma.507, 508 It is, however, difficult to 
disentangle drug exposure effects in three different risk periods: induction (dysplasia), latent 
(between dysplasia and cancer) and disease period (cancer). Ideally, this requires knowledge 
on exact timing of the first aberrant Barrett’s cell and subsequent stages towards HGD and 
EAC develop, which in practice is not possible. The fourth explanation for not observing a 
preventive effect in our study is the exposure prevalence, as over-the-counter use of NSAIDs 
was not captured. Putting these considerations together leads us to conclude that based on 
current evidence unguarded use of statins, NSAIDs, PPIs and low-dose aspirin for the purpose 
of EAC prevention should not be started when a patient is newly diagnosed with BE. The 
benefit-risk assessment does not seem positive. Large sample studies are needed that avoid 
the biases as stated above and should consider overall and cancer-specific survival. Even 
though effects on survival may seem marginal on an individual basis (e.g. a risk reduction of 
19% of dying from esophageal cancer by use of statins509), such a difference may potentially 
have large population impact. The risk-benefit balance and associated costs for prolonged 
survival of cancer patients should be taken into account as well. 
 
NSAIDS AND THE RISK OF UPPER GASTROINTESTINAL BLEEDING 
 
Although the pathophysiological effect of NSAIDs on the upper gastrointestinal (GI) tract is 
well-known, NSAID-related upper GI bleeding remains an important area of research. We 
know for several decades that particularly nonselective (ns) NSAIDs increase the risk of upper 
GI bleeding, ulcerations and complications by 2 to 4 fold, whereas selective COX-2 inhibitors 
are considered less harmful. However the effects of NSAIDs are not limited to the upper GI 
tract only, but extend to the lower GI tract as well.82, 330 In order to mitigate the increased risk 
of upper GI bleeding among NSAID users with increased risk of these events, clinical 
guidelines5, 99, 100, 315 suggest strategies as prescription of cyclo-oxygenase (COX)-2-selective 
inhibitors or concurrent use of gastroprotective agents (GPAs), such as proton pump inhibitors 
(PPIs). Although both preventive strategies aim to reduce the incidence of upper GI events, the 
risk of such complications cannot be eliminated completely; a considerable proportion of 
NSAID plus GPA users (6.3% to 8.5%) and COX-2 inhibitor users (3.7% to 8.9%) continues to 
experience upper GI events.76-79 Most of the clinical trials were not able to show a difference 
between COX-2 inhibitor use or NSAIDs+GPA in terms of the frequency of GI events, although 
the results may not easily be extrapolated to clinical practice due to selective inclusion of 
patients in trials, use of supra-therapeutic doses and exclusion of patients with frequently 
 
 
used concomitant medications as low-dose aspirin and corticosteroids.76-78, 82 Comparison of 
nsNSAIDs and selective COX-2 inhibitors was also done through observational studies. 
However, such studies are challenging in an observational setting since COX-2 inhibitors are 
preferentially prescribed to persons at higher risk of GI events. This phenomenon is referred to 
as ‘channeling’ 290, 291 of certain drugs – in this instance selective COX-2 inhibitors – to patients 
at high risk.294, 322, 510 This means that the baseline risk of developing the event of interest is not 
similar between the two groups of patients exposed to different drugs. This may arise due to 
differences in co-morbidity, which can cause confounding by indication. One way to deal with 
confounding by indication is the use of propensity scores, a method that is exponentially being 
used in (pharmaco)epidemiology studies as it allows in several ways to balance any of the 
baseline disproportionalities between the treatment groups and may mimic a randomized 
clinical trial.297, 302 However, identifying which information should be considered in the 
propensity score model in large structured electronic health record databases is challenging. 
The high-dimensional propensity score was developed to empirically identify a large number 
of covariates that may be confounders or proxies for otherwise unmeasurable confounders.302 
Computerization of health care provides us with large amounts of electronic data and often 
these data are not recorded in a structured way, e.g. discharge letters, notes from physicians 
are composed of abbreviated words, incomplete phrases and medical acronyms. In general 
investigators use structured information for creation of propensity scores. In this thesis we 
explored whether we could create a PS model using both unstructured and structured 
information using data from the IPCI medical record database, that contains a lot of textual 
unstructured information. It was possible to generate a PS model with use of unstructured 
free text and relevant covariates for the PS model to be identified automatically. 
While dealing with channeling of COX-2 inhibitors, we observed in this thesis that the 
risk of an upper GI event and upper GI bleeding does not differ between users of nsNSAIDs in 
combination with adherent use of a GPA and COX-2 inhibitor users. In a further analysis of the 
EU-ADR data, we also investigated whether concomitant use of drugs that increase the risk of 
upper GI events are adding up or have synergistic effects. We noticed that the risk of upper GI 
bleeding was increased for the combination of glucocorticoids and nonselective NSAIDs, the 
combined effect was stronger than adding up the separate effects. There were also drug 
combinations with selective COX-2 inhibitors that in combination showed an excess risk that 
exceeded the sum of the individual risks. Patients may not know that when they buy a 
painkiller over-the-counter – as they would normally have done – they expose themselves to a 
hazardous risk of bleeding especially if they are concurrently using other drugs. Many drug 
combinations can increase the upper GI risk, while the use of the concomitant drugs is 
common and often for long-term, e.g. aldosterone antagonists, glucocorticoids, low-dose 
aspirin and selective serotonin reuptake inhibitors. When an NSAID is indicated personalized 
medicine is important to consider the ‘safest’ group of NSAIDs for the patient. We provided 
strong evidence that this issue should be addressed by physicians, pharmacists and patients. 
However, whether risks and drug-drug interactions differ per individual type of NSAIDs is 
unclear. Also, to which extent the newer oral anticoagulants (nOACs) cause interaction with 
	 Summary	and	General	Discussion	|	307 
8
 
 
likely to be much smaller. Second we were rigorous in addressing biases that may have been 
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could be in the stage of BE to EAC, but also occur at an earlier stage, such as; prevention of BE 
or dysplasia development rather than of adenocarcinoma.507, 508 It is, however, difficult to 
disentangle drug exposure effects in three different risk periods: induction (dysplasia), latent 
(between dysplasia and cancer) and disease period (cancer). Ideally, this requires knowledge 
on exact timing of the first aberrant Barrett’s cell and subsequent stages towards HGD and 
EAC develop, which in practice is not possible. The fourth explanation for not observing a 
preventive effect in our study is the exposure prevalence, as over-the-counter use of NSAIDs 
was not captured. Putting these considerations together leads us to conclude that based on 
current evidence unguarded use of statins, NSAIDs, PPIs and low-dose aspirin for the purpose 
of EAC prevention should not be started when a patient is newly diagnosed with BE. The 
benefit-risk assessment does not seem positive. Large sample studies are needed that avoid 
the biases as stated above and should consider overall and cancer-specific survival. Even 
though effects on survival may seem marginal on an individual basis (e.g. a risk reduction of 
19% of dying from esophageal cancer by use of statins509), such a difference may potentially 
have large population impact. The risk-benefit balance and associated costs for prolonged 
survival of cancer patients should be taken into account as well. 
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know for several decades that particularly nonselective (ns) NSAIDs increase the risk of upper 
GI bleeding, ulcerations and complications by 2 to 4 fold, whereas selective COX-2 inhibitors 
are considered less harmful. However the effects of NSAIDs are not limited to the upper GI 
tract only, but extend to the lower GI tract as well.82, 330 In order to mitigate the increased risk 
of upper GI bleeding among NSAID users with increased risk of these events, clinical 
guidelines5, 99, 100, 315 suggest strategies as prescription of cyclo-oxygenase (COX)-2-selective 
inhibitors or concurrent use of gastroprotective agents (GPAs), such as proton pump inhibitors 
(PPIs). Although both preventive strategies aim to reduce the incidence of upper GI events, the 
risk of such complications cannot be eliminated completely; a considerable proportion of 
NSAID plus GPA users (6.3% to 8.5%) and COX-2 inhibitor users (3.7% to 8.9%) continues to 
experience upper GI events.76-79 Most of the clinical trials were not able to show a difference 
between COX-2 inhibitor use or NSAIDs+GPA in terms of the frequency of GI events, although 
the results may not easily be extrapolated to clinical practice due to selective inclusion of 
patients in trials, use of supra-therapeutic doses and exclusion of patients with frequently 
 
 
used concomitant medications as low-dose aspirin and corticosteroids.76-78, 82 Comparison of 
nsNSAIDs and selective COX-2 inhibitors was also done through observational studies. 
However, such studies are challenging in an observational setting since COX-2 inhibitors are 
preferentially prescribed to persons at higher risk of GI events. This phenomenon is referred to 
as ‘channeling’ 290, 291 of certain drugs – in this instance selective COX-2 inhibitors – to patients 
at high risk.294, 322, 510 This means that the baseline risk of developing the event of interest is not 
similar between the two groups of patients exposed to different drugs. This may arise due to 
differences in co-morbidity, which can cause confounding by indication. One way to deal with 
confounding by indication is the use of propensity scores, a method that is exponentially being 
used in (pharmaco)epidemiology studies as it allows in several ways to balance any of the 
baseline disproportionalities between the treatment groups and may mimic a randomized 
clinical trial.297, 302 However, identifying which information should be considered in the 
propensity score model in large structured electronic health record databases is challenging. 
The high-dimensional propensity score was developed to empirically identify a large number 
of covariates that may be confounders or proxies for otherwise unmeasurable confounders.302 
Computerization of health care provides us with large amounts of electronic data and often 
these data are not recorded in a structured way, e.g. discharge letters, notes from physicians 
are composed of abbreviated words, incomplete phrases and medical acronyms. In general 
investigators use structured information for creation of propensity scores. In this thesis we 
explored whether we could create a PS model using both unstructured and structured 
information using data from the IPCI medical record database, that contains a lot of textual 
unstructured information. It was possible to generate a PS model with use of unstructured 
free text and relevant covariates for the PS model to be identified automatically. 
While dealing with channeling of COX-2 inhibitors, we observed in this thesis that the 
risk of an upper GI event and upper GI bleeding does not differ between users of nsNSAIDs in 
combination with adherent use of a GPA and COX-2 inhibitor users. In a further analysis of the 
EU-ADR data, we also investigated whether concomitant use of drugs that increase the risk of 
upper GI events are adding up or have synergistic effects. We noticed that the risk of upper GI 
bleeding was increased for the combination of glucocorticoids and nonselective NSAIDs, the 
combined effect was stronger than adding up the separate effects. There were also drug 
combinations with selective COX-2 inhibitors that in combination showed an excess risk that 
exceeded the sum of the individual risks. Patients may not know that when they buy a 
painkiller over-the-counter – as they would normally have done – they expose themselves to a 
hazardous risk of bleeding especially if they are concurrently using other drugs. Many drug 
combinations can increase the upper GI risk, while the use of the concomitant drugs is 
common and often for long-term, e.g. aldosterone antagonists, glucocorticoids, low-dose 
aspirin and selective serotonin reuptake inhibitors. When an NSAID is indicated personalized 
medicine is important to consider the ‘safest’ group of NSAIDs for the patient. We provided 
strong evidence that this issue should be addressed by physicians, pharmacists and patients. 
However, whether risks and drug-drug interactions differ per individual type of NSAIDs is 
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other drugs should deserve attention in future research.511,512 The reach of scientific 
knowledge to the lay public is still an area that may deserve some attention. Despite news 
letters, radio interviews and guidelines, an interactive tool for patients to easily access and use 
may help towards a safer environment. By preventing upper GI bleedings through education, 
substantial reductions in health care costs can be achieved. Future studies should validate our 
findings and explore effects of subgroup interactions, such as aldosterone antagonists.  
 
NSAIDS AND THE RISK OF MICROSCOPIC COLITIS 
 
One of the most important functions of the colon is the resorption of water from the wastes 
that pass through. Inflammation of the colon interferes with this process and results in 
decreased water resorption and ultimately diarrhea. Microscopic colitis (MC) is a condition 
characterized by chronic watery diarrhea, normal radiological and endoscopic appearance, and 
microscopic inflammation of the colon. MC is recognized as a form of chronic inflammatory 
bowel diseases (IBD). IBD has been associated with an increased risk of colorectal cancer due 
to chronic inflammation.397 In recent years several studies reported on an increasing incidence 
of MC.371, 372, 395 Clinical awareness, more liberal use of colonoscopy, and routine random 
biopsy sampling in normal colonoscopies may have distorted the estimation of the ‘true’ 
incidence of the disease. These types of detection and diagnostic biases are, however, difficult 
to account for in incidence studies. In this thesis we dealt with this bias by estimating 
incidence not only on a general population level but also based on the number of 
colonoscopies. Our findings show that the actual incidence of MC remained fairly stable during 
a 10-year period in the Netherlands, and that increases that may be seen on the population 
level are due to increasing numbers of colonoscopies performed. The etiology of the disease is 
largely unknown, but because of its inflammatory character NSAIDs and PPIs have been 
suggested to alter MC development. Using a case-control design we showed that use of 
NSAIDs, PPIs, selective serotonin re-uptake inhibitors, low-dose aspirin, ACE-inhibitors, and 
beta-blockers were associated with an increased risk of MC. However, when taking 
confounding by indication, diagnostic delay and diagnostic bias into account (by comparing 
with subjects who have had a colonoscopy negative for colorectal cancer and MC), only PPIs 
and NSAIDs significantly increased the risk of MC. This finding was supported by dose-response 
analyses showing increasing estimates with higher cumulative doses used. The clinical 
implications of this study are that PPIs and NSAIDs should be avoided in subjects with a prior 
diagnosis of MC and careful evaluation about drug intake is needed when a patient is 
presenting with devastating watery diarrhea. 
Continued chronic inflammation of the colon may result in changes of cell 
compositions in the colon predisposing to development of precancerous lesions and cancer. If 
one would be able to disentangle an increased risk, extensive surveillance strategies may be 
implemented for patients with MC. Therefore we investigated the risk of colorectal polyps, 
adenomas and cancer in MC patients. We found that MC patients did not have an increased 
 
 
long-term risk of CRC as compared to the general population. MC patients are however more 
likely to develop colorectal polyps and adenomas on the long-term, which may resulted from 
prolonged colonic microscopic inflammation. Due to detection and diagnostic bias after MC 
diagnosis, more colorectal polyps, adenomas and CRC were diagnosed resulting in an 
increased risk of these outcomes in the first year following MC diagnosis. Nevertheless our 
findings did not suggest that a more extensive or tailored CRC screening program for MC 
patients than currently recommended for the general population should be considered. 
There is a large amount of data that shows that MC is a common GI disease with an 
important impact on the patients’ quality of life. Future research on MC should focus on 
shortening the diagnostic delay: e.g. primary care physicians, gastroenterologists and 
pathologists should be more aware of the disease. Unravelling the etiology of the disease and 
considering pharmacogenetic aspects may help educating physicians. Patients presenting to 
their physician with chronic diarrhea should be referred for colonoscopy or even only 
sigmoidoscopy 513, 514 with biopsy taking. As not all patients respond immediately to therapy 
and the disease is characterised by relapses careful monitoring of patients diarrhea symptoms 
and complaints is necessary. A follow-up colonoscopy for new MC patients after healing of the 
mucosal inflammation for assessment of colorectal polyps and cancer may be 
recommended,342 though colonoscopy on long-term is not needed for CRC screening. 
 
NSAIDS AND THE RISK OF CARDIOVASCULAR EVENTS 
 
After successful market introduction of the selective COX-2 inhibitors 10, 75 concerns were 
raised about their cardiovascular safety resulting in the voluntary withdrawal of rofecoxib in 
2004.11 Though the United States Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) concluded that selective COX-2 inhibitors increased the risk of 
cardiovascular events362 and posted the recommendation that these should be avoided in 
patients with ischemic heart disease, stroke or peripheral arterial disease89, 94, 95, it remained 
unclear what the cardiovascular risk of the traditional nsNSAIDs was. As part of the European 
Commission funded Safety of NSAIDs (SOS) Study we report on the risk of acute myocardial 
infarction with use of individual NSAIDs. We noticed that among twenty-eight individual NSAID 
compounds the risk of acute myocardial infarction varied with each individual agent, 13 of 
them were associated with a significant risk increase of small size. It appeared that the degree 
of COX-2 inhibition is not the unique feature determining the cardiovascular safety of NSAIDS. 
Patients with cardiovascular comorbid diseases often require co-prescriptions for comorbid 
conditions. This may challenge the physician for NSAID prescribing given the fact he needs to 
incorporate cardiovascular and gastrointestinal risk profiles, availability of drugs in his country 
and concomitant medications used. As we learned that risk of acute myocardial infarction, but 
upper GI bleeding as well, may differ per individual NSAID compound, it is important to 
balance and weigh individual patient risk to consider the relative safest NSAID for an individual 
patient. Despite some guidance from the clinical guidelines, it remains difficult for a physician 
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other drugs should deserve attention in future research.511,512 The reach of scientific 
knowledge to the lay public is still an area that may deserve some attention. Despite news 
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to tailor NSAID-therapy and appropriate gastric protection for an individual patient. As part of 
the SOS project we assessed for an individual patient given his/her upper GI and 
cardiovascular risk profile which individual NSAID should be preferred. We built an overall 
decision tool to assess on individual patient-level which individual NSAID is the preferred 
choice. Over a range of different scenarios we noticed that only a few NSAIDs always were 
considered the relative safest NSAIDs. Despite the fact that patient characteristics alter the risk 
of adverse events, such as age, sex and presence of comorbid diseases, this apparently did not 
affect the choice which NSAID yielded the lowest risk of upper GI complication, ischemic 
stroke, acute myocardial infarction and heart failure. However, as is common in 
pharmacoepidemiology, discrete ranking levels considering the ‘safest’ choice may not be 
clinically applicable as for some scenarios absolute differences are very small. However, since 
many of the NSAIDs included in the decision model are available world-wide over the counter, 
it may be an even safer strategy to take all NSAIDs off-the-counter. Also, considering the 
interactions with other chronically used drugs this would result in reductions of healthcare 
costs, an aspect currently highly important for government and medical decision makers. 
Prior studies have suggested that PPIs may reduce the efficacy of clopidogrel in 
patients with a history of acute coronary syndrome.515, 516 The clinical impact of these 
observations remains unclear. More recent studies did not observe a difference in mortality or 
ischemic cardiovascular events.169, 517, 518 There has been a recent signal that PPIs may 
adversely impact vascular function and increase the risk of acute myocardial infarction.519 
Before conclusions on this data-mining study can be drawn, further investigation towards any 
interaction or channeling of PPIs should be performed.  
 
POOLING OF DATA FROM MULTIPLE DATA SOURCES 
 
Scientific studies in the medical field using ‘big data’ are gaining popularity, as if the 
terminology by itself assigns scientific plausibility and importance to the study. There are 
currently many projects using ‘big data’ with a common data model or distributed network, for 
example the SOS study was performed using the model. Other projects with such networks 
include Mini-Sentinel,490, 493 HMO Research Network,494 the Observational Medical Outcomes 
Partnership (OMOP),489 the EU-ADR project346 and IMI-PROTECT.459 One of the key reasons that 
such widely distributed networks have been developed is the ambition to conduct large-scale 
epidemiologic studies meanwhile guaranteeing data privacy and legacy issues.346 Within these 
networks it is possible that data partners contribute summary data or results while keeping 
individual-level data locally and thereby account for security issues. However, the ‘optimal’ 
way to pool and aggregate site-, population- and study-specific estimates is an area that does 
not include fully developed and validated methods, let alone our assumption there should be 
an optimal way. We and others have shown that one-stage analyses (individual patient-level 
pooled data) and two-stage analyses (regular meta-analysis on site-specific estimates) perform 
very similar to each other in a setting where a common data model is used.485-487 How to 
 
 
proceed with these methods and to integrate this information in the field of observational 
studies and clinical trials when a common data model is not applied needs further exploration. 
For instance, whether factors as the differences in prevalence, associations between varying 
confounders and outcome in different study designs can affect the results of pooling in the 
two different methods should be clarified. Although it is assumed that clinical trials are free of 
confounding, combining of data from different trials may however be problematic, as study 
populations with very specific in- and exclusion criteria likely differ between trials. 
 
FUTURE PERSPECTIVES 
 
In general 
 
Scientific research in all areas of interest is growing rapidly and requires close collaboration 
between research groups. In this thesis the focus is directed towards drugs (NSAIDs and PPIs) 
and their effects on the gastrointestinal and cardiovascular system, and we have studied the 
effects by using several electronic health care databases. When looking at the aspect of 
‘combining’ databases, data and results; not only are studies being designed across countries 
but also data from different cohorts and countries are being aggregated or ‘pooled’ to obtain 
more robust estimates. Statistical models that allow a certain degree of heterogeneity 
between the studies are often considered standard, though individual patient-level pooling 
without taking the site-specific effects into account is often used nowadays. Whether the 
latter method may be applied in pooling results of randomized clinical trials, observational 
studies and clinical cohorts should be investigated. By pooling on individual patient-level main 
advantages are the availability of more flexible analyses and investigation of rare exposures. 
Site-specific elements such as confounders, differences in prescribing behaviors, health care 
and most importantly study populations, analysis and design may contribute to a substantial 
degree of heterogeneity. Different techniques to adjust for the ‘best’ confounders or selecting 
these automatically need more exploration in the area of medical healthcare records from 
hospitals and primary care practices where more unstructured data is available. Data mining 
techniques will allow for better characterization of data and covariates than currently used 
methods for identification of covariables. A large amount of data is stored and entered into 
medical records and there is an enormous gap between availability and our ability to use these 
data. Despite many efforts to ‘automate’ the use of this data and our ability to create more 
sophisticated models, clinical and a-priori knowledge remains an important pillar in all 
research facets. 
 Besides these concerns, international collaboration between groups and cohorts 
linking different registries will enable future research efforts to gain transatlantic knowledge 
and improve health care. In such way, otherwise unknown and remaining research questions 
can be addressed. Personalized medicine, public health and prevention are important targets 
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for future research in helping to focus more specifically on the ‘best’ and ‘safest’ care. 
However, in case large study populations are needed the results should be interpreted with 
caution by the general public. As high relative risks do not necessarily mean a clinically 
meaningful increase in absolute terms for the general population. 
 
Topic specific 
 
Clinical practice on Barrett’s esophagus and esophageal adenocarcinoma would benefit if 
research on this topic would focus on identifying optimal risk stratification models and 
markers for individual patients predictions on progression rates and prevention. Collaboration 
between large cohorts of BE patients across countries would offer large sample sizes for 
estimation of risk reductions on cancer and cancer-related mortality. 
 Upper GI bleeding is a traditional area of research with respect to drug-related 
adverse events. With the newer oral anticoagulants on the market, future research should 
identify interactions with these drugs and the clinical impact of other important interactions 
such as aldosterone antagonists with NSAIDs. Risk factors for patients on chronic therapies 
such as low-dose aspirin in need of gastroprotective agents but not being adherent to these 
should be identified. 
 Microscopic colitis in increasingly being recognized by physicians as well as a disease 
that significantly impacts quality of life of patients. Lack of knowledge resulting in diagnostic 
delay remains an important issue. When the etiology of the disease and the long-term 
consequences of MC are better understood such aspects may be encountered. Development 
of clinical decision models may aid the physician. 
 Much more clinical and observational research should distinguish between the 
effects of individual drugs or the effects of a group of drugs. As we showed for NSAID-related 
AMI, the risk of the outcome of interest may be different by individual drugs. One way to 
achieve this is the combination and pooling of data taking the above mentioned 
considerations into account. 
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NEDERLANDSE SAMENVATTING 
 
Een overzicht van de belangrijkste resultaten van studies beschreven in dit proefschrift 
is te zien in Tabel 1. 
 
Niet-steroïdale anti-inflammatoire medicijnen (NSAID’s) worden veelvuldig gebruikt 
voor pijnstilling en ontstekingsremming. Ze worden vaak gelijktijdig gebruikt met 
proton pomp remmers (PPI’s) die de belangrijkste middelen zijn om productie van 
maagzuur te remmen en zo de kans op complicaties van NSAID gebruik zoals maag-
darm bloedingen, verder bovenste tractus digestivus bloedingen, te verkleinen. In dit 
proefschrift is het gebruik en de veiligheid van NSAID’s en PPI’s bestudeerd. Na een 
algemene introductie in sectie 1 vervolgen we in sectie 2 met een review van het 
gebruik van PPI’s bij ouderen. PPI’s worden vaak gegeven aan mensen die NSAID’s 
gebruiken om zo het risico op NSAID-gerelateerde bovenste tractus digestivus erosies 
en ulcera te voorkomen. Echter, het gebruik van PPI’s geeft ook bijwerkingen, zoals 
beschreven in hoofdstuk 2.1. Het bewijs dat deze bijwerkingen ondersteunt is 
desalniettemin inconsistent en van matige sterkte. 
 
In sectie 3 wordt gekeken naar de frequentie van twee slokdarm aandoeningen, zoals 
Barrett slokdarm en slokdarm adenocarcinoom. Deze aandoeningen kunnen mogelijk 
worden voorkomen door gebruik van NSAID’s of PPI’s. De pathogenese van Barrett 
slokdarm bestaat uit langdurige gastroesofageale reflux vanuit de maag naar het 
onderste deel van de slokdarm. Vervolgens kan er door stapsgewijze progressie van 
Barrett slokdarm via laaggradige en hooggradige dysplasie uiteindelijke kwaadaardige 
groei van cellen (neoplasie) ontstaan. Momenteel worden patiënten met een Barrett 
slokdarm behandeld middels een PPI. In hoofdstuk 3.1 laten we zien dat de incidentie 
van Barrett slokdarm steeg in Nederland en het Verenigd Koninkrijk tot 2003 maar in 
de jaren daarna gelijk bleef. Dit in tegenstelling tot de incidentie van slokdarm 
adenocarcinoom die juist bleef stijgen tot nu toe. Slechts 0,3% van de patiënten met 
een Barrett slokdarm bleek uiteindelijk na verloop van tijd een slokdarm 
adenocarcinoom te ontwikkelen. Ondanks het lage risico op progessie is er gezien de 
nog steeds matige overleving van patiënten met slokdarm adenocarcinoom een hoge 
noodzaak om preventieve therapieën te ontdekken. In hoofdstuk 3.2 hebben we 
gekeken naar de preventieve werking van NSAID’s en PPI’s op het ontwikkelen van 
slokdarm adenocarcinoom bij patiënten met een Barrett slokdarm. Gebruik van 
NSAID’s en PPI’s bleek echter het risico op slokdarm adenocarcinoom niet te verlagen. 
 
Sectie 4 bekijkt het risico op bovenste tractus digestivus bloedingen en complicaties bij 
gebruik van NSAID’s. NSAID’s remmen het enzym cyclo-oxygenase (COX)-1 en COX-2. 
Nadat er nieuwere en potentieel veiligere NSAID’s ontwikkeld waren, de zogenoemde 
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selectieve COX-2 remmers, werden deze nieuwere middelen met name 
voorgeschreven aan patiënten met een hoog risico op een bovenste tractus digestivus 
complicatie. In hoofdstuk 4.1 demonstreren we dat het gebruik van een propensity 
score door middel van informatie uit een elektronisch patiënten dossier rekening kan 
houden met het selectief voorschrijven van de selectieve COX-2 remmers aan hoog 
risico patiënten. Bij patiënten met even hoog risico op bovenste tractus digestivus 
complicaties bleek dat gelijktijdig gebruik van een traditioneel niet-selectief (ns) NSAID 
met een PPI een even hoog risico op bovenste tractus digestivus complicaties gaf als 
gebruik van een selectieve COX-2 remmer (hoofdstuk 4.2). Het risico op een bovenste 
tractus digestivus complicatie is mede afhankelijk van patiënt karakteristieken en 
gelijktijdig gebruik van medicijnen. Alhoewel in richtlijnen beschreven staat dat 
sommige medicijncombinaties vermeden dienen te worden, was het onduidelijk in 
hoeverre het risico op een bovenste tractus digestivus bloeding is toegenomen en of er 
hierbij een verschil is tussen de klasse nsNSAID’s en klasse selectieve COX-2 remmers. 
In hoofdstuk 4.3 tonen we aan dat bij gelijktijdig gebruik van medicijnen met 
nsNSAID’s, selectieve COX-2 remmers of cardiovasculair aspirine het risico op een 
bovenste tractus digestivus bloeding verschilt tussen deze middelen en hoger is dan 
het risico dat we verwachtten op basis van de som van de individuele risico’s. 
 
In sectie 5 onderzoeken we effecten van NSAID’s en PPI’s op het onderste deel van het 
maag-darm stelsel, namelijk de dikke darm. Eerst bekijken we in hoofdstuk 5.1 de 
frequentie van microscopische colitis in Nederland en tonen aan dat de toename in 
nieuwe diagnoses van microscopische colitis in Nederland niet verklaard kan worden 
door een toename in het totale aantal colonoscopieën in de laatste tien jaar. Een 
colonoscopie is een diagnostische procedure om microscopische colitis te 
diagnosticeren. Vervolgens laten we in hoofdstuk 5.2 zien dat NSAID’s en PPI’s de kans 
op het ontwikkelen van microscopische colitis verhogen. In hoofdstuk 5.3 onderzoeken 
we de prognose van patiënten met microscopische colitis door gebruik te maken van 
nationale pathologie registers van Denemarken en Nederland. Patiënten met 
microscopische colitis werden vaker gediagnosticeerd met colorectale poliepen en 
adenomen dan in vergelijking met de algemene bevolking gedurende follow-up. 
 
We onderzoeken ook de effecten van NSAID’s op het cardiovasculaire systeem in sectie 
6. We konden het risico op het ontwikkelen van een acuut myocard infarct (hartaanval) 
voor gebruik van 28 verschillende NSAID’s schatten binnen een multi-nationaal project. 
Het risico op een acuut myocard infarct was verhoogd voor dertien verschillende 
NSAID’s zoals we laten zien in hoofdstuk 6.1. Door integratie van gegevens van NSAID’s 
en het risico op het maag-darm stelsel en het cardiovasculaire systeem ontwikkelden 
we een beslissingsmodel om voor een individuele patiënt, op basis van specifieke 
karakteristieken, te beoordelen welk individueel NSAID relatief gezien het veiligste is 
 
 
(hoofdstuk 6.2). Bij verschillende karakteristieken bleken celecoxib en ketoprofen 
relatief gezien het vaakst het veiligste, terwijl ketorolac en etoricoxib het minst te 
prefereren waren. 
 
Aangezien alle hoofdstukken in de eerdere secties gebaseerd zijn op gebruik van 
elektronische patiënten dossiers in databases van één of meerdere landen beschrijven 
we in sectie 7 (hoofdstuk 7.1) een methode om informatie, resultaten en data van 
verschillende databronnen te combineren. Individuele patiënt-level data analyse gaf 
vergelijkbare resultaten als de reguliere methode om resultaten te combineren 
namelijk meta-analyse. 
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5-ASA  5-Aminosalicylic Acid 
AIN  Acute Interstitial Nephritis 
AMI  Acute Myocardial Infarction 
AP  proportion attributable to interaction 
ATC  Anatomical Therapeutic Chemical  
BE  Barrett’s esophagus 
BIFAP Base de Datos para la Investigación Farmacoepidemiologica en Atención 
Primaria 
BMD  Bone Mineral Density 
BMI  Body Mass Index 
BNF  British National Formulary 
CC  Collagenous Colitis 
CD  Crohn’s Disease 
CDI  Clostridium difficile infection 
CI  Confidence Interval 
COX  Cyclo-oxygenase  
CPRD  Clinical Practice Research Datalink 
CRC  Colorectal Cancer 
CV  Cardiovascular 
CYP  Cytochrome P-450 
DDD  Defined Daily Dose 
DK  Denmark 
DNPR  Danish National Patient Register 
EAC  Esophageal Adenocarcinoma 
EHR  Electronic Healthcare Record  
EMA  European Medicines Agency 
ES  Spain 
EU   European Union 
EU-ADR Exploring and Understanding Adverse Drug Reactions by integrative mining 
of clinical records and biomedical knowledge 
FDA  Food and Drug Administration 
GE  Germany 
GERD  Gastroesophageal Reflux Disease 
GePaRD  German Pharmacoepidemiological Research Database 
GI  Gastrointestinal 
GP  General Practitioner 
GPA  Gastroprotective Agent 
GPRD  General Practitioner Research Database 
 
 
H2RA  Histamine-2 Receptor Antagonists 
Hd-PS  High Dimensional-Propensity Score 
HF  Heart Failure 
HGD  High-grade dysplasia 
H. pylori  Helicobacter pylori 
HSD  Health Search/CSD Longitudinal Patient Database 
IBD  Inflammatory Bowel Disease 
ICD  International Classification of Diseases 
ICPC  International Classification for Primary Care 
IPCI  Integrated Primary Care Information  
IQR  Interquartile Range 
IR  Incidence Rate 
IRR  Incidence Rate Ratio 
IS  Ischemic Stroke 
IT  Italy 
LC  Lymphocytic Colitis 
LDA  Low-dose Aspirin 
MC  Microscopic Colitis 
MI  Myocardial Infarction 
N adh  Non adherent 
NA  Not Applicable 
NIBLGD  Non-insulin blood glucose lowering drug 
NL  the Netherlands 
NSAID  Non-Steroidal Anti-Inflammatory Drugs 
nsNSAID  Nonselective Non-Steroidal Anti-inflammatory Drug 
OR  Odds Ratio 
OSSIFF  Osservatorio Interaziendale per la Farmacoepidemiologia e la 
Farmacoeconomia  
OTC  Over-the-counter 
PPIs  Proton Pump Inhibitors 
PS  Propensity Score 
PYs  Person-Years 
RERI  Relative Excess Risk due to Interaction 
S  Synergy index 
Safeguard Safety Evaluation of Adverse Reactions in Diabetes 
SIBO  Small Intestinal Bacterial Overgrowth 
SIR  Standardized Incidence Rate 
SISR  Sistema Informativo Sanitario Regionale 
SNOMED Systematized Nomenclature of Medicine 
SOS  Safety Of non-Steroidal anti-inflammatory drugs 
SSRI  Selective Serotonin Reuptake Inhibitor 
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